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European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
On 2 July 2009, the EFSA Panel on Dietetic products, Nutrition and Allergies (NDA) endorsed a draft 
Opinion on Dietary Reference Values for fats to be released for public consultation. This Scientific 
Report summarises the comments received through the public consultation and outlines how these 
were taken into account in the final opinion. 
EFSA had received contributions from 40 interested parties (individuals, non-governmental 
organisations, industry organisations, academia and national assessment bodies). 
The main comments which were received during the public consultation related to: the availability of 
more recent data, the nomenclature used, the use of a non-European food composition data base, the 
impact of genetic factors in modulating the absorption, metabolism and health effects of different fatty 
acids, the definition of “nutritionally adequate diet”, the use of Dietary Reference Values in the 
labelling of foods, the translation of advice into food-based dietary guidelines, nutrient goals and 
recommendations, certain risk management issues, and to Dietary Reference Values of fats, individual 
fatty acids, and cholesterol. 
All the public comments received that related to the remit of EFSA were assessed and the Opinion on 
Dietary Reference Values for fats has been revised taking relevant comments into consideration.  
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BACKGROUND 
On 2 July 2009, the EFSA Panel on Dietetic products, Nutrition and Allergies (NDA) endorsed a draft 
Opinion on Dietary Reference Values for fats to be released for public consultation.  
The scientific advice on nutrient intakes is important as the basis of Community action in the field of 
nutrition; for example such advice has in the past been used as the basis of nutrition labelling. The 
Scientific Committee for Food (SCF) report on nutrient and energy intakes for the European 
Community dates from 1993. 
The European Commission has asked EFSA to review and if necessary update such advice to ensure 
that the Community action in the area of nutrition is underpinned by the latest scientific advice. To this 
end, EFSA has been requested to consider the existing Population Reference Intakes for nutrients and 
certain other dietary components.  
Furthermore, and in order to communicate effectively on nutrition and on healthy diets to the public at 
large, it is generally more appropriate to express recommendations for the intake of individual 
nutrients or substances in food-based terms. To this end EFSA has also been asked by the European 
Commission to provide assistance on the translation of nutrient-based dietary recommendations for a 
healthy diet into food-based recommendations intended for the European population as a whole.  
In line with EFSA‟s policy on openness and transparency and in order for EFSA to receive comments 
from the scientific community and stakeholders on its work, EFSA engages in public consultations on 
key issues. The work on Dietary Reference Values (DRVs) including food-based dietary guidelines is 
considered to be such an issue. Accordingly, the draft Opinion on DRVs for fats was released for 
public consultation for ten weeks (from 5 August until 15 October 2009) on the EFSA website
4
. 
Stakeholders were informed and invited to submit comments.  
Together with other draft Opinions on DRVs, the draft Opinion on DRVs for fat was also discussed on 
a National Expert Meeting with Member States on Dietary Reference Values held in Barcelona on 
7 and 8 September 2009.  
EFSA has committed to publish the comments received during the public consultation as well as a 
short report on the outcome of the consultation, taking also into account comments received by 
Member States in the commenting period after the National Expert Meeting. 
COMMENTS RECEIVED 
At the end of the public consultation period in October 2009 had received contributions from 40 
interested parties (individuals, non-governmental organisations, industry organisations, academia and 
national assessment bodies). All comments received were scrutinised by the NDA secretariat and 
subsequently compiled with reference to the contributor and the section of the draft Opinion to which 
the comment referred (see Appendix). Comments submitted formally on behalf of an organisation 
appear with the name of the organisation. The comments received by Member States during the 
National Expert Meeting are published in the minutes of that meeting on the EFSA website. 
SCREENING AND EVALUATION OF COMMENTS RECEIVED 
1. General comments 
In general, the comments were constructive and aimed to help improving the draft Opinion. It was 
noted that several contributions copied or reiterated arguments brought forward already by other 
organisations.  
                                                     
 
4 http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1211902045161.htm 
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Several comments pointed out that available or actualised data on e.g. intake were not used in the 
Opinion and that not the most recent recommendations of national authorities were quoted. Also, a 
general comment was to clarify the criteria used in the selection of literature on the health effects of 
dietary fats that was used in the preparation of the draft Opinion. Differences between DRVs, nutrient 
goals and recommendations and food-based dietary guidelines (and between the bases used for 
establishing them) were not generally acknowledged in the comments received. Clarification on the 
purpose of European DRVs and how these relate to national DRVs, to nutrient goals and 
recommendations, and to food-based dietary guidelines was requested. 
2. Specific comments 
The main issues addressed in the comments are summarised below. 
Nomenclature: The Panel acknowledges the confusion caused by the use of different terms for the 
same type of dietary reference value and underlines the importance for the consistent use of such 
terms. Also, it was argued that the term “fats” comprises only solid fats as opposed to oils.  
Non-European food composition data base: EFSA is asked why US instead of European data were 
used for the tables with fatty acid composition of some foods and fats and oils.  
Genetic variability: EFSA is requested to consider the impact of genetic factors in modulating the 
absorption, metabolism and health effects of different fatty acids which might necessitate the setting of 
different dietary reference values for subjects with defined genetic backgrounds.  
Definition of “nutritionally adequate diet”: Several comments requested a definition of this term.  
Labelling of foods: There was a request to take into account the impact of DRVs for fats on food 
labelling and communication of nutrition information to the consumer. 
Food-based dietary guidelines: A comment requested EFSA to advise on recommended food group 
choices with respect to the content of fat and individual fatty acids to achieve a healthy eating pattern.  
Risk management: EFSA was requested to advise on measures to inhibit or promote the consumption 
of foods with certain characteristics or to ban or support the use of constituents in foods considered to 
impair or enhance health.  
Nutrient goals and recommendations: There was a request to provide, in addition to dietary 
reference values for energy, macro- and micronutrients, which are based on metabolic needs, markers 
of status, observed intakes in healthy populations, and/or valid indicators of health, recommendations 
on the quantitative nutrient composition of diets which are both feasible and suitable to maintain 
health.  
Total fat: Some comments suggested that the proposed lower bound of the Recommended Intake 
Range (RI) (20 E%) may be too low for the following reasons: in most European countries fat intake is 
around 30 E%; replacement of fat by carbohydrate could have adverse effects on blood lipids and 
health; 20 E% fat may increase the likelihood of essential fatty acids deficiency, likewise of some 
vitamins, particularly in children. It is noted that the RI for children between 3 and 18 years of life is 
not mentioned in Section 6.1. It is also suggested that the impact of the position of individual fatty 
acids on the glycerol backbone on their absorption, metabolism and health effects should be taken into 
account in setting DRVs.  
Saturated fatty acids (SFA): On the one hand, both recommendations for intake ranges (5 to 10 E%) 
and an Tolerable Upper Intake Level (UL) (10 E% or 12 E% in combination with TFA) are proposed. 
On the other hand, it was considered that a recommendation to keep SFA intake “as low as possible” 
is not a useful advice and perhaps not advisable, since replacement of SFA by carbohydrates does not 
appear to improve the ratio of total to HDL-cholesterol, and at appropriate levels of intake, SFA are 
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“essential”. It was suggested that SFA are not a homogenous group of fatty acids with respect to their 
metabolism and their effects on blood lipids, and that this should be taken into account by establishing 
different DRVs for different SFA. It was also proposed that, when judging the effects of different 
nutrients on blood lipids, the ratio of total to HDL-cholesterol should be used instead of LDL-
cholesterol concentrations since it is more predictive of the risk for cardiovascular diseases. An 
evaluation of the predictive strength of different biomarkers on disease outcomes (e.g. cardiovascular 
disease (CVD)) was suggested.  
Trans fatty acids (TFA): On the one hand, both recommendations for intake (0.5 to 1-2 E%) and an 
UL (1 E% or 12 E% in combination with SFA) are proposed. On the other hand, it was considered 
that a recommendation to keep TFA intake “as low as possible” is not a useful advice as cannot be 
easily converted to food label information. Elimination of TFA by eliminating some sources of TFA 
could have negative nutritional consequences on dietary patterns because TFA are not eaten as such 
but are natural constituents of many animal derived foods. The consumption of TFA has decreased in 
many European countries to presently low levels around 1 E% due to the restricted use of partially 
hydrogenated fats and oils in complex foods. The effects of TFA on biomarkers for risk of CVD and 
on CVD related outcomes differ according to the origin (i.e., from ruminant animals vs hydrogenation 
of fats and oils in technological processes). Therefore, DRVs or recommendations for TFA should be 
restricted to TFA industrially produced. Moreover, the consumption of TFA from ruminant animals is 
lower than that from “industrial” processes. Since conjugated linoleic acids (CLA) can contain trans 
double bonds, it should be considered as TFA. 
cis-monounsaturated fatty acids (MUFA): It was suggested that MUFA are indispensable in diets to 
fill gaps in energy expenditure and have by themselves physiological roles. Both Adequate Intake (AI) 
or RI and UL were proposed for MUFA. It was also suggested that different MUFA may have 
different physiological effects. 
n-6 polyunsaturated fatty acids, specifically linoleic acid (LA): On the one hand, it was suggested 
that the proposed AI for LA is too low because, even if the AI is suitable to prevent LA deficiency, a 
role for LA in reducing the risk of CVD is observed seen only at intake levels of at least 6 E% or 5 to 
8 E%. On the other hand, it was suggested to set an UL for LA because over-consumption of LA can 
lead to adverse effects, i.e., lipid peroxidation, increase in body fat and instability of atherosclerotic 
plaques as well as inhibition of desaturation of ALA. 
Arachidonic acid (ARA): It was felt that the physiological roles of ARA are not well described, that 
several groups in the population can be considered at risk of ARA deficiency (e.g., vegans, infants and 
toddlers fed complementary food devoid of ARA) since LA intake has no influence on ARA levels, 
and that ARA synthesis in the human body may be too low to meet the requirements. 
n-3 polyunsaturated acids, specifically α-linolenic acid (ALA): On the one hand, it was suggested 
that the proposed AI for ALA is too low because, even if the AI is suitable to prevent ALA deficiency, 
a role for ALA in reducing the risk of CVD has been observed at levels of intake 1 to 2 E%. This 
intake would also be appropriate to maintain a n-6/n-3 ratio below 5. The AI for ALA could include n-
3 LCPUFA up to 10 % of the value.  
Docosahexaenoic and eicosapentaenoic acids (DHA and EPA): The AI of 250 mg per day was 
considered to be too low and not optimal for the reduction of CVD risk, as beneficial effects have been 
observed with doses beyond 250 mg per day. Either an AI around 500 mg or two different AI, one for 
healthy subjects and one for secondary CDV prevention, were suggested.  
A paragraph on the benefits of n-3 LCPUFA on mental health in adults and the elderly was considered 
to be missing by some stakeholders.  
It was also noted that data on DHA accumulation in the brain in infants may have been incorrect.  
Outcome of the Public consultation on the Draft Opinion on  
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There was a request to mention that besides fish there are other sources of DHA and EPA, to 
differentiate in the description of studies between fish/fish oil and other sources like single cell oils, 
and to mention the amounts of n-3 LCPUFA provided in the studies.  
n-6/n-3 ratio: A reference value for the n-6/n-3 ratio in the diet was requested. 
Conjugated linoleic acids (CLA): The comments received relate to the presence of CLA in human 
milk, to the lack of intake data, and to missing effects on lipid peroxidation.  
Cholesterol: The comments received related to establishing DRVs (UL) and to a more extensive 
description of potential adverse effects of dietary cholesterol. 
INCORPORATION OF THE COMMENTS IN THE OPINION 
The EFSA NDA Working Group on Population Reference Intakes (PRI) was presented with the 
compilation of comments and discussed them at a dedicated meeting. Many of the comments were 
appropriate and aimed to enhance the scientific quality and clarity of the document. These comments 
were taken into account and the document was revised accordingly as follows: 
General comments: Section 4 has been updated with the most recent recommendations for fats from 
national and international bodies, and Annexes 2 and 3 reporting intake data for dietary fats in 
different European countries have been updated and re-structured to accommodate most recently 
published intake data. The Opinion on principles for deriving and applying DRVs has been modified 
to clarify the differences between DRVs, nutrient goals and recommendations and food-based dietary 
guidelines, clearly stating that the task of the Panel will be limited to establishing DRVs for 
Europeans. Different sections in this Opinion have been modified to be consistent with the 
terminology and concept underlined in the final Opinion on Principles.   
Nomenclature: Consistent with the scientific Opinion on Principles for deriving DRVs, which was 
amended based on the comments received during public consultation, the term “recommended intake 
range” has been replaced by “reference intake range”. Also, consistent terminology as defined in the 
Opinion on principles has been used throughout the Opinion on fats. With regards to the terms 
“dietary lipids” vs “dietary fat”, the Panel considers that both the terms “dietary fat” and “dietary 
lipids” include as main components triacylglycerols and phosphatidylcholine, and therefore no 
changes were introduced in the Opinion.   
Non-European food composition data base: The Panel chose this database because of its 
completeness. The choice does not signify correctness of values which, moreover, can have wide 
ranges. The food items were chosen to demonstrate in exemplary fashion only the widely differing 
fatty acid patterns of some foods and not with the intention of providing a data reference base. No 
changes in the Opinion were considered necessary. 
Genetic variability: The Panel considered this suggestion in the Opinion on Principles for deriving 
DRVs and will refer to the impact of genetic factors in modulating the absorption, metabolism and 
health effects of different nutrient (including fatty acids) (including this Opinion on DRVs for fat), 
where appropriate. However, the Panel considers that the present knowledge is insufficient to set 
specific DRVs for fats based on a particular genetic background.  
Definition of “nutritionally adequate diet”: “Nutritionally adequate diet” is a common expression to 
indicate food intake patterns that allow an adequate intake of all essential nutrients without the risk of 
an inadequate or excessive energy intake. The Panel considers that such diets are the goal of food-
based dietary guidelines and fulfil the criteria set out in the Opinion on the development of foodbased 
dietary guidelines. 
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Labelling of foods: This comment was considered to be outside the terms of reference (ToR) for this 
Opinion. No changes were introduced in the text.  
Food-based dietary guidelines: This request was considerd to be outside the ToR for this Opinion. 
On the one hand, EFSA has already provided guidance for developing food-based dietary guidelines; 
on the other, it is the task of managers in the field of public health and food safety. No changes were 
introduced in the text.  
Risk management: This task is clearly out of the ToR and up to risk managers in the field of public 
health and food safety. No changes were introduced in the text.  
Nutrient goals and recommendations: As clearly stated in the final version of the Opinion on 
Principles for deriving DRVs, the Panel considers that this request is outside the ToR. However, the 
Panel acknowledges that dietary reference values have to be converted into nutrient goals for the 
population and nutrient recommendations for individuals taking into account other considerations than 
pure scientific risk assessment (i.e., risk management). Also, the Panel has already provided guidelines 
on how to derive food-based dietary guidelines from DRVs and nutrient goals and recommendations. 
Total fat: The Panel considers that, due to the inconsistent use of nomenclature for DRVs in the draft 
Opinion highlighted above, the term RI (“reference” intake range), may have been misinterpreted as a 
“recommended” intake range. The lower bound of the RI for total fat is not a recommended intake but 
a reference intake and the Panel has outlined that total fat intakes at this level, even if compatible with 
good health under certain circumstances, can be accompanied by too low intakes of some vitamins 
and/or energy in certain population subgroups, particularly children. The RI for children between 
3 and 18 years of life is now mentioned in section 6.1 and Table 5 and it is the same as for adults (i.e., 
20 to 35 E%). Finally, it is mentioned in the Opinion that different positions of different fatty acids in 
the glycerol backbone may have different health effects, but the data available is considered 
insufficient for setting different DRVs. 
Saturated fatty acids (SFA): The Panel considers that intake recommendations or “target values” for 
consumption should be part of nutrient goals and recommendations and do not fulfil the criteria for the 
derivation of a DRV (see section above on nutrient goals and recommendations). This has been clearly 
stated in the final version of the Opinion. Also, the Panel does not consider SFA to be indispensable 
nutrients. They are, however, essential constituents of a diet as providers of energy and carriers of 
nutrients and they can, therefore, not be zero in a nutritionally adequate diet. Even if different SFA 
have different effects on blood lipids, the Panel considers that there are not sufficient data to set 
different DRVs for different SFA. The Panel considers that the ranking of the predictive strength of 
different biomarkers on disease risk is outside the ToR for this task. 
Trans fatty acids (TFA): The Panel considers that intake recommendations or “target values” for 
consumption should be part of nutrient goals and recommendations and do not fulfil the criteria for the 
derivation of a DRV (see section above on nutrient goals and recommendations). This has been clearly 
stated in the final version of the Opinion. The Panel refers to the definition of a “nutritionally adequate 
diet” above, which may contain some unavoidable amounts of TFA but considers that data at present 
are insufficient to derive an UL or an upper bound for a RI for TFA. Advice on the reduction of TFA 
in the diet by recommended food choices should be given in food based dietary guidelines. The Panel 
also considers that at present the available data are insufficient to derive different DRVs for TFA of 
different origin. Even if CLA are chemically TFA, the Panel decided to treat them separately from 
TFA with non-conjugated double bounds because specific physiological effects have been ascribed to 
CLA. 
cis-monounsaturated fatty acids (MUFA): The Panel notes that the available evidence does not 
allow attributing MUFA specific physiological effects that can be separated from the effects of 
replacing SFA (and TFA) or carbohydrates in the diet. Their role in the diet (e.g. effects of oleic acid 
on blood lipids when replacing carbohydrates, SFA and/or TFA), and the different physiological 
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effects different MUFA may have, should be taken into account when formulating nutrient goals and 
recommendations and food-based dietary guidelines. No changes have been introduced in the Opinion.  
n-6 polyunsaturated fatty acids, specifically linoleic acid (LA): The Panel acknowledges that WHO 
recommends a LA intake of at least 6 E% for the prevention of CVD. However, the Panel considers 
that the intake recommendation by WHO is not equivalent to the AI as derived by the Panel and 
should be integrated into nutrient goals and recommendations and/or food-based dietary guidelines, as 
part of the association between LA (and other PUFA) intake and the reduction of CVD risk can likely 
be attributed to the substitution of SFA. Also, the Panel considers that the data available are 
insufficient to derive an UL for LA, and that the quoted negative effects of LA consumption should be 
dealt with in nutrient goals and recommendations and/or food-based dietary guidelines.  
Arachidonic acid (ARA): ARA is mentioned in the Opinion as precursor of prostanoids and 
leukotrienes and comments are made on the ARA supply via food and endogenous synthesis. The 
Panel agrees that dietary LA has no influence on ARA levels but acknowledges that “low” levels of 
ARA are not equivalent to ARA deficiency and that even in subjects with demonstrated “low” ARA 
levels ARA deficiency symptoms have not been described. The Panel also considers that the data 
available do not permit to set a DRV (AR, PRI or AI, or UL) for ARA. 
n-3 polyunsaturated acids, specifically α-linolenic acid (ALA): The AI value for ALA has not been 
based on data on the prevention of CVD and the Panel refers to the lack of an association between 
ALA intake and risk for fatal coronary heart disease or coronary heart disease events in a very recent 
meta-analysis of prospective cohort studies with intakes ranging from 1.4 to 2.5 g/day (Skeaff and 
Miller, 2009). The Panel prefers to propose separate AI for ALA and n-3 LCPUFA because of the 
unpredictable conversion rate of ALA to EPA/DHA. The Panel agrees that in nutrient-based 
guidelines a balance between LA and ALA should be part of the advice. Taking into account current 
consumption data in Europe this would mean to increase current ALA intakes. 
Docosahexaenoic and eicosapentaenoic acids (DHA and EPA): The Panel has reconsidered the 
pertinent studies on the effects of n-3 LCPUFA on the risk of CVD and found the meta-analysis by 
Mozaffarian and Rimm (2006) particularly useful in setting an AI for DHA plus EPA, since daily 
doses for the effects were calculated and provided. That meta-analysis shows a significant threshold 
effect at intakes of 250 mg per day for cardiovascular mortality, whereas different doses (and time 
length) may be required for different mechanisms of action in order to obtain the effect, which may 
explain different findings in different studies depending on the background diet (DHA plus EPA level 
of intake) and risk level. The criticism on this meta-analysis relates to the graphic representation in 
which the number for the threshold might have been forced by the authors and was not real. Another 
problem is that observational and intervention studies are pooled, and that populations with very high 
baseline intakes are included, although an effort has been made to recalculate baseline risk in those 
cases. However, the Panel considers that this is the best available estimate to establish an AI for DHA 
and EPA on the basis of CVD risk in healthy populations, for which DRVs are meant. 
A new section (5.12) on cognitive decline and dementia has been included in the Opinion. 
More recent data on DHA accumulation in the brain in infants have been incorporated into the 
Opinion.  
Other sources of DHA and EPA have been mentioned in the Opinion.  
n-6/n-3 ratio: The Panel considered that setting a reference value for such a ratio cannot be done 
without consideration of the total amounts of the respective fatty acids in the diet or, vice versa, that it 
is preferable to consider the balance between n-6 and n-3 PUFA in nutrient goals and 
recommendations and food-based dietary guidelines taking into account their mutually inhibitory 
effects when one or the other is consumed in excess. No changes were considered necessary in the 
Opinion.  
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Conjugated linoleic acids (CLA): Information about the CLA content in human milk and a statement 
on the lack of intake data has been included in the Opinion. However, this information, or that on the 
effects of CLA on lipid peroxidation, does not change the conclusion that a DRV cannot be defined for 
CLA. No changes were considered necessary in the Opinion.  
Cholesterol: Section 5.2.7 already clearly depicts the lipoprotein changes observed following defined 
intakes of cholesterol. Section 5.8.4 depicts the weak relationship between dietary cholesterol and 
CVD. No changes were considered necessary in the Opinion.  
The Opinion was modified taking editorial comments into account where appropriate. Also, Annex 1 
and Annex 2 reporting intake data for fats in different European countries have been updated and re-
structured to accommodate most recently published intake data. 
EFSA wishes to thank all stakeholders for their contribution.  
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GLOSSARY / ABBREVIATIONS 
AI  Adequate Intake 
ALA  Alpha-Linolenic Acid 
AR  Average Requirement 
ARA  Arachidonic Acid 
CLA  Conjugated Linoleic Acids 
CVD  Cardiovascular Disease 
DHA  Docosahexaenoic Acid 
DRV  Dietary Reference Value 
EFSA  European Food Safety Authority 
EPA  Eicosapentaenoic Acid 
HDL  High Density Lipoprotein 
LA  Linoleic Acid 
LCPUFA Long Chain Polyunsaturated Fatty Acids 
MUFA  Cis-Monounsaturated Fatty Acids 
PRI  Population Reference Intake 
RI  Reference Intake ranges for macronutrients 
SCF  Scientific Committee on Food 
SFA  Saturated Fatty Acids 
TFA  Trans Fatty Acids 
ToR  Terms of Reference 
UL  Tolerable Upper Intake Level  
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APPENDIX 
COMMENTS RECEIVED ON THE DRAFT OPINION RELATED TO DIETARY REFERENCE VALUES FOR FATS DURING THE PUBLIC CONSULTATION PERIOD 
ORGANISATION CHAPTER TEXT COMMENT TEXT 
AFSSA 1. Introduction First of all, Afssa thanks Efsa for this huge and essential work for the definition of DRVs. This compilation of data and 
recommendations is a keystone element to support public health issues in European human nutrition. The contribution of 
national safety agencies may help Efsa and the NDA panel for the further discussions and amendments.  
 
1. General remarks 
Our comments on this draft document are mainly based on Afssa current work on the update of fatty acids Nutritional 
Recommendations for the French population (Opinion in process). This work includes a thematic and extensive review of the 
literature on fatty acids. Collective expertise was used to define each value proposed as ANC for each fatty acid or group of 
fatty acids. Afssa work was undertaken by a large group of experts (almost 12), all specialized in the field of fatty acids, in 
order to integrate the best state of current knowledge.  
Our first general remark concerns the approach of this draft document: it directly focuses on pathologies on a case by case basis, 
but does not deal with nutritional requirements. Indeed, the nutritional requirements are not taken into account, which is not in 
line with the definition of dietary references (RDAs, DRVs, ANCs…). Hence, the draft document seems to include more 
pharmacological data than nutritional one. 
For example, the Nutritional Recommendations for the French population are defined as the intake allowing the nutritional 
requirements of almost every individual of the population (97.5%) to be covered. For the specific case of fatty acids, our 
framework considers 3 steps: 
- Identification of nutritional/physiological requirements 
- Identification of data allowing the modulation of these requirements according to physiopathological data (prevention 
objective) 
- Integration and synthesis of available physiological and physiopathological data to define the ANC 
 
Furthermore, we note that dietary recommendations were only established on the basis of human studies, and consequently, a 
large part of the available literature has not taken into account. Assuming that a lot of nutrition data have been obtained and are 
continuously being obtained in animal models, all types of studies (in vitro, animal models, clinical and epidemiological 
studies) have to be considered. If one only uses human studies, dietary references can only be established for few nutrients. In 
addition, some chapters are short, despite the accessibility of many studies on the subject (example cancers). So an extensive 
review of the literature is essential. 
The NDA panel includes only “diet related diseases” (Heart disease, Cancer, Obesity, Diabetes), though fatty acids are also 
implicated in other physiologic functions (cerebral function, ageing) and in other pathologies (for example: Age-Related 
Macular Degeneration). 
 
The fact that a nutrient is synthesized by the body cannot be interpreted as an absence of nutritional requirements and so does 
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not mean that it is not required in the diet. Hence the term “Nutrient is synthesized by the body” cannot be used to justify the 
absence of proposition of DVRs for cis-MUFA, SFA, cholesterol. 
 
In the same line, the absence of data, even for a nutrient for which the intakes have to be reduced (SFA) cannot lead to consider 
that no defined recommendations are needed. So, the general recommendation “should be as low as possible” is not appropriate. 
Although, some fatty acids are synthesized by the body, all of them have nutritional utility. 
AFSSA 3. Dietary sources 
and intake data 
2. Specific remarks 
Section 3.1 gives an interesting panorama of dietary sources and consumption data in European countries. However, these data 
have not to be considered as a basis for the definition of DRVs. They only give an idea of the current nutritional context. 
AFSSA 6.1. Total fat L 1839: “At the lowest observed intake of total fat (20%E) in european countries no over signs of deficiencies have been 
observed neither adverse effects on serum lipids”.  
The status (nutritional requirements) in essential fatty acids is not any more covered with a total fat intake of 20 %. 
 
L 1841: « The panel proposes to set for adults a lower bound of the recommended intake range of 20E% and an upper bound of 
35 E%.” 
Regarding the recommendation of total fat, it rests on a non exhaustive review of literature. A total fat intake <30% probably 
leads to an increase of carbohydrates intakes (positive energy balance), which can be deleterious (impact of carbohydrates on 
metabolic syndrome). For a healthy population, a minimum of total fat intake of 30 % allows ensuring a minimum of essential 
PUFA. In addition, according to pathological data, there is no health benefit to reduce this intake below 30 %. 
Afssa has recommended fat intakes between 35 and 40 % of total energy intake for adults (male and female), considering an 
energy intake of 2000 kilocalories and an equilibrated energy balance. 
AFSSA 6.2. Saturated fatty 
acids (SAT) 
Another remark concerns SFA and MUFA which are always considered without differentiation into each group of fatty acids 
(example: a mixture of SFA). 
 
L 1867: “The panel recommends that SFA intake should be as low as possible within the context of a nutritionally adequate 
diet”.  
 
Current available data allow making distinction among SFAs. So, we would like to point out that, according to recent studies, 
SFAs should not be considered any more as a homogeneous group. SFAs differ according to their structure, metabolism, 
cellular function and deleterious effects when their intakes are excessive. Their impact on lipids metabolism and probably on 
health are different, namely the atherogenic effect of lauric, myristic and palmitic acids at high intakes and the absence of 
deleterious effects of short and middle chain fatty acids and stearic acid. 
 
We also note that plasma cholesterol as cardiovascular risk marker is insufficient to incriminate SFA as a whole. Indeed, 
caproïc, caprylic, capric acids do not have a cholesterolemic effect when compared to lauric, myristic, and palmitic acids. 
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Moreover, if the SFAs recommendation is “as low as possible» and knowing that the third of phospholipids comes from SFAs 
we can wonder how the structure of membranes could be assured. Afssa working group proposes recommendations on SFA 
“atherogenic effect at high intakes”, i.e lauric acid, myristic acid and palmitic acid (= 8 %E) and an upper limit for total TFA (= 
12 %E). 
 
We note that the effect of total fat on insulin-sensitivity is a matter of debate. However, only 2 studies are quoted in the draft 
document, the methodology of one of which might be discussed (small sample; experimental conditions not realistic).  
AFSSA 6.3. Cis-
monounsaturated 
fatty acids (Cis-
MUFA) 
L1876: “The panel therefore proposes not to set any DRV for cis-MUFA” 
Afssa considers that MUFA should not be considered any more as a heterogeneous group. Available data on cardiovascular 
risks allow setting a recommendation for oleic acid of 15-20 %, the value of 20 % be considered as an upper limit. 
 
AFSSA 6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
L 1896: “The panel proposes to set an AI for linoleic acid of 4%E” 
We agree with the recommendation for linoleic acid but we note that it doesn‟t refer to an upper intake level.  
 
There is some inconsistency between the summary and the conclusion on CV risk as the effect of linoleic acid is not even 
mentioned. The pooled study by Jakobsen et al (2009) could have been quoted. 
L 1910: “The panel proposes to set an AI for alpha-linolenic acid of 0,5%E” 
We propose to set an ANC for alpha-linolenic acid of 1%E. This value has been defined according to : (1) observational 
epidemiologic studies in cardiovascular field (2) the necessity to cover PUFA requirements in terms of cardiovascular 
prevention, (3) the aim to maintain a LA/ALA ratio<5. Moreover, we note that no intervention study is taken into account for 
the definition of the value for alpha-linolenic acid. 
 
L 1925: “The panel proposes to set an AI of 250 mg for EPA plus DHA based on considerations of cardiovascular health”  
Afssa proposes an ANC of 500mg for EPA+DHA considering specifically cardiovascular prevention. This recommendation is 
in line with literature and other international recommendation (ISSFAL). 
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AFSSA 6.5. Trans fatty 
acids (TFA) 
L 1943: “The available evidence indicates that TFA from ruminant sources have similar adverse effects on blood lipids and 
lipoproteins to those from industrial sources »  
This sentence should be put into perspective of some recent clinical and epidemiological studies. (Afssa, 2009; Chardigny JM. 
et al.,2008; Jakobsen MU. et al., 2008; Motard-Bélanger A. et al., 2008)  
We can observe that conjugated linoleic acid is not treated in this part thought they are also TFA.  
 
We will send you the full review of our opinion on the update of ANCs on fatty acids as soon as it will be completed and signed 
by the Afssa Executive Director. 
We are also available for further discussions with the NDA panel members, including further interview of the chair of the Afssa 
Working Group. 
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Anthill Conclusions and 
recommendations 
The last 4-5 years people have started to eat quite opposite to todays reccomendations regarding carbohydrates, saturated fats 
and n6-fats. The results is amazing. People who have suffered from chronical diseases, ordinary dieseses, overweight and an 
overall bad health are now getting much better. I have for the last 3,5 years daily read stunning experiences form former sick 
people who now are healthier than they''ve been in a long time. The major changes in their diets have been these. 1. 
Carbohydrate restriction, wich lower blood glucose and insulin levels wich also lower inflammation. 2. More saturated fatty 
acids as a replacement for the carbohydrate energy. 3. Less omega-6 fatty acid from margarins an vegetable oils, to stop the 
inflammation process and to get a better balance between n3 and n6. 
 
This way to eat has been adapted also by a lot of proffessionals and now they''ve also noticed the benefits of it. Every well done 
study in the past have the same conclusion also. Better blood glucose, blood pressure and blood lipids profile for diets with less 
carbohydrates and more fats.  
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In order to get as healthy as a man can be, you have to eat the way a man are supposed to eat. 
Arbeitskreis 
Omega-3 e. V. 
Conclusions and 
recommendations 
Line number 2026-2035 
 
Kommentar des Arbeitskreis Omega-3 e. V.  
 
Nach Meinung des Arbeitskreis Omega-3 e. V. – einer Initiative von Wissenschaft und Wirtschaft – ist der vorgeschlagene AI 
von 250 mg EPA/DHA für Erwachsene zu niedrig angesetzt. Nach Ansicht des Wissenschaftlichen Beirats des Arbeitskreis 
Omega-3 e. V. rechtferti-gen die Ergebnisse wissenschaftlicher Forschung eine höhere Zufuhr-empfehlung von mehr als 300 
mg EPA/DHA pro Tag [1] sowie eine zusätzliche tägliche Zufuhr von 200 mg DHA während Schwanger-schaft und Stillzeit 
[2]. Zahlreiche Fachorganisationen wie die ISSFAL, SACN und AHA [3-5] haben daher ihre Empfehlungen eben¬falls höher 
angesetzt (450-500 mg EPA/DHA pro Tag). Dies ist hin¬sichtlich der von der FDA als GRAS angesehenen Zufuhrmenge von 
bis zu 3 g EPA/DHA pro Tag gut zu rechtfertigen [6]. 
 
Der Arbeitskreis Omega-3 e. V. empfiehlt daher dringend, als  
AI für Erwachsene und junge Menschen im Alter von 2 bis 18 Jahren eine Menge von mehr als 300 mg EPA/DHA pro Tag 
festzulegen und für Schwangere und Stillende eine zusätzliche tägliche Zufuhrmenge von 200 mg DHA. 
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1. Introduction Comments on background and summary : 
 
The criteria to make conclusions should be consistent throughout the document. The summary should be consistent for all fats 
and in accordance with the information in the document. 
 
Lines 42+81+84+95+104 
It is not clear how the evidence is graded. In the summary and also further on in the document words such as the following are 
used: “there is evidence“ (line 42), “negative (beneficial) relationship“ (line 81), “also evidence“ (line 84), “no consistent 
evidence“ (line 95) and “no convincing evidence” (line 104). 
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Line 44 
In the context of obesity, calorie restriction is more effective for obesity treatment than dietary fat restriction. Indeed, dietary fat 
restriction did not prove to be superior to calorie restriction, thus strengthening the public health message that calories do count 
(Harvey-Berino, 1999; Donelly et al., 2008; Melanson et al., 2009) 
 
Line 48 
The 20 E% does not seem representative of the European fat intake. Indeed, according to Annex 1b of this draft opinion mean 
intakes are almost all above 30 E%. The population with very low intake is obviously a specific population (elderly men in 
Portugal). This confirms that the 20 E% as the lower bound of the intake range is not adapted for the general population. 
 
Line 50 
The value of 20 E% is not appropriate as it is not representative of the lowest intake in Europe. According to AFSSA (2001), 
the balance of fatty acid intake (especially PUFA) is more difficult to achieve below 30 E%. Besides, consumption of a low-fat 
diet (defined as containing 20% of energy from fat) was shown to induce atherogenic dyslipidemia (German and Dillard, 2004; 
Volek et al., 2009). 
There are other negative effects of too low fat intake. As mentioned in this report (lines 1068-1070) “Very low fat diets tend to 
increase the risk of an insufficient intake of PUFA, can impair the absorption of fat-soluble vitamins and be associated with 
insufficiency of other essential nutrients like zinc and B vitamins”. 
Studies have also suggested that interventions to lower dietary fat content and different fat compositions lead to a compensatory 
increase in sucrose content. There has been a concern that dietary recommendations aimed at achieving a low saturated-fat diet 
might lead to inappropriately increased sugar intake (Gibney et al., 1995) and some 
studies suggest that an inverse relationship exists between the intake of fat and simple sugars (Gibson, 1997; Lewis et al., 1992; 
Hackett, 1993). Other studies show that children with an intake of <30% of energy from fat consumed more carbohydrates 
(mainly sucrose) than those children whose diets contained >40% of energy from fat (Nicklas et al., 1992; Kennedy et al., 
1999). 
Recent advice to consume low-fat, high-carbohydrate diets to reduce serum LDL cholesterol levels can also result in reduced 
HDL levels and increased levels of triglycerides, small dense LDL and insulin, which have been shown to increase the risk of 
coronary heart disease (Krauss, 2001; Volek et al., 2008). 
Reducing total fat intake can lead to increased intake of carbohydrates. A high intake of carbohydrates (refined, high glycemic 
index) may adversely affect insulin homeostasis, satiety and weight gain (Mozaffarian, 2005) and can lead to a high synthesis of 
palmitic acid. Recent studies show that a lower fat-diet but rich in carbohydrates stimulated saturated fatty acids (SFA) 
synthesis - especially palmitate - at high rates (Wilke et al., 2009). 
 
Line 55 
The recommendation for total fat intake between 3 years and adult is missing. 
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1. Introduction Line 59 
 
It should be clear what is meant by expressions like “a mixture of SFA” and also if this mixture is nutritionally relevant. A 
meta-analysis of 60 controlled trials on effects of dietary fatty acids and carbohydrates on the ration of serum total to HDL-
cholesterol and on serum lipids by Mensink et al. (2003) showed no significant change when carbohydrates 
constituting 1% of energy were replaced iso-energetically with saturated fat. For individual SFA, the predicted ratio was 
significantly lower for lauric acid when replaced by carbohydrates constituting 1% of energy while no significant predicted 
changes were observed for palmitic, myristic or stearic acid, respectively. The researchers states that total:HDL cholesterol is a 
more sensitive and specific risk predictor than total cholesterol and concludes that isoenergetic replacement of SFAs with 
carbohydrates does not improve the serum total:HDL cholesterol. All natural fats contain both SFA, which do not change this 
ratio, and unsaturated fatty acids, which lower it. As a result, even the replacement of dairy fat and tropical fats with 
carbohydrates will increase the ration of total to HDL cholesterol. 
Jakobsen et al. (2009) showed that for a 5% lower energy intake from SFAs and a concomitant higher intake from 
carbohydrates, there was a significant direct association between carbohydrate and coronary events (hazard ratio: 1.07, 95% CI: 
1.01-1.14). 
 
Lines 59-60 
To reflect lines 1238-1240 of this scientific opinion, following information should be concluded in the summary: “There is a 
positive, dose-dependent relationship between the intake of a mixture of SFA and serum LDL and HDL cholesterol 
concentrations, when compared to carbohydrates. As a consequence, the total to HDL cholesterol ratio 
does not change.” 
 
Line 66 
It should be clear what the scientific evidence is for making the recommendation of a SFA intake “as low as possible”. 
The 2009 Joint FAO/WHO Expert Consultation on “Fats and Fatty Acids in Human Nutrition” sets dietary recommendations 
for total fat at 20-35 E% (acceptable macronutrient distribution range) compared to the population 
nutrient intake goal of 15-30 E% mentioned in the 2003 WHO report (Elmadfa and Kornsteiner, 2009). For children from 2 to 
18 years, the recommendation for the total dietary fat intake is 30-40 E% depending on activity (Uauy and Dangour, 2009). 
 
Lines 67 and 145 
It should be clear what is meant by a “nutritionally adequate diet”. A definition cannot be found in the text. 
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Association de la 
transformation 
laitière française  
1. Introduction Those comments are about the summary 
 
Line 67 
This recommendation does not reflect the recent scientific evidences about SFA. The evidence of the role of SFA in CHD is not 
conclusive (Mente et al., 2009). Studies provide only inconclusive evidence of the effects of modification of total, saturated, 
monounsaturated, polyunsaturated on cardiovascular morbidity and mortality (Howard et al., 2006; Ravnskov 1998; Mente et 
al., 2009; German & Dillard, 2004; Volk, 2007). Moreover, some studies show that in some case a greater saturated fat intake is 
associated with less progression of coronary atherosclerosis, whereas carbohydrate intake is associated with a greater 
progression (Mozaffarian et al., 2004; Griel et al., 2006). Besides, 
the Women Health Initiative (WHI) study indicates that the decrease of fat intake (leading to an intake of 9.5% SFA) did not 
significantly reduce the risk of stroke, coronary heart disease, or cerebro-vascular disease in postmenopausal women (Howard 
et al., 2006). 
In addition, a recommendation of “as low as possible” would not be achievable in normal life with a normal diet and would 
result in strict and impossible guidelines to follow. Moreover, this recommendation “as low as possible” is not relevant due to 
recent scientific results showing the real effect of SFA on health - especially on cardiovascular health 
(Skeaff and Miller, 2009; He et al., 2007; Mozaffarian, 2005, Hooper et al., 2001 and 2002) (for details see comments lines 
1627-1644). A low intake of SFA could lead to an excessive consumption of MUFA and PUFA, which could represent health 
hazards, especially with regard to intake of n-6 fatty acids (Lecerf, 2009; Ailhaud, 2006). 
SFA have different physiological functions depending on their chain length. Thus, SFA should not be evaluated as one single 
group (Sengupta 2006, Hashim, 1960; Tsuji, 2001; Yu et al., 1995; Kelly, 2001; Temme et al., 1997; Salter et al., 1998; Billet 
MA, 2000; Casey, 1995; Rioux, 2002; Peitzsch, 1993; Borgese, 1996; Dabadie, 2005). 
As a conclusion, a lot of scientific data shows that saturated fat has no negative effect but rather positive effects. It would 
therefore be unreasonable to consider all SFA as just one single group that would have negative impact on health. The different 
physiological functions of SFA should be taken into account in order to evaluate the nutritional 
reference values. 
 
Line 86 
However, nutritional recommendation should not stress n-6 PUFA over consumption but promote instead a good balance 
between n-3 PUFA and n-6 PUFA intake. The relative intake of n-6 to n-3 PUFA is indeed clearly emerging as a new factor in 
the development of adipose tissue (Ailhaud et al., 2008) 
 
Line 97 
There has been evidence on negative effects on health of excessive intakes of n-6 PUFA and lipid peroxidation (Elmadfa and 
Kornsteiner, 2009). It could also contribute to excessive adipose tissue development (Ailhaud, 2006; Lecerf, 2009). Therefore, 
an upper limit should be considered in order to protect consumer health. 
 
Line 128 
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The recommendation should take into account the ratio of n-3/n-6 PUFA as this would give a better idea of what should be 
considered as a balanced diet. Besides, the relative intake of n-6 to n-3 PUFA is clearly emerging as a new factor in the 
development of adipose tissue (Ailhaud et al., 2008). An optimal intake with a ratio of n-3/n-6 PUFA should also be fixed by 
EFSA, like it is the case in all the national and international recommendations. In order to determine this ratio, a conversion 
factor can be applied to LC PUFAs (LA to ARA, and ALA to EPA and DHA). For 
adults, this leads to an optimal n-6 PUFA: n-3 PUFA of 5:1. 
Association de la 
transformation 
laitière française  
1. Introduction Those comments are on the summary 
 
Lines 129-141 
If the limited data suggest that the effects of ruminant and industrial TFA on blood lipid profiles are similar when consumed in 
similar quantities, it is important to mention that very few people consume the high levels of ruminant TFA used in these 
studies and that observational studies do not support adverse CHD effects of ruminant TFA in amounts actually consumed 
(Mozaffarian et al., 2009). This is reinforced by the recent WHO scientific update on TFA (Uauy et al., 2009). Similarly, the 
recent AFSSA on TFA report states that TFA from natural origin do not present a risk in terms of cardiovascular disease as they 
are consumed at a low level (0,5 to 0,9% of the total energy intake) (AFSSA, 2009). 
The EFSA recommendation concerning the dietary reference value for TFA should therefore deal only with industrially derived 
TFA. TFA from natural origin should not be included. 
 
Line 145 
Total TFA should be replaced by TFA from industrial origin. 
 
Line 146 
It is irrelevant to compare industrial and natural trans fatty acids (TFA) when consumed in equivalent amounts. Stender et al. 
(2008) showed that the amount of TFA in industrial fat can be as high as 60% whereas the content of natural TFA in for 
instance milk fat is approximately 4%. 
In the WHO scientific update on trans fatty acids Uauy et al. (2009) summarises that evidence from observational studies in 
which estimated TFA consumption from industrial and ruminant sources of TFA has been distinguished and from studies in 
which specific TFAs have been measured utilizing biomarkers generally do not support an adverse effect of ruminant TFA, in 
the low amounts usually consumed, on risk of CHD. The intake of ruminant TFA is low in most populations and to date there is 
no conclusive evidence supporting an association with CHD risks in the amounts usually consumed. In contrast, TFA produced 
by partial hydrogenation of fats and oils should be considered industrial food additives having no demonstrable health benefits 
and clear risks to human health.  
A recent analysis from Denmark, a country with a relatively high intake of dairy products, showed no associations between 
absolute or energy-adjusted ruminant TFA intakes and CHD in an 18-year follow-up study of 3686 Danes, aged 30–71 years, 
without previous CHD at baseline (Jakobsen et al., 2007). 
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Lines 156-158 
Eggs are also a significant source of dietary cholesterol. They provide almost half of the dietary cholesterol in a western diet 
(Vorster et al., 1992). However, it is important to add that dietary cholesterol has very little influence on plasma cholesterol 
values which are regulated by numerous genetic and nutritional factors through cholesterol absorption or synthesis. Besides, 
there is no strong evidence that dietary cholesterol is related to CHD or stroke (Hu et al. 1999; Nakamura et al., 2004) 
Association de la 
transformation 
laitière française  
2. Categories, 
structure and 
function 
Line 394 
Protein myristoylation is only one way to regulate enzyme activity. Protein palmitoylation should be mentioned as well since it 
is one of the most frequent post-translational modifications found on proteins (Bijlmakers and March, 2003). 
 
Line 396 
The role of the position of fatty acids on the triglyceride backbone should be addressed. 
Addition of following paragraphs: The first key step governing the bioavailability and metabolic impact of dietary lipids is their 
digestion. Therefore, fats with the same fatty acid composition might differ in their metabolic impact, due to difference in 
triglyceride composition. Gastric lipase acts preferentially on fatty acids esterified at the sn-3 position, while pancreatic lipase 
has a preference for the sn-1 and sn-3 positions. In the chylomicrons, 75% of all fatty acids located at the sn-2 in dietary triacyl-
glycerols are maintained at this sn-2 position in the triacyl-glycerols of chylomicrons (Michalski, 2009; Armand, 2007). 
Especially for babies, C16:0 at the sn-2 position instead of sn-1 or sn-3 position is beneficial. It has been shown in a study with 
preterm infants (>35 weeks of gestation) that both palmitic acid and calcium absorption are improved and are comparable to 
infants who were breast-fed when an infant formula was used having 74% of the C16:0 at the sn2 position 
compared to an infant formula with the same amount of C16:0 but only 28% was positioned at sn2 (Lucas et al., 1997). 
Furthermore, for formula fed infants it has been shown that palmitic acid at sn-2 (instead of palmitic acid at sn-1 and sn-3) 
results in a significant increase in whole body bone mineral content and density, softer stool and less stool soap fatty acids 
(Kennedy et al., 1999b). 
 
Line 414 
Saturated fats are essential for cell membranes. In our brain, the two dominant fatty acids are palmitic acid and steraric acid 
(both around 20-25%) (Carver et al., 2001). 
Classification of saturated fatty acids (SFA) only from a biochemical point of view is no longer relevant (Lecerf, 2009). 
SFA must be considered individually according to their chain length because they all have different effects. Short-chain and 
medium-chain SFA are metabolised differently than long-chain SFA. Metabolism of SFA should be included in this scientific 
opinion. 
 
Lines 423-424 
The human body can synthesise substantial amounts of SFA. During a low fat / high carbohydrate diet up to 45% of the VLDL 
Outcome of the Public consultation on the Draft Opinion on  
Dietary Reference Values for fats 
 
24 EFSA Journal 2010; 8(5):1507 
ORGANISATION CHAPTER TEXT COMMENT TEXT 
triglycerides can be newly synthesized. The preferentially formed fatty acid by mammalian fatty acid synthase is palmitate 
(C16:0) (Cooper Hudgins et al., 1996). Recent studies show that a lower fat-diet but rich in carbohydrates stimulated saturated 
fatty acid synthesis (especially palmitate) at high rates (Wilke et al., 2009). 
Association de la 
transformation 
laitière française  
2. Categories, 
structure and 
function 
Line 461 
“The conversion of linoleic acid is very limited”: what is limited? 
For children: Olegard and Svennerholm (1971) found no differences in plasma and erythrocyte phoshoglyceride AA of 3-
month-old infants who either had been fed breast milk or were bottle fed with a milk formula with only traces of AA. This 
implies that LA is readily converted to AA in young infants. 
 
Line 475 
Goyens et al. (2006) does not give conversion rates of 8-12%. It rather states that “After the low-LA diet, the percentage of 
dietary ALA incorporated into the ALA plasma phospholipid compartment was significantly increased by 4% compared with 
the control diet (P 0.012). In contrast, consumption of the high-ALA diet significantly decreased the incorporation by 8% and 
12% compared with the control diet (P 0.001) and the low-LA diet (P 0.001), respectively.” 
 
Lines 483-486 
This paragraph should be extended and would fit better at line 441. 
 
Lines 487-492 
Add this paragraph: Vaccenic acid (the predominant TFA from ruminants) is converted into rumenic acid (cis-9, trans-11 CLA). 
Endogenous synthesis from vaccenic acid (trans-11 18:1; VA), the major biohydrogenation intermediate produced in the rumen, 
is the predominant source of cis-9, trans-11 CLA in milk fat (Lock et al. 2004). Some animal studies show that vaccenic acid 
could have a beneficial effect on plasma triglycerides, LDL cholesterol and inflammation (Wang et al., 2008). 
 
Line 492 
Add to the following sentence “TFA do not serve any vital functions” this: “in the present state of scientific data”. If there are 
scientific publications attesting the absence of vital function of TFA, those references should be specified and added. 
 
Lines 494-495 
Replace with following sentence: “CLA is a generic term for a group of...” 
The use of term “natural PUFA” is confusing here as it suggests that CLA is not from natural origin. Cis-9, trans-11 CLA 
(rumenic acid) is from natural origin as it comes from bioconversion of trans-vaccenic acid through the action of ¿9 desaturases 
(Lock et al. 2004). By contrast, trans-10, cis-12 CLA is mainly produced by industrial processing. 
 
Line 497 
The different types of cholesterol transporters should be explained within this scientific draft opinion (HDL, VLDL…) 
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Line 502 
Cholesterol is not “also” synthesised by the body but “mainly” synthesised by the body. Moreover, this endogenous production 
is regulated by the dietary intakes in healthy subjects. 
 
Line 503 
Cholesterol also plays an important role in “lipid raft” mechanisms for protein sorting at various stages of the secretory and 
endocytic pathways (van Meer and Sprong, 2004). Cholesterol is involved in the synthesis of vitamin D, in cell membranes 
construction, and participates to the digestion process with the creation of specific acids (AFSSA, 2001). 
 
Line 508 
Phytosterols should be covered in this scientific draft opinion as EFSA recently released a scientific opinion on this topic. 
Association de la 
transformation 
laitière française  
2. Categories, 
structure and 
function 
Lines 414-424 
As for PUFA, additional information about structure and functions of SFA should be added. SFA are components of reserve 
triglycerides, glycerophospholipids and sphingolipids (membrane structure, myeline…). SFA cannot be considered as a whole, 
in terms of structure, metabolism and cellular functions. They have to be classified regarding their chain length: 
 
- Structure and function of short and medium-chain fatty acids : 
Short and medium-chain SFA have a specific metabolism. As reported by Bach and Babayan (1982), triglycerides made of 
C6:0, C8:0, C10:0 and C12:0 (MCTs) have unique physical, chemical, and structural characteristics and their modifications 
(structured lipids) make special lipids tools for solving certain medical problems. They are indeed 
hydrolyzed both faster and more completely than long-chain triglycerides (LCTs). The products of this hydrolysis are absorbed 
as fast as glucose. MCTs are oxidized rapidly in the organism and they have a very low tendency to deposit as body fat. 
As reported by Sengupta et al. (2006), short-chain butyric acid is likely to have a protective function against colon cancer 
(inhibition of tumour proliferation, apoptosis induction). Short and medium-chain SFA have a hypocholesterolemic effect at 
physiological dose. This effect of diets high in C8:0 and C10:0 was shown in humans by Hashim (1960). Mediumchain SFA 
have also a beneficial role in adiposis. The human study of Tsuji et al. (2001) suggests weight loss with a diet high in medium-
chain fatty acids. C6:0, C8:0 and C10:0 have a role in weight reduction, reduced fat deposition, decrease of VLDL production, 
hypocholesterolemic effect and antiviral role (Rioux et al., 2007; Legrand, 2008; Neyts et al., 2000). 
 
- Structure and function of long-chain fatty acids : 
Long-chain SFA are converted, in part, by ¿9-desaturation in monounsaturated fatty acids, but with significantly different 
effectiveness, increasing with the length of the chain. Stearic acid is the best substrate of ¿9-desaturase; and its conversion to 
oleic acid is important (Legrand, 2002; Legrand, 200;, Kritchevsky, 1988). The long-chain stearic acid has no negative effects 
on cholesterol level (Yu et al.; 1995) and, as presented by Kelly (2001), it has a beneficial effect on 
thrombogenic and atherogenic risk factors in males. 
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Myristic acid has a positive action through an increase of HDL-cholesterol when consume at usual level (Temme et al., 1997; 
Salter et al., 1998; Billet MA, 2000). Some SFA regulate specifically the activity of proteins by acylation (myristoylation, 
palmitoylation). Some studies show that, for example, myristic acid plays a key role through its ability to acylate proteins, a 
reaction which is called N-terminal myristoylation. Various examples of important cellular regulations where the intervention of 
myristic acid is proven have been described (Casey, 1995; Rioux, 2002; Peitzsch, 1993; Borgese, 1996). Myristic acid also has 
a function in the biosynthesis of EPA and DHA (Dabadie et al., 2005; Rioux et al., 2005) and of sphyngolipids (Beauchamp et 
al., 2007). C20:0, C22:0, C24:0 have a role in nervous structure (myelinisation) (Bourre et al., 1976a and b). 
 
Line 430 
No information is given to what extent humans can synthesise MUFA. 
 
Line 441 
The role of n-3/n-6 PUFA ratio should be addressed. Because n-3 and n-6 PUFA are metabolised to LCPUFA by the same 
enzyme system, excess dietary LA (n-6) may decrease the formation of DHA (LCPUFA n-3) from LNA. In addition, AA 
(LCPUFA n-6) formation is lower when excess (n-3) LNA is provided (Uauy and Castillo, 2003). Both n-3 and n-6 
LCPUFA are needed. However, inWestern diets with ample n-6 PUFA, the balance between tissue n-3 and n-6 LCPUFA might 
be sub-optimal (Lands, 2008). 
Association de la 
transformation 
laitière française  
3. Dietary sources 
and intake data 
Line 572 
The 18:1 TFA profiles of ruminant fat and hydrogenated vegetable oils show considerable overlap for many isomers. However, 
in contrast to ruminant fat non-palm-based-vegetable cooking oil can contain considerable amounts (0.4-2.7%) of C18:2 trans-
cis, cis-trans and trans-trans, and C18:3 trans (up to 2.7%) (Tang, 2002). Partially hydrogenated 
vegetable oils can contain 1–65% of TFA, of which isomers of elaidic acid (trans-9 and trans-10 18:1) are the two most 
common isomers. 
On the other hand, dairy products contain smaller amounts of TFA (1–8% of total fatty acids in milk fat), and the main isomer is 
vaccenic acid (trans-11 18:1). Humans can utilize vaccenic acid, in the endogenous synthesis of rumenic acid (cis-9, trans-11 
18:2), a fatty acid that may not have a negative effect on biomarkers of CVD risk. These two sources of TFA differ in their TFA 
isomer distribution and contribution to dietary intake, and, as a consequence, they also may have different biological effects 
(Chardigny et al., 2008) 
 
Lines 574 and 579 
The actual content of TFA in wt% of total fatty acids in animal fat and industrial fat should be included in the table 4. The 
concentration of industrial hydrogenated TFA may be as high as 60%, whereas the maximum content of natural TFA in 
ruminant fat is about 6% (Stender et al., 2008). This information should also be included in the text in connection of the table 4. 
 
Line 583 
In humans the conversion rate of trans-vaccenic acid to rumenic acid is around 19% (Turpeinen et al., 2002) to 20% (Lock et 
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al., 2005). 
 
Line 593 
In France, more recent data than Volatier (2000) and Deschamp (2005) is available. The INCA 2 study, for example, is more 
recent and could be used for this paragraph and the annexes (AFSSA, 2009b). 
 
Line 605 
The presented data are not representative of the whole population but rather for a specific target group of the population (elderly 
in Portugal for example). Besides, some methods (like FFQ) are not accurate. 
 
Line 618 
Data for the lowest intake in Portugal are not representative as it concerns the elderly population which is not an average but an 
extreme level. Besides, data are not very accurate as it is FFQ method. 
 
Line 627 
In France, according to the INCA 2 study, the SFA intake is more around 15% than 17% (AFSSA, 2009b). 
 
Line 669 
For those countries where separate intake data for industrial TFA and natural TFA are available, those should be provided 
(Craig-Schmidt, 2006; Jakobsen, 2007). 
 
Lines 676-678 
The available data shows that total TFA intake has decreased close to WHO recommendation of 1 E%. This is due to 
reformulation of food products containing TFA originating from partially hydrogenated vegetable fats and oils. In the same 
report, WHO also mentions that most TFA are contributed by industrially hardened oils and that to promote cardiovascular 
health, diets should provide a very low intake of TFA from hydrogenated oils and fats (Uauy et al., 2009). 
 
Lines 681-682 
Leave out “including … from other sources”. Replace by (after line 684): In most European countries with a high TFA intake 
(>2.5 g/d), the major part of the TFA was from industrial sources (Craig-Schmidt, 2006). 
 
Line 690 
“In adults, average intakes range from nearly 200 mg/day to 655 mg/day”. This is not an average intake (replace “average” by 
“extreme range”): 655 mg/day concerns only one study for adult men. 
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Association de la 
transformation 
laitière française  
3. Dietary sources 
and intake data 
Lines 509-519 
Why are a US database used and a European database reference not required? Dietary databases indeed exist in Europe, for 
example, CIQUAL 2008 in France. European intake data should be given, where possible. 
No distinction is made between short-chain, medium-chain and long-chain SFA (see table in comments to line 530). 
 
Lines 513 
The purpose of including table 2 is not clear. The selection of fats does not cover the major food groups in the diet. Other 
animal fats, such as tallow, fish fat and vegetable oils and margarine as well as shortenings for industrial processing should be 
included in table 2. Isomers of trans 18:1 should also be included in the table. 
 
Lines 514 
In table 2 the ratio n-6/n-3 PUFA should be added as this is relevant information for the fatty acid balance of fats and oils. 
 
Lines 520-529 
The Dutch NEVO table for fatty fish provides following data: total fat (g) 23.8, SFA 5.6, MUFA 10.5 PUFA 5.1 (high SFA fish 
(g total fat/g SFA) = Mackerel (30.7, 7.4); Eel (35, 8.7); Herring (14, 3.3); Salmon (14.2, 3.7)). These numbers differ quite a lot 
from the fatty fish data given in table 3. 
The basis for the selection of animal-derived food products is not entirely clear as, for example, eggs are missing. Besides, it is 
inconsistent to choose on one side only lean meat but on the other side present only standard butter and full fat milk. Semi-
skimmed milk should be used instead as it is the most consumed type of milk in Europe. In France, for example, 73% of the 
milk consumed is semi-skimmed milk (data from CNIEL, Centre National Interprofessionnel de 
l''Economie Laitière, 2007). 
 
Line 523 
Several dietary databases exist in Europe, for example, CIQUAL 2008 in France. Why was US data used? 
 
Line 530 
The main characteristic of milk fat is the variety of fatty acids it contains: more than 400 different fatty acids. Milk fat contains 
typically around 65-70% SFA and 30-35% unsaturated fatty acids. Amongst saturated fatty acids in milk fat, there are typically 
around 10-13% short- and medium-chain SFA and typically around 50-55% long-chain SFA, including 
palmitic (min. 20 – max. 32%), myristic (min. 8 – max. 15% ) and stearic acid (min. 6 – max. 13%). Milk fat is also relatively 
rich in the short-chain SFA C4:0 (butyric acid, min. 7 – max. 14%). 
 
Line 532 
The lauric acid content in milk fat is more than 10-fold lower than that of coconut oil and palm kernel oil. Therefore, milk fat 
can - compared to these fats - not be called lauric acid rich (see table 2). 
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Lines 538-539 
For example, dairy fat contains a substantial amount of oleic acid (Legrand, 2008). In the French population, dairy products are 
also the first contributor of MUFA according to the INCA 2 study (AFSSA, 2009b) 
 
Line 551 
Appreciable amounts of ALA can also be found in animal and dairy fat. In France, for example, dairy products are the first 
contributor to ALA intake according the SUVIMAX adult consumption survey (SUVIMAX is a French survey done between 
1994 and 2002 on 13 000 people) (Astorg et al., 2004) 
 
Line 568 
There should not be a focus only on C18:1. Ruminant trans fats may contain up to 20% C16:1 (Stender et al., 2008) which 
shows that profiles of ruminant TFA and industrially produced TFA differ quite substantially (Mendis et al., 2008; Shingfield et 
al., 2008; IDF Bulletin 377, 2002). 
 
Lines 569-570 
The TFA content of margarine and fat spreads may vary, depending on the proportion of partially hydrogenated oils used. 
However, recent analyses have shown that products with high levels of industrially produced TFA are still available on the 
market (Stender et al., 2008). The range of TFA content in wt% of total fatty acids of those products should be added. 
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Association de la 
transformation 
laitière française  
4. Overview of 
dietary reference 
values and 
recommendations 
Line 693 
It is not clear on which criteria the chosen dietary guidelines were selected. 
 
Line 705 
It is important to mention that some national recommendations in Europe such as in France take into account the different 
effects of TFA according to their sources (natural or industrial) (AFSSA, 2009a). 
 
Lines 749-756 
The 2009 Joint FAO/WHO Expert Consultation on “Fats and Fatty Acids in Human Nutrition” sets dietary recommendations 
for total fat at 20-35 E% (acceptable macronutrient distribution range) compared to the population 
nutrient intake goal of 15-30 E% mentioned in the 2003 WHO report (Elmadfa and Kornsteiner, 2009). For children from 2 to 
18 years, the recommendation for the total dietary fat intake is 30-40 E% depending on activity (Uauy and Dangour, 2009). 
 
Lines 771-775 
Different SFA should be considered independently as there is evidence to indicate that certain SFA might have a beneficial role. 
Recent data show that the different SFA in milk fat have different effects on health. Several studies show that short-chain and 
medium-chain SFA do not have a negative impact on the blood lipid profile. They are easily digested 
and metabolised differently in the body compared to longer chain fatty acids. Certain long-chain SFA such as stearic acid act 
neutral on the cholesterol level. Myristic acid has various physiological roles in the body such as protein metabolism and the 
synthesis of n-3 long-chain fatty acids (Lecerf 2009, Legrand 2008, Rioux and Legrand 2007). 
 
Lines 776-779 
Only the newest guideline available should be used. The Health Council of the Netherlands has published updated dietary 
reference intakes for fats and fatty acids for the Netherlands in 2006. It is stated there that “The average intake of saturated fatty 
acids in the diet needs to be cut from 13 to 14 per cent of energy intake to less than 10 per cent.” 
Therefore, the dietary reference value for SFA for adults is < 10 E%. A mentioning of “as low as possible” cannot be found in 
the summary of the Dutch guidelines. 
 
Line 780 
The 2009 Joint FAO/WHO Expert Consultation on “Fats and Fatty Acids in Human Nutrition” confirms that the intake of SFA 
should not exceed a maximum level of 10 E% (Elmadfa and Kornsteiner, 2009). 
 
Lines 918-921 
Within the Nordic Nutrition Recommendations (2004), a maximum intake of 10 E% of SFA plus TFA is given. It is also 
mentioned that the intake of TFA from hydrogenated oils should be as “low as possible” (table 1). 
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Association de la 
transformation 
laitière française  
4. Overview of 
dietary reference 
values and 
recommendations 
Lines 930-933 
In 2005, AFSSA has done a review of studies on the metabolism and toxicity of TFA and their impact on health. They 
concluded that consumption of total TFA above 2% of total energy intake resulted in a significantly increased risk of CVD. At 
that time, they did not really distinguish the origin – natural or industrial - of TFA. New data concerning TFA content of food, 
population intakes as well as new scientific results from epidemiological and clinical studies have 
conducted AFSSA to reassess its previous conclusions (AFSSA, 2009a). AFSSA considers that: 
- The estimated average intake of TFA in the French population (around 1%) is lower than the threshold of 2% of the total 
energy intake. This is true for adults as well as for children independently of age and sex. The intake is lower than in 2005. 
- It is necessary to pursue the improvement of the food composition tables with regard to TFA. The contribution of different 
types of food to TFA intake should be considered in more detail, in particular the cheapest priced products, discount products, 
catering and small-scale ("artisanal") products etc. which are insufficiently known at this moment. 
- Considering the total TFA intake, the origin of the TFA, natural or industrial, should be taken into account. Concerning TFA 
of natural origin; consumption levels in the French population (0.5-0.9% of the total energy intake) are lower than levels 
identified as not posing a risk of CVD (1.5% of the total energy intake); TFA from industrial origin that are present in foods 
only have a technological function. Thus, AFSSA encourages the efforts to reduce the use of industrial TFA in human food, in 
order to reduce the risk of exposure. 
As a conclusion, the recommendation is to decrease TFA intake only concerns industrial TFA. 
 
Lines 934-937 
Only the newest guideline available should be used. The Health Council of the Netherlands has published updated dietary 
reference intakes for fats and fatty acids for the Netherlands in 2006. It is stated there that “mono trans fatty acid intake needs to 
be brought down from 1 to 2 per cent to less than 1 per cent.” Table 6 (line 2915) has to be updated 
accordingly with the dietary reference value of TFA for adults < 1 E% (instead of “as low as possible”). There only the values 
for EPA and DHA refer to the 2006 Dutch guidelines. 
 
Line 938 
The 2009 Joint FAO/WHO Expert Consultation on “Fats and Fatty Acids in Human Nutrition” confirms that the UL for TFA 
from ruminants and industrially produced sources should be <1% E. This recommendation is done with the focus on industrial 
trans fat being reduced to 0.5 E%. Ruminant trans fat intake was not recommended to be lowered because the average intake is 
at approximately 0.5 E% (Elmadfa and Kornsteiner, 2009). 
  
Line 939 
The Nutritional Recommendations for the French Population (AFSSA, 2001) indicate that the limitation of exogenous 
cholesterol does not seem to be justified for the general population, as dietary cholesterol has only very limited impact on blood 
cholesterol. 
 
Line 944 
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The Nutritional Recommendations for the French Population (AFSSA, 2001) indicate that for older children and adolescents it 
does not seem reasonable to recommend fat intake below 30 E%.  
 
Line 969 
The French recommendations for SFA intake for children are 8 to 12 E% (AFSSA, 2001). 
 
Line 1032 
The French recommendations for cholesterol intake for children after 3 years of age are 300 mg/day (AFSSA, 2001). 
 
Line 1035 
The recent AFSSA report should be taken into account for the overview of dietary recommendations in the table (AFSSA, 
2009a). Thus, a distinction between natural and industrial TFA should be made. The WHO recommendation also concerns only 
TFA from industrial origin. This should be specified here (WHO, 2003). 
Association de la 
transformation 
laitière française  
5.1. Dietary 
requirements 
Line 1050 
In purpose of defining dietary guidelines for nutrients such as fat, a transparent and systematic review of the scientific data has 
to be performed. In the present scientific overview “5.1 Dietary requirements”, the method used for selecting scientific data is 
not presented. 
 
Line 1067 
As mentioned in lines 614-616 “In adults average total fat intakes ranged from less than 30 E% to 47 E%. About 43% of the 
reported average data were between 30 and 35 E%; 13% were 40 E% or higher”. This average value (in addition to lower and 
upper end) is also important as it shows that for adults the fat intake is over 30% in more than 50% of the average data reported. 
 
Line 1068-1070 
This sentence should also be in the summary. 
 
Lines 1072-1073 
“Such low fat intakes are highly unlikely in European countries”: If very low fat intakes are very unlikely in Europe, the lowest 
recommended fat intake should not include this kind of low consumption as it is not representative. Under 30 E% of fat 
consumption, a balanced intake of the different fatty acid is indeed hard to achieve (AFSSA, 2001). 
 
Lines 1072-1074 
Please provide references for this statement. It seems important to take into account that reducing total fat intake can lead to an 
increase in carbohydrate intake. A high intake of carbohydrates (refined, high glycemic index) may adversely affect insulin 
homeostasis, satiety and weight gain (Mozaffarian, 2005) and can lead to a high synthesis of palmitic acid. Recent studies show 
that a lower fat-diet but rich in carbohydrates stimulated saturated fatty acid synthesis - especially palmitate - at high rates 
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(Wilke et al., 2009). 
 
Line 1118 
In lines 1109-1112 a clear example is given that diets containing less than 30 E% from fat can have negative effects on weight 
and vitamin intake. Only in the STRIP Trial evidence is provided that 25-30% has no negative effect on growth and 
neurological development. Furthermore, none of the studies presented found negative effects of higher fat intake 
(>35%) compared to lower fat intakes. Why than come to 25% as appropriate (line 1118) and in the table “Summary of DRVs 
for fats” (line 2055) to an RI of 20-35% for >4 year olds? It appears more prudent to advise a level of 30-40%. 
 
Line 1121 
Previous studies have suggested that interventions to lower dietary fat content and improved fat quality lead to a compensatory 
increase in sucrose content. There has been a concern that dietary recommendations aimed at achieving a low saturated fat diet 
might lead to inappropriately increased sugar intake (Gibney et al., 1995) and some studies suggest that an inverse relationship 
exists between the intake of fat and simple sugars (Gibson, 1997; Lewis et al., 1992; 
Hackett, 1993). Other studies show that children with an intake of <30% of energy from fat consumed more carbohydrates 
(mainly sucrose) than those children whose diets contained >40% of energy from fat (Nicklas et al., 1992; Kennedy et al., 
1999a). 
Moreover, restriction of fat in children is questionable (Olson, 2000). There is no evidence that low-fat diets in childhood will 
prevent atherosclerosis in adulthood. The claim that low-fat diets are safe in childhood is based on observations over a too short 
time to establish safety. If growth and development of children are not changed with low-fat diets, the proof of long-term safety 
is not substantiated. 
 
Lines 1139-1142 
Editorial comment: “A LA intake of less … the form of LA.” is also taken from Hansen et al., 1963. The reference should be 
cited after that sentence. 
Outcome of the Public consultation on the Draft Opinion on  
Dietary Reference Values for fats 
 
34 EFSA Journal 2010; 8(5):1507 
ORGANISATION CHAPTER TEXT COMMENT TEXT 
Association de la 
transformation 
laitière française  
5.10. Cancer Line 1778 
It should be added that it concerns TFA from industrial origin as the author indicate that ”a high serum level of trans 
monounsaturated fatty acids, presumably reflecting a high intake of industrially processed foods, is probably one factor 
contributing to increased risk of invasive breast cancer in women.” 
 
Line 1780 
It is not “associated” as there is “limited evidence” (WCRF/AICR, 2007) 
 
Line 1781 
There are only “limited-suggestive evidence” and no association (WCRF/AICR, 2007). 
 
Line 1785 
The WCRF/AICR Expert Report “Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective” (five 
years of work driven by an independent panel of 21 world renowned scientists) is the most recent and complete synthesis of the 
available scientific data on this topic. It would be pertinent to refer to this report systematically. For example, WCRF judged 
that: 
There is “limited evidence-no conclusion” to support a link between fats and oils or fatty acids composition and breast cancer 
risk, whatever the menopausal status. 
There is “limited evidence-suggestive” that butter increases lung cancer risk 
There is limited-suggestive evidence that foods containing animal fats increases colorectal cancer risk (not any word about olive 
oil) 
A new study from China suggests that increasing the intake of n-3 fatty acids, and decreasing intakes of n-6, could reduce the 
risk of colorectal cancer. The highest dietary ratio of n/3-n-6 was associated with a 95 per cent increase in the risk of women 
developing colorectal cancer, according to results of a study with 73.242 Chinese women participating in the Shanghai 
Women''s Health Study (Murff et al., 2009). 
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Association de la 
transformation 
laitière française  
5.2. Serum lipids 
and lipoproteins 
Line 1223 
In purpose of defining dietary guidelines for nutrients such as fat, a transparent and systematic review of the scientific data has 
to be performed. In the present scientific overview “5.2 Serum lipids and lipoproteins” the method used for selecting scientific 
data is not presented. 
 
Lines 1223-1228 
The relevance of lipoprotein markers should be mentioned and discussed in relation to their relevance for hard endpoints. 
A randomized clinical trial (RCT) that shows a statistically significant benefit in disease mortality rather than a benefit for a 
surrogate endpoint is the pinnacle of evidence–based medicine. However, this is not always feasible. Cholesterol markers have 
been used as surrogate endpoints to study the effect of dietary fat in RCTs - especially as a marker for CVD risk. 
For many years, the only biomarkers of CHD risk recognized by health authorities have been total cholesterol and LDL 
cholesterol. Recently, the Expert Panel of the WHO Scientific Update on trans fatty acids pronounced the ratio of total 
cholesterol to HDL cholesterol as the “best single lipid predictor of CHD risk” (Uauy et al., 2009). 
Extensive research has changed the simplistic view of atherosclerosis (the major underlying cause for CHD (Das, 2007)) as a 
disorder of pathological lipid deposition to a more complex concept of an ongoing inflammatory response (Stoll and Bendszus, 
2006). Therefore, effects on inflammatory markers are often included in newer RCTs. 
  
Lines 1231-1234 
No references are provided for this statement. 
 
Lines 1229-1236 
The conclusion of 5.2.1 is missing. According to EDA interpretation, these results show that at low intake of SFA (<10 E%) 
decreasing total fat intakes worsen the lipid profile leading to higher atherosclerosis risk (increases the total/HDL cholesterol 
ratio and TG, decreases serum concentrations of HDL cholesterol) (See also Mensink et al., 2003). 
The decrease of fat intake in men to 28% or 24% at stable body weight, leads to a decrease of LDL cholesterol but also to an 
decrease of HDL cholesterol, an increase of TG and LDL small and dense) (Lefebvre et al., 2005; Wood, 2006; Dreon, 1999). 
Association de la 
transformation 
laitière française  
5.2. Serum lipids 
and lipoproteins 
Line 1237 
Not only long-chain, but also medium-chain and short-chain fatty acids should be discussed for disease risk. Short and medium-
chain fatty acids are not transported via the chylomicron system, and are not linked to changes is lipoprotein profiles. This is 
also relevant for paragraphs 5.8 and 6.2. Their effects on CAD and cholesterol have not been a dietary issue (German and 
Dillard, 2004). There is some evidence that short and medium-chain fatty acids have antiviral and antitumor activity (German 
and Dillard, 2004). 
SFA cannot be considered as a whole, in terms of structure, metabolism and cellular functions (Parodi, 2009). Short and 
medium-chain SFA have a hypocholesterolemic effect at physiological dose (this effect of diets high in C8 and C10 was shown 
in humans by Hashim (1960). 
In a recent meta-analysis, the effects of the individual SFA on the serum lipoprotein profile have been estimated (Mensik et al., 
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2003). Iso-energetic replacement of carbohydrates with lauric, myristic and palmitic acids all resulted in increased total, LDL 
and HDL cholesterol concentrations. But as the cholesterol-raising effects of lauric acid were proportionally higher on HDL 
than on LDL cholesterol, replacement of carbohydrates by lauric acid resulted in a significantly lower total / HDL cholesterol 
ratio (The ratio of total to HDL cholesterol is a more powerful predictor of CHD risk than either total or LDL cholesterol levels 
(Stampfer et al., 1991)), which suggests a decrease in atherosclerotic risk. 
Stearic acid had the smallest effect on HDL cholesterol but lowered total and LDL cholesterol, and thus also decreased the total 
/ HDL cholesterol ratio. Palmitic acid is the only fatty acids which increased the total / HDL cholesterol ratio (Mensink et al., 
2003), fact confirmed in other studies (Salter et al., 1998; Billet MA, 2000). Stearic acid decreases LDL 
cholesterol, similar effect that oleic acid (Mensink, 2005). 
No differences between the effects of the different SFA on fasting serum triacylglycerol concentrations were detected (Mensink, 
2003) (see especially figure 3 of this study). 
Myristic acid has no hypercholesterolemic effect but has rather positive action through an increase of HDL-cholesterol when 
consume at usual level (Temme et al., 1997; Salter et al., 1998; Billet MA, 2000; Dabadie, 2005; Tholstrup et al., 1994 and 
2003b). Negative effects of myristic acid that have been described were only the result of massive doses that 
are well above the usual consumption (Staiger K et al., 2006). 
 
Lines 1238-1241  
The term “mixture” used here leads to an oversimplification and does not indicate which SFA are concerned. EFSA should 
indicate what the SFA involved are. Besides, SFA cannot be considered as a whole, in terms of structure, metabolism and 
cellular functions. Doses, population and references should also be indicated to support this statement. 
 
Line 1251 
The analysis of sub fractions in subjects given low carbohydrate diets with either higher or lower content of SFA shows that the 
saturated fat intake results in an increase in the larger buoyant LDL rather than the smaller LDL particles. The small, dense 
LDL particles have been associated with increased risk of CVD, whereas large LDL particles have not (Krauss, 2006). 
Mozaffarian et al. (2004) also show that in postmenopausal women with relatively low total fat intake, a greater saturated fat 
intake is associated with less progression of coronary atherosclerosis. The proposed hypothesis is that a decrease in fat intake 
leads to worsen the lipid profile: decrease of HDL cholesterol, increase of TG and B-phenotype of LDL (small and dense LDL) 
(Dreon et al., 1998; Dreon et al., 1999; Krauss et al., 2006; Lefebvre et al., 2005). 
Association de la 
transformation 
laitière française  
5.2. Serum lipids 
and lipoproteins 
Line 1314 
However, the intake of ruminant TFA is low in most populations. In the French diet, for example, the natural TFA intake ranges 
from 0.5-0.9% of the total energy intake (AFSSA, 2009a). This amount is far lower than the 3.7% tested in the Motard-Bélanger 
study (2008). The French intake values have been established by a consumption survey, INCA2 (2006- 
2007), on more than 4000 persons (AFSSA, 2009b). 
 
Lines 1326-1327 
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“The intervention studies do not provide evidence that a mixture of CLA isomers, cis-9, trans-11 CLA, or trans-10, cis-12 CLA 
have an impact on the serum lipoprotein profile.” However, as explained in this scientific opinion on line 1319-1321 some 
studies are showing that cis-9, trans-11 is more favourable as compared with trans-10, cis-12 CLA on lipoprotein 
profile. The conclusion should be also that more studies are needed on purified CLA isomers. 
 
Line 1340 
Kratz also conducted a systematic review on animal and human (intervention and observational) studies. Based on the results of 
these studies, the author found that an increase in dietary cholesterol intake resulted in only a minimal increase in the total/HDL 
cholesterol ratio, as most subjects can effectively adapt to higher levels of cholesterol intakes (Kratz, 2005). 
 
Lines 1342-1344 
“Under iso-energetic conditions, the most favourable lipoprotein profile to lower atherosclerotic risk is achieved when a mixture 
of SFA and TFA is replaced by a mixture of oleic acid, linoleic acid and fish fatty acids. These effects are dosedependent”. 
Those sentences should be removed from the scientific draft opinion: “mixture” does not mean anything and as shown in our 
previous comments it is not possible to consider SFA as a whole in terms of structure, metabolism and cellular functions. The 
same remark can be made for TFA: the difference should be made between industrial or natural TFA. The intake of ruminant 
TFA is indeed low in most populations. In the French diet, for example, the natural TFA intake ranges from 0.5-0.9% of the 
total energy intake (AFSSA, 2009a). This amount is far lower than the 3.7% tested in the Motard-Bélanger study (2008). The 
French intake values have been established by a consumption survey, INCA2 (2006-2007), on more than 4000 persons 
(AFSSA, 2009b). 
 
Lines 1341-1346 
The effect of stearic acid is neutral (Yu et al., 1995). The effects are also dose dependant. Myristic acid has no 
hypercholesterolemic effect but has rather positive action through an increase of HDL-cholesterol when consumed at usual level 
(Temme et al., 1997; Salter et al., 1998; Billet MA, 2000).  
Consumption of naturally occurring TFA at levels found in regular diets does not contribute to elevated risk of cardiovascular 
disease (see the European Parliament study, 2008). 
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Association de la 
transformation 
laitière française  
5.2. Serum lipids 
and lipoproteins 
Lines 1253-1254 
Cis-MUFA had similar effects on serum total cholesterol concentrations as carbohydrates in Hegsted et al. (1965). Thus, many 
researchers compared the effects on MUFA, in particular oleic acid, and carbohydrates on the distribution of cholesterol over 
the different lipoproteins (Grundy, 1986; Mensink and Katan, 1987). From these studies it appeared that effects of oleic acid 
and carbohydrates are indeed similar on total cholesterol concentrations, but that oleic acid increased HDL cholesterol and 
lowered VLDL cholesterol and triacylglycerol concentrations (Thijssen and Mensink, 2005). 
 
Line 1266 
Please provide reference for this statement 
 
Lines 1281-1282 
Remove: “like diets containing mixtures of SFA“. This sentence is not relevant in this part about TFA. Besides, the term 
“mixture” is not precise and does not mean anything about which fatty acids are concerned. 
 
Line 1284 
Clarke (2009) is not an intervention study. It is just a simulation. 
 
Lines 1294-1296 
Please provide reference for this statement. 
 
Lines 1297-1298 
“In most of the human intervention studies reviewed above, the effects of trans-MUFA from hydrogenated vegetable oils were 
assessed”. This sentence should be the introduction of the paragraph as there are two parts here, one about industrially produced 
TFA, the other one about ruminant TFA, starting line 1298. 
 
Lines 1298-1299 
Extreme high intakes of ruminant TFA (3.7 E% or 5 E%) indeed appear to have adverse effects on blood lipid profiles. 
However, these high levels of ruminant TFA cannot be reached with a normal diet. The habitual intake of ruminant TFA is far 
below this amount (Craig-Schmidt, 2006; Willett and Mozaffarian, 2008). On the other hand, ingesting 20-40g (> 5 E%) 
industrially produced TFA is not at all unrealistic (Stender et al., 2008). Why is this not mentioned? 
 
Line 1301 
“3.7% of energy from TF” This high percentage does not reflect the usual intake in European countries. In France, TFA intake 
from natural origin represent only 0.5-0.9% of the total energy intake (AFSSA, 2009a). 
 
Line 1307 
The European Parliament study on TFA (2008) aimed at providing background information to Members of the European 
Outcome of the Public consultation on the Draft Opinion on  
Dietary Reference Values for fats 
 
39 EFSA Journal 2010; 8(5):1507 
ORGANISATION CHAPTER TEXT COMMENT TEXT 
Parliament on TFA. The report highlighted the fact that although there was considerable scientific evidence showing a causative 
link between intake of industrially produced TFA and cardiovascular disease, scientific studies also revealed 
that consumption of naturally occurring TFA at levels found in regular diets do not contribute to elevated risk of cardiovascular 
disease. Therefore the authors mentioned that it is important to make a clear distinction between naturally occurring and 
industrially produced TFA when developing possible guidelines for action to reduce the intake of TFA. Any legal restrictions 
should be limited to industrially produced TFA. 
 
Line 1309 
Remove “like diets containing mixtures of SFA“. This sentence is not relevant in this part about TFA. Besides, the term 
“mixture” is not precise and does not mean anything about which fatty acids are concerned. 
 
Line 1311 
“Consumption of diets containing trans-MUFA also…” “Also” has to be removed as TFA and some SFA do not have the same 
effects on HDL cholesterol. 
 
Lines 1312-1314 
“The available evidence indicates that TFA from ruminant sources have similar adverse effects on blood lipids and lipoproteins 
to those from industrial sources”. This is true only at very high levels of TFA intake, corresponding to diets with 3.7% of 
energy from TFA - indeed 9 litres of semi-skimmed milk, 4 kg of yoghurt or 800g of camembert cheese – as 
the average content of TFA in milk fat is 5.39% of total fatty acids (AFSSA, 2005). 
Association de la 
transformation 
laitière française  
5.3. Haemostatic 
function 
Line 1362 
If the studies are far from consistent, those sentences should be reformulated. Suggestion: “Although C12:0 to C16:0 SFA have 
been suspected to increase factor VII levels as compared to stearic acid (C18:0), the studies were far from consistent and no 
conclusion can be made. Moreover, in one study, post-prandial increases in activity of factor VII were less after consumption of 
meals rich in SFA, especially stearic acid, than after a consumption of meals enriched with unsaturated fatty acids (Thijssen and 
Mensink, 2005; Tholstrup et al., 2003a).” 
 
Line 1364 
Relative to oleic acid, and unlike to n-6 PUFA, either medium-chain SFA or lauric or myristic or palmitic acids did not affect 
collagen-induced whole blood aggregation. Furthermore, ADP-induced platelet aggregation was not changed by medium-chain 
saturated fatty acids or myristic acid (Thijssen and Mensink, 2005; Temme et al., 1998). 
 
Line 1375 
According to the Thijssen and Mensik (2005), thromboxanes (TX) and prostaglandins (PG), two eicosanoids, play an important 
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role in the haemostatic balance. Both types of eicosanoids are synthesised from the C20 fatty acids, arachidonic acid (C20:4n-6) 
and EPA (C20:5n-3), after release from membrane phospholipids. 
Eicosanoids of the n-2 series, such as TXA2, are synthesized from the n-6 arachidonic acid in platelets, while prostaglandins I2 
(PGI2) is synthesised in the vascular endothelium. TXA2 is a potent vasoconstrictor and a stimulus for platelet aggregation, 
whereas PGI2 has opposite effects. Eicosanoids of the n-3 series such as TXA3 and PGI3 are principal metabolites of the n-3 
fatty acid EPA. TXA3 is less 
active than TXA2, meaning than the vasoconstrictor effects due to n-6 fatty acids is higher than the ones induced by the n-3 
fatty acids. The anti-aggregation effects of PGI3 and PGI2 are however comparable. 
Furthermore, n-6 PUFA increased urinary 11-dehydro-TXB2 excretion compared with saturated and monounsaturated fatty 
acids, which seemed to reflect an ADP-induced platelet aggregation (Lahoz et al., 1997; Thijssen and Mensik, 2005). Increased 
ADP-induced platelet aggregation is associated with increased atherosclerotic risk (Elwood et al., 1991; Thijssen and Mensik, 
2005). 
Association de la 
transformation 
laitière française  
5.4. Inflammation 
and immne 
function 
Line 1422 
Additional information: A randomized, controlled, 3-diet, 3-period crossover study was published in 2007 in the American 
Journal of Clinical Nutrition (Zhao et al., 2007). Hypercholesterolemic subjects (n=23) were assigned to 3 experimental diets: a 
diet high in ALA (6.5 E%), a diet high in LA (12.6 E%), and an average American diet for 6 weeks. Results 
showed that increased intakes of dietary ALA elicited anti-inflammatory effects by inhibiting pro-inflammatory cytokine 
production (IL-6, IL-1ß and TNF-a) in cultured PBMCs (Peripheral Blood Mononuclear Cells). Changes in PBMC ALA and 
EPA were associated with beneficial changes in TNF-a release. ALA could thus have some effects of reduction in 
the production of inflammatory cytokines. 
 
Line 1426 
This line correctly reports that TFA from hydrogenated sources (not ruminant sources) have been linked to adverse effects on 
inflammatory profile in epidemiological studies. Why is this not mentioned in the overall summary (line 129-146)? 
 
Lines 1434-1439 
While it is mentioned in the conclusion that no consistent picture has emerged on effects on n-6 PUFA, no references are 
provided for that in part 5.4.1. 
Association de la 
transformation 
laitière française  
5.7. Body weight 
control and energy 
balance 
Lines 1583-1593 
Profound quantitative and qualitative changes have taken place in the last four decades in the Western industrialised world, 
particularly the rising intake of n-6 and declining intake of n-3 PUFA. A recent review (Ailhaud et al., 2008) suggests that this 
imbalance in PUFA intake is an emerging risk factor contributing in addition to long-term net positive 
energy balance. The authors propose that several aspects of unbalanced PUFA metabolism conspire to stimulate fat cell 
formation and to increase the prevalence of overweight and obesity such as low n-3 PUFA intake, overestimation of linoleic 
acid requirement and significant increase in the LA:LNA ratio. Thus, nutritional recommendation should not stress 
the n-6 PUFA over consumption, and promote instead a good equilibration between n-3 PUFA and n-6 PUFA. 
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Line 1618 
It is important to add in the conclusion that based on some recent studies, nutritional recommendation on n-6 PUFA intake 
should not promote their over consumption but rather a good balance between n-3 PUFA and n-6 PUFA (Ailhaud et al., 2008). 
Association de la 
transformation 
laitière française  
5.8. Cardiovascular 
disease 
Line 1626 
General comment on this part about “Cardiovascular disease: the analysis on the effect of lipids on cardiovascular disease is 
quite poor compared to the analysis made on serum lipids and lipoproteins made in part 5.2.  
For example there is almost no data on stroke, which is actually a part of cardiovascular diseases and should be considered. 
Ecological studies suggest that saturated fat (mostly animal fat) is inversely associated with stroke. Some studies suggest that 
high intake of PUFA could have a negative effect on oxidation process and inflammatory mechanism involved in the stability of 
the plaque (Thies et al., 2003). 
Epidemiological studies show that saturated fat is either associated to a significant decreased risk of stroke (Framingham Study 
– ischemic stroke, Gilman, 1997; Nurses‟ Health study – hemorrhagic stroke, Iso, 2001; Japanese cohort of 4500 subjects - 
hemorrhagic stroke, Iso, 2003) or no related to the risk of stroke (Health professional Study, He, 2003) 
 
Line 1632 
What are the selection criteria for selecting only those four studies? 
 
Line 1628 
Concerning total fat, a reduction in fat intake is frequently construed as a recommendation in cardiovascular disease prevention. 
However, the question is now increasingly subject to debate (Mozaffarian et al., 2004). 
 
Line 1644 
Howard et al. (2006) also shows that no benefit was observed in terms of coronary disease, cardiovascular or cerebrovascular 
disease with the decrease of fat intake and decrease of SFA to 9.5%. On the contrary, for some women with cardiovascular 
history, there was an increase of their cardiovascular disease risk linked to a decrease of lipids and SFA 
intake. 
Association de la 
transformation 
laitière française  
5.8. Cardiovascular 
disease 
Line 1716 
The words “of SFA” should be deleted as not all SFA have the same effects. TFA should be replaced by “industrial TFA”. All 
research (either epidemiological or interventional studies) tends to show that in healthy people diets low in SFA were 
unsuccessful in reducing the incidence of cardiovascular disease. 
In this context, the recommendation “as low as possible” has neither scientific value nor scientific justification. 
 
Line 1720 
The genetic aspect should be included in this scientific draft opinion. There is a wide inter-individual variability in the response 
to dietary changes since genetic polymorphisms modulate the effects of nutrients. In terms of cardiovascular diseases, 
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polymorphisms at multiple genes have been associated with differential effects in terms of lipid metabolism. 
Many examples can be given. A habitually low saturated fat diet is associated with a beneficial lipoprotein profile only among 
homozygotes of the APOC3 promoter 455T-625T polymorphism. (25% of the population) (Brown S et al., 2003). 
Another example of a well-documented nutrigenetic interaction is that of the apoAI gene which is a major structural and 
functional component of HDL cholesterol. A significant interaction between this polymorphism and PUFA intake in 
determining plasma HDL cholesterol concentration has been demonstrated in women in the Framingham Study. In carriers of 
the A allele, higher PUFA intakes (>8 E%) were shown to be associated with higher HDL cholesterol, whereas in G/G 
homozygotes, the opposite effect was observed (Lovegrove and Gitau, 2008). 
The concept of gene-environment interactions modulating common disease risk factors is now well founded and should be 
taken into consideration for more individually targeted approaches to disease prevention and therapy (Ordovas, 2009). 
Association de la 
transformation 
laitière française  
5.8. Cardiovascular 
disease 
Lines 1627-1644 (last part of our comments on those lines) 
 
In conclusion, the results of the studies described above tend to show that dietary intervention in healthy people of diets low in 
total fat or SFA were unsuccessful or provided insufficient evidence in reducing the incidence of cardiovascular disease (for 
more details, see also Ravnskov, 1998; Ramsden et al., 2009). It also appears that in coronary heart disease, the 
overconsumption of n-6 PUFA must not be encouraged since it can increase plaque instability (Lecerf, 
2009). 
A recent systematic review of 146 prospective cohort studies and 43 RCTs from Europe, the US and Asia, investigating dietary 
factors related to CHD carried out by Mente et al. (2009) found insufficient evidence of an association between intake of total 
fat, SFA, PUFA, milk, meat and eggs and risk of CHD, but found protective associations for intakes of 
MUFA, fish, n-3 fatty acids, folate, whole grains, vitamins E and C, beta carotene, alcohol, fruit and fibre. A harmful 
association was found for TFA and foods with a high glycemic index. One of the conclusions stated “it is unlikely that 
modifying the intake of a few nutrients or foods would substantially influence coronary outcomes.” 
In a review paper from Parodi (2009), 24 reports of 11 cohorts were the only prospective cohort studies found which evaluated 
the association between SFA and risk of CHD. Among these, 4 studies found a significantly positive association between SFA 
intake and risk of CHD, 3 found no association and 2 found a negative association. Overall, 
these results are inconsistent and do not provide convincing evidence of an association between SFA and risk of CHD. 
The evidence extracted by Gibson et al. (2009) from 12 major prospective cohort studies involving more than 280.000 subjects 
does not consistently demonstrate a direct relationship between the intake of dairy foods and increased risk of CVD (CHD, IHD 
or myocardial infarct), even though it is recognized that dairy fat is a contributor of saturated fat intake and excess saturated fat 
intakes has been associated with a higher incidence of CVD. The authors noted that “the studies available for examining the 
effect of dairy food consumption on CHD are too varied in design, quality and dietary assessment methodology to evaluate the 
nature of the relationship.” 
From a meta-analysis of 15 cohort studies carried out by Elwood et al. (2008), the relative risk of stroke or heart disease in 
subjects with high milk or dairy consumption was 0.84 and 0.79 respectively, relative to the risk in those with low consumption. 
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Association de la 
transformation 
laitière française  
5.8. Cardiovascular 
disease 
Lines 1627-1644 (Part 2) 
Elmadfa and Kornsteiner (2009) stated that “The meta-analysis by Skeaff and Miller (2009) demonstrated that the relative risk 
of CHD death in the highest (14–18 E%) category of SFA consumption was not significantly different from that in the lowest 
(7–11 E%) category. High compared with low SFA consumption was not significantly related with 
diverse risk factors of CHD events.” 
Skeaff and Miller (2009) carried out a very recent and exhaustive review of cohort studies and controlled trials of dietary fats 
and CHD mortality or morbidity (search in the Cochrane Library, Cochrane reviews, article databases, systematic reviews, 
meta-analysis, etc.). 28 individual cohort studies were selected, in which there were about 6,600 CHD deaths 
amongst 280,000 participants during approximately 3.7 million person-years of follow-up. 
The authors state on p. 191: “According to the classic „diet-heart‟ hypothesis, high intake of SFAs and cholesterol and low 
intake of PUFAs increase serum cholesterol levels and risk of CHD. However, few within-population studies have been able to 
demonstrate consistent associations with any specific dietary lipids, with the exception of trans fats and n-3 fatty acids. The 
available evidence from cohort and randomized controlled trials is unsatisfactory and unreliable to make 
judgment about and substantiate the effects of dietary fat on risk of CHD.” Continuing further it is mentioned that 
“Furthermore, the evidence from cohort studies of dietary intake of fats and CHD is mostly unreliable (with few exceptions) 
because most studies have ignored the effects of measurement error and regression dilution bias.” 
According to the results of this study 
- Total fat: 
. Intake of total fat was not significantly associated with CHD mortality, with a RR for highest compared with the lowest 
category of 0.94 (95% CI of 0.74-1.18, p=0.583); 
. Intake of total fat was also unrelated to CHD events (RR 0.93, 95% CI 0.84-1.03, p=0.177); 
. No significant association of total fat intake with CHD mortality (RR 1.06, 95% CI 0.88-1.28, p=0.517) or CHD events (RR 
1.02, 95% CI 0.98-1.05, p=0.404) per 5% total energy increment in total fat intake ; 
. Overall, the mean or median total fat intake in all cohort studies varied from 27-47% total energy. 
- SFA: 
. Intake of SFA was not significantly associated with CHD mortality (RR 1.14, 95% CI 0.82-1.60, p=0.431) for highest 
compared to lowest category of SFA intake 
. SFA intake was not significantly associated with CHD events (RR 0.93, 95% CI 0.83-1.05, p=0.269 for high vs. low category) 
. No significant association of SFA intake with CHD death (RR 1.11, 95% CI 0.75-1.65, p=0.593) per 5% total energy 
increment in SFA intake 
. Overall, the mean or median SFA intake in all cohort studies varied from 9-20% total energy. 
- MUFA: 
No significant association with CHD mortality / CHD deaths or CHD events 
- PUFA: 
. Intake of PUFA was strongly significantly associated with CHD mortality with a RR 1.25, 95% CI 1.06-1.47, p=0.009) for 
highest compared to lowest category 
. High compared with low PUFA intake was not associated with CHD events (RR 0.97, 95% CI 0.74-1.27, p=0.825) for highest 
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compared to lowest category 
. Significant lower risk of CHD events (RR 0.84, 95% CI 0.70-1.00, p=0.049) per 5% total energy increment in PUFA intake, 
but not with CHD mortality. 
Moreover, the results of this review showed that the RR of fatal CHD was not reduced by either low-fat diets or diets with a 
high polyunsaturated to saturated fat ratio (P/S ratio). 
Association de la 
transformation 
laitière française  
5.8. Cardiovascular 
disease 
Lines 1645-1694 (first part of our comments on those lines) 
 
Two other clinical trials of dietary supplementation with n-3 fatty acids exist: the DART and Lyon Heart studies, which are both 
secondary prevention trials. 
The DART study (Burr et al., 1989; Burr et al., 2007) was conducted in 2003 men after myocardial infarction, with 3 treatment 
arms: reduction of SFA intake to 30% energy with a P/S ration of 1:0, an increase of fatty fish (200-400 g/week), or an increase 
in cereal fibres to 18g/d. Advice to modify fat intake did not confer any obvious benefit, perhaps partly because it entailed 
greater changes in dietary habits and was therefore inadequately followed. Indeed, the advice about dietary fat did not achieve 
the expected differences in intakes, partly because of incomplete compliance with the advice and partly because of spontaneous 
changes in the control group. After 2 years, total fat accounted for 31.4% and 35.2% in the fat-advice and the non-fat advice 
groups respectively, and the corresponding mean P/S ratio were 0.8 and 
0.4, although patients had regularly nutritional recommendations and advice given by a professionals of dietetics. 
However, the fish advice was associated with a 29% reduction in overall mortality, and this result was unaffected by adjusting 
variables at baseline. 
The Lyon Heart study (de Lorgeril et al., 1994; Renaud et al., 1994; de Lorgeril et al., 1999) was a randomized secondary 
prevention trial aimed at testing whether a Mediterranean type diet may reduce the rate of recurrence after a first myocardial 
infarction. The intervention diet was rich in a-linolenic acid (0.8% versus 0.3% in the control group) and provided around 30 
E% from fat, 8 E% from SFA (12% in the control group), 13 E% from MUFA (10% in the control group) and <4 E% from 
linoleic acid (n-6 LA) (>5% in the control group). The study lasted over a 5-year period and was conducted on 302 patients, 
compared to 303 control patients. There was also an additional follow-up after the 5 initial 
years for 46 months. The recurrent myocardial infarction, all cardiovascular events, and cardiac and total death were 
significantly decreased by > 70% in the group consuming the Mediterranean diet. These protective effects were not related to 
serum concentrations of total, LDL or HDL cholesterol. With regard to any association between the plasma concentration of 
major fatty acids and recurrence, only 18:3 n-3 and 22:6 n-3 tended to be inversely associated with recurrence of outcomes 
(p=0,11 and p=0,16 respectively) for myocardial infarction and cardiovascular deaths (no significance for other outcomes as 
heart failure, stroke, pulmonary or peripheral embolism, angina, thrombophlebitis). 
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Association de la 
transformation 
laitière française  
5.8. Cardiovascular 
disease 
Lines 1645-1694 (secont and last part of our comments on those lines) 
 
Skeaff and Miller (2009) conducted a very recent and exhaustive review of cohort studies and controlled trials of dietary fats 
and CHD mortality or morbidity (search in the Cochrane Library, Cochrane reviews, article databases, systematic reviews, 
meta-analysis, etc.).  
Results found that: 
 
- ALA: 
No association with intake of ALA and CHD death (RR 0.84, 95% CI 0.53-1.31, p=0.439) or CHD events (RR 1.05, 95% CI 
0.78-1.42, p=0.730) for highest compared to lowest category of intake  
- LC PUFA: 
. For cohort studies on n-3 LC PUFA, there were about 5,361 deaths amongst 256,000 participants during 4 million person-
years of follow-up. 
. Intake of n-3 LC PUFA or fish consumption were strongly associated with CHD mortality (RR 0.82, 95% Cl 0.71-0.94, 
p=0.006) for the highest compared with lowest category. 
. Intake of n-3 LC PUFA was not associated with decreased risk of CHD events, non fatal CHD, total myocardial infarction, 
sudden cardiac death. 
. For meta-analysis of randomized controlled trials of n-3 LC PUFA or fish and CHD, there were about 1,300 CHD deaths 
amongst 37,000 participants during 140,000 person-years of follow-up. Depending on the inclusion or exclusion of DART 
. 2 study, risk ratios of the different parameters were totally changed (either a reduction or a non significance), limiting the 
interpretation. 
Association de la 
transformation 
laitière française  
5.8. Cardiovascular 
disease 
Lines 1695-1700 
Non-conjugated polyunsaturated TFA should be addressed in relation to disease risk. There is evidence that polyunsaturated 
TFA (trans 18:2) could pose a higher risk for ischemic heart disease and sudden cardiac death and CHD than monounsaturated 
TFA (trans 18:1) (Lemaitre et al., 2006; Baylin et al., 2003) These polyunsaturated TFA are 
from industrial sources, and can only be found in trace levels in ruminant fats. 
The WHO experts come to a different conclusion. They do make a difference between ruminant and industrially produced TFA: 
“The current growing body of evidence from controlled trials and observational studies indicates that TFA consumption from 
partially hydrogenated oils adversely affects multiple cardiovascular risk factors and contributes 
significantly to increased risk of CHD events. Although ruminant TFAs cannot be removed entirely from the diet, their intake is 
low in most populations and to date there is no conclusive evidence supporting an association with CHD risks in the amounts 
usually consumed. In contrast, TFA produced by partial hydrogenation of fats and oils should be considered industrial food 
additives having no demonstrable health benefits and clear risks to human health. The WHO Scientific 
Update on TFA concludes that restaurants and food manufacturers should avoid using industrially derived TFA in food 
products and that governments should take steps to support alternative fats or oils for TFA replacement. The evidence on the 
effects of TFA and disease outcomes strongly supports the need to remove PHVO from the human food supply.” (Uauy et al., 
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2009). 
The limited data suggest that the experimental effects of ruminant and industrial TFA are similar when consumed in similar 
quantities, but very few persons consume such high levels of ruminant TFA, and observational studies do not support adverse 
CHD effects of ruminant TFA in amounts actually consumed (Mozaffarian et al., 2009). 
AFSSA concluded it its recent report that TFA from natural origin do not present a risk in terms of cardiovascular disease as 
they are consumed at very low level (0.5-0.9% of the total energy intake) (AFSSA, 2009a). 
 
Lines 1701-1712 
Incidence of nonfatal and fatal CHD and stroke corresponding to the daily egg consumption was determined in 37,851 men and 
80,082 women in 2 large prospective cohort studies (the Health Professionals Study and the Nurses Health study). Results 
showed no evidence for an overall significant association between egg consumption and risk of CHD and stroke, after 
adjustments for age, smoking and other potential CHD risk factors. The authors found a significant association between egg 
consumption and CHD and stroke in only a subgroup of diabetic patients (thus with abnormalities in lipid metabolism). 
Kratz also conducted a systematic review on animal and human (intervention and observational) studies. A large number of 
observational studies (Honolulu Heart Study, the Puerto-Rico Heart Health Program, the Lipid Research Clinics Prevalence 
Follow-up Study, the Nurses Health Study, the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study and the Hawaii 
Cardiovascular Study) did not find any relationship between the intake of dietary cholesterol and the risk 
of CHD. Moreover, some other studies which primarily found a potential positive link between cholesterol intakes and CHD 
noted that the results were no longer significant after adjustments for consumption of vegetable, proteins and fibres, since they 
usually go hand in hand in individual diets (Kratz, 2005). 
Association de la 
transformation 
laitière française  
6.1. Total fat Line 1831 
As mentioned in this scientific draft opinion (lines 1068-1070), “Very low fat diets tend to increase the risk of an insufficient 
intake of PUFA, can impair the absorption of fat-soluble vitamins and be associated with insufficiency of other essential 
nutrients like zinc and B vitamins”. 
 
Line 1840 
The 20 E% does not seem representative of the European fat intake. Indeed according to Annex 1b of this draft opinion means 
intakes are almost all above 30 E%. The population with very lower intake is obviously a specific population (elderly men in 
Portugal). This confirms that the 20 E% as the lower bound of the intake range is not appropriate for the general population. 
  
Line 1843 
The value of 20 E% is not appropriate: it is not representative of the low intake in Europe and according to AFSSA (2001) 
below 30 E% the balance of fatty acid intake (especially PUFA) is more difficult to achieve because of the composition of the 
usual food products. 
Besides, a growing body of evidence (observational, experimental, clinical trials and meta-analysis) indicates that the traditional 
diet – CHD paradigm (reduction of total and saturated fats and increase of carbohydrates) is inadequate. 
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Firstly, no positive relation in prospective cohorts and randomized trials between total fat reduction and incidence of CHD has 
been found. Secondly, reducing total fat leads to increase carbohydrates (Skeaff and Miller, 2009; Mozaffarian 2005; Elmadfa 
and Kornsteiner, 2009; Hooper et al., 2001 and 2002; Gordon et al., 1981). A high intake of carbohydrates (refined, high 
glycemic index) may adversely affect insulin homeostasis, satiety and weight gain (Mozaffarian, 2005). 
 
Line 1847 
The recommendation for total fat intake between 3 years and adult is missing. 
Association de la 
transformation 
laitière française  
6.2. Saturated fatty 
acids (SAT) 
Line 1851 
It should be clear what is meant with expressions like “a mixture of SFA” and also if this mixture is nutritionally relevant. In 
order to determine dietary reference values for nutrients, it is important to be aware of that no biochemical measurement in the 
human body can represent the effect of various nutrients. It is thus of greatest importance to 
examine the direct relationship between consumption of the food item/nutrient and the risk of disease.  
In the second paragraph of 6.2, the main discussion is made on SFA and LDL cholesterol and not cardiovascular disease. 
According toWHO, the ratio of total and HDL cholesterol is a more reliable biomarker. 
 
Lines 1851-1852 
This sentence does not represent the conclusion of the scientific opinion on line 1238-1240 where it is stated that “There is a 
positive, dose-dependent relationship between the intake of a mixture of SFA and serum LDL and HDL cholesterol 
concentrations, when compared to carbohydrates. As a consequence, the total to HDL cholesterol ratio does not change”. 
 
Line 1855 
However, Mozaffarian (2004) shows that in some case a greater saturated fat intake is associated with less progression of 
coronary atherosclerosis, whereas carbohydrate intake is associated with a greater progression. 
Besides, the Women Health Initiative (WHI) study indicates that no benefit was observed in terms of coronary disease, 
cardiovascular or cerebro-vascular disease with the decrease of fat intake and 9.5% SFA (Howard, 2006). 
Association de la 
transformation 
laitière française  
6.2. Saturated fatty 
acids (SAT) 
Line 1858 
The only link between SFA and health concerns total blood cholesterol (LDL and HDL). However, and contrary to 
carbohydrates which only increase the LDL cholesterol, SFA increase both HDL and LDL. Moreover, not all SFA but only a 
few have impacts on cholesterol so on this matter SFA cannot be considered as a whole. Only lauric, myristic and 
palmitic acids are known to increase total cholesterol, while short and medium-chain fatty acids are neutral (Mensink 2005 and 
2003; Temme et al., 1997; Salter et al., 1998; Billet MA, 2000; Dabadie, 2005; Tholstrup et al., 1994 and 2003b; Hashim, 1960; 
Parodi, 2009). 
In a recent meta-analysis, the effects of individual SFA on the serum lipoprotein profile have been estimated (Mensik et al., 
2003). Iso-energetic replacement of carbohydrates with lauric, myristic and palmitic acids all resulted in increased total, LDL 
and HDL cholesterol concentrations. But as the cholesterol-raising effects of lauric acid were proportionally higher on HDL 
than on LDL cholesterol, replacement of carbohydrates by lauric acid resulted in a significantly lower total 
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/ HDL cholesterol ratio, which suggests a decrease in atherosclerotic risk. Stearic acid had the smallest effect on HDL 
cholesterol but lowered total and LDL cholesterol, and thus also decreased the total / HDL cholesterol ratio. 
Palmitic acid is the only fatty acid which increased the total / HDL cholesterol ratio (Mensink, 2003), a fact confirmed in other 
studies (Salter et al., 1998; Billet MA, 2000). No differences between the effects of the different SFA on fasting serum 
triacylglycerol concentrations were detected (Mensink, 2003). 
Myristic acid had also been criticized for elevating cholesterol. However, these negative effects of myristic acid had been 
described with massive doses, doses which are much higher than usual consumption (Staiger et al., 2006). At usual level, 
myristic acid has no hypercholesterolemic effect but has rather positive action through an increase of HDLcholesterol (Temme 
et al., 1997; Salter et al., 1998; Billet MA, 2000; Legrand 2008). Moreover, myristic acid at usual level (1.6% total energy 
intake) is necessary for protein acylation and thus activation (Legrand, 2008). 
The recommendation should take into account the difference between the SFA. SFA have different physiological functions 
depending on their chain length, so should not be evaluated as one single group. 
 
Line 1868 
A recommendation of “as low as possible” would not be achievable in normal life with a normal diet and would result in strict 
and impossible guidelines to follow. Moreover, this recommendation “as low as possible” is not relevant due to recent scientific 
results showing the real effect of SFA on health - especially on cardiovascular health (Skeaff and Miller, 
2009; He et al., 2007; Mozaffarian, 2005, Hooper et al., 2001 and 2002) (for details see comments lines 1627-1644). A low 
intake of SFA could lead to an excessive consumption of MUFA and PUFA, which could represent health hazards, especially 
with regard to intake of n-6 fatty acids (Lecerf, 2009; Ailhaud, 2006). 
Association de la 
transformation 
laitière française  
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
Line 1882 
An optimal intake with a ratio of n-3/n-6 PUFA should also be fixed by EFSA, like it is the case in all the national and 
international recommendations. In order to determine this ratio, a conversion factor can be applied to LC PUFAs (LA to ARA, 
and ALA to EPA and DHA). For adults, this leads to an optimal n-6 PUFA: n-3 PUFA of 5:1. 
 
Line 1906 
The Panel proposes to set an AI for linoleic acid of 4 E%, with no UL for total or any of the n-6 PUFA. There has been 
evidence on negative effects on health of excessive intakes of n-6 PUFA and lipid peroxidation (Elmadfa and Kornsteiner, 
2009). It could also contribute to excessive adipose tissue development (Ailhaud, 2006; Lecerf, 2009).  
Therefore, an upper limit should be considered in order to protect consumer health. 
Association de la 
transformation 
laitière française  
6.5. Trans fatty 
acids (TFA) 
Line 1948 
According to the recent WHO scientific update on TFA the intake of ruminant TFA is low in most populations. To date there is 
no conclusive evidence supporting an association with coronary heart diseases risks in the amount of ruminant TFA consumed. 
In its recent report, AFSSA concluded that TFA from natural origin do not present a risk in terms of 
cardiovascular disease as they are consumed at very low level (0.5-0.9% of the total energy intake) (AFSSA, 2009a). 
The EFSA recommendation concerning the dietary reference value for TFAs should therefore deal only with industrially 
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derived TFA. 
 
Line 1952 
Intake of TFA from industrial origin should be as low as possible. Natural TFA should not be included in this recommendation. 
 
Line 1959 
This is due to the reduction in industrial TFA. 
Association de la 
transformation 
laitière française  
6.7. Cholesterol Line 1971 
It is important to add that dietary cholesterol has very little influence on plasma cholesterol values which are regulated by 
numerous genetic and nutritional factors through cholesterol absorption or synthesis. Besides, there is no strong evidence that 
dietary cholesterol is related to CHD or stroke (Hu andWillett, 2002; He et al., 2003) 
Association de la 
transformation 
laitière française  
Conclusions and 
recommendations 
Line 1978 
20 E% does not seem representative of the European fat intake. Indeed according to Annex 1b of this draft opinion means 
intakes are almost all above 30 E%. The population with very lower intake is obviously a specific population (elderly men in 
Portugal). This confirms that the 20 E% as the lower bound of the intake range is not adapted for the general population. 
Lines 1980-1981 
Value of 20 E% is not appropriate: it is not representative of the low intake in Europe and according to AFSSA, 2001 below 30 
E% the balance of fatty acid intake (especially PUFA) is more difficult to achieve because of the composition of the usual food 
products. 
Besides, a growing body of evidence (observational, experimental, clinical trials and meta-analysis) indicates that the traditional 
diet – CHD paradigm (reduction of total and saturated fats and increase of carbohydrates) is inadequate. First no positive 
relation in prospective cohorts and randomized trials between total fat reduction and incidence of CHD has been found. Second, 
reducing total fat leads to increase carbohydrates (Skeaff and Miller, 2009; Mozaffarian 2005; Elmadfa and Kornsteiner, 2009; 
Hooper et al., 2001 and 2002; Gordon et al., 1981). A high intake of carbohydrates (refined, high glycemic index) may 
adversely affect insulin homeostasis, satiety and weight gain (Mozaffarian, 2005). 
Lines 1992-1993 
Recommendation of “as low as possible” would not be achievable in normal life with a normal diet and would result in strict 
and impossible guidelines to follow. Moreover, this recommendation “as low as possible” is not relevant due to recent scientific 
results showing the real effect of SFA on health - especially on cardiovascular health (Skeaff and Miller, 
2009; He et al., 2007; Mozaffarian, 2005, Hooper et al., 2001 and 2002) (for details see comments lines 1627-1644). 
Lines 2001-2002 
An optimal intake with a ratio of n-3/n-6 PUFA should also be fixed by EFSA, like it is the case in all the national and 
international recommendations. In order to determine this ratio, a conversion factor can be applied to LC PUFAs (LA to ARA, 
and ALA to EPA and DHA). For adults, this leads to an optimal n-6 PUFA: n-3 PUFA of 5:1. 
Line 2017 
There has been evidence on negative effects on health of excessive intakes of n-6 PUFA and lipid peroxidation (Elmadfa and 
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Kornsteiner, 2009). It could also contribute to excessive adipose tissue development (Ailhaud, 2006; Lecerf, 2009). Therefore, 
an upper limit should be considered to protect consumer health. 
Lines 2041-2042 
Recommendation to reduced TFA intake to «as low as possible» should only concern industrial TFA. This has been 
recommended in numerous countries in Europe (Nordic Nutrition Recommendations, 2004; AFSSA, 2009b) as well as in the 
recent WHO scientific update on TFA (Uauy et al., 2009). EFSA recommendation concerning dietary 
reference value for TFA should therefore deal only with industrially produced TFA. 
Line 2055 
An AI 4% of LA is indeed based on lowest estimated mean intakes in E% (Elmadfa and Kornsteiner, 2009). However, this is 
not the level at which overt deficiency symptoms occur (this level is at least 2-fold lower): ISSFAL 
http://www.issfal.org.uk/lipid-matters/issfal-policy-statements/statement-3-pufa-in-adults.html Authors of these adult studies 
generally concluded that LA intakes of 1.0-2.5 E% would meet requirements but this conclusion was based mostly on 
minimizing the plasma level of 20:3 w9 (mead acid; a presumed biochemical marker of 
n-6 PUFA deficiency). Clinical condition of the infants was also considered in one study but otherwise, in these studies, clinical 
status was not informative. Several authors noted the difficulty in drawing conclusions about LA requirement from measuring 
plasma fatty acid profiles alone. On the basis of these results, it is concluded that 2E% LA is adequat for healthy adult humans 
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cortex and erytrocytes in human subjects. Brain Res Bulletin 56:79-85 
Casey PJ (1995) Protein lipidation in cell signaling. Science. Apr 14;268(5208):221-5. 
BEUC 6.5. Trans fatty 
acids (TFA) 
lines 145-146 and lines 2041-2042 
 
Given the large body of evidence which exists linking the high consumption of tfa to increased risk of CHD, BEUC believes 
that there is no reason to keep industrially produced trans fats in the food supply when they hold such a potential danger and can 
be removed. BEUC asks for the EFSA opinion to reflect the recommendations of WHO/FAO and several MS that trans fat 
intake should not exceed 1% of total calories – a figure which has been achieved in certain populations such as UK (which had 
set a target of 2%) . 
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CAOBISCO 3. Dietary sources 
and intake data 
CAOBISCO is of the opinion that the conclusions in the summary do not in all cases accurately reflect the content of the report. 
More precise, the nuance in the report is lacking in the summary. It is not immediately obvious on what basis the conclusions 
are drawn. Since the summary is generally the part that policy makers will read, it is important that the summary reflects the 
scientific state of the art, including the recent developments and nuances. Recently, two WHO scientific updates have been 
published in the European Journal of Clinical Nutrition (vol. 63, supplement 2s, pp S1-S75) and Annals of Nutrition and 
Metabolism (vol.55, no. 1-3: pp 5-300). It seems logical to take these two updates into account in the document. In conclusion, 
we would like to point out the following. Consumers do not eat saturated fats or unsaturated fats as such. They eat these 
nutrients in a matrix (food stuffs), as part of a balanced diet. In practice, the matrix influences the effects of the fatty acids, 
meaning that negative effects may not occur, or may be less pronounced, due to the presence of other nutrients in the food.  
  
on DRV‟s for saturated fatty acids  
Saturated fat:  
  
Why are all the saturated fats treated as one group in the summary? The unsaturated fats are split up in separate groups, but the 
saturated fats are treated as one group. Based on their different functions in human physiology and their different effects on 
cholesterol metabolism wouldn‟t it be more logical to talk about individual fatty acids instead of treating them as one single 
group (WHO update 2009: Elmadfa and Kornsteiner (2009) Ann Nutr Metabol 55:56-75 2009. In the EFSA report it is 
acknowledged that the four main dietary fatty acids have different effects on the lipoprotein profiles on one hand. On the other 
hand, there is only one DRV for saturated fatty acids defined – and the reason is that there are not enough data for setting 
individual reference values. Over the past years many papers have been written on the neutral lipoproteinaemic effect of stearic 
acid and we wonder whether these documents should be made available to EFSA.  
In the Summary in line 66,67 the following is written: „The Panel recommends that SFA intake should be as low as possible 
within the context of a nutritionally adequate diet‟. In the discussed scientific research in chapter 5 this recommendation is not 
supported. Furthermore, according to Table 5 (page 32), most Countries and also the WHO/FAO do set maximum of SFA at 10 
E%. In adults, average SFA intakes vary between less than 9 to nearly 17 E% and nearly 30% of the reported average intakes 
were 15 E% or higher (line 620-629). In addition, in several economically developed countries where the SAFA has fallen close 
to 10%, the capacity to decrease SFA much further is limited without major changes in dietary patterns, and is only likely to 
result in modest reductions in TC and LDL-C. We therefore believe it is appropriate to set a goal for SFA at 10 E%. In table 6 
(line 2915) the dietary reference value in the Netherlands is mentioned. However, these are the values from 2001, whereas the 
Dutch Health Council updated its advice in 2006. Therefore we recommend to use the most recent dietary guidelines.  
For saturated fat we can add that French food safety authority is currently reviewing the recommendations for the different fatty 
acids (expert Philippe Legrand)  
CAOBISCO 6.2. Saturated fatty 
acids (SAT) 
We are of the opinion that the conclusions in the summary do not in all cases accurately reflect the content of the report. More 
precise, the nuance in the report is lacking in the summary. Therefore, it is not immediately obvious on what basis the 
conclusions are drawn. Since the summary is generally the part that policy makers will read, it is important that the summary 
reflects the scientific state of the art, including the recent developments and nuances.  
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2. Recently, two WHO scientific updates have been published in the European Journal of Clinical Nutrition (vol. 63, 
supplement 2s, pp S1-S75) and Annals of Nutrition and Metabolism (vol.55, no. 1-3: pp 5-300). It seems logical to take these 
two updates into account in the document.  
3. In conclusion, we would like to point out the following. Consumers does not eat saturated fats or unsaturated fats as such. 
They eat these nutrients in a matrix (food stuffs), as part of a balanced diet. In practice, the matrix influences the effects of the 
fatty acids, meaning that negative effects may not occur, or may be less pronounced, due to the presence of other nutrients in the 
food.  
  
on DRV‟s for saturated fatty acids  
Saturated fat:  
  
Why are all the saturated fats treated as one group in the summary? The unsaturated fats are split up in separate groups, but the 
saturated fats are treated as one group. Based on their different functions in human physiology and their different effects on 
cholesterol metabolism wouldn‟t it be more logical to talk about individual fatty acids instead of treating them as one single 
group (WHO update 2009: Elmadfa and Kornsteiner (2009) Ann Nutr Metabol 55:56-75 2009  
  
In the EFSA report it is acknowledged that the four main dietary fatty acids have different effects on the lipoprotein profiles on 
one hand. On the other hand, there is only one DRV for saturated fatty acids defined – and the reason is that there are not 
enough data for setting individual reference values. Over the past years many papers have been written on the neutral 
lipoproteinaemic effect of stearic acid and I wonder whether these documents should be made available to EFSA. As an 
example Penny Kris-Etherton had written a review for Kraft shared with Caobisco. This could be used, among others.  
  
In the Summary in line 66,67 the following is written: „The Panel recommends that SFA intake should be as low as possible 
within the context of a nutritionally adequate diet‟. In the discussed scientific research in chapter 5 this recommendation is not 
supported. Furthermore, according to Table 5 (page 32), most Countries and also the WHO/FAO do set maximum of SFA at 10 
E%. In adults, average SFA intakes vary between less than 9 to nearly 17 E% and nearly 30% of the reported average intakes 
were 15 E% or higher (line 620-629). In addition, in several economically developed countries where the SAFA has fallen close 
to 10%, the capacity to decrease SFA much further is limited without major changes in dietary patterns, and is only likely to 
result in modest reductions in TC and LDL-C. We therefore believe it is appropriate to set a goal for SFA at 10 E%.  
  
In table 6 (line 2915) the dietary reference value in the Netherlands is mentioned. However, these are the values from 2001, 
whereas the Dutch Health Council updated its advice in 2006. Therefore we recommend to use the most recent dietary 
guidelines.  
For saturated fat we can add that French food safety authority is currently reviewing the recommendations for the different fatty 
acids (expert Philippe Legrand)  
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Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
2. Categories, 
structure and 
function 
Line 394 
Protein palmitoylation should be mentioned as well since it is one of the post-translational modifications found on proteins 
(Bijlmakers and March, 2003). 
 
Line 396 
The role of the position of fatty acids on the triglyceride backbone should be addressed. Addition of following paragraphs: The 
first key step governing the bioavailability and metabolic impact of dietary lipids is 
their digestion. Therefore, fats with the same fatty acid composition might differ in their metabolic impact, due to difference in 
triglyceride composition. Gastric lipase acts preferentially on fatty acids esterified at the sn-3 position, while pancreatic lipase 
has a preference for the sn-1 and sn-3 positions. In the chylomicrons, 75% of all fatty acids located at 
the sn-2 in dietary triacyl-glycerols are maintained at this sn-2 position in the triacyl-glycerols of chylomicrons (Michalski, 
2009; Armand, 2007). 
 
Especially for babies, C16:0 at the sn-2 position instead of sn-1 or sn-3 position is beneficial. It has been shown in a study with 
preterm infants (>35 weeks of gestation) that both palmitic acid and calcium absorption are improved and are comparable to 
infants who were breast-fed when an infant formula was used having 74% of the C16:0 at the sn2 position 
compared to an infant formula with the same amount of C16:0 but only 28% was positioned at sn2 (Lucas et al., 1997). 
Furthermore, for formula fed infants it has been shown that palmitic acid at sn-2 (instead of palmitic acid at sn-1 and sn- 3) 
results in a significant increase in whole body bone mineral content and density, softer stool and less stool soap fatty acids 
(Kennedy et al., 1999b). 
 
Line 414 
Saturated fats are essential for cell membranes. In our brain, the two dominant fatty acids are palmitic acid and steraric acid 
(both around 20-25%) (Carver et al., 2001). 
Classification of saturated fatty acids (SFA) only from a biochemical point of view is no longer relevant (Lecerf, 2009). SFA 
must be considered individually according to their chain length because they all have different effects. Short-chain and medium-
chain SFA are metabolised differently than long-chain SFA. Metabolism of SFA should be included in this scientific opinion. 
 
Lines 423-424 
The human body can synthesise substantial amounts of SFA. During a low fat / high carbohydrate diet up to 45% of the VLDL 
triglycerides can be newly synthesized. The preferentially formed fatty acid by mammalian fatty acid synthase is palmitate 
(C16:0) (Cooper Hudgins et al., 1996). Recent studies show that a lower fat-diet but rich in carbohydrates stimulated saturated 
fatty acid synthesis (especially palmitate) at high rates (Wilke et al., 2009). 
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Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
2. Categories, 
structure and 
function 
Line 461 
“The conversion of linoleic acid is very limited”: what is limited? 
For children: Olegard and Svennerholm (1971) found no differences in plasma and erythrocyte phoshoglyceride AA of 3-
month-old infants who either had been fed breast milk or were bottle fed with a milk formula with only traces of AA. This 
implies that LA is readily converted to AA in young infants. 
 
Line 475 
Goyens et al. (2006) does not give conversion rates of 8-12%. It rather states that “After the low-LA diet, the percentage of 
dietary ALA incorporated into the ALA plasma phospholipid compartment was significantly increased by 4% compared with 
the control diet (P 0.012). In contrast, consumption of the high-ALA diet significantly decreased the incorporation by 8% and 
12% compared with the control diet (P 0.001) and the low-LA diet (P 0.001), respectively.” 
 
Lines 483-486 
This paragraph should be extended and would fit better at line 441. 
 
Lines 487-492 
Add this paragraph: Vaccenic acid (the predominant TFA from ruminants) is converted into rumenic acid (cis-9, trans-11 CLA). 
Endogenous synthesis from vaccenic acid (trans-11 18:1; VA), the major biohydrogenation intermediate produced in the rumen, 
is the predominant source of cis-9, trans-11 CLA in milk fat (Lock et al. 2004). Some animal studies show that vaccenic acid 
could have a beneficial effect on plasma triglycerides, LDL cholesterol and inflammation (Wang et al.,2008). 
 
Line 492 
Add to the following sentence “TFA do not serve any vital functions” this: “in the present state of scientific data”. If there are 
scientific publications attesting the absence of vital function of TFA, those references should be specified and added. 
 
Lines 494-495 
Replace with following sentence: “CLA is a generic term for a group of...” 
The use of term “natural PUFA” is confusing here as it suggests that CLA is not from natural origin. Cis-9, trans-11 CLA 
(rumenic acid) is from natural origin as it comes from bioconversion of trans-vaccenic acid through the action of ¿9desaturases 
(Lock et al. 2004). By contrast, trans-10, cis-12 CLA is mainly produced by industrial processing. 
 
Line 497 
The different types of cholesterol transporters should be explained within this scientific draft opinion (HDL, VLDL…) 
 
Line 502 
Cholesterol is not “also” synthesised by the body but “mainly” synthesised by the body. Moreover, this endogenous production 
is regulated by the dietary intakes in healthy subjects. 
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Line 503 
Cholesterol also plays an important role in “lipid raft” mechanisms for protein sorting at various stages of the secretory and 
endocytic pathways (van Meer and Sprong, 2004). Cholesterol is involved in the synthesis of vitamin D, in cell membranes 
construction, and participates to the digestion process with the creation of specific acids (AFSSA, 2001). 
 
Line 508 
Phytosterols should be covered in this scientific draft opinion as EFSA recently released a scientific opinion on this topic. 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
2. Categories, 
structure and 
function 
Lines 414-424 
As for PUFA, additional information about structure and functions of SFA should be added. SFA are components of reserve 
triglycerides, glycerophospholipids and sphingolipids (membrane structure, myeline…). SFA cannot be considered as a whole, 
in terms of structure, metabolism and cellular functions. They have to be classified regarding their 
chain length:  
 
Structure and function of short and medium-chain fatty acids : 
Short and medium-chain SFA have a specific metabolism. As reported by Bach and Babayan (1982), triglycerides made of 
C6:0, C8:0, C10:0 and C12:0 (MCTs) have unique physical, chemical, and structural characteristics and their modifications 
(structured lipids) make special lipids tools for solving certain medical problems. They are indeed 
hydrolyzed both faster and more completely than long-chain triglycerides (LCTs). The products of this hydrolysis are absorbed 
as fast as glucose. MCTs are oxidized rapidly in the organism and they have a very low tendency to deposit as body fat. 
As reported by Sengupta et al. (2006), short-chain butyric acid is likely to have a protective function against colon cancer 
(inhibition of tumour proliferation, apoptosis induction). Short and medium-chain SFA have a hypocholesterolemic effect at 
physiological dose. This effect of diets high in C8:0 and C10:0 was shown in humans by Hashim (1960). Mediumchain SFA 
have also a beneficial role in adiposis. The human study of Tsuji et al. (2001) suggests weight loss with a diet high in medium-
chain fatty acids. C6:0, C8:0 and C10:0 have a role in weight reduction, reduced fat deposition, decrease of VLDL production, 
hypocholesterolemic effect and antiviral role (Rioux et al., 2007; Legrand, 2008; Neyts et al., 2000). 
 
Structure and function of long-chain fatty acids 
Long-chain SFA are converted, in part, by ¿9-desaturation in monounsaturated fatty acids, but with significantly different 
effectiveness, increasing with the length of the chain. Stearic acid is the best substrate of ¿9-desaturase; and its conversion to 
oleic acid is important (Legrand, 2002; Legrand, 200;, Kritchevsky, 1988). The long-chain stearic acid has no negative effects 
on cholesterol level (Yu et al.; 1995) and, as presented by Kelly (2001), it has a beneficial effect on 
thrombogenic and atherogenic risk factors in males. 
Myristic acid has a positive action through an increase of HDL-cholesterol when consume at usual level (Temme et al., 1997; 
Salter et al., 1998; Billet MA, 2000). Some SFA regulate specifically the activity of proteins by acylation (myristoylation, 
palmitoylation). Some studies show that, for example, myristic acid plays a key role through its ability to acylate proteins, a 
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reaction which is called N-terminal myristoylation. Various examples of important cellular regulations where the intervention of 
myristic acid is proven have been described (Casey, 1995; Rioux, 2002; Peitzsch, 1993; Borgese, 1996). Myristic acid also has 
a function in the biosynthesis of EPA and DHA (Dabadie et al., 2005; Rioux et al., 
2005) and of sphyngolipids (Beauchamp et al., 2007). C20:0, C22:0, C24:0 have a role in nervous structure (myelinisation) 
(Bourre et al., 1976a and b). 
 
Line 430 
No information is given to what extent humans can synthesise MUFA. 
 
Line 441 
The role of n-3/n-6 PUFA ratio should be addressed. Because n-3 and n-6 PUFA are metabolised to LCPUFA by the same 
enzyme system, excess dietary LA (n-6) may decrease the formation of DHA (LCPUFA n-3) from LNA. In addition, AA 
(LCPUFA n-6) formation is lower when excess (n-3) LNA is provided (Uauy and Castillo, 2003). Both n-3 and n-6 LCPUFA 
are needed. However, inWestern diets with ample n-6 PUFA, the balance between tissue n-3 and n-6 LCPUFA might be sub-
optimal (Lands, 2008). 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
3. Dietary sources 
and intake data 
Line 572 
The 18:1 TFA profiles of ruminant fat and hydrogenated vegetable oils show considerable overlap for many isomers. However, 
in contrast to ruminant fat non-palm-based-vegetable cooking oil can contain considerable amounts (0.4-2.7%) of C18:2 trans-
cis, cis-trans and trans-trans, and C18:3 trans (up to 2.7%) (Tang, 2002). Partially hydrogenated vegetable oils can contain 1–
65% of TFA, of which isomers of elaidic acid (trans-9 and trans-10 18:1) are the two most common isomers. 
On the other hand, dairy products contain smaller amounts of TFA (1–8% of total fatty acids in milk fat), and the main isomer is 
vaccenic acid (trans-11 18:1). Humans can utilize vaccenic acid, in the endogenous synthesis of rumenic acid (cis-9, trans-11 
18:2), a fatty acid that may not have a negative effect on biomarkers of CVD risk. These two sources of TFA differ in their TFA 
isomer distribution and contribution to dietary intake, and, as a consequence, they also may have different biological effects 
(Chardigny et al., 2008) 
 
Lines 574 and 579 
The actual content of TFA in wt% of total fatty acids in animal fat and industrial fat should be included in the table 4. The 
concentration of industrial hydrogenated TFA may be as high as 60%, whereas the maximum content of natural TFA in 
ruminant fat is about 6% (Stender et al., 2008). This information should also be included in the text in connection of the table 4. 
 
Line 583 
In humans the conversion rate of trans-vaccenic acid to rumenic acid is around 19% (Turpeinen et al., 2002) to 20% (Lock et 
al., 2005). 
 
Line 593 
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In France, more recent data than Volatier (2000) and Deschamp (2005) is available. The INCA 2 study, for example, is more 
recent and could be used for this paragraph and the annexes (AFSSA, 2009b). 
 
Line 605 
The presented data are not representative of the whole population but rather for a specific target group of the population (elderly 
in Portugal for example). Besides, some methods (like FFQ) are not accurate. 
 
Line 618 
Data for the lowest intake in Portugal are not representative as it concerns the elderly population which is not an average but an 
extreme level. Besides, data are not very accurate as it is FFQ method. 
 
Line 627 
In France, according to the INCA 2 study, the SFA intake is more around 15% than 17% (AFSSA, 2009b). 
 
Line 669 
For those countries where separate intake data for industrial TFA and natural TFA are available, those should be provided 
(Craig-Schmidt, 2006; Jakobsen, 2007). 
 
Lines 676-678 
The available data shows that total TFA intake has decreased close to WHO recommendation of 1 E%. This is due to 
reformulation of food products containing TFA originating from partially hydrogenated vegetable fats and oils. In the same 
report, WHO also mentions that most TFA are contributed by industrially hardened oils and that to promote cardiovascular 
health, diets should provide a very low intake of TFA from hydrogenated oils and fats (Uauy et al., 2009). 
 
Lines 681-682 
Leave out “including … from other sources”. Replace by (after line 684): In most European countries with a high TFA intake 
(>2.5 g/d), the major part of the TFA was from industrial sources (Craig-Schmidt, 2006). 
 
Line 690 
“In adults, average intakes range from nearly 200 mg/day to 655 mg/day”. This is not an average intake (replace “average” by 
“extreme range”): 655 mg/day concerns only one study for adult men. 
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Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
3. Dietary sources 
and intake data 
Lines 509-519 
Why are a US database used and a European database reference not required? Dietary databases indeed exist in Europe, for 
example, CIQUAL 2008 in France. European intake data should be given, where possible. 
No distinction is made between short-chain, medium-chain and long-chain SFA (see our comments to line 530). 
 
Lines 513 
The purpose of including table 2 is not clear. The selection of fats does not cover the major food groups in the diet. Other 
animal fats, such as tallow, fish fat and vegetable oils and margarine as well as shortenings for industrial processing should be 
included in table 2. Isomers of trans 18:1 should also be included in the table. 
 
Lines 514 
In table 2 the ratio n-6/n-3 PUFA should be added as this is relevant information for the fatty acid balance of fats and oils. 
 
Lines 520-529 
The Dutch NEVO table for fatty fish provides following data: total fat (g) 23.8, SFA 5.6, MUFA 10.5 PUFA 5.1 (high SFA fish 
(g total fat/g SFA) = Mackerel (30.7, 7.4); Eel (35, 8.7); Herring (14, 3.3); Salmon (14.2, 3.7)). These numbers differ quite a lot 
from the fatty fish data given in table 3. 
The basis for the selection of animal-derived food products is not entirely clear as, for example, eggs are missing. Besides, it is 
inconsistent to choose on one side only lean meat but on the other side present only standard butter and full fat milk. Semi-
skimmed milk should be used instead as it is the most consumed type of milk in Europe. In France, for example, 73% of the 
milk consumed is semi-skimmed milk (data from CNIEL, Centre National Interprofessionnel de 
l''Economie Laitière, 2007). 
 
Line 523 
Several dietary databases exist in Europe, for example, CIQUAL 2008 in France. Why was US data used? 
 
Line 530 
The main characteristic of milk fat is the variety of fatty acids it contains: more than 400 different fatty acids. Milk fat contains 
typically around 65-70% SFA and 30-35% unsaturated fatty acids. Amongst saturated fatty acids in milk fat, there are typically 
around 10-13% short- and medium-chain SFA and typically around 50-55% long-chain SFA, including palmitic (min. 20 – 
max. 32%), myristic (min. 8 – max. 15% ) and stearic acid (min. 6 – max. 13%). Milk fat is also relatively rich in the short-
chain SFA C4:0 (butyric acid, min. 7 – max. 14%). 
 
Line 532 
The lauric acid content in milk fat is more than 10-fold lower than that of coconut oil and palm kernel oil. Therefore, milk fat 
can - compared to these fats - not be called lauric acid rich (see table 2). 
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Lines 538-539 
For example, dairy fat contains a substantial amount of oleic acid (Legrand, 2008). In the French population, dairy products are 
also the first contributor of MUFA according to the INCA 2 study (AFSSA, 2009b) 
 
Line 551 
Appreciable amounts of ALA can also be found in animal and dairy fat. In France, for example, dairy products are the first 
contributor to ALA intake according the SUVIMAX adult consumption survey (SUVIMAX is a French survey done between 
1994 and 2002 on 13 000 people) (Astorg et al., 2004) 
 
Line 568 
There should not be a focus only on C18:1. Ruminant trans fats may contain up to 20% C16:1 (Stender et al., 2008) which 
shows that profiles of ruminant TFA and industrially produced TFA differ quite substantially (Mendis et al., 2008; Shingfield et 
al., 2008; IDF Bulletin 377, 2002). 
 
Lines 569-570 
The TFA content of margarine and fat spreads may vary, depending on the proportion of partially hydrogenated oils used. 
However, recent analyses have shown that products with high levels of industrially produced TFA are still available on the 
market (Stender et al., 2008). The range of TFA content in wt% of total fatty acids of those products should be added. 
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Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
4. Overview of 
dietary reference 
values and 
recommendations 
For the whole part 4 it is not clear on which criteria the chosen dietary guidelines were selected. 
 
Line 705 
It is important to mention that some national recommendations in Europe such as in France take into account the different 
effects of TFA according to their sources (natural or industrial) (AFSSA, 2009a). 
 
Lines 749-756 
The 2009 Joint FAO/WHO Expert Consultation on “Fats and Fatty Acids in Human Nutrition” sets dietary recommendations 
for total fat at 20-35 E% (acceptable macronutrient distribution range) compared to the population 
nutrient intake goal of 15-30 E% mentioned in the 2003 WHO report (Elmadfa and Kornsteiner, 2009). For children from 2 to 
18 years, the recommendation for the total dietary fat intake is 30-40 E% depending on activity (Uauy and Dangour, 2009). 
 
Lines 771-775 
Different SFA should be considered independently as there is evidence to indicate that certain SFA might have a beneficial role. 
Recent data show that the different SFA in milk fat have different effects on health. Several studies show that short-chain and 
medium-chain SFA do not have a negative impact on the blood lipid profile. They are easily digested 
and metabolised differently in the body compared to longer chain fatty acids. Certain long-chain SFA such as stearic acid act 
neutral on the cholesterol level. Myristic acid has various physiological roles in the body such as protein metabolism and the 
synthesis of n-3 long-chain fatty acids (Lecerf 2009, Legrand 2008, Rioux and Legrand 2007). 
 
Lines 776-779 
Only the newest guideline available should be used. The Health Council of the Netherlands has published updated dietary 
reference intakes for fats and fatty acids for the Netherlands in 2006. It is stated there that “The average intake of saturated fatty 
acids in the diet needs to be cut from 13 to 14 per cent of energy intake to less than 10 per cent.” 
Therefore, the dietary reference value for SFA for adults is < 10 E%. A mentioning of “as low as possible” cannot be found in 
the summary of the Dutch guidelines. 
 
Line 780 
The 2009 Joint FAO/WHO Expert Consultation on “Fats and Fatty Acids in Human Nutrition” confirms that the intake of SFA 
should not exceed a maximum level of 10 E% (Elmadfa and Kornsteiner, 2009). 
 
Lines 918-921 
Within the Nordic Nutrition Recommendations (2004), a maximum intake of 10 E% of SFA plus TFA is given. It is also 
mentioned that the intake of TFA from hydrogenated oils should be as “low as possible” (table 1). 
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Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
4. Overview of 
dietary reference 
values and 
recommendations 
Lines 930-933 
In 2005, AFSSA has done a review of studies on the metabolism and toxicity of TFA and their impact on health. They 
concluded that consumption of total TFA above 2% of total energy intake resulted in a significantly increased risk of CVD. At 
that time, they did not really distinguish the origin – natural or industrial - of TFA. New data concerning TFA content of food, 
population intakes as well as new scientific results from epidemiological and clinical studies have conducted AFSSA to reassess 
its previous conclusions (AFSSA, 2009a). AFSSA considers that: 
• The estimated average intake of TFA in the French population (around 1%) is lower than the threshold of 2% of the total 
energy intake. This is true for adults as well as for children independently of age and sex. The intake is lower than in 2005. 
• It is necessary to pursue the improvement of the food composition tables with regard to TFA. The contribution of different 
types of food to TFA intake should be considered in more detail, in particular the cheapest priced products, discount products, 
catering and small-scale ("artisanal") products etc. which are insufficiently known at this moment. 
• Considering the total TFA intake, the origin of the TFA, natural or industrial, should be taken into account. Concerning TFA 
of natural origin; consumption levels in the French population (0.5-0.9% of the total energy intake) are lower than levels 
identified as not posing a risk of CVD (1.5% of the total energy intake); TFA from industrial origin that are present in foods 
only have a technological function. Thus, AFSSA encourages the efforts to reduce the use of industrial TFA in human food, in 
order to reduce the risk of exposure. 
As a conclusion, the recommendation is to decrease TFA intake only concerns industrial TFA. 
 
Lines 934-937 
Only the newest guideline available should be used. The Health Council of the Netherlands has published updated dietary 
reference intakes for fats and fatty acids for the Netherlands in 2006. It is stated there that “mono trans fatty acid intake needs to 
be brought down from 1 to 2 per cent to less than 1 per cent.” Table 6 (line 2915) has to be updated accordingly with the dietary 
reference value of TFA for adults < 1 E% (instead of “as low as possible”). There only the values for EPA and DHA refer to the 
2006 Dutch guidelines. 
 
Line 938 
The 2009 Joint FAO/WHO Expert Consultation on “Fats and Fatty Acids in Human Nutrition” confirms that the UL for TFA 
from ruminants and industrially produced sources should be <1% E. This recommendation is done with the focus on industrial 
trans fat being reduced to 0.5 E%. Ruminant trans fat intake was not recommended to be lowered because the average intake is 
at approximately 0.5 E% (Elmadfa and Kornsteiner, 2009). 
  
Line 939 
The Nutritional Recommendations for the French Population (AFSSA, 2001) indicate that the limitation of exogenous 
cholesterol does not seem to be justified for the general population, as dietary cholesterol has only very limited impact on blood 
cholesterol. 
 
Line 944 
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The Nutritional Recommendations for the French Population (AFSSA, 2001) indicate that for older children and adolescents it 
does not seem reasonable to recommend fat intake below 30 E%. 
 
Line 969 
The French recommendations for SFA intake for children are 8 to 12 E% (AFSSA, 2001). 
 
Line 1032 
The French recommendations for cholesterol intake for children after 3 years of age are 300 mg/day (AFSSA, 2001). 
 
Line 1035 
The recent AFSSA report should be taken into account for the overview of dietary recommendations in the table (AFSSA, 
2009a). Thus, a distinction between natural and industrial TFA should be made. The WHO recommendation also concerns only 
TFA from industrial origin. This should be specified here (WHO, 2003). 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
5.1. Dietary 
requirements 
line 1050 
In purpose of defining dietary guidelines for nutrients such as fat, a transparent and systematic review of the scientific 
data has to be performed. In the present scientific overview “5.1 Dietary requirements”, the method used for selecting 
scientific data is not presented. 
 
Line 1067 
As mentioned in lines 614-616 “In adults average total fat intakes ranged from less than 30 E% to 47 E%. About 43% of the 
reported average data were between 30 and 35 E%; 13% were 40 E% or higher”. This average value (in addition to lower and 
upper end) is also important as it shows that for adults the fat intake is over 30% in more than 50% of the average data reported. 
 
Line 1068-1070 
This sentence should also be in the summary. 
 
Lines 1072-1073 
“Such low fat intakes are highly unlikely in European countries”: If very low fat intakes are very unlikely in Europe, the lowest 
recommended fat intake should not include this kind of low consumption as it is not representative. Under 30 E% of fat 
consumption, a balanced intake of the different fatty acid is indeed hard to achieve (AFSSA, 2001). 
 
Lines 1072-1074 
Please provide references for this statement. It seems important to take into account that reducing total fat intake can lead to an 
increase in carbohydrate intake. A high intake of carbohydrates (refined, high glycemic index) may adversely affect insulin 
homeostasis, satiety and weight gain (Mozaffarian, 2005) and can lead to a high synthesis of palmitic acid. Recent studies show 
that a lower fat-diet but rich in carbohydrates stimulated saturated fatty acid synthesis - especially palmitate - at high rates 
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(Wilke et al., 2009). 
 
Line 1118 
In lines 1109-1112 a clear example is given that diets containing less than 30 E% from fat can have negative effects on weight 
and vitamin intake. Only in the STRIP Trial evidence is provided that 25-30% has no negative effect on growth and 
neurological development. Furthermore, none of the studies presented found negative effects of higher fat intake (>35%) 
compared to lower fat intakes. Why than come to 25% as appropriate (line 1118) and in the table “Summary of DRVs for fats” 
(line 2055) to an RI of 20-35% for >4 year olds? It appears more prudent to advise a level of 30-40%. 
 
Line 1121 
Previous studies have suggested that interventions to lower dietary fat content and improved fat quality lead to a compensatory 
increase in sucrose content. There has been a concern that dietary recommendations aimed at achieving a low saturated fat diet 
might lead to inappropriately increased sugar intake (Gibney et al., 1995) and some studies suggest that an inverse relationship 
exists between the intake of fat and simple sugars (Gibson, 1997; Lewis et al., 1992; Hackett, 1993). Other studies show that 
children with an intake of <30% of energy from fat consumed more carbohydrates (mainly sucrose) than those children whose 
diets contained >40% of energy from fat (Nicklas et al., 1992; Kennedy et al., 1999a). 
Moreover, restriction of fat in children is questionable (Olson, 2000). There is no evidence that low-fat diets in childhood will 
prevent atherosclerosis in adulthood. The claim that low-fat diets are safe in childhood is based on observations over a too short 
time to establish safety. If growth and development of children are not changed with low-fat diets, the proof of long-term safety 
is not substantiated. 
 
Lines 1139-1142 
Editorial comment: “A LA intake of less … the form of LA.” is also taken from Hansen et al., 1963. The reference should be 
cited after that sentence. 
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5.10. Cancer Line 1778 
It should be added that it concerns TFA from industrial origin as the author indicate that ”a high serum level of trans 
monounsaturated fatty acids, presumably reflecting a high intake of industrially processed foods, is probably one factor 
contributing to increased risk of invasive breast cancer in women.” 
 
Line 1780 
It is not “associated” as there is “limited evidence” (WCRF/AICR, 2007) 
 
Line 1781 
There are only “limited-suggestive evidence” and no association (WCRF/AICR, 2007). 
 
Line 1785 
The WCRF/AICR Expert Report “Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective” (five 
years of work driven by an independent panel of 21 world renowned scientists) is the most recent and complete synthesis of the 
available scientific data on this topic. It would be pertinent to refer to this report systematically. 
For example, WCRF judged that: 
- There is “limited evidence-no conclusion” to support a link between fats and oils or fatty acids composition and breast cancer 
risk, whatever the menopausal status. 
- There is “limited evidence-suggestive” that butter increases lung cancer risk 
- There is limited-suggestive evidence that foods containing animal fats increases colorectal cancer risk (not any word about 
olive oil) 
A new study from China suggests that increasing the intake of n-3 fatty acids, and decreasing intakes of n-6, could reduce the 
risk of colorectal cancer. The highest dietary ratio of n/3-n-6 was associated with a 95 per cent increase in the risk of women 
developing colorectal cancer, according to results of a study with 73.242 Chinese women participating in the Shanghai 
Women''s Health Study (Murff et al., 2009). 
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5.2. Serum lipids 
and lipoproteins 
Line 1223 
In purpose of defining dietary guidelines for nutrients such as fat, a transparent and systematic review of the scientific 
data has to be performed. In the present scientific overview “5.2 Serum lipids and lipoproteins” the method used for 
selecting scientific data is not presented. 
 
Lines 1223-1228 
The relevance of lipoprotein markers should be mentioned and discussed in relation to their relevance for hard endpoints. 
A randomized clinical trial (RCT) that shows a statistically significant benefit in disease mortality rather than a benefit for a 
surrogate endpoint is the pinnacle of evidence–based medicine. However, this is not always feasible. Cholesterol markers have 
been used as surrogate endpoints to study the effect of dietary fat in RCTs - especially as a marker for CVD risk. 
For many years, the only biomarkers of CHD risk recognized by health authorities have been total cholesterol and LDL 
cholesterol. Recently, the Expert Panel of the WHO Scientific Update on trans fatty acids pronounced the ratio of total 
cholesterol to HDL cholesterol as the “best single lipid predictor of CHD risk” (Uauy et al., 2009). 
Extensive research has changed the simplistic view of atherosclerosis (the major underlying cause for CHD (Das, 2007)) as a 
disorder of pathological lipid deposition to a more complex concept of an ongoing inflammatory response (Stoll and Bendszus, 
2006). Therefore, effects on inflammatory markers are often included in newer RCTs. 
 
Lines 1231-1234 
No references are provided for this statement. 
 
Lines 1229-1236 
The conclusion of 5.2.1 is missing. According to EDA interpretation, these results show that at low intake of SFA (<10 E%) 
decreasing total fat intakes worsen the lipid profile leading to higher atherosclerosis risk (increases the total/HDL cholesterol 
ratio and TG, decreases serum concentrations of HDL cholesterol) (See also Mensink et al., 2003). 
The decrease of fat intake in men to 28% or 24% at stable body weight, leads to a decrease of LDL cholesterol but also to an 
decrease of HDL cholesterol, an increase of TG and LDL small and dense) (Lefebvre et al., 2005; Wood, 2006; Dreon, 1999). 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
5.2. Serum lipids 
and lipoproteins 
Line 1237 
 
Not only long-chain, but also medium-chain and short-chain fatty acids should be discussed for disease risk. Short and medium-
chain fatty acids are not transported via the chylomicron system, and are not linked to changes is lipoprotein profiles. This is 
also relevant for paragraphs 5.8 and 6.2. Their effects on CAD and cholesterol have not been a dietary issue (German and 
Dillard, 2004). There is some evidence that short and medium-chain fatty acids have antiviral and antitumor activity (German 
and Dillard, 2004). 
SFA cannot be considered as a whole, in terms of structure, metabolism and cellular functions (Parodi, 2009). Short and 
medium-chain SFA have a hypocholesterolemic effect at physiological dose (this effect of diets high in C8 and C10 was shown 
in humans by Hashim (1960). 
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In a recent meta-analysis, the effects of the individual SFA on the serum lipoprotein profile have been estimated (Mensik et al., 
2003). Iso-energetic replacement of carbohydrates with lauric, myristic and palmitic acids all resulted in increased total, LDL 
and HDL cholesterol concentrations. But as the cholesterol-raising effects of lauric acid were proportionally higher on HDL 
than on LDL cholesterol, replacement of carbohydrates by lauric acid resulted in a significantly lower total / HDL cholesterol 
ratio (The ratio of total to HDL cholesterol is a more powerful predictor of CHD risk than either total or LDL cholesterol levels 
(Stampfer et al., 1991)), which suggests a decrease in atherosclerotic risk. 
Stearic acid had the smallest effect on HDL cholesterol but lowered total and LDL cholesterol, and thus also decreased the total 
/ HDL cholesterol ratio. Palmitic acid is the only fatty acids which increased the total / HDL cholesterol ratio (Mensink et al., 
2003), fact confirmed in other studies (Salter et al., 1998; Billet MA, 2000). Stearic acid decreases LDL cholesterol, similar 
effect that oleic acid (Mensink, 2005). 
No differences between the effects of the different SFA on fasting serum triacylglycerol concentrations were detected (Mensink, 
2003) (see especially figure 3 of this study). 
Myristic acid has no hypercholesterolemic effect but has rather positive action through an increase of HDL-cholesterol when 
consume at usual level (Temme et al., 1997; Salter et al., 1998; Billet MA, 2000; Dabadie, 2005; Tholstrup et al., 1994 and 
2003b). Negative effects of myristic acid that have been described were only the result of massive doses that 
are well above the usual consumption (Staiger K et al., 2006). 
 
Lines 1238-1241  
The term “mixture” used here leads to an oversimplification and does not indicate which SFA are concerned. EFSA should 
indicate what the SFA involved are. Besides, SFA cannot be considered as a whole, in terms of structure, metabolism and 
cellular functions. Doses, population and references should also be indicated to support this statement. 
 
Line 1251 
The analysis of sub fractions in subjects given low carbohydrate diets with either higher or lower content of SFA shows that the 
saturated fat intake results in an increase in the larger buoyant LDL rather than the smaller LDL particles. The small, dense 
LDL particles have been associated with increased risk of CVD, whereas large LDL particles have not (Krauss, 2006). 
Mozaffarian et al. (2004) also show that in postmenopausal women with relatively low total fat intake, a greater saturated fat 
intake is associated with less progression of coronary atherosclerosis. The proposed hypothesis is that a decrease in fat intake 
leads to worsen the lipid profile: decrease of HDL cholesterol, increase of TG and B-phenotype of LDL (small and dense LDL) 
(Dreon et al., 1998; Dreon et al., 1999; Krauss et al., 2006; Lefebvre et al., 2005). 
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5.2. Serum lipids 
and lipoproteins 
Line 1314 
However, the intake of ruminant TFA is low in most populations. In the French diet, for example, the natural TFA intake ranges 
from 0.5-0.9% of the total energy intake (AFSSA, 2009a). This amount is far lower than the 3.7% tested in the Motard-Bélanger 
study (2008). The French intake values have been established by a consumption survey, INCA2 (2006- 
2007), on more than 4000 persons (AFSSA, 2009b). 
 
Lines 1326-1327 
“The intervention studies do not provide evidence that a mixture of CLA isomers, cis-9, trans-11 CLA, or trans-10, cis-12 CLA 
have an impact on the serum lipoprotein profile.” However, as explained in this scientific opinion on line 1319-1321 some 
studies are showing that cis-9, trans-11 is more favourable as compared with trans-10, cis-12 CLA on lipoprotein 
profile. The conclusion should be also that more studies are needed on purified CLA isomers. 
 
Line 1340 
Kratz also conducted a systematic review on animal and human (intervention and observational) studies. Based on the results of 
these studies, the author found that an increase in dietary cholesterol intake resulted in only a minimal increase in the total/HDL 
cholesterol ratio, as most subjects can effectively adapt to higher levels of cholesterol intakes (Kratz, 2005). 
 
Lines 1342-1344 
“Under iso-energetic conditions, the most favourable lipoprotein profile to lower atherosclerotic risk is achieved when a mixture 
of SFA and TFA is replaced by a mixture of oleic acid, linoleic acid and fish fatty acids. These effects are dosedependent”. 
Those sentences should be removed from the scientific draft opinion: “mixture” does not mean anything and as shown in 
our previous comments it is not possible to consider SFA as a whole in terms of structure, metabolism and cellular functions. 
The same remark can be made for TFA: the difference should be made between industrial or natural TFA. The intake of 
ruminant TFA is indeed low in most populations. In the French diet, for example, the natural TFA intake ranges from 0.5-0.9% 
of the total energy intake (AFSSA, 2009a). This amount is far lower than the 3.7% tested in the Motard- Bélanger study (2008). 
The French intake values have been established by a consumption survey, INCA2 (2006-2007), on more than 4000 persons 
(AFSSA, 2009b). 
 
Lines 1341-1346 
The effect of stearic acid is neutral (Yu et al., 1995). The effects are also dose dependant. Myristic acid has no 
hypercholesterolemic effect but has rather positive action through an increase of HDL-cholesterol when consumed at usual level 
(Temme et al., 1997; Salter et al., 1998; Billet MA, 2000). 
Consumption of naturally occurring TFA at levels found in regular diets does not contribute to elevated risk of cardiovascular 
disease (see the European Parliament study, 2008). 
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5.2. Serum lipids 
and lipoproteins 
Lines 1253-1254 
Cis-MUFA had similar effects on serum total cholesterol concentrations as carbohydrates in Hegsted et al. (1965). Thus, many 
researchers compared the effects on MUFA, in particular oleic acid, and carbohydrates on the distribution of cholesterol over 
the different lipoproteins (Grundy, 1986; Mensink and Katan, 1987). From these studies it appeared that effects of oleic acid 
and carbohydrates are indeed similar on total cholesterol concentrations, but that oleic acid increased HDL cholesterol and 
lowered VLDL cholesterol and triacylglycerol concentrations (Thijssen and Mensink, 2005). 
 
Line 1266 
Please provide reference for this statement 
 
Lines 1281-1282 
Remove: “like diets containing mixtures of SFA“. This sentence is not relevant in this part about TFA. Besides, the term 
“mixture” is not precise and does not mean anything about which fatty acids are concerned. 
 
Line 1284 
Clarke (2009) is not an intervention study. It is just a simulation. 
 
Lines 1294-1296 
Please provide reference for this statement. 
 
Lines 1297-1298 
“In most of the human intervention studies reviewed above, the effects of trans-MUFA from hydrogenated vegetable oils were 
assessed”. This sentence should be the introduction of the paragraph as there are two parts here, one about industrially produced 
TFA, the other one about ruminant TFA, starting line 1298. 
 
Lines 1298-1299 
Extreme high intakes of ruminant TFA (3.7 E% or 5 E%) indeed appear to have adverse effects on blood lipid profiles. 
However, these high levels of ruminant TFA cannot be reached with a normal diet. The habitual intake of ruminant TFA is far 
below this amount (Craig-Schmidt, 2006; Willett and Mozaffarian, 2008). On the other hand, ingesting 20-40g (> 5 E%) 
industrially produced TFA is not at all unrealistic (Stender et al., 2008). Why is this not mentioned? 
 
Line 1301 
“3.7% of energy from TF” This high percentage does not reflect the usual intake in European countries. In France, TFA intake 
from natural origin represent only 0.5-0.9% of the total energy intake (AFSSA, 2009a). 
 
Line 1307 
The European Parliament study on TFA (2008) aimed at providing background information to Members of the European 
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Parliament on TFA. The report highlighted the fact that although there was considerable scientific evidence showing a causative 
link between intake of industrially produced TFA and cardiovascular disease, scientific studies also revealed 
that consumption of naturally occurring TFA at levels found in regular diets do not contribute to elevated risk of cardiovascular 
disease. Therefore the authors mentioned that it is important to make a clear distinction between naturally occurring and 
industrially produced TFA when developing possible guidelines for action to reduce the intake of TFA. Any legal restrictions 
should be limited to industrially produced TFA. 
 
Line 1309 
Remove “like diets containing mixtures of SFA“. This sentence is not relevant in this part about TFA. Besides, the term 
“mixture” is not precise and does not mean anything about which fatty acids are concerned. 
 
Line 1311 
“Consumption of diets containing trans-MUFA also…” “Also” has to be removed as TFA and some SFA do not have the same 
effects on HDL cholesterol. 
 
Lines 1312-1314 
“The available evidence indicates that TFA from ruminant sources have similar adverse effects on blood lipids and lipoproteins 
to those from industrial sources”. This is true only at very high levels of TFA intake, corresponding to diets with 3.7% of 
energy from TFA - indeed 9 litres of semi-skimmed milk, 4 kg of yoghurt or 800g of camembert cheese – as 
the average content of TFA in milk fat is 5.39% of total fatty acids (AFSSA, 2005). 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
5.3. Haemostatic 
function 
Line 1362 
If the studies are far from consistent, those sentences should be reformulated. Suggestion: “Although C12:0 to C16:0 SFA have 
been suspected to increase factor VII levels as compared to stearic acid (C18:0), the studies were far from consistent and no 
conclusion can be made. Moreover, in one study, post-prandial increases in activity of factor VII were less after consumption of 
meals rich in SFA, especially stearic acid, than after a consumption of meals enriched with 
unsaturated fatty acids (Thijssen and Mensink, 2005; Tholstrup et al., 2003a).” 
 
Line 1364 
Relative to oleic acid, and unlike to n-6 PUFA, either medium-chain SFA or lauric or myristic or palmitic acids did not affect 
collagen-induced whole blood aggregation. Furthermore, ADP-induced platelet aggregation was not changed by medium-chain 
saturated fatty acids or myristic acid (Thijssen and Mensink, 2005; Temme et al., 1998). 
 
Line 1375 
According to the Thijssen and Mensik (2005), thromboxanes (TX) and prostaglandins (PG), two eicosanoids, play an important 
role in the haemostatic balance. Both types of eicosanoids are synthesised from the C20 fatty acids, arachidonic acid (C20:4n-6) 
and EPA (C20:5n-3), after release from membrane phospholipids. 
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Eicosanoids of the n-2 series, such as TXA2, are synthesized from the n-6 arachidonic acid in platelets, while prostaglandins I2 
(PGI2) is synthesised in the vascular endothelium. TXA2 is a potent vasoconstrictor and a stimulus for platelet aggregation, 
whereas PGI2 has opposite effects. 
Eicosanoids of the n-3 series such as TXA3 and PGI3 are principal metabolites of the n-3 fatty acid EPA. TXA3 is less active 
than TXA2, meaning than the vasoconstrictor effects due to n-6 fatty acids is higher than the ones induced by the n-3 fatty 
acids. The anti-aggregation effects of PGI3 and PGI2 are however comparable. Furthermore, n-6 PUFA increased urinary 11-
dehydro-TXB2 excretion compared with saturated and monounsaturated fatty acids, which seemed to reflect an ADP-induced 
platelet aggregation (Lahoz et al., 1997; Thijssen and Mensik, 2005). Increased ADP-induced platelet aggregation is associated 
with increased atherosclerotic risk (Elwood et al., 1991; 
Thijssen and Mensik, 2005). 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
5.4. Inflammation 
and immne 
function 
Line 1422 
Additional information: A randomized, controlled, 3-diet, 3-period crossover study was published in 2007 in the American 
Journal of Clinical Nutrition (Zhao et al., 2007). Hypercholesterolemic subjects (n=23) were assigned to 3 experimental diets: a 
diet high in ALA (6.5 E%), a diet high in LA (12.6 E%), and an average American diet for 6 weeks. Results 
showed that increased intakes of dietary ALA elicited anti-inflammatory effects by inhibiting pro-inflammatory cytokine 
production (IL-6, IL-1ß and TNF-a) in cultured PBMCs (Peripheral Blood Mononuclear Cells). Changes in PBMC ALA and 
EPA were associated with beneficial changes in TNF-a release. ALA could thus have some effects of reduction in 
the production of inflammatory cytokines. 
 
Line 1426 
This line correctly reports that TFA from hydrogenated sources (not ruminant sources) have been linked to adverse effects on 
inflammatory profile in epidemiological studies. Why is this not mentioned in the overall summary (line 129-146)? 
 
Lines 1434-1439 
While it is mentioned in the conclusion that no consistent picture has emerged on effects on n-6 PUFA, no references are 
provided for that in part 5.4.1. 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
5.7. Body weight 
control and energy 
balance 
Lines 1583-1593 
Profound quantitative and qualitative changes have taken place in the last four decades in the Western industrialised world, 
particularly the rising intake of n-6 and declining intake of n-3 PUFA. A recent review (Ailhaud et al., 2008) suggests that this 
imbalance in PUFA intake is an emerging risk factor contributing in addition to long-term net positive 
energy balance. The authors propose that several aspects of unbalanced PUFA metabolism conspire to stimulate fat cell 
formation and to increase the prevalence of overweight and obesity such as low n-3 PUFA intake, overestimation of linoleic 
acid requirement and significant increase in the LA:LNA ratio.  
Thus, nutritional recommendation should not stress the n-6 PUFA over consumption, and promote instead a good equilibration 
between n-3 PUFA and n-6 PUFA. 
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Line 1618 
It is important to add in the conclusion that based on some recent studies, nutritional recommendation on n-6 PUFA intake 
should not promote their over consumption but rather a good balance between n-3 PUFA and n-6 PUFA (Ailhaud et al., 2008). 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
5.8. Cardiovascular 
disease 
Line 1626 
General comment on this part about “Cardiovascular disease: the analysis on the effect of lipids on cardiovascular disease is 
quite poor compared to the analysis made on serum lipids and lipoproteins made in part 5.2. 
For example there is almost no data on stroke, which is actually a part of cardiovascular diseases and should be considered. 
Ecological studies suggest that saturated fat (mostly animal fat) is inversely associated with stroke. Some studies suggest that 
high intake of PUFA could have a negative effect on oxidation process and inflammatory mechanism involved in the stability of 
the plaque (Thies et al., 2003). 
Epidemiological studies show that saturated fat is either associated to a significant decreased risk of stroke (Framingham Study 
– ischemic stroke, Gilman, 1997; Nurses‟ Health study – hemorrhagic stroke, Iso, 2001; Japanese cohort of 4500 subjects - 
hemorrhagic stroke, Iso, 2003) or no related to the risk of stroke (Health professional Study, He, 2003) 
 
Line 1632 
What are the selection criteria for selecting only those four studies? 
 
Line 1628 
Concerning total fat, a reduction in fat intake is frequently construed as a recommendation in cardiovascular disease prevention. 
However, the question is now increasingly subject to debate (Mozaffarian et al., 2004). 
 
Line 1644 
Howard et al. (2006) also shows that no benefit was observed in terms of coronary disease, cardiovascular or cerebrovascular 
disease with the decrease of fat intake and decrease of SFA to 9.5%. On the contrary, for some women with cardiovascular 
history, there was an increase of their cardiovascular disease risk linked to a decrease of lipids and SFA 
intake. 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
5.8. Cardiovascular 
disease 
Line 1627 to 1644 (continuation of our comments already done on this lines) 
Elmadfa and Kornsteiner (2009) stated that “The meta-analysis by Skeaff and Miller (2009) demonstrated that the relative risk 
of CHD death in the highest (14–18 E%) category of SFA consumption was not significantly different from that in the lowest 
(7–11 E%) category. High compared with low SFA consumption was not significantly related with diverse risk factors of CHD 
events.” 
 
Skeaff and Miller (2009) carried out a very recent and exhaustive review of cohort studies and controlled trials of dietary fats 
and CHD mortality or morbidity (search in the Cochrane Library, Cochrane reviews, article databases, systematic reviews, 
meta-analysis, etc.). 28 individual cohort studies were selected, in which there were about 6,600 CHD deaths amongst 280,000 
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participants during approximately 3.7 million person-years of follow-up. 
The authors state on p. 191: “According to the classic „diet-heart‟ hypothesis, high intake of SFAs and cholesterol and low 
intake of PUFAs increase serum cholesterol levels and risk of CHD. However, few within-population studies have been able to 
demonstrate consistent associations with any specific dietary lipids, with the exception of trans fats and n-3 fatty acids. The 
available evidence from cohort and randomized controlled trials is unsatisfactory and unreliable to make judgment about and 
substantiate the effects of dietary fat on risk of CHD.” Continuing further it is mentioned that “Furthermore, the evidence from 
cohort studies of dietary intake of fats and CHD is mostly unreliable (with few exceptions) because most studies have ignored 
the effects of measurement error and regression dilution bias.” 
According to the results of this study : 
- Total fat: 
Intake of total fat was not significantly associated with CHD mortality, with a RR for highest compared with the lowest 
category of 0.94 (95% CI of 0.74-1.18, p=0.583); 
Intake of total fat was also unrelated to CHD events (RR 0.93, 95% CI 0.84-1.03, p=0.177); 
No significant association of total fat intake with CHD mortality (RR 1.06, 95% CI 0.88-1.28, p=0.517) or CHD events (RR 
1.02, 95% CI 0.98-1.05, p=0.404) per 5% total energy increment in total fat intake ; 
Overall, the mean or median total fat intake in all cohort studies varied from 27-47% total energy. 
- SFA: 
Intake of SFA was not significantly associated with CHD mortality (RR 1.14, 95% CI 0.82-1.60, p=0.431) for highest compared 
to lowest category of SFA intake 
SFA intake was not significantly associated with CHD events (RR 0.93, 95% CI 0.83-1.05, p=0.269 for high vs. low category) 
No significant association of SFA intake with CHD death (RR 1.11, 95% CI 0.75-1.65, p=0.593) per 5% total energy increment 
in SFA intake 
Overall, the mean or median SFA intake in all cohort studies varied from 9-20% total energy. 
- MUFA: 
No significant association with CHD mortality / CHD deaths or CHD events 
- PUFA: 
Intake of PUFA was strongly significantly associated with CHD mortality with a RR 1.25, 95% CI 1.06-1.47, p=0.009) for 
highest compared to lowest category 
High compared with low PUFA intake was not associated with CHD events (RR 0.97, 95% CI 0.74-1.27, p=0.825) for highest 
compared to lowest category 
Significant lower risk of CHD events (RR 0.84, 95% CI 0.70-1.00, p=0.049) per 5% total energy increment in PUFA intake, but 
not with CHD mortality. 
Moreover, the results of this review showed that the RR of fatal CHD was not reduced by either low-fat diets or diets with a 
high polyunsaturated to saturated fat ratio (P/S ratio). 
to continue.... 
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de l''Economie 
Laitiere 
5.8. Cardiovascular 
disease 
Line 1627 to 1644 (end of our comment already done on those lines) 
 
In conclusion, the results of the studies described above tend to show that dietary intervention in healthy people of diets low in 
total fat or SFA were unsuccessful or provided insufficient evidence in reducing the incidence of cardiovascular disease (for 
more details, see also Ravnskov, 1998; Ramsden et al., 2009). It also appears that in coronary heart disease, the 
overconsumption of n-6 PUFA must not be encouraged since it can increase plaque instability (Lecerf, 2009). 
 
A recent systematic review of 146 prospective cohort studies and 43 RCTs from Europe, the US and Asia, investigating dietary 
factors related to CHD carried out by Mente et al. (2009) found insufficient evidence of an association between intake of total 
fat, SFA, PUFA, milk, meat and eggs and risk of CHD, but found protective associations for intakes of MUFA, fish, n-3 fatty 
acids, folate, whole grains, vitamins E and C, beta carotene, alcohol, fruit and fibre. A harmful association was found for TFA 
and foods with a high glycemic index. One of the conclusions stated “it is unlikely that modifying the intake of a few nutrients 
or foods would substantially influence coronary outcomes.” 
 
In a review paper from Parodi (2009), 24 reports of 11 cohorts were the only prospective cohort studies found which evaluated 
the association between SFA and risk of CHD. Among these, 4 studies found a significantly positive association between SFA 
intake and risk of CHD, 3 found no association and 2 found a negative association. Overall, these results are inconsistent and do 
not provide convincing evidence of an association between SFA and risk of CHD. 
The evidence extracted by Gibson et al. (2009) from 12 major prospective cohort studies involving more than 280.000 subjects 
does not consistently demonstrate a direct relationship between the intake of dairy foods and increased risk of CVD (CHD, IHD 
or myocardial infarct), even though it is recognized that dairy fat is a contributor of saturated fat intake and excess saturated fat 
intakes has been associated with a higher incidence of CVD. The authors noted that “the studies available for examining the 
effect of dairy food consumption on CHD are too varied in design, quality and dietary assessment methodology to evaluate the 
nature of the relationship.” 
From a meta-analysis of 15 cohort studies carried out by Elwood et al. (2008), the relative risk of stroke or heart disease in 
subjects with high milk or dairy consumption was 0.84 and 0.79 respectively, relative to the risk in those with low consumption. 
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Line 1716 
The words “of SFA” should be deleted as not all SFA have the same effects. TFA should be replaced by “industrial TFA”. 
All research (either epidemiological or interventional studies) tends to show that in healthy people diets low in SFA were 
unsuccessful in reducing the incidence of cardiovascular disease. 
In this context, the recommendation “as low as possible” has neither scientific value nor scientific justification. 
 
Line 1720 
The genetic aspect should be included in this scientific draft opinion. There is a wide inter-individual variability in the response 
to dietary changes since genetic polymorphisms modulate the effects of nutrients. In terms of cardiovascular diseases, 
polymorphisms at multiple genes have been associated with differential effects in terms of lipid metabolism. 
Many examples can be given. A habitually low saturated fat diet is associated with a beneficial lipoprotein profile only among 
homozygotes of the APOC3 promoter 455T-625T polymorphism. (25% of the population) (Brown S et al., 2003). 
Another example of a well-documented nutrigenetic interaction is that of the apoAI gene which is a major structural and 
functional component of HDL cholesterol. A significant interaction between this polymorphism and PUFA intake in 
determining plasma HDL cholesterol concentration has been demonstrated in women in the Framingham Study. In carriers of 
the A allele, higher PUFA intakes (>8 E%) were shown to be associated with higher HDL cholesterol, whereas in G/G 
homozygotes, the opposite effect was observed (Lovegrove and Gitau, 2008). 
The concept of gene-environment interactions modulating common disease risk factors is now well founded and should be 
taken into consideration for more individually targeted approaches to disease prevention and therapy (Ordovas, 2009). 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
5.8. Cardiovascular 
disease 
Lines 1627-1644 
While CHD and ischemic stroke share some major risk factors, limited epidemiological data on dietary fats and vascular disease 
risk indicate that ischemic stroke is affected differently (different or opposite effect) by these fatty acids than is CHD. 
Specifically, the association between saturated fat / animal fat intake and ischemic stroke remains elusive (He et al. 2007). A 
clear distinction should be made between CVD, CHD and stroke, and the newest literature should be included. Besides, there 
are no intervention studies that analyse the effect of specific SFA variation: all those studies are based on a variation linked to 
the total fat intake or other fatty acids intakes (Lecerf, 2009). 
A growing body of evidence (observational, experimental, and clinical trial) indicates that the traditional diet – CHD paradigm 
(reduction of total and saturated fats and increase of carbohydrates) is inadequate. 
Mozaffarian (2005) conducted a systematic MEDLINE search in order to identify observational studies, clinical trials, 
experimental studies and reviews of dietary fats or carbohydrates and CHR risk in humans from 1966 to June 2005. The author 
conducted a careful selection based on relevance, strength (designs and methods), precision of effects, endpoints etc. 
Precedence was given to randomized controlled trials and prospective observational studies. Globally, results showed that there 
was little evidence that replacement of SFA with carbohydrates (which lowers total fat intake) reduced CHD risk. In details, 
results showed that: 
- For total fat: 
A lower total fat intake also reduce serum HDL cholesterol and increase TG, resulting in little overall net change in CHD risk in 
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men and potentially high risk CHD in women 
Reducing total fat leads to an increase in carbohydrates. A high intake of carbohydrates (refined, high glycemic index) may 
adversely affect insulin homeostasis, satiety and weight gain 
No positive relation in prospective cohorts and randomized trials between total fat reduction and incidence of CHD (ex: Nurses‟ 
Health Study) 
- For saturated fats: 
In metabolic trials, replacement of SFA with carbohydrates produce little change in the total:HDL ratio and specific SFA have 
differing effects on lipid physiology (Mensik 2003) 
The author found in this search: 
2 prospective studies observing a positive relation between SFA intake and CHD (the Western Electric Study; the 
Ireland-Boston Diet-Heart Study) 
3 other studies observing a positive relation from some CHD endpoints or in some population but not others 
(Framingham Study; Lipid Research Clinics, Cohort follow up study in the US) 
7 other studies observing no significant association between SFA intake and CHD (including Nurses‟ Health Study, Puerto Rico 
Heart Health Program, Zutphen Study, Honolulu Program, the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study and 2 
studies from Morris et al. 1977 and Gordon et al., 1981). 
Results of randomized trials replacing SFA with PUFA have been inconsistent 
No clinical trials have been specifically designed to evaluate the effect of replacing SFA with carbohydrates on the 
incidence of CHD. 
For more details on the effects of SFA on cardiovascular disease, see also Morris et al. (1977) and Gordon et al. (1981). 
A Cochrane and MEDLINE meta-analysis (Hooper et al., 2001 and 2002) based on 18,196 subjects with 30,901 personyears of 
observation from 27 randomised intervention trials, and a total of 40 intervention arms lasting at least 6 months found small 
effects with reduced or modified dietary fat on overall mortality (0.98, 95% CI 0.86-1.12), with a nonsignificant trend towards 
reduced cardiovascular mortality (0.91, 95% CI 0.77-1.07) or events (0.86; 95% CI 0.72-1.03). 
Results were different if participants were at high initial cardiovascular risk (0.84; 95% CI: 0.70-0.99), suggesting a protection 
from fat reduction, or at low cardiovascular risk (0.82; 0.56-1.20), suggesting no effect. 
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Lines 1645-1694 (end of our comments already done on those lines) 
 
Skeaff and Miller (2009) conducted a very recent and exhaustive review of cohort studies and controlled trials of dietary fats 
and CHD mortality or morbidity (search in the Cochrane Library, Cochrane reviews, article databases, systematic reviews, 
meta-analysis, etc.). Results found that: 
- ALA: 
No association with intake of ALA and CHD death (RR 0.84, 95% CI 0.53-1.31, p=0.439) or CHD events (RR 1.05, 95% CI 
0.78-1.42, p=0.730) for highest compared to lowest category of intake 
- LC PUFA: 
For cohort studies on n-3 LC PUFA, there were about 5,361 deaths amongst 256,000 participants during 4 million person-years 
of follow-up. 
Intake of n-3 LC PUFA or fish consumption were strongly associated with CHD mortality (RR 0.82, 95% Cl 0.71-0.94, 
p=0.006) for the highest compared with lowest category. 
Intake of n-3 LC PUFA was not associated with decreased risk of CHD events, non fatal CHD, total myocardial infarction, 
sudden cardiac death. 
For meta-analysis of randomized controlled trials of n-3 LC PUFA or fish and CHD, there were about 1,300 CHD deaths 
amongst 37,000 participants during 140,000 person-years of follow-up. Depending on the inclusion or exclusion of DART 2 
study, risk ratios of the different parameters were totally changed (either a reduction or a non significance), limiting the 
interpretation. 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
5.8. Cardiovascular 
disease 
Lines 1645-1694 (first part of our comments on those lines) 
Two other clinical trials of dietary supplementation with n-3 fatty acids exist: the DART and Lyon Heart studies, which are both 
secondary prevention trials. 
The DART study (Burr et al., 1989; Burr et al., 2007) was conducted in 2003 men after myocardial infarction, with 3 treatment 
arms: reduction of SFA intake to 30% energy with a P/S ration of 1:0, an increase of fatty fish (200-400 g/week), or an increase 
in cereal fibres to 18g/d. Advice to modify fat intake did not confer any obvious benefit, perhaps partly because it entailed 
greater changes in dietary habits and was therefore inadequately followed. Indeed, the advice about dietary fat did not achieve 
the expected differences in intakes, partly because of incomplete compliance with the advice and partly because of spontaneous 
changes in the control group. After 2 years, total fat accounted for 31.4% and 35.2% in the fat-advice and the non-fat advice 
groups respectively, and the corresponding mean P/S ratio were 0.8 and 
0.4, although patients had regularly nutritional recommendations and advice given by a professionals of dietetics. 
However, the fish advice was associated with a 29% reduction in overall mortality, and this result was unaffected by adjusting 
variables at baseline. 
 
The Lyon Heart study (de Lorgeril et al., 1994; Renaud et al., 1994; de Lorgeril et al., 1999) was a randomized secondary 
prevention trial aimed at testing whether a Mediterranean type diet may reduce the rate of recurrence after a first myocardial 
infarction. The intervention diet was rich in a-linolenic acid (0.8% versus 0.3% in the control group) and 
provided around 30 E% from fat, 8 E% from SFA (12% in the control group), 13 E% from MUFA (10% in the control group) 
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and <4 E% from linoleic acid (n-6 LA) (>5% in the control group). The study lasted over a 5-year period and was conducted on 
302 patients, compared to 303 control patients. There was also an additional follow-up after the 5 initial 
years for 46 months. The recurrent myocardial infarction, all cardiovascular events, and cardiac and total death were 
significantly decreased by > 70% in the group consuming the Mediterranean diet. These protective effects were not related to 
serum concentrations of total, LDL or HDL cholesterol. With regard to any association between the plasma concentration of 
major fatty acids and recurrence, only 18:3 n-3 and 22:6 n-3 tended to be inversely associated with recurrence of outcomes 
(p=0,11 and p=0,16 respectively) for myocardial infarction and cardiovascular deaths (no 
significance for other outcomes as heart failure, stroke, pulmonary or peripheral embolism, angina, thrombophlebitis). 
to continue... 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
5.8. Cardiovascular 
disease 
Lines 1695-1700 
Non-conjugated polyunsaturated TFA should be addressed in relation to disease risk. There is evidence that polyunsaturated 
TFA (trans 18:2) could pose a higher risk for ischemic heart disease and sudden cardiac death and CHD than monounsaturated 
TFA (trans 18:1) (Lemaitre et al., 2006; Baylin et al., 2003) These polyunsaturated TFA are from industrial sources, and can 
only be found in trace levels in ruminant fats. 
The WHO experts come to a different conclusion. They do make a difference between ruminant and industrially produced TFA: 
“The current growing body of evidence from controlled trials and observational studies indicates that TFA consumption from 
partially hydrogenated oils adversely affects multiple cardiovascular risk factors and contributes 
significantly to increased risk of CHD events. Although ruminant TFAs cannot be removed entirely from the diet, their intake is 
low in most populations and to date there is no conclusive evidence supporting an association with CHD risks in the amounts 
usually consumed. In contrast, TFA produced by partial hydrogenation of fats and oils should be considered industrial food 
additives having no demonstrable health benefits and clear risks to human health. The WHO Scientific 
Update on TFA concludes that restaurants and food manufacturers should avoid using industrially derived TFA in food 
products and that governments should take steps to support alternative fats or oils for TFA replacement. The evidence on the 
effects of TFA and disease outcomes strongly supports the need to remove PHVO from the human food supply.” (Uauy et al., 
2009). 
The limited data suggest that the experimental effects of ruminant and industrial TFA are similar when consumed in similar 
quantities, but very few persons consume such high levels of ruminant TFA, and observational studies do not support adverse 
CHD effects of ruminant TFA in amounts actually consumed (Mozaffarian et al., 2009). 
AFSSA concluded it its recent report that TFA from natural origin do not present a risk in terms of cardiovascular disease as 
they are consumed at very low level (0.5-0.9% of the total energy intake) (AFSSA, 2009a). 
 
Lines 1701-1712 
Incidence of nonfatal and fatal CHD and stroke corresponding to the daily egg consumption was determined in 37,851 men and 
80,082 women in 2 large prospective cohort studies (the Health Professionals Study and the Nurses Health study). Results 
showed no evidence for an overall significant association between egg consumption and risk of CHD and stroke, after 
adjustments for age, smoking and other potential CHD risk factors. The authors found a significant association between egg 
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consumption and CHD and stroke in only a subgroup of diabetic patients (thus with abnormalities in lipid metabolism). 
Kratz also conducted a systematic review on animal and human (intervention and observational) studies. A large number 
of observational studies (Honolulu Heart Study, the Puerto-Rico Heart Health Program, the Lipid Research Clinics Prevalence 
Follow-up Study, the Nurses Health Study, the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study and the Hawaii 
Cardiovascular Study) did not find any relationship between the intake of dietary cholesterol and the risk 
of CHD. Moreover, some other studies which primarily found a potential positive link between cholesterol intakes and CHD 
noted that the results were no longer significant after adjustments for consumption of vegetable, proteins and fibres, since they 
usually go hand in hand in individual diets (Kratz, 2005). 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
6.1. Total fat Line 1831 
As mentioned in this scientific draft opinion (lines 1068-1070), “Very low fat diets tend to increase the risk of an insufficient 
intake of PUFA, can impair the absorption of fat-soluble vitamins and be associated with insufficiency of other essential 
nutrients like zinc and B vitamins”. 
 
Line 1840 
The 20 E% does not seem representative of the European fat intake. Indeed according to Annex 1b of this draft opinion means 
intakes are almost all above 30 E%. The population with very lower intake is obviously a specific population (elderly men in 
Portugal). This confirms that the 20 E% as the lower bound of the intake range is not appropriate for the general population. 
  
Line 1843 
The value of 20 E% is not appropriate: it is not representative of the low intake in Europe and according to AFSSA (2001) 
below 30 E% the balance of fatty acid intake (especially PUFA) is more difficult to achieve because of the composition of the 
usual food products. 
Besides, a growing body of evidence (observational, experimental, clinical trials and meta-analysis) indicates that the traditional 
diet – CHD paradigm (reduction of total and saturated fats and increase of carbohydrates) is inadequate. Firstly, no positive 
relation in prospective cohorts and randomized trials between total fat reduction and incidence of CHD has been found. 
Secondly, reducing total fat leads to increase carbohydrates (Skeaff and Miller, 2009; Mozaffarian 2005; Elmadfa and 
Kornsteiner, 2009; Hooper et al., 2001 and 2002; Gordon et al., 1981). A high intake of carbohydrates (refined, high glycemic 
index) may adversely affect insulin homeostasis, satiety and weight gain (Mozaffarian, 2005). 
 
Line 1847 
The recommendation for total fat intake between 3 years and adult is missing. 
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6.2. Saturated fatty 
acids (SAT) 
Line 1851 
It should be clear what is meant with expressions like “a mixture of SFA” and also if this mixture is nutritionally relevant. 
In order to determine dietary reference values for nutrients, it is important to be aware of that no biochemical measurement in 
the human body can represent the effect of various nutrients. It is thus of greatest importance to examine the direct relationship 
between consumption of the food item/nutrient and the risk of disease. 
In the second paragraph of 6.2, the main discussion is made on SFA and LDL cholesterol and not cardiovascular disease. 
According toWHO, the ratio of total and HDL cholesterol is a more reliable biomarker. 
 
Lines 1851-1852 
This sentence does not represent the conclusion of the scientific opinion on line 1238-1240 where it is stated that “There s a 
positive, dose-dependent relationship between the intake of a mixture of SFA and serum LDL and HDL cholesterol 
cncentrations, when compared to carbohydrates. As a consequence, the total to HDL cholesterol ratio does not change”. 
 
Line 1855 
However, Mozaffarian (2004) shows that in some case a greater saturated fat intake is associated with less progression of 
coronary atherosclerosis, whereas carbohydrate intake is associated with a greater progression. 
Besides, the Women Health Initiative (WHI) study indicates that no benefit was observed in terms of coronary disease, 
cardiovascular or cerebro-vascular disease with the decrease of fat intake and 9.5% SFA (Howard, 2006). 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
6.2. Saturated fatty 
acids (SAT) 
Line 1858 
The only link between SFA and health concerns total blood cholesterol (LDL and HDL). However, and contrary to 
carbohydrates which only increase the LDL cholesterol, SFA increase both HDL and LDL. Moreover, not all SFA but only a 
few have impacts on cholesterol so on this matter SFA cannot be considered as a whole. Only lauric, myristic and palmitic acids 
are known to increase total cholesterol, while short and medium-chain fatty acids are neutral (Mensink 2005 and 2003; Temme 
et al., 1997; Salter et al., 1998; Billet MA, 2000; Dabadie, 2005; Tholstrup et al., 1994 and 2003b; Hashim, 1960; Parodi, 2009). 
In a recent meta-analysis, the effects of individual SFA on the serum lipoprotein profile have been estimated (Mensik et al., 
2003). Iso-energetic replacement of carbohydrates with lauric, myristic and palmitic acids all resulted in increased total, LDL 
and HDL cholesterol concentrations. But as the cholesterol-raising effects of lauric acid were proportionally higher on HDL 
than on LDL cholesterol, replacement of carbohydrates by lauric acid resulted in a significantly lower total 
/ HDL cholesterol ratio, which suggests a decrease in atherosclerotic risk. Stearic acid had the smallest effect on HDL 
cholesterol but lowered total and LDL cholesterol, and thus also decreased the total / HDL cholesterol ratio. 
Palmitic acid is the only fatty acid which increased the total / HDL cholesterol ratio (Mensink, 2003), a fact confirmed in other 
studies (Salter et al., 1998; Billet MA, 2000). No differences between the effects of the different SFA on fasting serum 
triacylglycerol concentrations were detected (Mensink, 2003). 
Myristic acid had also been criticized for elevating cholesterol. However, these negative effects of myristic acid had been 
described with massive doses, doses which are much higher than usual consumption (Staiger et al., 2006). At usual level, 
myristic acid has no hypercholesterolemic effect but has rather positive action through an increase of HDL-cholesterol (Temme 
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et al., 1997; Salter et al., 1998; Billet MA, 2000; Legrand 2008). Moreover, myristic acid at usual level (1.6% total energy 
intake) is necessary for protein acylation and thus activation (Legrand, 2008).The recommendation should take into account the 
difference between the SFA. SFA have different physiological functions depending on their chain length, so should not be 
evaluated as one single group. 
 
Line 1868 
A recommendation of “as low as possible” would not be achievable in normal life with a normal diet and would result in strict 
and impossible guidelines to follow. Moreover, this recommendation “as low as possible” is not relevant due to recent scientific 
results showing the real effect of SFA on health - especially on cardiovascular health (Skeaff and Miller, 
2009; He et al., 2007; Mozaffarian, 2005, Hooper et al., 2001 and 2002) (for details see comments lines 1627-1644). A low 
intake of SFA could lead to an excessive consumption of MUFA and PUFA, which could represent health hazards, especially 
with regard to intake of n-6 fatty acids (Lecerf, 2009; Ailhaud, 2006). 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
Line 1882 
An optimal intake with a ratio of n-3/n-6 PUFA should also be fixed by EFSA, like it is the case in all the national and 
international recommendations. In order to determine this ratio, a conversion factor can be applied to LC PUFAs (LA to ARA, 
and ALA to EPA and DHA). For adults, this leads to an optimal n-6 PUFA: n-3 PUFA of 5:1. 
 
Line 1906 
The Panel proposes to set an AI for linoleic acid of 4 E%, with no UL for total or any of the n-6 PUFA. There has been 
evidence on negative effects on health of excessive intakes of n-6 PUFA and lipid peroxidation (Elmadfa and Kornsteiner, 
2009). It could also contribute to excessive adipose tissue development (Ailhaud, 2006; Lecerf, 2009). 
Therefore, an upper limit should be considered in order to protect consumer health. 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
6.5. Trans fatty 
acids (TFA) 
Line 1948 
According to the recent WHO scientific update on TFA the intake of ruminant TFA is low in most populations. To date there is 
no conclusive evidence supporting an association with coronary heart diseases risks in the amount of ruminant TFA consumed. 
In its recent report, AFSSA concluded that TFA from natural origin do not present a risk in terms of 
cardiovascular disease as they are consumed at very low level (0.5-0.9% of the total energy intake) (AFSSA, 2009a). 
The EFSA recommendation concerning the dietary reference value for TFAs should therefore deal only with industrially 
derived TFA. 
 
Line 1952 
Intake of TFA from industrial origin should be as low as possible. Natural TFA should not be included in this recommendation. 
 
Line 1959 
This is due to the reduction in industrial TFA. 
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Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
6.7. Cholesterol Line 1971 
It is important to add that dietary cholesterol has very little influence on plasma cholesterol values which are regulated by 
numerous genetic and nutritional factors through cholesterol absorption or synthesis. Besides, there is no strong evidence that 
dietary cholesterol is related to CHD or stroke (Hu andWillett, 2002; He et al., 2003) 
Centre National 
Interprofessionnel 
de l''Economie 
Laitiere 
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CF&R 6.1. Total fat line 50 : Who in Europe is eating with only 20% of total fat in the food intake ? What amount of food intake would need 
someone eating a ration with only 20 % of the energy coming from fat ? How could we achieve it with the current food supply ? 
 
the recommandations from the different european institutes are between 30 an 35% for normal weight population. It should not 
been lowered to 20 to 35 % just like this. 
CF&R 6.2. Saturated fatty 
acids (SAT) 
line 67 :  
- "as low as possible" for SFA is an impossible guideline to use for labelling. When you want to express the proportion of the 
recommanded daily amount of SFA brought by a portion of any food, you cannot devide by zero or "as low as possible" 
example : 30 g of cheese brings 4 g of SFA - The actual GDA is 20 g for SFA. So 30 g of cheese brings 25% of the GDA. 
Quid with "as low as possible" ? I do not know how to calculate 4/"as low as possible" 
 
- there are SFA in animal products. The guideline "as low as possible" means "animal product as low as possible" Is it really 
what we want ? The european nutritionnal way is composed with animal products for centuries : has it fail for such a long time 
? 
Where will we get calcium, iron, some vitamins from ? 
Chambre Syndicale 
de la Margarine 
(French Margarine 
Association) 
Conclusions and 
recommendations 
For LA and ALA DRVs, EFSA recommends a level based on the lowest estimated mean intakes of the various populations 
groupe in Europe where deficiencies symptoms are not present. i.e. 4 E% for LA and 0.5 E% for ALA.  
However:  
- ALA/LA deficiency is virtually non-existent in Western societies 
- FAO/WHO recommands higher intakes of ALA/LA, because it has shown to reduce the risk of CV disease (LA 5-8 E% and 
ALA 1-2 E% for the total population) and not only to prevent ALA/LA deficiency. 
=> higher intake would help th e population to reach dietary intakes recommanded to prevent the major chronic diseases, which 
are the real public health issue 
 
EFSA set DRV for LA to 4 E% and for 0,5 E%, wich leads to a ratio w6/w3 of 8. However recommandation asks for a higher 
ratio (5 for adults according to AFSSA, French agency for food safety). 
Outcome of the Public consultation on the Draft Opinion on  
Dietary Reference Values for fats 
 
98 EFSA Journal 2010; 8(5):1507 
ORGANISATION CHAPTER TEXT COMMENT TEXT 
 
For SAFA and TFA ,no accurate limit of intake have been set. Indeed EFSA recommans both to be as low as possible. But 
deleterious health effects of SAFA in cardiovascular disease have been shown, and we regret no upper limit have been set. 
EFSA states (ligne 60/63) that "There is also evidence from dietary intervention studies that decreasing the intakes of products 
rich in SAFA by replacement with products rich in n-6 PUFA [...]decreased the number of cardiovascular events." It should be 
highlighted than replacement by n-3 PUFA decreased the number of CV events too. 
 
In view of the importance of dietary cholesterol in the blood cholestreol concentration, we regrets however that EFSA does not 
propose a recommendation on cholesterol intake. 
 
The Panel also proposes to set the total fat recommanded intake between 20 E% and 35 E%, wich is not in line with the french 
recommandation of AFSSA. 
EDA 2. Categories, 
structure and 
function 
¿ Line 394 
Protein myristoylation is only one way to regulate enzyme activity. Protein palmitoylation should be mentioned as well since it 
is one of the most frequent post-translational modifications found on proteins (Bijlmakers and March, 2003).  
 
¿ Line 396 
The role of the position of fatty acids on the triglyceride backbone should be addressed.  
Addition of following paragraphs: The first key step governing the bioavailability and metabolic impact of dietary lipids is their 
digestion. Therefore, fats with the same fatty acid composition might differ in their metabolic impact, due to difference in 
triglyceride composition. Gastric lipase acts preferentially on fatty acids esterified at the sn-3 position, while pancreatic lipase 
has a preference for the sn-1 and sn-3 positions. In the chylomicrons, 75% of all fatty acids located at the sn-2 in dietary triacyl-
glycerols are maintained at this sn-2 position in the triacyl-glycerols of chylomicrons (Michalski, 2009; Armand, 2007).  
Especially for babies, C16:0 at the sn-2 position instead of sn-1 or sn-3 position is beneficial. It has been shown in a study with 
preterm infants (>35 weeks of gestation) that both palmitic acid and calcium absorption are improved and are comparable to 
infants who were breast-fed when an infant formula was used having 74% of the C16:0 at the sn2 position compared to an 
infant formula with the same amount of C16:0 but only 28% was positioned at sn2 (Lucas et al., 1997). Furthermore, for 
formula fed infants it has been shown that palmitic acid at sn-2 (instead of palmitic acid at sn-1 and sn-3) results in a significant 
increase in whole body bone mineral content and density, softer stool and less stool soap fatty acids (Kennedy et al., 1999b). 
 
¿ Line 414 
Saturated fats are essential for cell membranes. In our brain, the two dominant fatty acids are palmitic acid and steraric acid 
(both around 20-25%) (Carver et al., 2001).  
Classification of saturated fatty acids (SFA) only from a biochemical point of view is no longer relevant (Lecerf, 2009). SFA 
must be considered individually according to their chain length because they all have different effects. Short-chain and medium-
chain SFA are metabolised differently than long-chain SFA. Metabolism of SFA should be included in this scientific opinion. 
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¿ Lines 423-424 
The human body can synthesise substantial amounts of SFA. During a low fat / high carbohydrate diet up to 45% of the VLDL 
triglycerides can be newly synthesized. The preferentially formed fatty acid by mammalian fatty acid synthase is palmitate 
(C16:0) (Cooper Hudgins et al., 1996). Recent studies show that a lower fat-diet but rich in carbohydrates stimulated saturated 
fatty acid synthesis (especially palmitate) at high rates (Wilke et al., 2009). 
EDA 2. Categories, 
structure and 
function 
¿ Line 461 
“The conversion of linoleic acid is very limited”: what is limited? 
For children: Olegard and Svennerholm (1971) found no differences in plasma and erythrocyte phoshoglyceride AA of 3-
month-old infants who either had been fed breast milk or were bottle fed with a milk formula with only traces of AA. This 
implies that LA is readily converted to AA in young infants. 
 
¿ Line 475 
Goyens et al. (2006) does not give conversion rates of 8-12%. It rather states that “After the low-LA diet, the percentage of 
dietary ALA incorporated into the ALA plasma phospholipid compartment was significantly increased by 4% compared with 
the control diet (P 0.012). In contrast, consumption of the high-ALA diet significantly decreased the incorporation by 8% and 
12% compared with the control diet (P 0.001) and the low-LA diet (P 0.001), respectively.” 
 
¿ Lines 483-486 
This paragraph should be extended and would fit better at line 441.  
 
¿ Lines 487-492 
Add this paragraph: Vaccenic acid (the predominant TFA from ruminants) is converted into rumenic acid (cis-9, trans-11 CLA). 
Endogenous synthesis from vaccenic acid (trans-11 18:1; VA), the major biohydrogenation intermediate produced in the rumen, 
is the predominant source of cis-9, trans-11 CLA in milk fat (Lock et al. 2004). Some animal studies show that vaccenic acid 
could have a beneficial effect on plasma triglycerides, LDL cholesterol and inflammation (Wang et al., 2008). 
 
¿ Line 492 
Add to the following sentence “TFA do not serve any vital functions” this: “in the present state of scientific data”. If there are 
scientific publications attesting the absence of vital function of TFA, those references should be specified and added. 
 
¿ Lines 494-495 
Replace with following sentence: “CLA is a generic term for a group of...”  
The use of term “natural PUFA” is confusing here as it suggests that CLA is not from natural origin. Cis-9, trans-11 CLA 
(rumenic acid) is from natural origin as it comes from bioconversion of trans-vaccenic acid through the action of ¿9 desaturases 
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(Lock et al. 2004). By contrast, trans-10, cis-12 CLA is mainly produced by industrial processing. 
 
¿ Line 497 
The different types of cholesterol transporters should be explained within this scientific draft opinion (HDL, VLDL…) 
 
¿ Line 502 
Cholesterol is not “also” synthesised by the body but “mainly” synthesised by the body. Moreover, this endogenous production 
is regulated by the dietary intakes in healthy subjects. 
 
¿ Line 503 
Cholesterol also plays an important role in “lipid raft” mechanisms for protein sorting at various stages of the secretory and 
endocytic pathways (van Meer and Sprong, 2004). Cholesterol is involved in the synthesis of vitamin D, in cell membranes 
construction, and participates to the digestion process with the creation of specific acids (AFSSA, 2001). 
 
¿ Line 508 
Phytosterols should be covered in this scientific draft opinion as EFSA recently released a scientific opinion on this topic. 
EDA 2. Categories, 
structure and 
function 
¿ Lines 414-424 
As for PUFA, additional information about structure and functions of SFA should be added. SFA are components of reserve 
triglycerides, glycerophospholipids and sphingolipids (membrane structure, myeline…). SFA cannot be considered as a whole, 
in terms of structure, metabolism and cellular functions. They have to be classified regarding their chain length: 
Structure and function of short and medium-chain fatty acids 
Short and medium-chain SFA have a specific metabolism. As reported by Bach and Babayan (1982), triglycerides made of 
C6:0, C8:0, C10:0 and C12:0 (MCTs) have unique physical, chemical, and structural characteristics and their modifications 
(structured lipids) make special lipids tools for solving certain medical problems. They are indeed hydrolyzed both faster and 
more completely than long-chain triglycerides (LCTs). The products of this hydrolysis are absorbed as fast as glucose. MCTs 
are oxidized rapidly in the organism and they have a very low tendency to deposit as body fat.  
As reported by Sengupta et al. (2006), short-chain butyric acid is likely to have a protective function against colon cancer 
(inhibition of tumour proliferation, apoptosis induction). Short and medium-chain SFA have a hypocholesterolemic effect at 
physiological dose. This effect of diets high in C8:0 and C10:0 was shown in humans by Hashim (1960). Medium-chain SFA 
have also a beneficial role in adiposis. The human study of Tsuji et al. (2001) suggests weight loss with a diet high in medium-
chain fatty acids. C6:0, C8:0 and C10:0 have a role in weight reduction, reduced fat deposition, decrease of VLDL production, 
hypocholesterolemic effect and antiviral role (Rioux et al., 2007; Legrand, 2008; Neyts et al., 2000). 
Structure and function of long-chain fatty acids 
Long-chain SFA are converted, in part, by ¿9-desaturation in monounsaturated fatty acids, but with significantly different 
effectiveness, increasing with the length of the chain. Stearic acid is the best substrate of ¿9-desaturase; and its conversion to 
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oleic acid is important (Legrand, 2002; Legrand, 200;, Kritchevsky, 1988). The long-chain stearic acid has no negative effects 
on cholesterol level (Yu et al.; 1995) and, as presented by Kelly (2001), it has a beneficial effect on thrombogenic and 
atherogenic risk factors in males.  
Myristic acid has a positive action through an increase of HDL-cholesterol when consume at usual level (Temme et al., 1997; 
Salter et al., 1998; Billet MA, 2000). Some SFA regulate specifically the activity of proteins by acylation (myristoylation, 
palmitoylation). Some studies show that, for example, myristic acid plays a key role through its ability to acylate proteins, a 
reaction which is called N-terminal myristoylation. Various examples of important cellular regulations where the intervention of 
myristic acid is proven have been described (Casey, 1995; Rioux, 2002; Peitzsch, 1993; Borgese, 1996). Myristic acid also has 
a function in the biosynthesis of EPA and DHA (Dabadie et al., 2005; Rioux et al., 2005) and of sphyngolipids (Beauchamp et 
al., 2007). C20:0, C22:0, C24:0 have a role in nervous structure (myelinisation) (Bourre et al., 1976a and b). 
 
¿ Line 430 
No information is given to what extent humans can synthesise MUFA.  
 
¿ Line 441 
The role of n-3/n-6 PUFA ratio should be addressed. Because n-3 and n-6 PUFA are metabolised to LCPUFA by the same 
enzyme system, excess dietary LA (n-6) may decrease the formation of DHA (LCPUFA n-3) from LNA. In addition, AA 
(LCPUFA n-6) formation is lower when excess (n-3) LNA is provided (Uauy and Castillo, 2003). Both n-3 and n-6 LCPUFA 
are needed. However, in Western diets with ample n-6 PUFA, the balance between tissue n-3 and n-6 LCPUFA might be sub-
optimal (Lands, 2008).  
EDA 3. Dietary sources 
and intake data 
¿ Line 530 
The main characteristic of milk fat is the variety of fatty acids it contains: more than 400 different fatty acids. Milk fat contains 
typically around 65-70% SFA and 30-35% unsaturated fatty acids. Amongst saturated fatty acids in milk fat, there are typically 
around 10-13% short- and medium-chain SFA and typically around 50-55% long-chain SFA, including palmitic (min. 20 – 
max. 32%), myristic (min. 8 – max. 15% ) and stearic acid (min. 6 – max. 13%). Milk fat is also relatively rich in the short-
chain SFA C4:0 (butyric acid, min. 7 – max. 14%).  
 
Degree of unsaturation Common name Structure Average (%) Min (%) Max (%) 
Saturated 69 57 80 
Short and medium-chain Butyric acid C4:0 8.5 7 14 
Caproic Acid C6:0 4 2 7 
Caprylic Acid C8:0 1.8 1 3.5 
Capric Acid C10:0 3 1.5 5 
Long-chain Lauric Acid C12:0 3.6 2.5 7 
Myristic Acid C14:0 10.5 8 15 
Palmitic Acid C16:0 23.5 20 32 
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Stearic Acid C18:0 10 6 13 
Odd-numbered 2.5 1.5 3.5 
Branched 1.1 0.7 1.8 
Other 0.7 0.3 2 
Monounsaturated 27 18 36 
Palmitoleic Acid C16:1 1.4  
Oleic Acid C18:1 21 13 28 
Other 5.5  
Diunsaturated 2.5 1 4.3 
Linoleic Acid (LA) C18:2 1.8  
Other 0.7  
Polyunsaturated 0.8 0.4 2 
Linolenic Acid (ALA) C18:3 0.4  
Other 0.4  
Fatty acid derivatives 0.6  
Keto 0.3  
Hydroxy 0.3  
Fatty alcohol 0  
Fatty aldehyde 0  
TOTAL 99.9  
 
Table: Fatty acids in milk fat, Walstra P., Woulters J.T., Geurts T.J., 2006, Dairy Science and Technology, 2nd edition 
EDA 3. Dietary sources 
and intake data 
¿ Line 532 
The lauric acid content in milk fat is more than 10-fold lower than that of coconut oil and palm kernel oil. Therefore, milk fat 
can - compared to these fats - not be called lauric acid rich (see table 2). 
 
¿ Lines 538-539 
For example, dairy fat contains a substantial amount of oleic acid (Legrand, 2008). In the French population, dairy products are 
also the first contributor of MUFA according to the INCA 2 study (AFSSA, 2009b)  
 
¿ Line 545 
Safflower oil should be included as an example since it is higher in linoleic acid (72%) than the product examples given.  
 
¿ Line 551 
Appreciable amounts of ALA can also be found in animal and dairy fat. In France, for example, dairy products are the first 
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contributor to ALA intake according the SUVIMAX adult consumption survey (SUVIMAX is a French survey done between 
1994 and 2002 on 13 000 people) (Astorg et al., 2004) 
 
¿ Line 568 
There should not be a focus only on C18:1. Ruminant trans fats may contain up to 20% C16:1 (Stender et al., 2008) which 
shows that profiles of ruminant TFA and industrially produced TFA differ quite substantially (Mendis et al., 2008; Shingfield et 
al., 2008; IDF Bulletin 377, 2002).  
 
¿ Lines 569-570 
The TFA content of margarine and fat spreads may vary, depending on the proportion of partially hydrogenated oils used. 
However, recent analyses have shown that products with high levels of industrially produced TFA are still available on the 
market (Stender et al., 2008). The range of TFA content in wt% of total fatty acids of those products should be added. 
 
¿ Line 572 
The 18:1 TFA profiles of ruminant fat and hydrogenated vegetable oils show considerable overlap for many isomers. However, 
in contrast to ruminant fat non-palm-based-vegetable cooking oil can contain considerable amounts (0.4-2.7%) of C18:2 trans-
cis, cis-trans and trans-trans, and C18:3 trans (up to 2.7%) (Tang, 2002). Partially hydrogenated vegetable oils can contain 1–
65% of TFA, of which isomers of elaidic acid (trans-9 and trans-10 18:1) are the two most common isomers.  
On the other hand, dairy products contain smaller amounts of TFA (1–8% of total fatty acids in milk fat), and the main isomer is 
vaccenic acid (trans-11 18:1). Humans can utilize vaccenic acid, in the endogenous synthesis of rumenic acid (cis-9, trans-11 
18:2), a fatty acid that may not have a negative effect on biomarkers of CVD risk. These two sources of TFA differ in their TFA 
isomer distribution and contribution to dietary intake, and, as a consequence, they also may have different biological effects 
(Chardigny et al., 2008) 
 
¿ Lines 574 and 579 
The actual content of TFA in wt% of total fatty acids in animal fat and industrial fat should be included in the table 4. The 
concentration of industrial hydrogenated TFA may be as high as 60%, whereas the maximum content of natural TFA in 
ruminant fat is about 6% (Stender et al., 2008). This information should also be included in the text in connection of the table 4.  
 
¿ Line 583 
In humans the conversion rate of trans-vaccenic acid to rumenic acid is around 19% (Turpeinen et al., 2002) to 20% (Lock et 
al., 2005).  
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EDA 3. Dietary sources 
and intake data 
¿ Line 593 
In France, more recent data than Volatier (2000) and Deschamp (2005) is available. The INCA 2 study, for example, is more 
recent and could be used for this paragraph and the annexes (AFSSA, 2009b). 
 
¿ Line 605 
The presented data are not representative of the whole population but rather for a specific target group of the population (elderly 
in Portugal for example). Besides, some methods (like FFQ) are not accurate. 
 
¿ Line 618 
Data for the lowest intake in Portugal are not representative as it concerns the elderly population which is not an average but an 
extreme level. Besides, data are not very accurate as it is FFQ method. 
 
¿ Line 627 
In France, according to the INCA 2 study, the SFA intake is more around 15% than 17% (AFSSA, 2009b). 
 
¿ Line 669 
For those countries where separate intake data for industrial TFA and natural TFA are available, those should be provided 
(Craig-Schmidt, 2006; Jakobsen, 2007). 
 
¿ Lines 676-678 
The available data shows that total TFA intake has decreased close to WHO recommendation of 1 E%. This is due to 
reformulation of food products containing TFA originating from partially hydrogenated vegetable fats and oils. In the same 
report, WHO also mentions that most TFA are contributed by industrially hardened oils and that to promote cardiovascular 
health, diets should provide a very low intake of TFA from hydrogenated oils and fats (Uauy et al., 2009).  
 
¿ Lines 681-682 
Leave out “including … from other sources”. Replace by (after line 684): In most European countries with a high TFA intake 
(>2.5 g/d), the major part of the TFA was from industrial sources (Craig-Schmidt, 2006).  
 
¿ Line 690 
“In adults, average intakes range from nearly 200 mg/day to 655 mg/day”. This is not an average intake (replace “average” by 
“extreme range”): 655 mg/day concerns only one study for adult men. 
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EDA 3. Dietary sources 
and intake data 
¿ Lines 509-519 
Why are a US database used and a European database reference not required? Dietary databases indeed exist in Europe, for 
example, CIQUAL 2008 in France. European intake data should be given, where possible.  
No distinction is made between short-chain, medium-chain and long-chain SFA (see table in comments to line 530).  
 
¿ Lines 513  
The purpose of including table 2 is not clear. The selection of fats does not cover the major food groups in the diet. Other 
animal fats, such as tallow, fish fat and vegetable oils and margarine as well as shortenings for industrial processing should be 
included in table 2. Isomers of trans 18:1 should also be included in the table.  
 
¿ Lines 514 
In table 2 the ratio n-6/n-3 PUFA should be added as this is relevant information for the fatty acid balance of fats and oils.  
 
¿ Lines 520-529 
The Dutch NEVO table for fatty fish provides following data: total fat (g) 23.8, SFA 5.6, MUFA 10.5 PUFA 5.1 (high SFA fish 
(g total fat/g SFA) = Mackerel (30.7, 7.4); Eel (35, 8.7); Herring (14, 3.3); Salmon (14.2, 3.7)). These numbers differ quite a lot 
from the fatty fish data given in table 3. 
The basis for the selection of animal-derived food products is not entirely clear as, for example, eggs are missing. Besides, it is 
inconsistent to choose on one side only lean meat but on the other side present only standard butter and full fat milk. Semi-
skimmed milk should be used instead as it is the most consumed type of milk in Europe. In France, for example, 73% of the 
milk consumed is semi-skimmed milk (data from CNIEL, Centre National Interprofessionnel de l''Economie Laitière, 2007). 
 
¿ Line 523 
Several dietary databases exist in Europe, for example, CIQUAL 2008 in France. Why was US data used? 
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EDA 4. Overview of 
dietary reference 
values and 
recommendations 
¿ Lines 930-933 
In 2005, AFSSA has done a review of studies on the metabolism and toxicity of TFA and their impact on health. They 
concluded that consumption of total TFA above 2% of total energy intake resulted in a significantly increased risk of CVD. At 
that time, they did not really distinguish the origin – natural or industrial - of TFA. New data concerning TFA content of food, 
population intakes as well as new scientific results from epidemiological and clinical studies have conducted AFSSA to reassess 
its previous conclusions (AFSSA, 2009a). AFSSA considers that:  
•The estimated average intake of TFA in the French population (around 1%) is lower than the threshold of 2% of the total 
energy intake. This is true for adults as well as for children independently of age and sex. The intake is lower than in 2005. 
•It is necessary to pursue the improvement of the food composition tables with regard to TFA. The contribution of different 
types of food to TFA intake should be considered in more detail, in particular the cheapest priced products, discount products, 
catering and small-scale ("artisanal") products etc. which are insufficiently known at this moment. 
•Considering the total TFA intake, the origin of the TFA, natural or industrial, should be taken into account. Concerning TFA of 
natural origin; consumption levels in the French population (0.5-0.9% of the total energy intake) are lower than levels identified 
as not posing a risk of CVD (1.5% of the total energy intake); TFA from industrial origin that are present in foods only have a 
technological function. Thus, AFSSA encourages the efforts to reduce the use of industrial TFA in human food, in order to 
reduce the risk of exposure.  
As a conclusion, the recommendation is to decrease TFA intake only concerns industrial TFA. 
 
¿ Lines 934-937 
Only the newest guideline available should be used. The Health Council of the Netherlands has published updated dietary 
reference intakes for fats and fatty acids for the Netherlands in 2006. It is stated there that “mono trans fatty acid intake needs to 
be brought down from 1 to 2 per cent to less than 1 per cent.” Table 6 (line 2915) has to be updated accordingly with the dietary 
reference value of TFA for adults < 1 E% (instead of “as low as possible”). There only the values for EPA and DHA refer to the 
2006 Dutch guidelines.  
 
¿ Line 938 
The 2009 Joint FAO/WHO Expert Consultation on “Fats and Fatty Acids in Human Nutrition” confirms that the UL for TFA 
from ruminants and industrially produced sources should be <1% E. This recommendation is done with the focus on industrial 
trans fat being reduced to 0.5 E%. Ruminant trans fat intake was not recommended to be lowered because the average intake is 
at approximately 0.5 E% (Elmadfa and Kornsteiner, 2009). 
 
¿ Line 939 
The Nutritional Recommendations for the French Population (AFSSA, 2001) indicate that the limitation of exogenous 
cholesterol does not seem to be justified for the general population, as dietary cholesterol has only very limited impact on blood 
cholesterol. 
 
¿ Line 944 
Outcome of the Public consultation on the Draft Opinion on  
Dietary Reference Values for fats 
 
107 EFSA Journal 2010; 8(5):1507 
ORGANISATION CHAPTER TEXT COMMENT TEXT 
The Nutritional Recommendations for the French Population (AFSSA, 2001) indicate that for older children and adolescents it 
does not seem reasonable to recommend fat intake below 30 E%. 
 
¿ Line 969 
The French recommendations for SFA intake for children are 8 to 12 E% (AFSSA, 2001). 
 
¿ Line 1032 
The French recommendations for cholesterol intake for children after 3 years of age are 300 mg/day (AFSSA, 2001). 
 
¿ Line 1035 
The recent AFSSA report should be taken into account for the overview of dietary recommendations in the table (AFSSA, 
2009a). Thus, a distinction between natural and industrial TFA should be made. The WHO recommendation also concerns only 
TFA from industrial origin. This should be specified here (WHO, 2003). 
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EDA 4. Overview of 
dietary reference 
values and 
recommendations 
It is not clear on which criteria the chosen dietary guidelines were selected. 
 
¿ Line 705 
It is important to mention that some national recommendations in Europe such as in France take into account the different 
effects of TFA according to their sources (natural or industrial) (AFSSA, 2009a). 
 
¿ Lines 749-756 
The 2009 Joint FAO/WHO Expert Consultation on “Fats and Fatty Acids in Human Nutrition” sets dietary recommendations 
for total fat at 20-35 E% (acceptable macronutrient distribution range) compared to the population nutrient intake goal of 15-30 
E% mentioned in the 2003 WHO report (Elmadfa and Kornsteiner, 2009). For children from 2 to 18 years, the recommendation 
for the total dietary fat intake is 30-40 E% depending on activity (Uauy and Dangour, 2009).  
 
¿ Lines 771-775 
Different SFA should be considered independently as there is evidence to indicate that certain SFA might have a beneficial role. 
Recent data show that the different SFA in milk fat have different effects on health. Several studies show that short-chain and 
medium-chain SFA do not have a negative impact on the blood lipid profile. They are easily digested and metabolised 
differently in the body compared to longer chain fatty acids. Certain long-chain SFA such as stearic acid act neutral on the 
cholesterol level. Myristic acid has various physiological roles in the body such as protein metabolism and the synthesis of n-3 
long-chain fatty acids (Lecerf 2009, Legrand 2008, Rioux and Legrand 2007). 
 
¿ Lines 776-779 
Only the newest guideline available should be used. The Health Council of the Netherlands has published updated dietary 
reference intakes for fats and fatty acids for the Netherlands in 2006. It is stated there that “The average intake of saturated fatty 
acids in the diet needs to be cut from 13 to 14 per cent of energy intake to less than 10 per cent.” Therefore, the dietary 
reference value for SFA for adults is < 10 E%. A mentioning of “as low as possible” cannot be found in the summary of the 
Dutch guidelines.  
 
¿ Line 780 
The 2009 Joint FAO/WHO Expert Consultation on “Fats and Fatty Acids in Human Nutrition” confirms that the intake of SFA 
should not exceed a maximum level of 10 E% (Elmadfa and Kornsteiner, 2009). 
 
¿ Lines 918-921 
Within the Nordic Nutrition Recommendations (2004), a maximum intake of 10 E% of SFA plus TFA is given. It is also 
mentioned that the intake of TFA from hydrogenated oils should be as “low as possible” (table 1). 
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EDA 5.1. Dietary 
requirements 
In purpose of defining dietary guidelines for nutrients such as fat, a transparent and systematic review of the scientific data has 
to be performed. In the present scientific overview “5.1 Dietary requirements”, the method used for selecting scientific data is 
not presented. 
 
¿ Line 1067 
As mentioned in lines 614-616 “In adults average total fat intakes ranged from less than 30 E% to 47 E%. About 43% of the 
reported average data were between 30 and 35 E%; 13% were 40 E% or higher”. This average value (in addition to lower and 
upper end) is also important as it shows that for adults the fat intake is over 30% in more than 50% of the average data reported.  
 
¿ Line 1068-1070 
This sentence should also be in the summary.  
 
¿ Lines 1072-1073 
“Such low fat intakes are highly unlikely in European countries”: If very low fat intakes are very unlikely in Europe, the lowest 
recommended fat intake should not include this kind of low consumption as it is not representative. Under 30 E% of fat 
consumption, a balanced intake of the different fatty acid is indeed hard to achieve (AFSSA, 2001). 
 
¿ Lines 1072-1074 
Please provide references for this statement. 
It seems important to take into account that reducing total fat intake can lead to an increase in carbohydrate intake. A high 
intake of carbohydrates (refined, high glycemic index) may adversely affect insulin homeostasis, satiety and weight gain 
(Mozaffarian, 2005) and can lead to a high synthesis of palmitic acid. Recent studies show that a lower fat-diet but rich in 
carbohydrates stimulated saturated fatty acid synthesis - especially palmitate - at high rates (Wilke et al., 2009). 
 
¿ Line 1118 
In lines 1109-1112 a clear example is given that diets containing less than 30 E% from fat can have negative effects on weight 
and vitamin intake. Only in the STRIP Trial evidence is provided that 25-30% has no negative effect on growth and 
neurological development. Furthermore, none of the studies presented found negative effects of higher fat intake (>35%) 
compared to lower fat intakes. Why than come to 25% as appropriate (line 1118) and in the table “Summary of DRVs for fats” 
(line 2055) to an RI of 20-35% for >4 year olds? It appears more prudent to advise a level of 30-40%. 
 
¿ Line 1121 
Previous studies have suggested that interventions to lower dietary fat content and improved fat quality lead to a compensatory 
increase in sucrose content. There has been a concern that dietary recommendations aimed at achieving a low saturated fat diet 
might lead to inappropriately increased sugar intake (Gibney et al., 1995) and some studies suggest that an inverse relationship 
exists between the intake of fat and simple sugars (Gibson, 1997; Lewis et al., 1992; Hackett, 1993). Other studies show that 
children with an intake of <30% of energy from fat consumed more carbohydrates (mainly sucrose) than those children whose 
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diets contained >40% of energy from fat (Nicklas et al., 1992; Kennedy et al., 1999a). 
Moreover, restriction of fat in children is questionable (Olson, 2000). There is no evidence that low-fat diets in childhood will 
prevent atherosclerosis in adulthood. The claim that low-fat diets are safe in childhood is based on observations over a too short 
time to establish safety. If growth and development of children are not changed with low-fat diets, the proof of long-term safety 
is not substantiated. 
 
¿ Lines 1139-1142 
Editorial comment: “A LA intake of less … the form of LA.” is also taken from Hansen et al., 1963. The reference should be 
cited after that sentence.  
EDA 5.10. Cancer ¿ Line 1778 
It should be added that it concerns TFA from industrial origin as the author indicate that ”a high serum level of trans 
monounsaturated fatty acids, presumably reflecting a high intake of industrially processed foods, is probably one factor 
contributing to increased risk of invasive breast cancer in women.” 
 
¿ Line 1780 
It is not “associated” as there is “limited evidence” (WCRF/AICR, 2007) 
 
¿ Line 1781 
There are only “limited-suggestive evidence” and no association (WCRF/AICR, 2007). 
 
¿ Line 1785 
The WCRF/AICR Expert Report “Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective” (five 
years of work driven by an independent panel of 21 world renowned scientists) is the most recent and complete synthesis of the 
available scientific data on this topic. It would be pertinent to refer to this report systematically. 
For example, WCRF judged that:  
There is “limited evidence-no conclusion” to support a link between fats and oils or fatty acids composition and breast cancer 
risk, whatever the menopausal status.  
There is “limited evidence-suggestive” that butter increases lung cancer risk. 
There is limited-suggestive evidence that foods containing animal fats increases colorectal cancer risk (not any word about olive 
oil). 
A new study from China suggests that increasing the intake of n-3 fatty acids, and decreasing intakes of n-6, could reduce the 
risk of colorectal cancer. The highest dietary ratio of n/3-n-6 was associated with a 95 per cent increase in the risk of women 
developing colorectal cancer, according to results of a study with 73.242 Chinese women participating in the Shanghai 
Women''s Health Study (Murff et al., 2009).  
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EDA 5.2. Serum lipids 
and lipoproteins 
¿ Line 1237 
Not only long-chain, but also medium-chain and short-chain fatty acids should be discussed for disease risk. Short and medium-
chain fatty acids are not transported via the chylomicron system, and are not linked to changes is lipoprotein profiles. This is 
also relevant for paragraphs 5.8 and 6.2. Their effects on CAD and cholesterol have not been a dietary issue (German and 
Dillard, 2004). There is some evidence that short and medium-chain fatty acids have antiviral and antitumor activity (German 
and Dillard, 2004).  
SFA cannot be considered as a whole, in terms of structure, metabolism and cellular functions (Parodi, 2009). Short and 
medium-chain SFA have a hypocholesterolemic effect at physiological dose (this effect of diets high in C8 and C10 was shown 
in humans by Hashim (1960).  
In a recent meta-analysis, the effects of the individual SFA on the serum lipoprotein profile have been estimated (Mensik et al., 
2003). Iso-energetic replacement of carbohydrates with lauric, myristic and palmitic acids all resulted in increased total, LDL 
and HDL cholesterol concentrations. But as the cholesterol-raising effects of lauric acid were proportionally higher on HDL 
than on LDL cholesterol, replacement of carbohydrates by lauric acid resulted in a significantly lower total / HDL cholesterol 
ratio (The ratio of total to HDL cholesterol is a more powerful predictor of CHD risk than either total or LDL cholesterol levels 
(Stampfer et al., 1991)), which suggests a decrease in atherosclerotic risk.  
Stearic acid had the smallest effect on HDL cholesterol but lowered total and LDL cholesterol, and thus also decreased the total 
/ HDL cholesterol ratio. Palmitic acid is the only fatty acids which increased the total / HDL cholesterol ratio (Mensink et al., 
2003), fact confirmed in other studies (Salter et al., 1998; Billet MA, 2000). Stearic acid decreases LDL cholesterol, similar 
effect that oleic acid (Mensink, 2005). 
No differences between the effects of the different SFA on fasting serum triacylglycerol concentrations were detected (Mensink, 
2003) (see especially figure 3 of this study). 
Myristic acid has no hypercholesterolemic effect but has rather positive action through an increase of HDL-cholesterol when 
consume at usual level (Temme et al., 1997; Salter et al., 1998; Billet MA, 2000; Dabadie, 2005; Tholstrup et al., 1994 and 
2003b). Negative effects of myristic acid that have been described were only the result of massive doses that are well above the 
usual consumption (Staiger K et al., 2006). 
 
¿ Lines 1238-1241 
The term “mixture” used here leads to an oversimplification and does not indicate which SFA are concerned. EFSA should 
indicate what the SFA involved are. Besides, SFA cannot be considered as a whole, in terms of structure, metabolism and 
cellular functions. Doses, population and references should also be indicated to support this statement. 
 
¿ Line 1251 
The analysis of sub fractions in subjects given low carbohydrate diets with either higher or lower content of SFA shows that the 
saturated fat intake results in an increase in the larger buoyant LDL rather than the smaller LDL particles. The small, dense 
LDL particles have been associated with increased risk of CVD, whereas large LDL particles have not (Krauss, 2006).  
Mozaffarian et al. (2004) also show that in postmenopausal women with relatively low total fat intake, a greater saturated fat 
intake is associated with less progression of coronary atherosclerosis. The proposed hypothesis is that a decrease in fat intake 
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leads to worsen the lipid profile: decrease of HDL cholesterol, increase of TG and B-phenotype of LDL (small and dense LDL) 
(Dreon et al., 1998; Dreon et al., 1999; Krauss et al., 2006; Lefebvre et al., 2005).  
EDA 5.2. Serum lipids 
and lipoproteins 
¿ Lines 1253-1254 
Cis-MUFA had similar effects on serum total cholesterol concentrations as carbohydrates in Hegsted et al. (1965). Thus, many 
researchers compared the effects on MUFA, in particular oleic acid, and carbohydrates on the distribution of cholesterol over 
the different lipoproteins (Grundy, 1986; Mensink and Katan, 1987). From these studies it appeared that effects of oleic acid 
and carbohydrates are indeed similar on total cholesterol concentrations, but that oleic acid increased HDL cholesterol and 
lowered VLDL cholesterol and triacylglycerol concentrations (Thijssen and Mensink, 2005). 
 
¿ Line 1266 
Please provide reference for this statement 
 
¿ Lines 1281-1282 
Remove: “like diets containing mixtures of SFA“. This sentence is not relevant in this part about TFA. Besides, the term 
“mixture” is not precise and does not mean anything about which fatty acids are concerned. 
 
¿ Line 1284 
Clarke (2009) is not an intervention study. It is just a simulation. 
 
¿ Lines 1294-1296 
Please provide reference for this statement.  
 
¿ Lines 1297-1298 
“In most of the human intervention studies reviewed above, the effects of trans-MUFA from hydrogenated vegetable oils were 
assessed”. This sentence should be the introduction of the paragraph as there are two parts here, one about industrially produced 
TFA, the other one about ruminant TFA, starting line 1298. 
 
¿ Lines 1298-1299 
Extreme high intakes of ruminant TFA (3.7 E% or 5 E%) indeed appear to have adverse effects on blood lipid profiles. 
However, these high levels of ruminant TFA cannot be reached with a normal diet. The habitual intake of ruminant TFA is far 
below this amount (Craig-Schmidt, 2006; Willett and Mozaffarian, 2008). On the other hand, ingesting 20-40g (> 5 E%) 
industrially produced TFA is not at all unrealistic (Stender et al., 2008). Why is this not mentioned? 
 
¿ Line 1301 
“3.7% of energy from TF” This high percentage does not reflect the usual intake in European countries. In France, TFA intake 
from natural origin represent only 0.5-0.9% of the total energy intake (AFSSA, 2009a).  
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¿ Line 1307 
The European Parliament study on TFA (2008) aimed at providing background information to Members of the European 
Parliament on TFA. The report highlighted the fact that although there was considerable scientific evidence showing a causative 
link between intake of industrially produced TFA and cardiovascular disease, scientific studies also revealed that consumption 
of naturally occurring TFA at levels found in regular diets do not contribute to elevated risk of cardiovascular disease. 
Therefore the authors mentioned that it is important to make a clear distinction between naturally occurring and industrially 
produced TFA when developing possible guidelines for action to reduce the intake of TFA. Any legal restrictions should be 
limited to industrially produced TFA. 
 
 
¿ Line 1309 
Remove “like diets containing mixtures of SFA“. This sentence is not relevant in this part about TFA. Besides, the term 
“mixture” is not precise and does not mean anything about which fatty acids are concerned. 
 
¿ Line 1311  
“Consumption of diets containing trans-MUFA also…” “Also” has to be removed as TFA and some SFA do not have the same 
effects on HDL cholesterol. 
EDA 5.2. Serum lipids 
and lipoproteins 
¿ Lines 1312-1314 
“The available evidence indicates that TFA from ruminant sources have similar adverse effects on blood lipids and lipoproteins 
to those from industrial sources”. This is true only at very high levels of TFA intake, corresponding to diets with 3.7% of 
energy from TFA - indeed 9 litres of semi-skimmed milk, 4 kg of yoghurt or 800g of camembert cheese – as the average 
content of TFA in milk fat is 5.39% of total fatty acids (AFSSA, 2005). 
 
¿ Line 1314 
However, the intake of ruminant TFA is low in most populations. In the French diet, for example, the natural TFA intake ranges 
from 0.5-0.9% of the total energy intake (AFSSA, 2009a). This amount is far lower than the 3.7% tested in the Motard-Bélanger 
study (2008). The French intake values have been established by a consumption survey, INCA2 (2006-2007), on more than 
4000 persons (AFSSA, 2009b). 
 
¿ Lines 1326-1327 
“The intervention studies do not provide evidence that a mixture of CLA isomers, cis-9, trans-11 CLA, or trans-10, cis-12 CLA 
have an impact on the serum lipoprotein profile.” However, as explained in this scientific opinion on line 1319-1321 some 
studies are showing that cis-9, trans-11 is more favourable as compared with trans-10, cis-12 CLA on lipoprotein profile. The 
conclusion should be also that more studies are needed on purified CLA isomers. 
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¿ Line 1340 
Kratz also conducted a systematic review on animal and human (intervention and observational) studies. Based on the results of 
these studies, the author found that an increase in dietary cholesterol intake resulted in only a minimal increase in the total/HDL 
cholesterol ratio, as most subjects can effectively adapt to higher levels of cholesterol intakes (Kratz, 2005).  
 
¿ Lines 1342-1344 
“Under iso-energetic conditions, the most favourable lipoprotein profile to lower atherosclerotic risk is achieved when a mixture 
of SFA and TFA is replaced by a mixture of oleic acid, linoleic acid and fish fatty acids. These effects are dose-dependent”.  
Those sentences should be removed from the scientific draft opinion: “mixture” does not mean anything and as shown in our 
previous comments it is not possible to consider SFA as a whole in terms of structure, metabolism and cellular functions. The 
same remark can be made for TFA: the difference should be made between industrial or natural TFA. The intake of ruminant 
TFA is indeed low in most populations. In the French diet, for example, the natural TFA intake ranges from 0.5-0.9% of the 
total energy intake (AFSSA, 2009a). This amount is far lower than the 3.7% tested in the Motard-Bélanger study (2008). The 
French intake values have been established by a consumption survey, INCA2 (2006-2007), on more than 4000 persons 
(AFSSA, 2009b). 
 
¿ Lines 1341-1346 
The effect of stearic acid is neutral (Yu et al., 1995). The effects are also dose dependant. Myristic acid has no 
hypercholesterolemic effect but has rather positive action through an increase of HDL-cholesterol when consumed at usual level 
(Temme et al., 1997; Salter et al., 1998; Billet MA, 2000).  
Consumption of naturally occurring TFA at levels found in regular diets does not contribute to elevated risk of cardiovascular 
disease (see the European Parliament study, 2008).  
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EDA 5.2. Serum lipids 
and lipoproteins 
In purpose of defining dietary guidelines for nutrients such as fat, a transparent and systematic review of the scientific data has 
to be performed. In the present scientific overview “5.2 Serum lipids and lipoproteins” the method used for selecting scientific 
data is not presented. 
 
¿ Lines 1223-1228 
The relevance of lipoprotein markers should be mentioned and discussed in relation to their relevance for hard endpoints.  
A randomized clinical trial (RCT) that shows a statistically significant benefit in disease mortality rather than a benefit for a 
surrogate endpoint is the pinnacle of evidence–based medicine. However, this is not always feasible. Cholesterol markers have 
been used as surrogate endpoints to study the effect of dietary fat in RCTs - especially as a marker for CVD risk. 
For many years, the only biomarkers of CHD risk recognized by health authorities have been total cholesterol and LDL 
cholesterol. Recently, the Expert Panel of the WHO Scientific Update on trans fatty acids pronounced the ratio of total 
cholesterol to HDL cholesterol as the “best single lipid predictor of CHD risk” (Uauy et al., 2009).  
Extensive research has changed the simplistic view of atherosclerosis (the major underlying cause for CHD (Das, 2007)) as a 
disorder of pathological lipid deposition to a more complex concept of an ongoing inflammatory response (Stoll and Bendszus, 
2006). Therefore, effects on inflammatory markers are often included in newer RCTs.  
 
¿ Lines 1231-1234 
No references are provided for this statement. 
 
¿ Lines 1229-1236 
The conclusion of 5.2.1 is missing. According to EDA interpretation, these results show that at low intake of SFA (<10 E%) 
decreasing total fat intakes worsen the lipid profile leading to higher atherosclerosis risk (increases the total/HDL cholesterol 
ratio and TG, decreases serum concentrations of HDL cholesterol) (See also Mensink et al., 2003). 
The decrease of fat intake in men to 28% or 24% at stable body weight, leads to a decrease of LDL cholesterol but also to an 
decrease of HDL cholesterol, an increase of TG and LDL small and dense) (Lefebvre et al., 2005; Wood, 2006; Dreon, 1999).  
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EDA 5.3. Haemostatic 
function 
¿ Line 1362 
If the studies are far from consistent, those sentences should be reformulated. Suggestion: “Although C12:0 to C16:0 SFA have 
been suspected to increase factor VII levels as compared to stearic acid (C18:0), the studies were far from consistent and no 
conclusion can be made. Moreover, in one study, post-prandial increases in activity of factor VII were less after consumption of 
meals rich in SFA, especially stearic acid, than after a consumption of meals enriched with unsaturated fatty acids (Thijssen and 
Mensink, 2005; Tholstrup et al., 2003a).” 
 
¿ Line 1364 
Relative to oleic acid, and unlike to n-6 PUFA, either medium-chain SFA or lauric or myristic or palmitic acids did not affect 
collagen-induced whole blood aggregation. Furthermore, ADP-induced platelet aggregation was not changed by medium-chain 
saturated fatty acids or myristic acid (Thijssen and Mensink, 2005; Temme et al., 1998).  
 
¿ Line 1375 
According to the Thijssen and Mensik (2005), thromboxanes (TX) and prostaglandins (PG), two eicosanoids, play an important 
role in the haemostatic balance. Both types of eicosanoids are synthesised from the C20 fatty acids, arachidonic acid (C20:4n-6) 
and EPA (C20:5n-3), after release from membrane phospholipids.  
Eicosanoids of the n-2 series, such as TXA2, are synthesized from the n-6 arachidonic acid in platelets, while prostaglandins I2 
(PGI2) is synthesised in the vascular endothelium. TXA2 is a potent vasoconstrictor and a stimulus for platelet aggregation, 
whereas PGI2 has opposite effects.  
Eicosanoids of the n-3 series such as TXA3 and PGI3 are principal metabolites of the n-3 fatty acid EPA. TXA3 is less active 
than TXA2, meaning than the vasoconstrictor effects due to n-6 fatty acids is higher than the ones induced by the n-3 fatty 
acids. The anti-aggregation effects of PGI3 and PGI2 are however comparable.  
Furthermore, n-6 PUFA increased urinary 11-dehydro-TXB2 excretion compared with saturated and monounsaturated fatty 
acids, which seemed to reflect an ADP-induced platelet aggregation (Lahoz et al., 1997; Thijssen and Mensik, 2005). Increased 
ADP-induced platelet aggregation is associated with increased atherosclerotic risk (Elwood et al., 1991; Thijssen and Mensik, 
2005).  
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EDA 5.4. Inflammation 
and immne 
function 
¿ Line 1422 
Additional information: A randomized, controlled, 3-diet, 3-period crossover study was published in 2007 in the American 
Journal of Clinical Nutrition (Zhao et al., 2007). Hypercholesterolemic subjects (n=23) were assigned to 3 experimental diets: a 
diet high in ALA (6.5 E%), a diet high in LA (12.6 E%), and an average American diet for 6 weeks. Results showed that 
increased intakes of dietary ALA elicited anti-inflammatory effects by inhibiting pro-inflammatory cytokine production (IL-6, 
IL-1ß and TNF-a) in cultured PBMCs (Peripheral Blood Mononuclear Cells). Changes in PBMC ALA and EPA were 
associated with beneficial changes in TNF-a release. ALA could thus have some effects of reduction in the production of 
inflammatory cytokines.  
 
¿ Line 1426 
This line correctly reports that TFA from hydrogenated sources (not ruminant sources) have been linked to adverse effects on 
inflammatory profile in epidemiological studies. Why is this not mentioned in the overall summary (line 129-146)? 
 
¿ Lines 1434-1439 
While it is mentioned in the conclusion that no consistent picture has emerged on effects on n-6 PUFA, no references are 
provided for that in part 5.4.1.  
EDA 5.7. Body weight 
control and energy 
balance 
¿ Lines 1583-1593 
Profound quantitative and qualitative changes have taken place in the last four decades in the Western industrialised world, 
particularly the rising intake of n-6 and declining intake of n-3 PUFA. A recent review (Ailhaud et al., 2008) suggests that this 
imbalance in PUFA intake is an emerging risk factor contributing in addition to long-term net positive energy balance. The 
authors propose that several aspects of unbalanced PUFA metabolism conspire to stimulate fat cell formation and to increase 
the prevalence of overweight and obesity such as low n-3 PUFA intake, overestimation of linoleic acid requirement and 
significant increase in the LA:LNA ratio. Thus, nutritional recommendation should not stress the n-6 PUFA over consumption, 
and promote instead a good equilibration between n-3 PUFA and n-6 PUFA. 
 
¿ Line 1618 
It is important to add in the conclusion that based on some recent studies, nutritional recommendation on n-6 PUFA intake 
should not promote their over consumption but rather a good balance between n-3 PUFA and n-6 PUFA (Ailhaud et al., 2008). 
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EDA 5.8. Cardiovascular 
disease 
¿ Line 1626 
General comment on this part about “Cardiovascular disease: the analysis on the effect of lipids on cardiovascular disease is 
quite poor compared to the analysis made on serum lipids and lipoproteins made in part 5.2.  
For example there is almost no data on stroke, which is actually a part of cardiovascular diseases and should be considered. 
Ecological studies suggest that saturated fat (mostly animal fat) is inversely associated with stroke. Some studies suggest that 
high intake of PUFA could have a negative effect on oxidation process and inflammatory mechanism involved in the stability of 
the plaque (Thies et al., 2003).  
Epidemiological studies show that saturated fat is either associated to a significant decreased risk of stroke (Framingham Study 
– ischemic stroke, Gilman, 1997; Nurses‟ Health study – hemorrhagic stroke, Iso, 2001; Japanese cohort of 4500 subjects - 
hemorrhagic stroke, Iso, 2003) or no related to the risk of stroke (Health professional Study, He, 2003) 
 
¿ Line 1632 
What are the selection criteria for selecting only those four studies? 
 
¿ Line 1628 
Concerning total fat, a reduction in fat intake is frequently construed as a recommendation in cardiovascular disease prevention. 
However, the question is now increasingly subject to debate (Mozaffarian et al., 2004). 
 
¿ Line 1644 
Howard et al. (2006) also shows that no benefit was observed in terms of coronary disease, cardiovascular or cerebro-vascular 
disease with the decrease of fat intake and decrease of SFA to 9.5%. On the contrary, for some women with cardiovascular 
history, there was an increase of their cardiovascular disease risk linked to a decrease of lipids and SFA intake. 
EDA 5.8. Cardiovascular 
disease 
¿ Lines 1627-1644 
 
A Cochrane and MEDLINE meta-analysis (Hooper et al., 2001 and 2002) based on 18,196 subjects with 30,901 person-years of 
observation from 27 randomised intervention trials, and a total of 40 intervention arms lasting at least 6 months found small 
effects with reduced or modified dietary fat on overall mortality (0.98, 95% CI 0.86-1.12), with a non-significant trend towards 
reduced cardiovascular mortality (0.91, 95% CI 0.77-1.07) or events (0.86; 95% CI 0.72-1.03). Results were different if 
participants were at high initial cardiovascular risk (0.84; 95% CI: 0.70-0.99), suggesting a protection from fat reduction, or at 
low cardiovascular risk (0.82; 0.56-1.20), suggesting no effect.  
Elmadfa and Kornsteiner (2009) stated that “The meta-analysis by Skeaff and Miller (2009) demonstrated that the relative risk 
of CHD death in the highest (14–18 E%) category of SFA consumption was not significantly different from that in the lowest 
(7–11 E%) category. High compared with low SFA consumption was not significantly related with diverse risk factors of CHD 
events.” 
Skeaff and Miller (2009) carried out a very recent and exhaustive review of cohort studies and controlled trials of dietary fats 
and CHD mortality or morbidity (search in the Cochrane Library, Cochrane reviews, article databases, systematic reviews, 
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meta-analysis, etc.). 28 individual cohort studies were selected, in which there were about 6,600 CHD deaths amongst 280,000 
participants during approximately 3.7 million person-years of follow-up.  
The authors state on p. 191: “According to the classic „diet-heart‟ hypothesis, high intake of SFAs and cholesterol and low 
intake of PUFAs increase serum cholesterol levels and risk of CHD. However, few within-population studies have been able to 
demonstrate consistent associations with any specific dietary lipids, with the exception of trans fats and n-3 fatty acids. The 
available evidence from cohort and randomized controlled trials is unsatisfactory and unreliable to make judgment about and 
substantiate the effects of dietary fat on risk of CHD.” Continuing further it is mentioned that “Furthermore, the evidence from 
cohort studies of dietary intake of fats and CHD is mostly unreliable (with few exceptions) because most studies have ignored 
the effects of measurement error and regression dilution bias.” 
According to the results of this study  
Total fat:  
¿Intake of total fat was not significantly associated with CHD mortality, with a RR for highest compared with the lowest 
category of 0.94 (95% CI of 0.74-1.18, p=0.583); 
¿Intake of total fat was also unrelated to CHD events (RR 0.93, 95% CI 0.84-1.03, p=0.177); 
¿No significant association of total fat intake with CHD mortality (RR 1.06, 95% CI 0.88-1.28, p=0.517) or CHD events (RR 
1.02, 95% CI 0.98-1.05, p=0.404) per 5% total energy increment in total fat intake ; 
¿Overall, the mean or median total fat intake in all cohort studies varied from 27-47% total energy.  
 
SFA:  
¿Intake of SFA was not significantly associated with CHD mortality (RR 1.14, 95% CI 0.82-1.60, p=0.431) for highest 
compared to lowest category of SFA intake 
¿SFA intake was not significantly associated with CHD events (RR 0.93, 95% CI 0.83-1.05, p=0.269 for high vs. low category) 
¿No significant association of SFA intake with CHD death (RR 1.11, 95% CI 0.75-1.65, p=0.593) per 5% total energy 
increment in SFA intake 
¿Overall, the mean or median SFA intake in all cohort studies varied from 9-20% total energy.  
EDA 5.8. Cardiovascular 
disease 
¿ Lines 1627-1644 
 
continued: 
 
MUFA:  
¿No significant association with CHD mortality / CHD deaths or CHD events 
 
PUFA:  
¿Intake of PUFA was strongly significantly associated with CHD mortality with a RR 1.25, 95% CI 1.06-1.47, p=0.009) for 
highest compared to lowest category 
¿High compared with low PUFA intake was not associated with CHD events (RR 0.97, 95% CI 0.74-1.27, p=0.825) for highest 
compared to lowest category 
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¿Significant lower risk of CHD events (RR 0.84, 95% CI 0.70-1.00, p=0.049) per 5% total energy increment in PUFA intake, 
but not with CHD mortality.  
Moreover, the results of this review showed that the RR of fatal CHD was not reduced by either low-fat diets or diets with a 
high polyunsaturated to saturated fat ratio (P/S ratio).  
 
In conclusion, the results of the studies described above tend to show that dietary intervention in healthy people of diets low in 
total fat or SFA were unsuccessful or provided insufficient evidence in reducing the incidence of cardiovascular disease (for 
more details, see also Ravnskov, 1998; Ramsden et al., 2009). It also appears that in coronary heart disease, the 
overconsumption of n-6 PUFA must not be encouraged since it can increase plaque instability (Lecerf, 2009).  
 
A recent systematic review of 146 prospective cohort studies and 43 RCTs from Europe, the US and Asia, investigating dietary 
factors related to CHD carried out by Mente et al. (2009) found insufficient evidence of an association between intake of total 
fat, SFA, PUFA, milk, meat and eggs and risk of CHD, but found protective associations for intakes of MUFA, fish, n-3 fatty 
acids, folate, whole grains, vitamins E and C, beta carotene, alcohol, fruit and fibre. A harmful association was found for TFA 
and foods with a high glycemic index. One of the conclusions stated “it is unlikely that modifying the intake of a few nutrients 
or foods would substantially influence coronary outcomes.” 
In a review paper from Parodi (2009), 24 reports of 11 cohorts were the only prospective cohort studies found which evaluated 
the association between SFA and risk of CHD. Among these, 4 studies found a significantly positive association between SFA 
intake and risk of CHD, 3 found no association and 2 found a negative association. Overall, these results are inconsistent and do 
not provide convincing evidence of an association between SFA and risk of CHD.  
The evidence extracted by Gibson et al. (2009) from 12 major prospective cohort studies involving more than 280.000 subjects 
does not consistently demonstrate a direct relationship between the intake of dairy foods and increased risk of CVD (CHD, IHD 
or myocardial infarct), even though it is recognized that dairy fat is a contributor of saturated fat intake and excess saturated fat 
intakes has been associated with a higher incidence of CVD. The authors noted that “the studies available for examining the 
effect of dairy food consumption on CHD are too varied in design, quality and dietary assessment methodology to evaluate the 
nature of the relationship.” 
From a meta-analysis of 15 cohort studies carried out by Elwood et al. (2008), the relative risk of stroke or heart disease in 
subjects with high milk or dairy consumption was 0.84 and 0.79 respectively, relative to the risk in those with low consumption. 
EDA 5.8. Cardiovascular 
disease 
¿ Lines 1627-1644 
While CHD and ischemic stroke share some major risk factors, limited epidemiological data on dietary fats and vascular disease 
risk indicate that ischemic stroke is affected differently (different or opposite effect) by these fatty acids than is CHD. 
Specifically, the association between saturated fat / animal fat intake and ischemic stroke remains elusive (He et al. 2007). A 
clear distinction should be made between CVD, CHD and stroke, and the newest literature should be included. Besides, there 
are no intervention studies that analyse the effect of specific SFA variation: all those studies are based on a variation linked to 
the total fat intake or other fatty acids intakes (Lecerf, 2009). 
A growing body of evidence (observational, experimental, and clinical trial) indicates that the traditional diet – CHD paradigm 
(reduction of total and saturated fats and increase of carbohydrates) is inadequate.  
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Mozaffarian (2005) conducted a systematic MEDLINE search in order to identify observational studies, clinical trials, 
experimental studies and reviews of dietary fats or carbohydrates and CHR risk in humans from 1966 to June 2005. The author 
conducted a careful selection based on relevance, strength (designs and methods), precision of effects, endpoints etc. 
Precedence was given to randomized controlled trials and prospective observational studies. Globally, results showed that there 
was little evidence that replacement of SFA with carbohydrates (which lowers total fat intake) reduced CHD risk. In details, 
results showed that:  
 
 
For total fat:  
A lower total fat intake also reduce serum HDL cholesterol and increase TG, resulting in little overall net change in CHD risk in 
men and potentially high risk CHD in women 
Reducing total fat leads to an increase in carbohydrates. A high intake of carbohydrates (refined, high glycemic index) may 
adversely affect insulin homeostasis, satiety and weight gain 
No positive relation in prospective cohorts and randomized trials between total fat reduction and incidence of CHD (ex: Nurses‟ 
Health Study) 
 
For saturated fats:  
In metabolic trials, replacement of SFA with carbohydrates produce little change in the total:HDL ratio and specific SFA have 
differing effects on lipid physiology (Mensik 2003) 
The author found in this search:  
2 prospective studies observing a positive relation between SFA intake and CHD (the Western Electric Study; the Ireland-
Boston Diet-Heart Study)  
3 other studies observing a positive relation from some CHD endpoints or in some population but not others (Framingham 
Study; Lipid Research Clinics, Cohort follow up study in the US) 
7 other studies observing no significant association between SFA intake and CHD (including Nurses‟ Health Study, Puerto Rico 
Heart Health Program, Zutphen Study, Honolulu Program, the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study and 2 
studies from Morris et al. 1977 and Gordon et al., 1981).  
Results of randomized trials replacing SFA with PUFA have been inconsistent 
No clinical trials have been specifically designed to evaluate the effect of replacing SFA with carbohydrates on the incidence of 
CHD.  
 
For more details on the effects of SFA on cardiovascular disease, see also Morris et al. (1977) and Gordon et al. (1981). 
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EDA 5.8. Cardiovascular 
disease 
¿ Lines 1645-1694 
 
continued:  
 
Skeaff and Miller (2009) conducted a very recent and exhaustive review of cohort studies and controlled trials of dietary fats 
and CHD mortality or morbidity (search in the Cochrane Library, Cochrane reviews, article databases, systematic reviews, 
meta-analysis, etc.). Results found that:  
 
ALA: 
No association with intake of ALA and CHD death (RR 0.84, 95% CI 0.53-1.31, p=0.439) or CHD events (RR 1.05, 95% CI 
0.78-1.42, p=0.730) for highest compared to lowest category of intake 
 
LC PUFA: 
For cohort studies on n-3 LC PUFA, there were about 5,361 deaths amongst 256,000 participants during 4 million person-years 
of follow-up.  
Intake of n-3 LC PUFA or fish consumption were strongly associated with CHD mortality (RR 0.82, 95% Cl 0.71-0.94, 
p=0.006) for the highest compared with lowest category.  
Intake of n-3 LC PUFA was not associated with decreased risk of CHD events, non fatal CHD, total myocardial infarction, 
sudden cardiac death.  
For meta-analysis of randomized controlled trials of n-3 LC PUFA or fish and CHD, there were about 1,300 CHD deaths 
amongst 37,000 participants during 140,000 person-years of follow-up. Depending on the inclusion or exclusion of DART 2 
study, risk ratios of the different parameters were totally changed (either a reduction or a non significance), limiting the 
interpretation.  
 
¿ Lines 1695-1700 
Non-conjugated polyunsaturated TFA should be addressed in relation to disease risk. There is evidence that polyunsaturated 
TFA (trans 18:2) could pose a higher risk for ischemic heart disease and sudden cardiac death and CHD than monounsaturated 
TFA (trans 18:1) (Lemaitre et al., 2006; Baylin et al., 2003) These polyunsaturated TFA are from industrial sources, and can 
only be found in trace levels in ruminant fats. 
The WHO experts come to a different conclusion. They do make a difference between ruminant and industrially produced TFA: 
“The current growing body of evidence from controlled trials and observational studies indicates that TFA consumption from 
partially hydrogenated oils adversely affects multiple cardiovascular risk factors and contributes significantly to increased risk 
of CHD events. Although ruminant TFAs cannot be removed entirely from the diet, their intake is low in most populations and 
to date there is no conclusive evidence supporting an association with CHD risks in the amounts usually consumed. In contrast, 
TFA produced by partial hydrogenation of fats and oils should be considered industrial food additives having no demonstrable 
health benefits and clear risks to human health. The WHO Scientific Update on TFA concludes that restaurants and food 
manufacturers should avoid using industrially derived TFA in food products and that governments should take steps to support 
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alternative fats or oils for TFA replacement. The evidence on the effects of TFA and disease outcomes strongly supports the 
need to remove PHVO from the human food supply.” (Uauy et al., 2009). 
The limited data suggest that the experimental effects of ruminant and industrial TFA are similar when consumed in similar 
quantities, but very few persons consume such high levels of ruminant TFA, and observational studies do not support adverse 
CHD effects of ruminant TFA in amounts actually consumed (Mozaffarian et al., 2009). 
AFSSA concluded it its recent report that TFA from natural origin do not present a risk in terms of cardiovascular disease as 
they are consumed at very low level (0.5-0.9% of the total energy intake) (AFSSA, 2009a).  
EDA 5.8. Cardiovascular 
disease 
¿ Lines 1645-1694 
 
Two other clinical trials of dietary supplementation with n-3 fatty acids exist: the DART and Lyon Heart studies, which are both 
secondary prevention trials.  
The DART study (Burr et al., 1989; Burr et al., 2007) was conducted in 2003 men after myocardial infarction, with 3 treatment 
arms: reduction of SFA intake to 30% energy with a P/S ration of 1:0, an increase of fatty fish (200-400 g/week), or an increase 
in cereal fibres to 18g/d. Advice to modify fat intake did not confer any obvious benefit, perhaps partly because it entailed 
greater changes in dietary habits and was therefore inadequately followed. Indeed, the advice about dietary fat did not achieve 
the expected differences in intakes, partly because of incomplete compliance with the advice and partly because of spontaneous 
changes in the control group. After 2 years, total fat accounted for 31.4% and 35.2% in the fat-advice and the non-fat advice 
groups respectively, and the corresponding mean P/S ratio were 0.8 and 0.4, although patients had regularly nutritional 
recommendations and advice given by a professionals of dietetics. However, the fish advice was associated with a 29% 
reduction in overall mortality, and this result was unaffected by adjusting variables at baseline.  
The Lyon Heart study (de Lorgeril et al., 1994; Renaud et al., 1994; de Lorgeril et al., 1999) was a randomized secondary 
prevention trial aimed at testing whether a Mediterranean type diet may reduce the rate of recurrence after a first myocardial 
infarction. The intervention diet was rich in a-linolenic acid (0.8% versus 0.3% in the control group) and provided around 30 
E% from fat, 8 E% from SFA (12% in the control group), 13 E% from MUFA (10% in the control group) and <4 E% from 
linoleic acid (n-6 LA) (>5% in the control group). The study lasted over a 5-year period and was conducted on 302 patients, 
compared to 303 control patients. There was also an additional follow-up after the 5 initial years for 46 months. The recurrent 
myocardial infarction, all cardiovascular events, and cardiac and total death were significantly decreased by > 70% in the group 
consuming the Mediterranean diet. These protective effects were not related to serum concentrations of total, LDL or HDL 
cholesterol. With regard to any association between the plasma concentration of major fatty acids and recurrence, only 18:3 n-3 
and 22:6 n-3 tended to be inversely associated with recurrence of outcomes (p=0,11 and p=0,16 respectively) for myocardial 
infarction and cardiovascular deaths (no significance for other outcomes as heart failure, stroke, pulmonary or peripheral 
embolism, angina, thrombophlebitis). 
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EDA 5.8. Cardiovascular 
disease 
¿ Lines 1701-1712 
Incidence of nonfatal and fatal CHD and stroke corresponding to the daily egg consumption was determined in 37,851 men and 
80,082 women in 2 large prospective cohort studies (the Health Professionals Study and the Nurses Health study). Results 
showed no evidence for an overall significant association between egg consumption and risk of CHD and stroke, after 
adjustments for age, smoking and other potential CHD risk factors. The authors found a significant association between egg 
consumption and CHD and stroke in only a subgroup of diabetic patients (thus with abnormalities in lipid metabolism). 
Kratz also conducted a systematic review on animal and human (intervention and observational) studies. A large number of 
observational studies (Honolulu Heart Study, the Puerto-Rico Heart Health Program, the Lipid Research Clinics Prevalence 
Follow-up Study, the Nurses Health Study, the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study and the Hawaii 
Cardiovascular Study) did not find any relationship between the intake of dietary cholesterol and the risk of CHD. Moreover, 
some other studies which primarily found a potential positive link between cholesterol intakes and CHD noted that the results 
were no longer significant after adjustments for consumption of vegetable, proteins and fibres, since they usually go hand in 
hand in individual diets (Kratz, 2005).  
 
¿ Line 1716 
The words “of SFA” should be deleted as not all SFA have the same effects. TFA should be replaced by “industrial TFA”. 
All research (either epidemiological or interventional studies) tends to show that in healthy people diets low in SFA were 
unsuccessful in reducing the incidence of cardiovascular disease.  
In this context, the recommendation “as low as possible” has neither scientific value nor scientific justification.  
 
¿ Line 1720 
The genetic aspect should be included in this scientific draft opinion. There is a wide inter-individual variability in the response 
to dietary changes since genetic polymorphisms modulate the effects of nutrients. In terms of cardiovascular diseases, 
polymorphisms at multiple genes have been associated with differential effects in terms of lipid metabolism. Many examples 
can be given. A habitually low saturated fat diet is associated with a beneficial lipoprotein profile only among homozygotes of 
the APOC3 promoter 455T-625T polymorphism. (25% of the population) (Brown S et al., 2003). Another example of a well-
documented nutrigenetic interaction is that of the apoAI gene which is a major structural and functional component of HDL 
cholesterol. A significant interaction between this polymorphism and PUFA intake in determining plasma HDL cholesterol 
concentration has been demonstrated in women in the Framingham Study. In carriers of the A allele, higher PUFA intakes (>8 
E%) were shown to be associated with higher HDL cholesterol, whereas in G/G homozygotes, the opposite effect was observed 
(Lovegrove and Gitau, 2008). 
The concept of gene-environment interactions modulating common disease risk factors is now well founded and should be 
taken into consideration for more individually targeted approaches to disease prevention and therapy (Ordovas, 2009). 
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EDA 6.1. Total fat ¿ Line 1831 
As mentioned in this scientific draft opinion (lines 1068-1070), “Very low fat diets tend to increase the risk of an insufficient 
intake of PUFA, can impair the absorption of fat-soluble vitamins and be associated with insufficiency of other essential 
nutrients like zinc and B vitamins”. 
 
¿ Line 1840 
The 20 E% does not seem representative of the European fat intake. Indeed according to Annex 1b of this draft opinion means 
intakes are almost all above 30 E%. The population with very lower intake is obviously a specific population (elderly men in 
Portugal). This confirms that the 20 E% as the lower bound of the intake range is not appropriate for the general population. 
 
¿ Line 1843 
The value of 20 E% is not appropriate: it is not representative of the low intake in Europe and according to AFSSA (2001) 
below 30 E% the balance of fatty acid intake (especially PUFA) is more difficult to achieve because of the composition of the 
usual food products. 
Besides, a growing body of evidence (observational, experimental, clinical trials and meta-analysis) indicates that the traditional 
diet – CHD paradigm (reduction of total and saturated fats and increase of carbohydrates) is inadequate. Firstly, no positive 
relation in prospective cohorts and randomized trials between total fat reduction and incidence of CHD has been found. 
Secondly, reducing total fat leads to increase carbohydrates (Skeaff and Miller, 2009; Mozaffarian 2005; Elmadfa and 
Kornsteiner, 2009; Hooper et al., 2001 and 2002; Gordon et al., 1981). A high intake of carbohydrates (refined, high glycemic 
index) may adversely affect insulin homeostasis, satiety and weight gain (Mozaffarian, 2005).  
 
¿ Line 1847 
The recommendation for total fat intake between 3 years and adult is missing. 
Outcome of the Public consultation on the Draft Opinion on  
Dietary Reference Values for fats 
 
126 EFSA Journal 2010; 8(5):1507 
ORGANISATION CHAPTER TEXT COMMENT TEXT 
EDA 6.2. Saturated fatty 
acids (SAT) 
¿ Line 1851 
It should be clear what is meant with expressions like “a mixture of SFA” and also if this mixture is nutritionally relevant. 
In order to determine dietary reference values for nutrients, it is important to be aware of that no biochemical measurement in 
the human body can represent the effect of various nutrients. It is thus of greatest importance to examine the direct relationship 
between consumption of the food item/nutrient and the risk of disease.  
In the second paragraph of 6.2, the main discussion is made on SFA and LDL cholesterol and not cardiovascular disease. 
According to WHO, the ratio of total and HDL cholesterol is a more reliable biomarker. 
 
¿ Lines 1851-1852 
This sentence does not represent the conclusion of the scientific opinion on line 1238-1240 where it is stated that “There is a 
positive, dose-dependent relationship between the intake of a mixture of SFA and serum LDL and HDL cholesterol 
concentrations, when compared to carbohydrates. As a consequence, the total to HDL cholesterol ratio does not change”. 
 
¿ Line 1855 
However, Mozaffarian (2004) shows that in some case a greater saturated fat intake is associated with less progression of 
coronary atherosclerosis, whereas carbohydrate intake is associated with a greater progression. 
Besides, the Women Health Initiative (WHI) study indicates that no benefit was observed in terms of coronary disease, 
cardiovascular or cerebro-vascular disease with the decrease of fat intake and 9.5% SFA (Howard, 2006). 
EDA 6.2. Saturated fatty 
acids (SAT) 
¿ Line 1858 
The only link between SFA and health concerns total blood cholesterol (LDL and HDL). However, and contrary to 
carbohydrates which only increase the LDL cholesterol, SFA increase both HDL and LDL. Moreover, not all SFA but only a 
few have impacts on cholesterol so on this matter SFA cannot be considered as a whole. Only lauric, myristic and palmitic acids 
are known to increase total cholesterol, while short and medium-chain fatty acids are neutral (Mensink 2005 and 2003; Temme 
et al., 1997; Salter et al., 1998; Billet MA, 2000; Dabadie, 2005; Tholstrup et al., 1994 and 2003b; Hashim, 1960; Parodi, 2009).  
In a recent meta-analysis, the effects of individual SFA on the serum lipoprotein profile have been estimated (Mensik et al., 
2003). Iso-energetic replacement of carbohydrates with lauric, myristic and palmitic acids all resulted in increased total, LDL 
and HDL cholesterol concentrations. But as the cholesterol-raising effects of lauric acid were proportionally higher on HDL 
than on LDL cholesterol, replacement of carbohydrates by lauric acid resulted in a significantly lower total / HDL cholesterol 
ratio, which suggests a decrease in atherosclerotic risk. Stearic acid had the smallest effect on HDL cholesterol but lowered total 
and LDL cholesterol, and thus also decreased the total / HDL cholesterol ratio.  
Palmitic acid is the only fatty acid which increased the total / HDL cholesterol ratio (Mensink, 2003), a fact confirmed in other 
studies (Salter et al., 1998; Billet MA, 2000). No differences between the effects of the different SFA on fasting serum 
triacylglycerol concentrations were detected (Mensink, 2003).  
Myristic acid had also been criticized for elevating cholesterol. However, these negative effects of myristic acid had been 
described with massive doses, doses which are much higher than usual consumption (Staiger et al., 2006). At usual level, 
myristic acid has no hypercholesterolemic effect but has rather positive action through an increase of HDL-cholesterol (Temme 
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et al., 1997; Salter et al., 1998; Billet MA, 2000; Legrand 2008). Moreover, myristic acid at usual level (1.6% total energy 
intake) is necessary for protein acylation and thus activation (Legrand, 2008).  
The recommendation should take into account the difference between the SFA. SFA have different physiological functions 
depending on their chain length, so should not be evaluated as one single group.  
 
¿ Line 1868 
A recommendation of “as low as possible” would not be achievable in normal life with a normal diet and would result in strict 
and impossible guidelines to follow. Moreover, this recommendation “as low as possible” is not relevant due to recent scientific 
results showing the real effect of SFA on health - especially on cardiovascular health (Skeaff and Miller, 2009; He et al., 2007; 
Mozaffarian, 2005, Hooper et al., 2001 and 2002) (for details see comments lines 1627-1644). A low intake of SFA could lead 
to an excessive consumption of MUFA and PUFA, which could represent health hazards, especially with regard to intake of n-6 
fatty acids (Lecerf, 2009; Ailhaud, 2006). 
EDA 6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
¿ Line 1882 
An optimal intake with a ratio of n-3/n-6 PUFA should also be fixed by EFSA, like it is the case in all the national and 
international recommendations. In order to determine this ratio, a conversion factor can be applied to LC PUFAs (LA to ARA, 
and ALA to EPA and DHA). For adults, this leads to an optimal n-6 PUFA: n-3 PUFA of 5:1.  
 
¿ Line 1906 
The Panel proposes to set an AI for linoleic acid of 4 E%, with no UL for total or any of the n-6 PUFA. There has been 
evidence on negative effects on health of excessive intakes of n-6 PUFA and lipid peroxidation (Elmadfa and Kornsteiner, 
2009). It could also contribute to excessive adipose tissue development (Ailhaud, 2006; Lecerf, 2009). Therefore, an upper limit 
should be considered in order to protect consumer health.  
EDA 6.5. Trans fatty 
acids (TFA) 
¿ Line 1948 
According to the recent WHO scientific update on TFA the intake of ruminant TFA is low in most populations. To date there is 
no conclusive evidence supporting an association with coronary heart diseases risks in the amount of ruminant TFA consumed. 
In its recent report, AFSSA concluded that TFA from natural origin do not present a risk in terms of cardiovascular disease as 
they are consumed at very low level (0.5-0.9% of the total energy intake) (AFSSA, 2009a). The EFSA recommendation 
concerning the dietary reference value for TFAs should therefore deal only with industrially derived TFA. 
 
¿ Line 1952 
Intake of TFA from industrial origin should be as low as possible. Natural TFA should not be included in this recommendation. 
 
¿ Line 1959 
This is due to the reduction in industrial TFA. 
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EDA 6.7. Cholesterol ¿ Line 1971 
It is important to add that dietary cholesterol has very little influence on plasma cholesterol values which are regulated by 
numerous genetic and nutritional factors through cholesterol absorption or synthesis. Besides, there is no strong evidence that 
dietary cholesterol is related to CHD or stroke (Hu and Willett, 2002; He et al., 2003). 
EDA Conclusions and 
recommendations 
¿ Line 1978 
The 20 E% does not seem representative of the European fat intake. Indeed according to Annex 1b of this draft opinion means 
intakes are almost all above 30 E%. The population with very lower intake is obviously a specific population (elderly men in 
Portugal). This confirms that the 20 E% as the lower bound of the intake range is not adapted for the general population. 
 
¿ Lines 1980-1981 
The value of 20 E% is not appropriate: it is not representative of the low intake in Europe and according to AFSSA, 2001 below 
30 E% the balance of fatty acid intake (especially PUFA) is more difficult to achieve because of the composition of the usual 
food products. 
Besides, a growing body of evidence (observational, experimental, clinical trials and meta-analysis) indicates that the traditional 
diet – CHD paradigm (reduction of total and saturated fats and increase of carbohydrates) is inadequate. First no positive 
relation in prospective cohorts and randomized trials between total fat reduction and incidence of CHD has been found. Second, 
reducing total fat leads to increase carbohydrates (Skeaff and Miller, 2009; Mozaffarian 2005; Elmadfa and Kornsteiner, 2009; 
Hooper et al., 2001 and 2002; Gordon et al., 1981). A high intake of carbohydrates (refined, high glycemic index) may 
adversely affect insulin homeostasis, satiety and weight gain (Mozaffarian, 2005).  
 
¿ Lines 1985 
The recommendation for total fat intake between 3 years and adult is missing. 
 
¿ Lines 1992-1993 
A recommendation of “as low as possible” would not be achievable in normal life with a normal diet and would result in strict 
and impossible guidelines to follow. Moreover, this recommendation “as low as possible” is not relevant due to recent scientific 
results showing the real effect of SFA on health - especially on cardiovascular health (Skeaff and Miller, 2009; He et al., 2007; 
Mozaffarian, 2005, Hooper et al., 2001 and 2002) (for details see comments lines 1627-1644). 
 
¿ Lines 2001-2002 
An optimal intake with a ratio of n-3/n-6 PUFA should also be fixed by EFSA, like it is the case in all the national and 
international recommendations. In order to determine this ratio, a conversion factor can be applied to LC PUFAs (LA to ARA, 
and ALA to EPA and DHA). For adults, this leads to an optimal n-6 PUFA: n-3 PUFA of 5:1. 
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EDA Conclusions and 
recommendations 
¿ Line 2017 
There has been evidence on negative effects on health of excessive intakes of n-6 PUFA and lipid peroxidation (Elmadfa and 
Kornsteiner, 2009). It could also contribute to excessive adipose tissue development (Ailhaud, 2006; Lecerf, 2009). Therefore, 
an upper limit should be considered in order to protect consumer health. 
 
¿ Lines 2041-2042 
The recommendation to reduced TFA intake to «as low as possible» should only concern industrial TFA. This has been 
recommended in numerous countries in Europe (Nordic Nutrition Recommendations, 2004; AFSSA, 2009b) as well as in the 
recent WHO scientific update on TFA (Uauy et al., 2009). The EFSA recommendation concerning the dietary reference value 
for TFA should therefore deal only with industrially produced TFA. 
 
¿ Line 2055 
An AI 4% of LA is indeed based on lowest estimated mean intakes in E% (Elmadfa and Kornsteiner, 2009). However, this is 
not the level at which overt deficiency symptoms occur (this level is at least 2-fold lower): ISSFAL 
http://www.issfal.org.uk/lipid-matters/issfal-policy-statements/statement-3-pufa-in-adults.html  
The authors of these adult studies generally concluded that LA intakes of 1.0-2.5 E% would meet requirements but this 
conclusion was based mostly on minimizing the plasma level of 20:3 w9 (mead acid; a presumed biochemical marker of n-6 
PUFA deficiency). The clinical condition of the infants was also considered in one study but otherwise, in these studies, clinical 
status was not informative. Several authors specifically noted the difficulty in drawing conclusions about LA requirement from 
measuring plasma fatty acid profiles alone. On the basis of these results, it is concluded that 2 E% LA is adequate for healthy 
adult humans. 
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proinflammatory cytokine production by peripheral bllod mononuclear cells in hypercholesterolemic subjects, American 
Journal of Clinical Nutrition 85: 385-391. 
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EFPRA 6.1. Total fat Dear Madam, dear Sir, 
 
EFPRA, the European Animal Fat Processors and Renderers Association, has read with much interest EFSA‟s statement on 
dietary reference values for fat. 
 
First of all, we want to underline the point that EFPRA fully supports CLITRAVI‟s comments sent to EFSA on 15 October 
2009. 
 
In addition to these comments, EFPRA want to highlight three further points: 
 
- On lines 66-67: Recent literature studies (available at the EFPRA secretariat) that also take the TFA content into account show 
very little or no effect from SFA on CHD. The problem of earlier studies on SFA is that often the “hidden” TFA content was 
not taken into account and/or the focus was limited to LDL effects. When TFA is not taken into account SFA will be assigned 
all the negative effect of TFA. Regarding cholesterol level the total HDL:ratio is the most important factor to predict effects on 
CHD and not only the LDL effects. Just taking HDL into account, SFA would be the healthiest fat. However the ratio predict 
that SF has no effect on risk of CHD. This is supported by the nurses health study 2005 (Harvard school of public health). SFA 
does not increase risk of heart disease of women and have little effect in men. 
 
 
- On lines 56-69: There is growing evidence that the CHD paradigm (or American paradox) is inadequate. In practice total fat 
was replaced by carbohydrates and not by PUFA. EFPRA is of the firm view that a reduction of SF (as low as possible) almost 
certainly will lead to an increase of intake of carbohydrates. A higher intake of carbohydrates does not improve the total 
HDL:ratio (Jacobsen et all 2009) and this could cause an even higher risk of CHD.  
 
 
- On lines 56-69: The body needs SFAs because they are necessary for building cell membranes, nervous structures, and 
phospholipids. As such SF intake at appropriate levels is essential for the body and human health.  
 
We trust that EFSA will give EFPRA‟s position its due consideration. 
 
Yours sincerely, 
 
Steve Woodgate and Johan van der Veen 
Technical Director and Scientific Expert 
EFPRA  
Outcome of the Public consultation on the Draft Opinion on  
Dietary Reference Values for fats 
 
140 EFSA Journal 2010; 8(5):1507 
ORGANISATION CHAPTER TEXT COMMENT TEXT 
ENSA  3. Dietary sources 
and intake data 
Lines 685-692: These figures clearly show that European adults tend to have a too high intake of dietary cholesterol compared 
to recommendations to limit the intake of dietary cholesterol below 300mg/d (cf. lines 939 to 942). As the Panel concluded that 
there is a positive relationship between the intake of dietary cholesterol with serum LDL concentrations, the fact that the 
average intake of dietary cholesterol is too high in European countries reinforces the need for clear and understandable 
information about dietary cholesterol. DRV for dietary cholesterol would enable people to control their dietary cholesterol 
intake and therefore maintain a healthy cholesterol blood level.  
ENSA  4. Overview of 
dietary reference 
values and 
recommendations 
Lines 939-942: There are additional sources which recommend to limit the intake of dietary cholesterol below 300mg/d. ENSA 
calls on the EFSA to also make reference to the following ones:  
¿European guidelines on cardiovascular disease prevention in clinical practice – Third Joint Task force of European and other 
Societies on Cardiovascular disease prevention in clinical practice, European Heart Journal 2003; 24,1601-1610  
¿ Belgian Superior Health Council (SHC) – Food recommendations for Belgium Revision November 2006 HGR 7145-2 
¿AHA Scientific statement – Diet and lifestyle recommendations revision 2006 –A scientific statement from the American 
Heart Association Nutrition Committee Circulation 2006; 114:82-96 
ENSA  6. Data on which to 
base dietary 
reference values 
Lines 1964 to 1972: ENSA believes that a DRV should be set also for dietary cholesterol. This is justified from a public health 
perspective given the fact that the negative effects of too high intakes of dietary cholesterol on health have clearly been 
demonstrated (cf. lines 1328 to 1340; 1701 to 1712; 1745 to 1751). In addition, ENSA sees an urgent need for a DRV to be set 
for dietary cholesterol in light of the Panel‟s conclusion that current average intake levels of dietary cholesterol among 
European adults are often well above the generally accepted and recommended intake limits (cf. lines 685 to 692 and lines 939 
to 942).  
 
Furthermore, information on dietary cholesterol is a highly relevant marker for consumers to identify foods which are also high 
in saturated fats. From a consumer point of view, dietary cholesterol is far more easy to understand than the difference between 
healthy (unsaturated) and less healthy (saturated ) fatty acids . Information on dietary cholesterol would enable consumers to 
make easier, quicker, and more informed food choices which fit in a healthy lifestyle.  
 
As a result, ENSA believes that the Panel should set a DRV for dietary cholesterol, which should be in line with the DRV for 
saturated fats – i.e. as low as possible, or at least in line with the generally accepted and recommended intake limits – i.e. max 
300mg/day for adults.  
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ENSA  Conclusions and 
recommendations 
Lines 2047 to 2054: ENSA believes that a DRV should be set also for dietary cholesterol. This is justified from a public health 
perspective given the fact that the negative effects of too high intakes of dietary cholesterol on health have clearly been 
demonstrated (cf. lines 1328 to 1340; 1701 to 1712; 1745 to 1751). In addition, ENSA sees an urgent need for a DRV to be set 
for dietary cholesterol in light of the Panel‟s conclusion that current average intake levels of dietary cholesterol among 
European adults are often well above the generally accepted and recommended intake limits (cf. lines 685 to 692 and lines 939 
to 942).  
 
Furthermore, information on dietary cholesterol is a highly relevant marker for consumers to identify foods which are also high 
in saturated fats. From a consumer point of view, dietary cholesterol is far more easy to understand than the difference between 
healthy (unsaturated) and less healthy (saturated) fatty acids. Information on dietary cholesterol would enable consumers to 
make easier, quicker, and more informed food choices which fit in a healthy lifestyle.  
 
As a result, ENSA believes that the Panel should set a DRV for dietary cholesterol, which should be in line with the DRV for 
saturated fats – i.e. as low as possible, or at least in line with the generally accepted and recommended intake limits – i.e. max 
300mg/day for adults.  
Food Standards 
Agency  
1. Introduction Introduction 
In EFSA opinions it is not always clear how evidence has been identified for inclusion. EFSA should consider including a 
section detailing the methodology used to review the scientific evidence which would provide a more transparent approach and 
more comprehensive review of the literature. This should include how they selected the studies to include and how study quality 
was assessed. 
Food Standards 
Agency  
3. Dietary sources 
and intake data 
Section 3.2 Intake data 
This section refers to annex 2b, which details dietary intakes of ALA, EPA and DHA in different EU countries. The data 
presented is from a limited number of countries (Austria, France, Germany, NL and Sweden). With regards to EPA/DHA 
intakes we are not surprised that intakes are low in these countries. EFSA should seek out data from Mediterranean countries to 
improve the comparison. 
 
Data from the UK National Diet and Nutrition Survey (NDNS) is missing.  
Details can be found at http://www.food.gov.uk/science/dietarysurveys/ndnsdocuments/ 
 
The NDNS programme aims to provide comprehensive, cross-sectional information on the dietary habits and nutritional status 
of the population of Great Britain. The results of the surveys within the programme are used to develop nutrition policy at a 
national and local level and to contribute to the evidence base for Government advice on healthy eating. 
 
The UK would be happy to supply this information on request. 
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Food Standards 
Agency  
4. Overview of 
dietary reference 
values and 
recommendations 
Section 4.1.4.2 (p28) 
We note that several member states including the UK, the Netherlands and France have recommendations for EPA/DHA that 
are higher than the EFSA proposed DRV. The Netherlands (Health Council) recommend 450mg EPA and DHA, AFSSA 
(France) value of 500mg/day based on usual consumption. The UK recommendation is based on the Scientific Advisory 
Committee on Nutrition (SACN) recommendation of 450mg/day. SACN based on the balance of the scientific evidence from 
RCTS and observational studies and on two portions of fish, one oily (one portion is 2.8g DHA/EPA/week) and one white (one 
portion average 0.4g/DHA/EPA week). This is a weekly total of 3.2g/week which equates to 450mg/day.  
 
EFSA should revisit their opinion on the DRV for EPA/DHA with a view to increasing it to 450mg/day (also see comment on 
section 5.8.1.1) 
Food Standards 
Agency  
5.2. Serum lipids 
and lipoproteins 
Section 5.2.2 serum lipids 
We note that several meta analyses are mentioned in the introduction to this section (5.2) but more details are required. In 
addition evidence from good quality prospective studies should be included. A list of references is included at the end of this 
section. 
 
For example in the review by Mensink et al (2003) the combined results of 60 randomised controlled dietary trials of the effects 
of dietary fatty acids and carbohydrates on the ratio of blood total to high density lipoprotein (HDL) cholesterol found that this 
ratio decreased when saturated fatty acids were replaced by cis-unsaturated fatty acids. 
  
Prospective cohort studies from various countries that followed people for a number of years demonstrate a strong positive 
association between blood cholesterol levels and the incidence of heart disease; those study populations with higher mean 
cholesterol levels experience higher heart disease mortality (Martin et al., 1986; Goldbourt et al., 1985; Reed et al., 1986; Rose 
& Shipley, 1986; Pocock et al., 1989).  
 
The randomised controlled trial remains the best study design for demonstrating cause effect relationships. Randomised 
controlled trials support the positive association between blood cholesterol levels and risk of developing heart disease. A review 
of 28 randomised controlled trials (Law et al., 1994) showed that most of the benefit in reduction of risk is achieved after two 
years, and the full benefit after five years. 
 
Some of the best evidence for the beneficial effects of lowering LDL-cholesterol levels on the risk of developing heart disease 
comes from randomised controlled trials of a family of LDL-cholesterol lowering drugs called statins. The combined results of 
14 randomised controlled trials of statins with a total of 90,056 participants found that a reduction in LDL-cholesterol of 1 
mmol/L sustained over a period of 5 years produces a reduction in major vascular events of 23% (Cholesterol Treatment 
Trialists‟ Collaborators, 2005). 
 
While the effect of reducing dietary intakes of saturated fat on LDL-cholesterol levels is much smaller than the effect of statin 
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treatment, a benefit remains for reducing population intakes of saturated fat and we believe that EFSA should be able to set an 
upper level based on the scientific evidence available. 
 
References 
Cholesterol Treatment Trialists‟ Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis 
of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78. 
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Food Standards 
Agency  
5.8. Cardiovascular 
disease 
First comment for this section (5.8): 
Section 5.8.1 CVD and saturated fat 
 
The evidence reviewed for beneficial effects of reducing saturated fat intake on risk of developing CVD in this section is 
incomplete, a list of suggested references is provided at the end of this response. Most noticeably the meta analysis by Truswell 
(1994) is missing. In this meta-analysis of 17 dietary trials (of which 16 were randomised) with a total of 92,623 participants 
(Truswell, 1994) found that a 10% fall in blood total cholesterol levels, achieved by dietary means, was associated with a 6% 
reduction in total mortality and a 13% reduction in coronary events. When the five trials with the largest reductions in total 
blood cholesterol levels (13%) were analysed separately then there was an 11% reduction in total mortality and a 30% reduction 
in coronary events. 
 
The Nurses‟ Health Study, a large prospective cohort study conducted in the USA, provides one of the best opportunities to 
examine the relationship between intake of saturated fat and the risk of developing heart disease. When 80,082 women were 
followed for 14 years, 939 new cases of coronary heart disease (CHD) were diagnosed (Hu et al., 1997). It was found that an 
increased intake of saturated or trans fat was associated with an increased risk of CHD while an increased intake of 
monounsaturated or polyunsaturated fat was associated with decreased risk of CHD. It was estimated that replacement of 5% 
energy from saturated fat with energy from unsaturated fat reduced CHD risk by 42%. When the 78,778 women remaining after 
20 years were studied, 1,766 new cases of CHD were diagnosed (Oh et al., 2005). However, in this analysis the association 
between saturated fat and CHD risk was no longer significant, suggesting a weaker association between intake of saturated fat 
and risk of CHD than previously reported from epidemiological studies. The associations between trans fat and polyunsaturated 
fat and CHD risk persisted. 
 
Other prospective cohort studies on the relationship between intakes of saturated fat and the risk of developing heart disease 
have been carried out and these have been reviewed (Hu et al, 2001; Hu & Willett, 2002). However, only two individual cohort 
studies, the Honolulu Heart Program (McGee et al., 1984) and the Ireland-Boston Diet-Heart Study (Kushi et al., 1985), have 
demonstrated a significant positive association between intake of saturated fat and risk of developing heart disease. 
 
Overall, the totality of the evidence suggests that reducing dietary saturated fat intake reduces the risk of developing heart 
disease. 
 
Refs 
Truswell AS. Review of dietary intervention studies: effect on coronary events and on total mortality. Aust NZ J Med 
1994;24:98-106. 
 
Hu FB, Stampfer MJ, Manson J et al. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med 
1997;337:1491-9. 
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Hu FB, Manson JE, Willett WC. Types of dietary fat and risk of coronary heart disease: a critical review. JACN 2001;20(1):5-
19. 
 
Hu FB and Willett WC. Optimal diets for prevention of coronary heart disease. JAMA 2002;288(20):2569-78. 
 
Kushi LH, Lew RA, Stare FJ, Ellison CR, el Lozy M, Bourke G, Daly L, Graham I, Hickey N, Mulcahy R, et al. Diet and 20-
year mortality from coronary heart disease. The Ireland-Boston Diet-Heart Study. N Engl J Med. 1985;312(13):811-8. 
 
McGee DL, Reed DM, Yano K, Kagan A, Tillotson J. Ten-year incidence of coronary heart disease in the Honolulu Heart 
Program. Am J Epid. 1984;119(5):667-76. 
 
Oh K, Hu FB, Manson JE, Stampfer MJ, Willett WC. Dietary fat intake and risk of coronary heart disease in women: 20 years 
of follow-up of the Nurses‟ Health Study. Am J Epid. 2005;161:672-679. 
 
(please also see second comment for this section on 5.8.1.1) 
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Food Standards 
Agency  
5.8. Cardiovascular 
disease 
Second comment on this section 
 
Section 5.8.1.1 
The EFSA opinion appears to be based on a recent meta analysis by Mozaffarian and Rimm 2006. We believe this meta 
analysis to be flawed. This meta-analysis does not include details on study quality and includes the DART 2 study (Burr et al 
2003) which SACN excluded from their report on “ Advice on fish consumption: benefits and risk” due to methodological 
flaws including compliance only being assessed in a subset of subjects and interruption in the trial due to funding problems. 
The Cochrane systematic review (Hooper et al 2004) is missing from the paper. 
Reference 
 
Hooper et al (2004) Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Hooper L et al. Cochrane 
Database Syst Rev. (2004) 
 
The peer reviewed literature reflects three different approaches to reviewing the literature for n3 fatty acids and CVD. (1) The 
review by Mozaffarian and Rimm 2006 combines data 15 prospective cohort studies and five RCTS (including DART 2) of fish 
or fish oil.  
 
(2) The review by Hooper et al focuses on 12 RCTs including DART 2. It is important to note that removal of the 
methodologically flawed DART 2 study (Burr et al 2003) changes the conclusion of the Hooper review from no effect to a clear 
benefit. 
 
(3) The review by SACN bases its advice on both 23 observational studies and three (of four available) RCTs as they excluded 
data from DART 2 (Burr et al 2003) due to methodological flaws including compliance only being assessed in a subset of 
subjects and interruption in the trial due to funding problems. Data from observational studies suggest that there is a plateau 
effect in high risk population around 0.9g/day. In reaching its conclusions the SACN also looked at data from fatty acid analysis 
from blood and blood compartments, which suggests a positive effect with no plateau effect. SACNs approach is consistent 
with other advisory committees. 
 
The FDA has recently produced a summary on published research on the beneficial effects of fish consumption, which EFSA 
may find helpful in informing their review. This can be found at 
http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2009-N-0018-Rpt%202%20pg1-100.pdf 
We believe that EFSA should base their DRV on evidence from both cohort studies and good quality RCTs. 
Food Standards 
Agency  
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
Section 6.4  
n6:n3 ratio 
N6/n3 ratio, the Agency agrees with EFSAs decision not to set a ratio for n3:n6. In 2006 the Agency convened a research 
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PUFA) workshop of international scientific experts which discussed research on the n3:n6 ratio and made the following 
recommendations including: 
 (1)Based upon theoretical and scientific ground (reviewed at the workshop) use of the n6:n3 ratio to estimate CVD risk should 
be abandoned  
 (2)Further research on dietary fatty acids would benefit from focusing on the effects of absolute amounts of individual n6 and 
VLC n3 fatty acids on cardiovascular risk factors and other physiological outcomes related to risk of chronic disease. 
 
The workshop report Stanley JC et al (2007) British Journal of Nutrition 98: 1305-1310 is available on the FSA website 
(http://www.food.gov.uk/science/research/researchinfo/nutritionresearch/dietandcardiovasc/reports/ 
 
FSA note that at the national experts meeting one member state disagreed with EFSAs view on the n6:n3 ratio and that EFSA 
agreed to revisit the evidence for this section. The UK expects that the above workshop report (and studies reported in it) will 
help strengthen EFSAs view that a specific value should not be set for n6:n3 ratio. 
 
6.4.2 n3 PUFA 
FSA is concerned regarding the EFSA DRV for EPA/DHA of 250mg/day. We would like to see levels closer to 450mg/day 
which better reflects the evidence, rather than the EFSA proposed value of 250mg/day. The EFSA 250mg/day level is out of 
line with several national recommendations including the Netherlands, France and UK. The UK recommendation is based on 
the Scientific Advisory Committee on Nutrition (SACN) recommendation of 450mg/day. SACN based on the balance of the 
scientific evidence from RCTS and observational studies and on two portions of fish, one oily (one portion is 2.8g 
DHA/EPA/week) and one white (one portion average 0.4g/DHA/EPA week). This is a weekly total of 3.2g/week which equates 
to 450mg/day.  
 
(see comment under section 5.8.1.1, regarding meta analysis use for EFSAs recommendation) 
 
We appreciate that EFSA‟s role is risk assessment but they should still be able to make a recommendation to the risk managers 
at the Commission to guide the policymakers who are not scientific experts in this area and so rely on EFSA to provide 
technical/ scientific advice. 
 
Setting 250 mg for EPA/DHA will mean that „source of claims‟ will be allowed on foods such as white fish that contain very 
little EPA/DHA and will be of little practical benefit to consumers because it will not help the consumer to distinguish between 
levels of EPA/DHA in oily and white fish.  
Food Standards 
Agency  
Conclusions and 
recommendations 
Please see these comments on n-3 fattyacids, total fat and saturated fat and the additional comments on MUFA and trans fat in 
an additional comment box 
 
Conclusions and recommendations: 
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n3 PUFA 
We are pleased to see that EFSA have decided to set a separate DRV for ALA and EPA/DHA . We agree that the conversion 
rate of ALA to DHA/EPA in the body is extremely low and so ALA cannot be assumed to have the same effects as EPA/DHA. 
 
FSA is concerned regarding the EFSA DRV for EPA/DHA of 250mg/day. We would like to see levels closer to 450mg/day 
rather than the EFSA proposed value of 250mg/day. (see comment under 5.8.1.1 and 6.4.2 for full details). 
 
Total fat 
FSA agree with the suggested DRV of 20-35% energy but it is not clear how this figure is derived given that EFSA do not 
propose a DRV for MUFA, saturated fats or trans fats. 
 
Saturated fat 
FSA are concerned that EFSA did not set an upper level for saturated fat but just states “as low as possible”. How can this be 
translated into meaningful dietary guideline in relation to total fat? It should be possible to recommend a guidance level (if it is 
not possible to set a UL) for saturated fat as this is such an important public health issue. Several national members have set 
levels for example the UK Committee on Medical Aspects of Food Policy (COMA), DH 1994) advised that people should 
consume on average no more than 11% of food energy as saturated fat. 
 
See comments on section 5.8.1 and section 5.2.2 for comments on saturated fat, cholesterol and CVD and lists of references for 
consideration by EFSA. 
Gentofte University 
Hospital 
4. Overview of 
dietary reference 
values and 
recommendations 
 
We are surprised to find that you in chapter 4, Overview of dietary reference values and recommendations do not include 
legislation (line 199). In subsection 4.1.5, Trans fatty acids (lines 912 to 938), is only mentioned the Nordic recommendation 
NNR, 2004, and not the Danish legislation concerning trans fatty acids. Even before the publication of the Nordic Nutrition 
Recommendation, the Danish Government introduced a legislation requiring that no more than 2 % of the fat in foods was 
industrially produced trans fat. On March 22, 2007, the European Commission dropped its infringement proceedings against 
Denmark over the trans fat limit because of increased scientific evidence on the dangers of trans fats. This legislation overrules 
the Nordic Nutrition recommendation in Denmark and should in our opinion be mentioned. Likewise the legislation in 
Switzerland and in the US remains unmentioned in the report. 
A reference to the report from The Danish Nutrition Council "The influence of trans fatty acids on health" is missing in the 
references. 
http://www.meraadet.dk/gfx/uploads/rapporter_pdf/Trans%20fatty%20acids_4.th%20ed._UK_www.pdf 
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German Federation 
for Food Law and 
Food Science, 
Godesberger Allee 
142-148, 53175 
Bonn 
1. Introduction Lines:  
 
70-71 
93-94 
149-150 
1877-1878 
1902-1903 
1962-1963 
1996-1997 
2014 
2045-2046 
 
Concerning the above mentioned lines we would like to comment as follows: 
 
In the Draft Scientific Opinion "Dietary reference values for fat" the following statements are given: "The panel proposes not to 
set any DRV" [...] for cis-MUFA, n-6-PUFA and CLA.  
 
We suggest to express this statement more open, e.g. "According to the current scientific evidence it is actually not possible to 
set any DRV."  
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German Federation 
for Food Law and 
Food Science, 
Godesberger Allee 
142-148, 53175 
Bonn 
6.3. Cis-
monounsaturated 
fatty acids (Cis-
MUFA) 
Lines:  
 
70-71 
93-94 
149-150 
1877-1878 
1902-1903 
1962-1963 
1996-1997 
2014 
2045-2046 
 
Concerning the above mentioned lines we would like to comment as follows: 
 
In the Draft Scientific Opinion "Dietary reference values for fat" the following statements are given: "The panel proposes not to 
set any DRV" [...] for cis-MUFA, n-6-PUFA and CLA.  
 
We suggest to express this statement more open, e.g. "According to the current scientific evidence it is actually not possible to 
set any DRV."  
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German Federation 
for Food Law and 
Food Science, 
Godesberger Allee 
142-148, 53175 
Bonn 
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
Lines:  
 
70-71 
93-94 
149-150 
1877-1878 
1902-1903 
1962-1963 
1996-1997 
2014 
2045-2046 
 
Concerning the above mentioned lines we would like to comment as follows: 
 
In the Draft Scientific Opinion "Dietary reference values for fat" the following statements are given: "The panel proposes not to 
set any DRV" [...] for cis-MUFA, n-6-PUFA and CLA.  
 
We suggest to express this statement more open, e.g. "According to the current scientific evidence it is actually not possible to 
set any DRV."  
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German Federation 
for Food Law and 
Food Science, 
Godesberger Allee 
142-148, 53175 
Bonn 
6.6. Conjugated 
linoleic acid (CLA) 
Lines:  
 
70-71 
93-94 
149-150 
1877-1878 
1902-1903 
1962-1963 
1996-1997 
2014 
2045-2046 
 
Concerning the above mentioned lines we would like to comment as follows: 
 
In the Draft Scientific Opinion "Dietary reference values for fat" the following statements are given: "The panel proposes not to 
set any DRV" [...] for cis-MUFA, n-6-PUFA and CLA.  
 
We suggest to express this statement more open, e.g. "According to the current scientific evidence it is actually not possible to 
set any DRV."  
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German Federation 
for Food Law and 
Food Science, 
Godesberger Allee 
142-148, 53175 
Bonn 
Conclusions and 
recommendations 
Lines:  
 
70-71 
93-94 
149-150 
1877-1878 
1902-1903 
1962-1963 
1996-1997 
2014 
2045-2046 
 
Concerning the above mentioned lines we would like to comment as follows: 
 
In the Draft Scientific Opinion "Dietary reference values for fat" the following statements are given: "The panel proposes not to 
set any DRV" [...] for cis-MUFA, n-6-PUFA and CLA.  
 
We suggest to express this statement more open, e.g. "According to the current scientific evidence it is actually not possible to 
set any DRV."  
 
German Nutrition 
Society (DGE) 
2. Categories, 
structure and 
function 
Line 474:  
The conversion factors mentioned here are “8 – 12 %” but in line 1177 “5 + 0.5 %”. What is correct ?? 
German Nutrition 
Society (DGE) 
4. Overview of 
dietary reference 
values and 
recommendations 
Line 786:  
Here is a wrong citation of the DACH Reference Values. 
 
Line 836:  
“A ratio of…..between 3 and 9 : 1” would be the correct wording. 
 
Line 874:  
“recommendation”, this is an ”estimated value” ! 
 
Line 940:  
The Eurodiet also recommended a maximum intake of 300 mg cholesterol [Kafatos AG, Codrington CA ( eds): EURODiet. 
Public Health Nutrition 4 (2001) p 290] 
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German Nutrition 
Society (DGE) 
5. Criteria 
(endpoints) on 
which to base the 
dietary reference 
values 
Line 1070:  
Here the risk of increasing triglycerides and decreasing HDL-cholesterol is missing. 
 
Line 1177: See also line 47:  
The conversion factors mentioned here are “8 – 12 %” but in line 1177 “5 + 0.5 %”. What is correct ?? 
 
Line 1202: See line 126:  
“To this intake should be added 100-200 mg of preformed DHA” The correct recommendation is: “Pregnant and lactating 
women should aim to achieve an average dietary intake of at least 200 mg DHA/d” [Koletzko et al. Br J Nutr 98 (2007) 873 – 
877], but not in addition! 
 
Line 1235: See line 48: 
“total fat 20 E% …neither adverse effects on serum lipids”. Low fat diets with <25 E% fat will induce hypertriglyceridemia and 
decrease HDL-cholesterol [Knopp et al. JAMA 278 (1997) 1509 -1515 and DRI, page 780], especially in obese people which 
reach in most European countries more than 50 % of the population. In contrast vegetarians reach seldom more than 1 %. The 
lowest intake level should be changed to 25 E%. 
German Nutrition 
Society (DGE) 
6.1. Total fat Line 1837:  
A dose-response relationship is documented by Yu Poth et al. [Yu Poth et al. Am J Clin Nutr 69 (1999) 632–646] and is cited in 
the Guideline “Fat” of the German Nutrition Society (DGE 2006: http://www.dge.de/leitlinie). 
 
Line 1841: See line 48 
“total fat 20 E% …neither adverse effects on serum lipids”. Low fat diets with <25 E% fat will induce hypertriglyceridemia and 
decrease HDL-cholesterol [Knopp et al. JAMA 278 (1997) 1509 -1515 and DRI, page 780], especially in obese people which 
reach in most European countries more than 50 % of the population. In contrast vegetarians reach seldom more than 1 %. The 
lowest intake level should be changed to 25 E%. 
German Nutrition 
Society (DGE) 
6.2. Saturated fatty 
acids (SAT) 
Line 1867:  
“SFA intake should be as low as possible within the context of a nutritionally adequate diet”. This recommendation is too weak. 
SFA <10 E% is recommended by several authorities around the world (section 4.1.2.) and practically achievable (line 1872) and 
effective (DGE 2006: http://www.dge.de/leitlinie). To specify no guiding value because the average intake of SFA in adults in 
many EU Member States exceeds 10 E% might not be an argument against this figure, since there is no evidence that the 
consumption of more then 10 E% as SFA does not increase the risk for CHD… 
 
Line 1868: See line 145: 
“Nutritionally adequate diet”: Where is the definition or the description of this phrase?  
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German Nutrition 
Society (DGE) 
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
Line 1882:  
The ratio n-3 / n-6 is very important for the conversion of ALA to EPA and DHA (Goyens et al. 2006). Of course the ratio per 
se does not have an importance independent of absolute levels of intake, but with the levels recommended (sections 6.4.1. and 
6.4.2.) it should be pointed out, that it is more necessary to enhance ALA (consumption) than to decrease LA (and in this 
connection the ratio would be changed) to increase the synthesis of EPA and DHA [Goyens PLL et al. Am J Clin Nutr 84 
(2006) 44-53]. This is not addressed in the present text! We have to keep in mind that sea fish resources are limited and many 
people don`t like fish. 
 
Line 1905: 
The discussion concerning safety aspects is too limited and should go deeper [Eritsland J. Am J Clin Nutr 71 (2000) 197S – 
201S]. The importance of Vitamin E as an antioxidant is not addressed. 
German Nutrition 
Society (DGE) 
6.5. Trans fatty 
acids (TFA) 
Line 1937: See line 130: 
“TFA are not synthesized by the human body”. That is not correct, since during the catabolism of PUFA within the cells there 
are catabolites with trans-configuration. Therefore this sentence should be deleted.  
 
Line 1954:  
An intake of TFA <1% is practically achievable and very well based. There is convincing evidence (DGE 2006: 
http://www.dge.de/leitlinie) for this recommendation and a convincing support by a recent WHO Scientific Update [Uauy R et 
al. Eur J Clin Nutr 63 (2009) S68–S75]. It is a pity that the European Food Safety Agency will not banish the TFA of industrial 
origin! 
German Nutrition 
Society (DGE) 
6.7. Cholesterol Line 1971: See line 157: 
There are foods with high cholesterol content but less SFA, i.e. eggs, liver, hide, oysters or mussels. These cholesterol carriers 
will not be covered by this formulation. Therefore 300 mg cholesterol remains a necessary and suitable guiding value (DGE 
2006: http://www.dge.de/leitlinie). Compare also lines 1704 to 1709 
German Nutrition 
Society (DGE) 
References It is a pity that the “Evidence based guideline: Fat consumption and certain nutrition-related diseases” of the German Nutrition 
Society was not noticed preparing this Draft Scientific Opinion. The DGE-Guideline documents the relationship between the 
consumption of fat (and fatty acids) and the risk of certain nutrition-related diseases, based on a systematic analysis and 
assessment of the existing literature: 
http://www.dge.de/leitlinie 
http://www.dge.de/pdf/ws/ll-fett/11-Summary-DGE-guideline-fat-11-2006.pdf 
http://www.dge.de/pdf/ws/ll-fett/12-Implementation-of-the-Guideline-DGE-guideline-fat-11-2006.pdf 
Global Oranization 
for EPA and DHA 
Omega-3s 
2. Categories, 
structure and 
function 
Section 2.1.3.2 
L471-L477 – This section identifies the limited ability of alpha-linolenic acid (ALA) to serve as a source of DHA. A recent 
ISSFAL position paper by Brenna and co-workers confirms that conversion of ALA to DHA is less than 1% in adults, this 
reference may be a useful addition to the Opinion (Brenna JT, Salem N, et al. Prostaglandins Leukot Essent Fatty Acids 80:85-
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91, 2009. See Summary Statement #2). Unfortunately, the limited conversion of ALA to DHA is not sufficiently identified 
throughout the current draft opinion. Specifically, the Summary (L107) recognizes that the body converts ALA to DHA and 
EPA but fails to quantify the limited extent of conversion. In addition, throughout the entire Opinion, there is an absence of any 
mention of stearidonic acid (SDA), an intermediate omega-3 fatty acid in the conversion of ALA to EPA. We respectfully 
suggest that language from L474 be added to the opinion Summary, specifically, “The human body can synthesize EPA and/or 
DHA from precursor fatty acids including alpha-linolenic acid and stearidonic acid; however, the conversion of these fatty acids 
into DHA may be even less than 1%” at line 107. 
 
L480 – The Committee notes that “the developing brain accumulates large amounts of DHA both pre- and postnatally (until two 
years of age)…”. We respectfully disagree, however, with the limitation of DHA accumulation only “until two years of age”. 
Classic research by Martinez indicates that DHA accumulation by the brain postnatally “is still very significant until at least 2 
years of age” [emphasis added], specifically, Martinez provides data for children up to 2.7 years (J Pediatr 120:S129-39, 1992 
Pg. S132 Fig. 3A). More recent data from Carver and coworkers (Carver JD, et al. Brain Research Bulletin 56:79-85, 2001. Pg. 
82 Fig. 1; Pg. 84 Table 2) indicates that levels of DHA in the cerebral cortex increases steadily up to the age of 18 years. 
Finally, it is well known that the brain growth spurt begins during the third trimester and continues throughout the first 3-4 
years of life (Dobbing J and Sands J. Archives of Disease in Childhood, 48:757-767, 1973. Pg. 765), this important 
developmental period is recognized as a period of critical brain growth and neuronal development. Collectively, these data 
support recognition of an expanded range of DHA accumulation by the postnatal brain in the current Opinion or elimination of 
the “until two years of age” language without an effort to specify further.  
Global Oranization 
for EPA and DHA 
Omega-3s 
4. Overview of 
dietary reference 
values and 
recommendations 
Section 4.1.4.2 
L866-L867 – notes the U.S. IOM recommendation for DHA and EPA contribution toward reversing an n-3 fatty acid deficiency 
but fails to recognize the level of contribution specified by the IOM. i.e. up to 10%. We respectfully request the following 
revised language be considered for L866-867, “Small amounts of EPA and DHA (up to 10%) can contribute towards reversing 
an n-3 fatty acid deficiency and can therefore contribute towards the AI for alpha-linolenic acid.” 
L1012-L1014 – We respectfully request the following revised language be considered for 1012-1014, “Small amounts of EPA 
and DHA (up to 10%) can contribute towards reversing an n-3 fatty acid deficiency and can therefore contribute towards the AI 
for alpha-linolenic acid.” 
Global Oranization 
for EPA and DHA 
Omega-3s 
4. Overview of 
dietary reference 
values and 
recommendations 
Section 4.1.4.2 
L866-L867 – notes the U.S. IOM recommendation for DHA and EPA contribution toward reversing an n-3 fatty acid deficiency 
but fails to recognize the level of contribution specified by the IOM. i.e. up to 10%. We respectfully request the following 
revised language be considered for L866-867, “Small amounts of EPA and DHA (up to 10%) can contribute towards reversing 
an n-3 fatty acid deficiency and can therefore contribute towards the AI for alpha-linolenic acid.” 
L1012-L1014 – We respectfully request the following revised language be considered for 1012-1014, “Small amounts of EPA 
and DHA (up to 10%) can contribute towards reversing an n-3 fatty acid deficiency and can therefore contribute towards the AI 
for alpha-linolenic acid.” 
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Global Oranization 
for EPA and DHA 
Omega-3s 
5.1. Dietary 
requirements 
Section 5.1.2.2  
L1176-L1180 – This section identifies the limited ability of alpha-linolenic acid (ALA) to serve as a source of DHA. A recent 
ISSFAL position paper by Brenna and co-workers confirms that conversion of ALA to DHA is less than 1% in adults, this 
reference may be a useful addition to the Opinion (Brenna JT, Salem N, et al. Prostaglandins Leukot Essent Fatty Acids 80:85-
91, 2009. See Summary Statement #2).  
 
L1199-L1207 – This section provides sound rationale for a DHA requirement during pregnancy and nursing. However, recent 
expert group recommendations and guidelines are not mentioned. Specifically, the Consensus recommendations on behalf of the 
European Commission research projects Perinatal Lipid Metabolism (PeriLip) and Early Nutrition Programming (EARNEST) 
should be recognized. In addition, the benefits to maternal and infant health noted by the PeriLip/EARNEST document should 
also be recognized, specifically, slightly longer pregnancy duration, reduced risk of preterm birth, and somewhat higher birth 
weight (Koletzko B, Cetin I, et al. Br J Nutr 98:873-877, 2007; Conclusions and Recommendations #2,6).  
 
L1220 – We respectfully request that “such small amounts of” be removed from this sentence. Given the very limited intake and 
availability of DHA, particularly from 6-24 months of age, classification of 100 mg as a small amount could be misleading as it 
suggests a goal readily accomplished as part of the normal diet. In fact, the most common source of DHA other than infant 
formula is fatty fish. Fish and seafood, however, are typically restricted by parents to at least 3 years of age due to allergy 
related concerns (ESPGHAN Committee on Nutrition, J Pedi Gastro Nutr 46:99-110, 2008. Pg. 104-105).  
Global Oranization 
for EPA and DHA 
Omega-3s 
5.11. Nervous 
system function 
Section 5.11  
L1817 – This sentence appears to contradict recommendations made by the Committee in the Conclusions of the current 
opinion. This sentence notes that optimal amounts of LC-PUFAs cannot be specified for infants in the second six months of life, 
however, the Conclusions (L2029-2030) indicate a proposed “… AI of 100 mg DHA for older infants (> 7 months of age) and 
young children below the age of 24 months”. We respectfully request that section 5.11 reflect the Panel‟s conclusion regarding 
an optimal level of DHA during the second six months of life.  
Global Oranization 
for EPA and DHA 
Omega-3s 
5.2. Serum lipids 
and lipoproteins 
Section 5.2.4.2  
L1274-1279 – This section recognizes the role of EPA and/or DHA in triglyceride reduction but does not recognize the 
independent role of DHA in this regard. A recent analysis of 16 studies of algal DHA supplementation (0.7-6.0 g/d) reports that 
“clinical trials with algal-DHA as a TG oil have demonstrated a marked reduction in serum TG levels (up to 26%) in normal 
individuals and in those with HTG or combined hyperlipidemia.” (Ryan AS, et al. Am J Therapeutics 16:183-92. Table 2). We 
respectfully request that the independent role of DHA for TG reduction be recognized in this section. Additionally, recognition 
of the independent role of DHA for elevation of HDL is also requested (Ryan AS, et al. Am J Therapeutics 16:183-92, 2009 
Table 3).  
 
L1279 – We respectfully request that the terminology “fish oil fatty acids” be replaced with EPA and/or DHA as it is more 
appropriate to recognize the beneficial nutrients as opposed to any one dietary source. These nutrients are not limited to fish oil 
but currently available from fish, marine microalgae and numerous fortified and enriched foods and beverages.  
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Global Oranization 
for EPA and DHA 
Omega-3s 
5.3. Haemostatic 
function 
Section 5.3.4.2  
L1377-L1384 – These lines recognize the role of EPA and DHA in hemostasis. It is important to note that changes in bleeding 
times resulting from decreased platelet aggregation as noted in L1380-L1382 are within a clinically normal range and 
considered a benefit as opposed to a safety issue in the general population (Lavie CJ, et al. J Am Coll Cardiol 54:585-594, 
2009).  
 
Section 5.3.7 
L1399-L1400 – We respectfully request the following revised language be considered, “An exception may be the n-3 LCPUFA, 
which may decrease platelet aggregation in particular at intakes above 1 g but without clinically adverse changes in bleeding in 
the general healthy population.” 
Global Oranization 
for EPA and DHA 
Omega-3s 
5.4. Inflammation 
and immne 
function 
Section 5.4.4  
L1437 – We respectfully request that “fish oil” be removed as it could be misleading to suggest that only fish oil can provide 
beneficial n-3 LCPUFA. These nutrients are not limited to fish oil but currently available from fish, marine microalgae and 
numerous fortified and enriched foods and beverages.  
Global Oranization 
for EPA and DHA 
Omega-3s 
5.5. Blood pressure Section 5.5.4.2  
L1464-L1473 - We respectfully request that the terminology “fish oil” be replaced with EPA and/or DHA since these nutrients 
are available from multiple sources in addition to fish oil such as DHA from marine microalgae. It seems more appropriate to 
recognize a particular intake level of the beneficial nutrients as opposed to any one dietary source. Studies of blood pressure in 
response to algal-DHA supplementation are available and suggest at least equal reductions compared to EPA and DHA from 
fish oil (Ryan AS, et al. Am J Therapeutics 16:183-92. Table 3).  
 
Section 5.5.7 
L1486 – We respectively request “fish oil” be removed and n-3 LCPUFA rather than n-3 PUFA be used in this sentence. 
Authors provide data only for n-3 LCPUFA and blood pressure reduction therefore n-3 LCPUFA is a more appropriate term 
than n-3 PUFA which would typically include ALA. In addition, it could be misleading to suggest that only fish oil can provide 
beneficial n-3 LCPUFA. These nutrients are not limited to fish oil but currently available from fish, marine microalgae and 
numerous fortified and enriched foods and beverages.  
Global Oranization 
for EPA and DHA 
Omega-3s 
5.8. Cardiovascular 
disease 
Section 5.8.4  
L1716 - We respectfully request that the term “fish oil” be replaced with EPA and DHA since these nutrients are available from 
multiple sources in addition to fish oil, such as marine microalgae, and it seems more appropriate to recognize a particular 
intake level of the beneficial nutrients as opposed to any one dietary source. Modifying the language in this section would also 
be consistent with that used in EFSA‟s scientific opinion regarding labelling reference intake values for n-3 and cardiovascular 
disease prevention (The EFSA Journal, 1176:1-11, 2009) and with L1919-1924 of the current opinion.  
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Global Oranization 
for EPA and DHA 
Omega-3s 
5.8. Cardiovascular 
disease 
We applaud the Panel‟s proposal to establish a DRV of 250 mg/day for EPA + DHA. While significant benefits can be 
demonstrated with a dose of 250 mg/day, we believe that optimal benefits for the general population can be achieved with a 
higher dose. Thus said, 250 mg/day should be considered a minimal, rather than an optimal, intake. We encourage the Panel to 
reevaluate its current proposal and establish the DRV based on the optimal level.  
 
While the Panel proposed 250 mg/day, it recognized that cardiovascular benefits were demonstrated within the range of 250-
500 mg/day. See L1920-L1923-“With respect to cardiovascular diseases, prospective epidemiological and dietary intervention 
studies indicate that oily fish consumption or n-3 LCPUFA dietary supplements (equivalent to a range of 250-500 mg of EPA + 
DHA/day ) decrease the risk of mortality from CHD and sudden cardiac death.” Furthermore, the Panel calls 250 mg/day a 
„sufficient‟ not „optimal‟ dose for primary prevention in healthy adults. See L1923-L1924-“An intake of 250 mg/day of EPA + 
DHA appears to be sufficient for primary prevention in healthy subjects.” 
 
Caution should be exercised in establishing an intake of the n-3 LCPUFAs of 250 mg/day as optimal. Instead, the consumption 
of 250 mg/day of the n-3 LCPUFAs should be considered a minimum recommended intake. The publications considered in the 
Opinion include meta-analyses that combine estimates of low intake from background dietary consumption and higher intakes 
from supplements. It is clear that there is a positive correlation between realized benefits and intake with increasing doses 
towards 250 mg/day; however, due to the uncertainties inherent in the analysis, the benefit above this level is not as clear, and it 
can only be concluded that maximum efficacy lies above 250 mg/day, but closer to 500 mg/day as discussed above. Although 
the population will realize significant benefits by establishing a DRV of 250 mg/day, it is also likely that many in the population 
will not realize the maximum benefits.  
Global Oranization 
for EPA and DHA 
Omega-3s 
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
Section 6.4.2  
L1915 - This sentence recognizes the ability of the body to synthesize DHA and EPA from a-linolenic acid but does not identify 
the limited extent of this conversion. A recent ISSFAL position paper by Brenna and co-workers (Brenna JT, Salem N, et al. 
Prostaglandins Leukot Essent Fatty Acids 80:85-91, 2009. See Summary Statement #2) confirms that conversion of ALA to 
DHA is less than 1% in adults. Unfortunately, the limited conversion of ALA to DHA is not sufficiently identified throughout 
the current draft opinion. In addition, throughout the entire Opinion, there is an absence of any mention of stearidonic acid 
(SDA), an intermediate omega-3 fatty acid in the conversion of ALA to EPA. We respectfully suggest that language from L474 
be added to this sentence, specifically, “The human body can synthesize EPA and/or DHA from precursor fatty acids including 
alpha-linolenic acid and stearidonic acid; however, the conversion of these fatty acids into DHA may be even less than 1%” at 
line 107. 
Global Oranization 
for EPA and DHA 
Omega-3s 
Conclusions and 
recommendations 
Conclusions and Recommendations 
L2024 - This sentence recognizes the ability of the body to synthesize DHA and EPA from a-linolenic acid but does not identify 
the limited extent of this conversion. A recent ISSFAL position paper by Brenna and co-workers (Brenna JT, Salem N, et al. 
Prostaglandins Leukot Essent Fatty Acids 80:85-91, 2009. See Summary Statement #2) confirms that conversion of ALA to 
DHA is less than 1% in adults. We respectfully suggest that language from L474 be added to this sentence, specifically, “The 
human body can synthesize EPA and/or DHA from alpha-linolenic acid and stearidonic acid; however, the conversion of ALA 
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into DHA may be even less than 1%”. 
L2029-L2030 – Conclusions regarding a DHA AI for children > 7 months until the age of 24 months are not reflected in the 
opinion Summary. We respectfully request that the conclusions from L2020-L2030 be added to the Summary. 
Global Oranization 
for EPA and DHA 
Omega-3s 
References The following references correspond to those cited in the comments associated with Chapter/Section: 5.8 Cardiovascular 
Disease  
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Heart of Mersey 1. Introduction Lines 293 – 314: Heart of Mersey acknowledges there are difficulties in establishing DRV‟s when considering their potential 
use and possible misinterpretation e.g. whether they are to be used for developing population goals in relation to appropriate 
dietary composition, food labelling purposes, to interpret dietary information for individuals or sub groups within the 
population. For example the previous RDA‟s developed in the UK in 1979 (were established as average amounts of a nutrient 
which should be provided per head in a group of people if the needs of practically all members of the group are to be met) had 
many disadvantages in that they were used inappropriately, had a limited degree of accuracy, a single figure was open to 
misinterpretation and they were wrongly used to assess the adequacy of an individual‟s diet. 
 
If establishing DRV‟s for energy, fats , fatty acids, sugars and starches it needs to be considered that at higher levels of 
consumption there is likely to be evidence of undesirable effects and for this purpose reasonable parameters or values need to be 
established. Heart of Mersey acknowledge that the current UK DRV‟s need to be reviewed. For the purpose of this consultation 
and given the importance of DRVs for a variety of applications, as stated above, where the evidence is insufficient, EFSA 
should adopt a precautionary approach and develop the best estimates based on the available evidence. 
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Heart of Mersey Conclusions and 
recommendations 
Cis-monounsaturated fatty acids (cis-MUFA) 
Lines 69-71: Cis-MUFA are synthesised by the body, have no known role in preventing or promoting diet related diseases, and 
are therefore not required in the diet. The Panel therefore proposes not to set any DRV for cis-MUFA.  
 
Cis-polyunsaturated fatty acids (cis-PUFA) 
Lines 73 -76:In view of the different metabolic effects of the various dietary cis-PUFA, the Panel proposes not to formulate a 
DRV for the intake of total cis-PUFA. Also, the Panel proposes not to set specific values for the n-3 / n-6 ratio as available data 
are insufficient to recommend a ratio independent of absolute levels of intake.  
 
There is strong evidence to show that where monounsaturated and polyunsaturated fats are eaten in place of carbohydrates, they 
decrease levels of harmful LDL cholesterol. Yet we still have no strict guidelines regarding their intake. In the UK Cis- MUFA 
intake is recommended as 12% of energy and 6% of energy should be derived from cis- PUFA‟s. Diets rich in monounsaturated 
fats also lower LDL –cholesterol, reducing the risk of CHD.  
Heart of Mersey Conclusions and 
recommendations 
Lines 63-65: The Panel recommends that SFA intake should be as low as possible within the context of a nutritionally adequate 
diet. Lines 1989-1991:There is no threshold of SFA intake below which no adverse effects are observed. Thus, no UL can be 
set. 
 
When translating nutritional information to the population, we need a recommended maximum intake of saturated fats or 
desirable population intake to support dietary goals/guidelines. If no upper limit is established this will lead to over 
consumption of saturated fat when considering the lipid profile of the diet COMA the former UK government committee on 
nutrition made recommendations in 1991 to reduce intake of total fat particularly saturated fat, so that consumption does not 
exceed 10 % of dietary energy. EFSA should initially set an interim target of 10% SFA intake which can subsequently be 
revised downwards once it has been met. HoM strongly suggests that this level may need to be reviewed due to the dose 
dependent relationship between intake of saturated fat and serum LDL cholesterol. HoM would support an intake „as low as 
possible‟ within the context of a nutritionally balanced diet, ideally 7 E% in line with Japanese consumption. 
Heart of Mersey Conclusions and 
recommendations 
n-3 polyunsaturated fatty acids (n-3 PUFA) 
Lines 115 -121: Taking into account that available data is insufficient to derive an AR, the Panel proposes to set an AI for adults 
of 250 mg for EPA plus DHA based on considerations of cardiovascular health. 
The Panel proposes an AI of 100 mg DHA for older infants (> 7 months of age) and young children below the age of 24 
months. For the age period 2-18 years, the Panel proposes no AI for DHA plus EPA. However dietary advice for children 
should be consistent with advice for the adult population. The Panel considers that during pregnancy and lactation an adequate 
n-3 LC-PUFA supply consists of the AI for adults (250 mg DHA plus EPA) and 100-200 mg additional preformed DHA. 
 
HoM strongly supports the recommendations for the establishment of an AI for EPA plus DHA based on cardiovascular health 
for both children and adults. Consumption of omega 3 oils (average of 250mg/d for adults) is related to a 35% lower risk of 
CHD death. 
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Central and Eastern European countries with the biggest increases in dietary intake of ALA have seen the largest recent 
DECREASES in cardiovascular mortality (Zatonski et al, Eur J Epidemiol 2008;23(1):3-10. 
Heart of Mersey Conclusions and 
recommendations 
Trans fatty acids (TFA) 
TFA are not synthesised by the human body, but are also not required in the diet. Therefore, no PRI, AR, or AI is set. Higher 
intakes of TFA have been consistently associated to an increased risk of CHD. There is a limit to which the intake of TFA can 
be lowered without compromising adequacy of intake of essential nutrients. Therefore, the Lines 2041-2: The Panel 
recommends that TFA intake should be as low as possible within the context of a nutritionally adequate diet. 
 
Trans fatty acids have a very negative impact on cardiovascular health. Recent large meta-analysis of randomised trials and 
prospective cohort studies found that replacing 1% of food energy from trans fats with plant based unsaturated fats reduced 
CHD risk by 12% ³. Trans fatty acids can occur naturally in ruminant products but most are produced artificially (Industrial 
Trans Fats). Trans fatty acids have no nutritional benefit.  
HoM would strongly recommend that an EU population intake target for trans fatty acids is set and used to monitor the 
elimination of industrial TFAs from food production. This has been achieved in Denmark and is ongoing in Austria as 
demonstrated by the low average population trans fat intakes of 0.5-0.6%E. The rest of the EU deserves equal health benefits. 
IMACE - 
International 
Margarine 
Association of the 
Countries of 
Europe 
1. Introduction Chapter Summary-Lines 77-128 
IMACE reacts on the proposed DRVs for linoleic acid (LA) and alpha-linolenic acid (ALA). The EFSA panel recommends, 
based on the „minimal level to prevent deficiency symptoms‟, AI levels of 4 E% for LA and 0.5 E% for ALA. LA and ALA 
deficiencies are virtually non-existent in the general population, whereas Cardiovascular Disease (CVD) is indisputably a major 
public health issue in Europe as it is the leading cause of mortality: 4.3 million deaths per year that make up 48% of all deaths 
in Europe (CVD statistics 2008). 
 
IMACE believes that EFSA should consider disease risk reduction in relation to the nutrient intake pattern, in line with current 
insights that dietary recommendations should also take prevention of morbidity and premature mortality via optimal nutrition 
into account. In fact, several other authoritative bodies do so: The US Institute of Medicine set Acceptable Macronutrient 
Distribution Ranges of 5-10 E% for LA and 0.6-1.2 E% for ALA (Dietary Reference Intakes for Energy, Carbohydrate, Fiber, 
Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Institute of Medicine (IoM) 2002). The WHO judged the evidence that 
LA and ALA decrease the risk of CVD as „convincing‟ and recommended 5-8 E% for n-6 fatty acids and 1-2 E% for n-3 fatty 
acids (Joint WHO/FAO expert consultation. Diet, Nutrition, and the prevention of chronic diseases. WHO Technical report 
series 916. Geneva 2003). The EC-sponsored Eurodiet report (2001) recommends intakes of 4-8 E% for LA and of 2 g for 
ALA, which is about 0.8 E% . 
 
Lines 151-159 
Information on dietary cholesterol is a highly relevant marker for consumers to identify foods which are also high in saturated 
fats.Information on dietary cholesterol would enable consumers to make easier, quicker, and more informed food choices which 
fit in a healthy lifestyle. IMACE believes that the Panel should set a DRV for dietary cholesterol, which should be in line with 
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the DRV for saturated fats. 
IMACE - 
International 
Margarine 
Association of the 
Countries of 
Europe 
3. Dietary sources 
and intake data 
Chapter 3-Lines 685-692: IMACE comments 
The figures indicated for cholesterol, clearly show that European adults tend to have a too high intake of dietary cholesterol 
compared to recommendations to limit the intake of dietary cholesterol below 300mg/d (cf. lines 939 to 942). As the Panel 
concluded that there is a positive relationship between the intake of dietary cholesterol with serum LDL concentrations, the fact 
that the average intake of dietary cholesterol is too high in European countries reinforces the need for clear and understandable 
information about dietary cholesterol. DRV for dietary cholesterol would enable people to control their dietary cholesterol 
intake and therefore maintain a healthy cholesterol blood level. 
IMACE - 
International 
Margarine 
Association of the 
Countries of 
Europe 
4. Overview of 
dietary reference 
values and 
recommendations 
Chapter 4-Lines 939-942: IMACE comments 
There are additional sources which recommend to limit the intake of dietary cholesterol below 300mg/day i.e.  
¿European guidelines on cardiovascular disease prevention in clinical practice – Third Joint Task force of European and other 
Societies on Cardiovascular disease prevention in clinical practice, European Heart Journal 2003; 24,1601-1610  
¿AHA Scientific statement – Diet and lifestyle recommendations revision 2006 –A scientific statement from the American 
Heart Association Nutrition Committee Circulation 2006; 114:82-96 
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IMACE - 
International 
Margarine 
Association of the 
Countries of 
Europe 
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
Chapter 6-Lines 1891–1894:IMACE comments 
EFSA states that “There is [also] evidence from dietary intervention studies that decreasing the intakes of products rich in SFA 
by a replacement of products rich in n-6 PUFA (without changing total fat intake) reduced the number of cardiovascular 
events.”  
This is strongly supported by a recent pooled analysis of cohort studies, which confirms a significant inverse relation between 
„increased PUFA at the expense of SFA‟ and coronary heart disease risk throughout the normal population range of intake 
(Jakobsen et al, Am J Clin Nutr 2009;89:1425-32). The median total PUFA intake in the 11 populations included in this 
analysis varied between 2.3 E% and 9.0 E%, with most populations having an intake of around 5-6 E%. The highest (90th 
percentile) PUFA intake levels ranged from 3.7 E% to 10.4 E%, and were between 7 E% and 9 E% for most populations. 
Because LA makes up approximately 80 to 90% of total dietary PUFA, it can be derived that in these general populations, 
intakes of at least 6 E% for LA and of at least 1.0 E% are associated with the lowest risk of CHD. 
A DRV for ALA of 1 E% would also be in line with the 2 g/day as ALA that EFSA recently recommended to the Commission 
as labelling reference intake values (Question No EFSA-Q-2009-00548, adopted on 30 June 2009). Two g ALA per day in a 
2000 kcal/d diet corresponds to ~0.9E%. 
IMACE - 
International 
Margarine 
Association of the 
Countries of 
Europe 
6.5. Trans fatty 
acids (TFA) 
Chapter 6-Lines 1936-1959:IMACE comments 
IMACE welcomes the EFSA statement that "The available evidence indicates that TFA from ruminant sources have similar 
adverse effects on blood lipids and lipoproteins similar to those from industrial sources...The available evidence is insufficient 
to establish whether there is any difference between equivalent amounts of ruminants and industrially produced TFA and risk of 
CHD." 
IMACE - 
International 
Margarine 
Association of the 
Countries of 
Europe 
6.7. Cholesterol Chapter 6-Lines 1964 to 1972: IMACE comments 
A DRV should be set also for dietary cholesterol. This is justified from a public health perspective given the fact that the 
negative effects of too high intakes of dietary cholesterol on health have clearly been demonstrated (cf. lines 1328 to 1340; 1701 
to 1712; 1745 to 1751). In addition, IMACE sees an urgent need for a DRV to be set for dietary cholesterol in light of the 
Panel‟s conclusion that current average intake levels of dietary cholesterol among European adults are often well above the 
generally accepted and recommended intake limits (cf. lines 685 to 692 and lines 939 to 942).  
 
Furthermore, information on dietary cholesterol is a highly relevant marker for consumers to identify foods which are also high 
in saturated fats. From a consumer point of view, dietary cholesterol is far more easy to understand than the difference between 
healthy (unsaturated) and less healthy (saturated ) fatty acids . Information on dietary cholesterol would enable consumers to 
make easier, quicker, and more informed food choices which fit in a healthy lifestyle.  
 
As a result, IMACE believes that the Panel should set a DRV for dietary cholesterol, which should be in line with the DRV for 
saturated fats – i.e. as low as possible, or at least in line with the generally accepted and recommended intake limits – i.e. max 
300mg/day for adults.  
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IMACE - 
International 
Margarine 
Association of the 
Countries of 
Europe 
Conclusions and 
recommendations 
Chapter Conclusions-Lines 2003-2035:IMACE comments 
The proposed average intake levels of 4E% for LA and 0.5 E% for ALA, are based on prevention of deficiency symptoms. This 
is in contrast with other international dietary recommendations that, taking prevention of CHD into account, advice 
substantially higher intake levels of LA and ALA for optimal health. From the available evidence, it can be derived that AI 
levels for preventing cardiovascular diseases should be at least 6 E% for LA and 1 E% for ALA.  
 
IMACE believes that with the currently proposed AI levels, EFSA does not seize the opportunity to help the European 
population achieving intakes of LA and ALA that have been shown to reduce the risk of CHD. If the EU implements these 
recommendations of the EFSA panel, evidence-based claims and other communications aimed at motivating consumers to 
increase intakes of LA and ALA will be extremely difficult to make.  
 
Chapter Conclusions-Lines 2047 to 2054: IMACE comments 
A DRV should be set also for dietary cholesterol as it is justified from a public health perspective given the fact that the 
negative effects of too high intakes of dietary cholesterol on health have clearly been demonstrated (cf. lines 1328 to 1340; 1701 
to 1712; 1745 to 1751). There is an urgent need for a DRV to be set for dietary cholesterol in light of the Panel‟s conclusion that 
current average intake levels of dietary cholesterol among European adults are often well above the generally accepted and 
recommended intake limits (cf. lines 685 to 692 and lines 939 to 942). Furthermore, information on dietary cholesterol is a 
highly relevant marker for consumers to identify foods which are also high in saturated fats. Information on dietary cholesterol 
would enable consumers to make easier, quicker, and more informed food choices which fit in a healthy lifestyle.  
 
IMACE believes that the Panel should set a DRV for dietary cholesterol, which should be in line with the DRV for saturated 
fats – i.e. as low as possible, or at least in line with the generally accepted and recommended intake limits – i.e. max 300mg/day 
for adults. 
 
Joint Dutch 
Product Bo 
Conclusions and 
recommendations 
1992-1993. 
The Dutch Product Boards together represent the meat, eggs, dairy, fish, fats and oil and fruits and vegetable sectors in the 
Netherlands. 
We would like to submit comments to the summary but since this is not possible we submit our comments to the conclusions 
and recommendations chapter, under the same headings as in the summary 
 
Why are all the saturated fats treated as one group in the summary? The unsaturated fats are split up in separate groups, but the 
saturated fats are treated as one group. As stated in chapter 5.2.2 several saturated fats have different effects on cholesterol 
metabolism.  
 
In the Summary in line 66,67 the following is written: „The Panel recommends that SFA intake should be as low as possible 
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within the context of a nutritionally adequate diet‟.  
In the discussed scientific research in chapter 5 this recommendation is not supported. Furthermore, according to Table 5 (page 
32), most Countries and also the WHO/FAO set the maximum SFA at 10 E%. In infants average intakes of SFA where between 
11-13 E%. In adults, average SFA intakes vary between 9 to 17 E% and nearly 30% of the reported average intakes were 15 E% 
or higher (line 620-629).  
In addition: in several economically developed countries where the SFA is close to 10%, the capacity to decrease SFA much 
further is limited to major changes in dietary patterns, and is only likely to result in modest reductions in TC and LDL-C 
We therefore believe it is appropriate to set the recommendation for SFA at 10 E%.  
Joint Dutch 
Product Bo 
Conclusions and 
recommendations 
line 1973 
The Dutch Product Boards together represent the meat, eggs, dairy, fish, fats and oils and fruits and vegetable sectors in the 
Netherlands. 
We would like to submit general comments and comments to the summary, but as this is not possible we submit these 
comments in the ''conclusions and recommendations chapter. 
 
General remarks 
- The Dutch Product Boards are of the opinion that the conclusions in the summary do not reflect accurately the content of the 
report. More precise, the nuance in the report is lacking in the summary. Therefore, it is not immediately obvious on what basis 
the conclusions are drawn. Since the summary is generally the only part that policy makers read, it is important that the 
summary reflects the scientific state of the art, including the recent developments and nuances. 
 
- Recently, two WHO scientific updates were published in the European Journal of Clinical Nutrition (vol. 63, supplement 2s, 
pp S1-S75) and Annals of Nutrition and Metabolism (vol.55, no. 1-3: pp 5-300). It seems logical to take these two updates into 
account in the document.  
Joint Dutch 
Product Bo 
Conclusions and 
recommendations 
line 1973, conclusions and recommendations. 
 
The Dutch Product Boards together represent the meat, eggs, dairy, fish, fats and oil and fruits and vegetable sectors in the 
Netherlands. 
We would like to submit comments to the summary but since this is not possible we submit this comment to the conclusions 
and recommendations chapter. 
 
General remark: 
We would like to point out the following. Consumers do not eat saturated fats or unsaturated fats as such. They eat these 
nutrients in a matrix (food stuffs), as part of a balanced diet. In practice, the matrix influences the effects of the fatty acids, 
meaning that negative effects may not occur, or may be less pronounced, due to the presence of other nutrients in the food.  
In addition, basic food groups provide many positive nutrients such as vitamins, minerals and protein. Avoiding such foods 
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because of the presence of saturated fats or trans fats, may therefore not always be the preferred choice for consumers. 
Joint Dutch 
Product Bo 
Conclusions and 
recommendations 
line 1982-1985 and line 2055: 
The Dutch Product Boards together represent the meat, eggs, dairy, fish, fats and oil and fruits and vegetable sectors in the 
Netherlands. 
We would like to submit comments to the summary but since this is not possible we submit our comments to the conclusions 
and recommendations chapter, under the same headings as in the summary. 
 
What is the lower bound of the recommendation intake range of fat for children between 4-18 years? In line 50-55 no specific 
recommendation level is mentioned for children older than 4 years. In line 54 The Panel states that fat intakes below 25E% have 
been associated with low vitamin levels in some young children. So why then come to a lower bound of 20E% as stated in the 
table on line 2055 for children >4 years? It appears more prudent to recommend a total fat intake of at least 25E% for children. 
Joint Dutch 
Product Bo 
Conclusions and 
recommendations 
Line 1986: 
The Dutch Product Boards together represent the meat, eggs, dairy, fish, fats and oil and fruits and vegetable sectors in the 
Netherlands. 
We would like to submit a comment to the Annex on page 93. 
 
On page 93 (line 2915) the dietary reference value in the Netherlands is mentioned. However, these are the values from 2001, 
whereas the Dutch Health Council updated its advice in 2006. Therefore we recommend using the most recent dietary 
guidelines. 
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Joint Dutch 
Product Bo 
Conclusions and 
recommendations 
Line 2010-20112, n-6 PUFA 
The Dutch Product Boards together represent the meat, eggs, dairy, fish, fats and oil and fruits and vegetable sectors in the 
Netherlands. 
We would like to submit comments to the summary but since this is not possible we submit our comments to the conclusions 
and recommendations chapter, under the same headings as in the summary 
 
Why has the Panel set an AI for linoleic acid on 4 E% to prevent deficiencies as stated in line 89-91? This is in contrast with the 
WHO that set an AI of 2.5 E% LA to prevent deficiencies. In addition, why didn''t The Panel take into account the effect of n-6 
PUFA on prevention of chronic diseases? This would be in line with the recommendation of the WHO, that judges the evidence 
that replacing SAFA by PUFA reduces the risk of CHD events as ''convincing'' and recommends a minimal intake level of 
PUFA of 6 E% to prevent chronic diseases. 
Joint Dutch 
Product Bo 
Conclusions and 
recommendations 
line 2021-2023, n-3 PUFA 
The Dutch Product Boards together represent the meat, eggs, dairy, fish, fats and oil and fruits and vegetable sectors in the 
Netherlands. 
We would like to submit comments to the summary but since this is not possible we submit our comments to the conclusions 
and recommendations chapter, under the same headings as in the summary 
 
Why has the Panel set the AI for a-linolenic acid on 0.5 E%? The WHO has set in her recent scientific update the AI of 0.5 E% 
of a-linolenic acid to prevent deficiency. Total n3-pufa (ALA+ EPA+ DHA) should be between 0,5-2 E% (of which n3 
LCPUFA, based on a 2000 kcal diet should be 0,1-0,9 E%) as part of a healthy heart diet, possibly preventing some chronic 
diseases. The Dutch Health Council has set the AI for a-linolenic acid on 1 E%. 
Joint Dutch 
Product Bo 
Conclusions and 
recommendations 
line 2039-2042: Trans fatty acids 
 
The Dutch Product Boards together represent the meat, eggs, dairy, fish, fats and oil and fruits and vegetable sectors in the 
Netherlands. 
We would like to submit comments to the summary but since this is not possible we submit our comments to the conclusions 
and recommendations chapter, under the same headings as in the summary 
 
We suggest adding to the statement of The Panel in the summary the following: 
The intake of TFA is close to the recommendation levels in most European countries, and are therefore not a public health issue 
anymore. The intake of total TFA is low because of the efforts made by the food industry in reducing the amount of industrial 
TFA in their products (and these efforts are ongoing). The level of ruminant TFA in meat (products) and dairy products is 
already naturally low. 
Lipid Nutrition 1. Introduction SUMMARY 
line 147-150 
There is strong evidence that CLA reduces fat in humans and this can be deemed to prevent obesity or weight gain.  
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Lipid Nutrition 2. Categories, 
structure and 
function 
Line 583-586 
 
Addition: 
Cis-9, trans-11 CLA and Trans-10, cis-12 CLA are also found in small quantities in human breastmilk in a 80/20-ratio. 
(Lipids. Vol.41, no 9(2006); Human Milk Fatty Acid Composition Varies Most in DHA). 
 
Delete: 
line 585 --> Trans-10, cis-12 CLA is mainly found in supplements and produced by industrial processing. 
 
Add: 
New line 585: Commercial available CLA for use in food supplements and foodstufs contains Cis-9, trans-11 CLA and Trans-
10, cis-12 CLA in a 50/50-ratio. 
Lipid Nutrition 3. Dietary sources 
and intake data 
Between lines 684 and 685 There is a missing chapter on Intake data from CLA: 
 
New chapter 3.2.6 CLA 
Ritzenthaler et al. (2001) estimated the mean background dietary CLA intake (from all isomers) to be 212 and 151 mg/day for 
men and women, respectively. This study, with 51 men and 51 women between ages of 18 and 60, compared 3 day food 
duplicates with dietary records and food-frequency questionnaires. Earlier surveys, estimated intake to be 137 and 52 mg/day in 
college-aged males and females, respectively (Ritzenthaler et al., 1998), or 291 and 15 mg/day in lactating women with high- 
and low-dairy diets (Park et al., 1999). Herbel et al. (1998) reported 127 mg/day as the average daily CLA intake in a study with 
healthy young men and women. Thus, the mean daily dietary CLA intake from the background diet can be estimated at 212 and 
151 mg/day for men and women, with subgroups consuming up to 300 mg/day. 
 
Commercial CLA-rich oil has been available on the EU market since 1995, mainly in food supplements. Typically these deliver 
a dose of up to 3 g of CLA per daily serving.  
Lipid Nutrition 5.4. Inflammation 
and immne 
function 
line 1430-1428 
This evaluation is not correct ! 
This is quite the contrary, there are numerous human and animal studies which show clear effects of CLA on immune function. 
These include reduction in pro-inflammatory cytokines, increases in antibodies, reduction in cold symptoms, and reduction in 
allergy symptoms. 
 
(on request I can send an extensive overview of the relevent published literature ! -->contact: 
jaap.kluifhooft@lipidnutrition.com) 
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Lipid Nutrition 5.7. Body weight 
control and energy 
balance 
line 1606-1617 
Remark/finetuning scientific evaluation: 
The Gaullier paper should not be used as a definitive trial to state that CLA causes fat loss from around the legs. That trial had a 
large number of women who typically gain fat from around the legs. This is why they observed fat mass from around that 
region. Also, several of the trials show a within group reduction in fat around the abdomen.  
Lipid Nutrition 5.7. Body weight 
control and energy 
balance 
line 1614 
typo: "trans-10, cis-9 CLA" should read "trans-10, cis-12 CLA"  
London 
Metropolitan 
University 
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
 
We, the undersigned 22 scientific researchers and clinicians, specialising in omega-3 fatty acids, urge EFSA to withdraw and 
reconsider Para 6.4.2 in its entirety. The current text suffers from fundamental problems: 
 
1. It includes, without qualification, the statement that "The human body can synthesize EPA and DHA from alpha-linolenic 
acid". In fact, the conversion rate is so low, especially for DHA, that consumers would receive little or none of the health 
benefits associated with DHA. There is much recent research on this point, summarised in the official ISSFAL position on 
conversion, published in 2008. 
 
2. The AI of 250mg/d for combined EPA plus DHA is too low. Over the past 20 years, there have been 15 recommendations on 
EPA/DHA intakes by specialist organisations and committees. The average of these recommendations is 566mg/d. EFSA 
should reconsider its AI in the light of the much higher recommendations set by scientists who specialise in this field. 
 
3. There is no mention of mental health at all in this section. In fact, there is a great deal of research documenting the benefits of 
LC n-3 PUFA on mental well-being throughout the life cycle, from foetal brain development to the amelioration of Alzheimer''s 
disease. The most recent major research review relevant to mental well being was published by the Food & Drug 
Administration earlier this year, "Summary of published research on the beneficial effects of fish consumption and omega-3 
fatty acids for certain neurodevelopmental and caridovascular endpoints". EFSA should consider this large body of research 
evidence fully and carefully, then make recommendations appropriate for mental as well as physical health. 
 
In addition, earlier in section 6.4, the report declines to make any recommendation on the n-3/n-6 ratio. In fact, it is increasingly 
recognised that these fatty acids are physiological competitors. Therefore, the large and rising preponderance of n-6 fats in 
western diets is having a detrimental effect. EFSA should look at this question again. 
 
These are all basic scientific points. Therefore, EFSA should reconsider its conclusions and advice on omega-3 fatty acids 
afresh, right from the beginning. 
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Professor of Neurophysiology 
Oxford University 
 
Dr Peter Sullivan 
Department of Paediatrics 
Oxford University 
 
Prof Jack Winkler 
Director, Nutrition Policy Unit 
London Metropolitan University 
 
Martek Biosciences 
Corporation 
2. Categories, 
structure and 
function 
(Lines 453- 464) - Even though the Panel assumes that internal conversion of LA to AA (20:4n-6) is sufficient in most diets and 
proposes to not establish a DRV for AA, this scientific document should reflect the physiological importance of AA. AA is a 
substrate for production of eicosanoids, an essential component of cell membranes, and an important factor in cell signaling 
pathways. It is involved with regulation of gene expression and is important for neural development and function. AA is in all 
cell membranes and is found at particularly high levels in neural membranes, particularly those of the brain. This language 
should be consistently recognized throughout the Opinion including lines 92-94 of the Summary. (Institute of Medicine, Dietary 
Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids, The National 
Academies Press, Washington, DC 2005, pgs. 426-427.)  
Martek Biosciences 
Corporation 
2. Categories, 
structure and 
function 
L471-477 – This section identifies the limited ability of alpha-linolenic acid (ALA) to serve as a source of DHA. A recent 
ISSFAL position paper by Brenna and co-workers confirms that conversion of ALA to DHA is less than 1% in adults, this 
reference may be a useful addition to the Opinion(Brenna JT, Salem N, et al. Prostaglandins, Leukotrienes and Essential Fatty 
Acids 80:85-91, 2009. See Summary Statement #2). Unfortunately, the limited conversion ALA to DHA is not sufficiently 
identified throughout the current draft opinion. Specifically, the Summary (L107) recognizes that the body converts ALA to 
DHA and EPA but fails to quantify the limited extent of conversion. We respectfully suggest that language from L474 be added 
to the opinion Summary, specifically, “The human body can synthesise EPA and DHA from a-linolenic acid, however, the 
conversion of ALA into DHA may be even less than 1%” at line 107. 
 
L480 – The Committee notes that “the developing brain accumulates large amounts of DHA both pre- and postnatally (until two 
years of age)…”. We respectfully disagree, however, with the limitation of DHA accumulation only “until two years of age”. 
Classic research by Martinez indicates that DHA accumulation by the brain postnatally “is still very significant until at least 2 
years of age” [emphasis added], specifically, Martinez provides data for children up to 2.7 years(J Pediatr 120:S129-39, 1992 
Pg. S132 Fig. 3A). More recent data from Carver and coworkers (Carver JD, et al. Brain Research Bulletin 56:79-85, 2001. Pg. 
82 Fig. 1; Pg. 84 Table 2) indicates that levels of DHA in the cerebral cortex increases steadily up to the age of 18 years. 
Finally, it is well known that the brain growth spurt begins during the third trimester and continues throughout the first 3-4 
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years of life (Dobbing J and Sands J. Archives of Disease in Childhood, 48:757-767, 1973. Pg. 765), this important 
developmental period is recognized as a period of critical brain growth and neuronal development. Collectively, these data 
support recognition of an expanded range of DHA accumulation by the postnatal brain in the current Opinion or elimination of 
the “until two years of age” language without an effort to specify further.  
Martek Biosciences 
Corporation 
3. Dietary sources 
and intake data 
Line 548 – The Panel recognizes meat as a source of AA (20:4n-6). This statement should also recognize the production of AA 
from fungal sources. Fungal AA is the predominant source of AA in infant formula. 
Martek Biosciences 
Corporation 
4. Overview of 
dietary reference 
values and 
recommendations 
L866-867 – notes the U.S. IOM recommendation for DHA and EPA contribution toward reversing an n-3 fatty acid deficiency 
but fails to recognize the level of contribution specified by the IOM, i.e up to 10%. We respectfully request the following 
revised language be considered for L866-867, “Small amounts of EPA and DHA (up to 10%) can contribute towards reversing 
an n-3 fatty acid deficiency and can therefore contribute towards the AI for alpha-linolenic acid.” 
 
L1012-1013 – We respectfully request the following revised language be considered for L866-867, “Small amounts of EPA and 
DHA (up to 10%) can contribute towards reversing an n-3 fatty acid deficiency and can therefore contribute towards the AI for 
alpha-linolenic acid.” 
Martek Biosciences 
Corporation 
5.1. Dietary 
requirements 
L1176-1180 – This section identifies the limited ability of alpha-linolenic acid (ALA) to serve as a source of DHA. A recent 
ISSFAL position paper by Brenna and co-workers confirms that conversion of ALA to DHA is less than 1% in adults, this 
reference may be a useful addition to the Opinion(Brenna JT, Salem N, et al. Prostaglandins, Leukotrienes and Essential Fatty 
Acids 80:85-91, 2009. See Summary Statement #2).  
 
L1199-L1207 – This section provides sound rationale for a DHA requirement during pregnancy and nursing. However, recent 
expert group recommendations and guidelines are not mentioned. Specifically, the Consensus recommendations on behalf of the 
European Commission research projects Perinatal Lipid Metabolism (PeriLip) and Early Nutrition Programming (EARNEST) 
could be recognized. In addition, the benefits to maternal and infant health noted by the PeriLip/EARNEST document should 
also be recognized, specifically, slightly longer pregnancy duration, reduced risk of preterm birth, and somewhat higher birth 
weight (Koletzko B, Cetin I, et al. Br J Nutr 98:873-877, 2007; Conclusions and Recommendations #2,6).  
 
L1220 – We respectfully request that “such small amounts of” be removed from this sentence. Given the very limited intake and 
availability of DHA, particularly from 6-24 months of age, classification of 100 mg as a small amount could be misleading as it 
suggests a goal readily accomplished as part of the normal diet. In fact, the most common source of DHA other than infant 
formula is fatty fish. Fish and seafood, however, are typically restricted by parents to at least 3 years of age due to allergy 
related concerns (ESPGHAN Committee on Nutrition, J Pedi Gastro Nutr 46:99-110, 2008. Pg. 104-105). 
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Martek Biosciences 
Corporation 
5.1. Dietary 
requirements 
Line 1154 - In their Opinion, the Panel makes no recommendation for a DRV for ARA (20:4n-6). However, the Panel should 
make clear that the reasoning for this is based on information available from a plentiful, meat-based diet in healthy adults only. 
In general, research is lacking regarding an optimal intake of ARA for special populations. In addition, research does not 
indicate that there is not a need for ARA, especially for some populations. ARA is in all cell membranes and is found at 
particularly high levels in neural membranes, particularly those of the brain. Endogenous synthesis of ARA by the infant is 
insufficient to meet the demands of the growth and development. Tissue levels drop rapidly following birth unless dietary ARA 
is supplied in either human milk or a supplemented infant formula (Clandinin M, et al. Pediatr Res 1997;42:819-25, Table 8, p. 
824). During the weaning period, the introduction of complementary feedings can vary greatly with regard to n-6 PUFA content 
and there may be many months of transition into the adult diet (C. Agostoni, et al. J Ped Gastr Nutr. 2008;46(1):99-110). ARA 
continues to be an important diet component during this transition and only a combination of ARA with DHA (22:6n-3) has 
shown neurocognitive benefits for infants. Importantly, all studies used to support the recent EFSA Article 14 opinion regarding 
DHA and visual development of infants provided DHA in combination with ARA. The developmental benefits of formula and 
complementary foods supplemented with both ARA and DHA continue well beyond the period of supplementation and extend 
into early childhood (Birch E, et al. Early Hum Dev. 2007;83(5):279-84). We respectfully request that the ARA be recognized 
as associated with neurodevelopmental outcomes.  
Martek Biosciences 
Corporation 
5.11. Nervous 
system function 
L1817 – This sentence appears to contradict recommendations made by the Committee in the Conclusions of the current 
opinion. This sentence notes that optimal amounts of LC-PUFAs can not be specified for infants in the second six months of 
life, however, the Conclusions (L2029-2030) indicate a proposed “… AI of 100 mg DHA for older infants (> 7 months of age) 
and young children below the age of 24 months”. We respectfully request that section 5.11 reflect the Panel‟s conclusion 
regarding an optimal level of DHA during the second six months of life.  
Martek Biosciences 
Corporation 
5.11. Nervous 
system function 
Line 1804 – The current Opinion should reflect that only infant formulas which contain the combination of DHA and ARA 
show neurocognitive benefit and benefits that extend well beyond the period of supplementation (Birch E, et al. Early Hum 
Dev. 2007;83(5):279-84). In fact, all studies used to support the recent EFSA Article 14 opinion regarding DHA and visual 
development of infants provided DHA in combination with ARA. During the weaning period, the introduction of 
complementary feedings can vary greatly with regard to n-6 PUFA content and there may be many months of transition into the 
adult diet (C. Agostoni, et al. J Ped Gastr Nutr. 2008;46(1):99-110). We respectfully request that the Committee recognize that 
ARA may be limited during complementary feeding although an AI can not yet be defined.  
 
Line 1812 – The current Opinion should note that recommendations provided by the Committee are consistent with the EU 
Directive for Infant Formula and Follow-on Formula. The Opinion should be clear that the required combination of ARA with 
DHA applies to follow-on formula as well as infant formula.  
Outcome of the Public consultation on the Draft Opinion on  
Dietary Reference Values for fats 
 
177 EFSA Journal 2010; 8(5):1507 
ORGANISATION CHAPTER TEXT COMMENT TEXT 
Martek Biosciences 
Corporation 
5.2. Serum lipids 
and lipoproteins 
L1274-1279 – This section recognizes the role of EPA and DHA in triglyceride reduction but does not recognize the 
independent role of DHA in this regard. A recent analysis of 16 studies of algal DHA supplementation reports that “clinical 
trials with algal-DHA as a TG oil have demonstrated a marked reduction in serum TG levels (up to 26%) in normal individuals 
and in those with HTG or combined hyperlipidemia.” (Ryan AS, et al. Am J Therapeutics 16:183-92. Table 2). We respectfully 
request that the independent role of DHA for TG reduction be recognized in this section. Additionally, recognition of the 
independent role of DHA for elevation of HDL is also requested (Ryan AS, et al. Am J Therapeutics 16:183-92. Table 3).  
 
L1279 – We respectfully request that the terminology “fish oil fatty acids” be replaced with EPA and/or DHA as it is more 
appropriate to recognize the beneficial nutrients as opposed to any one dietary source. These nutrients are not limited to fish oil 
but currently available from fish, marine microalgae and numerous fortified and enriched foods and beverages.  
Martek Biosciences 
Corporation 
5.3. Haemostatic 
function 
L1377-L1386 – These lines recognize the role of EPA and DHA in hemostasis. It is important to note that changes in bleeding 
times resulting from decreased platelet aggregation as noted in L1380-L1382 are within a clinically normal range and 
considered a benefit as opposed to a safety issue in the general population (Lavie CJ, et al. J Am Coll Cardiol 54:585-594, 
2009).  
 
L1399-L1400 – We respectfully request the following revised language be considered, “An exception may be the n-3 LCPUFA, 
which may decrease platelet aggregation in particular at intakes above 1 g but without clinically adverse changes in bleeding in 
the general healthy population.” 
Martek Biosciences 
Corporation 
5.4. Inflammation 
and immne 
function 
L1437 – We respectfully request that “fish oil” be removed as it could be misleading to suggest that only fish oil can provide 
beneficial n-3 LCPUFA. These nutrients are not limited to fish oil but currently available from fish, marine microalgae and 
numerous fortified and enriched foods and beverages.  
Martek Biosciences 
Corporation 
5.5. Blood pressure L1464-L1473 - We respectfully request that the terminology “fish oil” be replaced with EPA and/or DHA since these nutrients 
are available from multiple sources in addition to fish oil such as DHA from marine microalgae. It seems more appropriate to 
recognize a particular intake level of the beneficial nutrients as opposed to any one dietary source. Studies of blood pressure in 
response to algal-DHA supplementation are available and suggest at least equal reductions in response to DHA as compared to 
EPA and DHA from fish oil (Ryan AS, et al. Am J Therapeutics 16:183-92. Table 3).  
 
L1486 – We respectively request “fish oil” be removed and n-3 LCPUFA rather than n-3 PUFA be used in this sentence. 
Authors provide data only for n-3 LCPUFA and blood pressure reduction therefore n-3 LCPUFA is a more appropriate term 
than n-3 PUFA which would typically include ALA. In addition, it could be misleading to suggest that only fish oil can provide 
beneficial n-3 LCPUFA. These nutrients are not limited to fish oil but currently available from fish, marine microalgae and 
numerous fortified and enriched foods and beverages.  
Martek Biosciences 
Corporation 
5.8. Cardiovascular 
disease 
L1716 - We respectfully request that the term “fish oil” be replaced with EPA and DHA since these nutrients are available from 
multiple sources in addition to fish oil, such as marine microalgae, and it seems more appropriate to recognize a particular 
intake level of the beneficial nutrients as opposed to any one dietary source. Modifying the language in this section would also 
be consistent with that used in EFSA‟s scientific opinion regarding labelling reference intake values for n-3 and cardiovascular 
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disease prevention (The EFSA Journal, 1176:1-11, 2009) and with L1919-1924 of the current opinion.  
Martek Biosciences 
Corporation 
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
L1915 - This sentence recognizes the ability of the body to synthesize DHA and EPA from a-linolenic acid but does not identify 
the limited extent of this conversion. A recent ISSFAL position paper by Brenna and co-workers (Brenna JT, Salem N, et al. 
Prostaglandins, Leukotrienes and Essential Fatty Acids 80:85-91, 2009. See Summary Statement #2) confirms that conversion 
of ALA to DHA is less than 1% in adults. Unfortunately, the limited conversion ALA to DHA is not sufficiently identified 
throughout the current draft opinion. We respectfully suggest that language from L474 be added to this sentence, specifically, 
“The human body can synthesise EPA and DHA from a-linolenic acid, however, the conversion of ALA into DHA may be even 
less than 1%”. 
Martek Biosciences 
Corporation 
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
Line 1901 - Even though the Panel assumes that internal conversion of LA to ARA is sufficient in most diets and proposes to 
not establish a DRV for ARA (20:4n-6) this scientific document should reflect the physiological importance of ARA. ARA is a 
substrate for production of eicosanoids, an essential component of cell membranes, and an important factor in cell signaling 
pathways. It is involved with regulation of gene expression and is important for neural development and function. ARA is in all 
cell membranes and is found at particularly high levels in neural membranes, particularly those of the brain. (Institute of 
Medicine, Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids, 
The National Academies Press, Washington, DC 2005, pgs. 426-427). This scientific document should indicate the populations 
at risk for suboptimal ARA status including: vegans, particularly during the perinatal period; those with low intake of LA 
(18:2n-6); and, infants and toddlers during complementary feeding.  
Martek Biosciences 
Corporation 
Conclusions and 
recommendations 
L2024 - This sentence recognizes the ability of the body to synthesize DHA and EPA from a-linolenic acid but does not identify 
the limited extent of this conversion. A recent ISSFAL position paper by Brenna and co-workers (Brenna JT, Salem N, et al. 
Prostaglandins, Leukotrienes and Essential Fatty Acids 80:85-91, 2009. See Summary Statement #2) confirms that conversion 
of ALA to DHA is less than 1% in adults. We respectfully suggest that language from L474 be added to this sentence, 
specifically, “The human body can synthesise EPA and DHA from a-linolenic acid, however, the conversion of ALA into DHA 
may be even less than 1%”. 
 
L2029-2030 – Conclusions regarding a DHA AI for children > 7 months until the age of 24 months are not reflected in the 
opinion Summary. We respectfully request that the conclusions from L2020-2030 be added to the Summary. 
Martek Biosciences 
Corporation 
Conclusions and 
recommendations 
Line 2013 - Even though the Panel assumes that internal conversion of LA to ARA is sufficient in most diets and proposes to 
not establish a DRV for ARA (20:4n-6) this scientific document should reflect the physiological importance of ARA. ARA is a 
substrate for production of eicosanoids, an essential component of cell membranes, and an important factor in cell signaling 
pathways. It is involved with regulation of gene expression and is important for neural development and function ARA is in all 
cell membranes and is found at particularly high levels in neural membranes, particularly those of the brain. (Institute of 
Medicine, Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids, 
The National Academies Press, Washington, DC 2005, pgs. 426-427). This scientific document should indicate the populations 
at risk for suboptimal ARA status including: vegans, particularly during the perinatal period; those with low intake of LA 
(18:2n-6); and, infants and toddlers during complementary feeding.  
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National Center of 
Public Health 
Protection 
1. Introduction Line 349: 
It is more precisely to state - "Dietary fats mainly consist of triacylglycerols, which are...", since fat consists of heterogeneous 
mixture of different TG (ie not "triacylglycerol"). 
Ref.: 1) IUPAC. Joint Comm IUNS & IUPAC Commission on Food (2001) Lexicon of Lipid Nutrition (IUPAC Techn Rep) 
Pure Appl Chem 73: 685-744.  
2) SM Grundy. Dietary Fat. In: Present Knowledge in Nutrition 7th ed, p.44 
 
Line 380: 
It is more precisely to state - "Due to its physical properties, cholesterol, a steroid, is also included in dietary fats". (Cholesterol 
is not a fat, strictly categorizing). 
Ref.: 1) IoM (2005) DRI for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. The 
National Academies Press, Washington DC, p.424. 
2) IUPAC. Joint Comm IUNS & IUPAC Commission on Food (2001) Lexicon of Lipid Nutrition (IUPAC Techn Rep) Pure 
Appl Chem 73: 685-744. 
National Center of 
Public Health 
Protection 
2. Categories, 
structure and 
function 
Lines 444 and 445: 
Eicosanoid cascade include also Thromboxanes (cyclooxygenase pathway) - an important class of eicosanoids. 
Ref.: 1) IoM (2005) DRI for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. The 
National Academies Press, Washington DC, p. 434 
2) IUPAC (2001) Joint Comm IUNS & IUPAC Commission on Food. Lexicon of Lipid Nutrition (IUPAC Techn Rep). Pure 
Appl Chem 73: 685-744 
 
Lines 443 and 454: 
Here the abbreviation of Arachidonic acid (AA) (and also in lines 1813, 1815) is different from that in the other chapters - Lines 
1155, 1158, 1160, 1161, 1271, 2055, 2246, where it is (ARA) - so an unification is necessary. 
National Center of 
Public Health 
Protection 
4. Overview of 
dietary reference 
values and 
recommendations 
Additionally some technical aid: 
 
Line 862 : 
 
...".. a alpha-linolenic..." should become ".. an alpha-...." 
National Center of 
Public Health 
Protection 
5.6. Glucose 
tolerance and 
insulin sensitivity 
Additionally some technical aid : 
 
Line 1523 : 
 
..."..sourcers.." should become ".. sources" 
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National Center of 
Public Health 
Protection 
5.8. Cardiovascular 
disease 
Additionally some technical aid : 
 
Line 1629 : 
 
"A reviewe.." should become ".. review..." 
National Center of 
Public Health 
Protection 
6.1. Total fat Additionally some technical aid : 
 
Line 1836 : 
 
.."..the available" should become ". The available.." 
National Center of 
Public Health 
Protection 
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
Additionally some technical aid : 
 
Line 1886 : 
 
"...to derive a, AR.." should become ".. an AR..." 
National Center of 
Public Health 
Protection 
Conclusions and 
recommendations 
Additionally some technical aid : 
 
Line 2005 : 
"...to derive an LTI.." should become ".. a LTI.." 
 
Line 2055 : 
Summary ... 
Row "EPA + DHA" - third column "Children" 
"AI 7-24 mths.." should become " 7-24 months.." 
National Center of 
Public Health 
Protection 
References Additionally some technical aid : 
 
Annex 3 : 
 
Table 6 : 
Line 2917 : 
 
Third row, First column : 
 
"SAFA" should become "SFA" 
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National Center of 
Public Health 
Protection 
References An unification is necessary for the presentation of references - eg: 
 
Lines 2086 and 2087: 
Int J Obes Relat Metab Disord 24: 1545-1552. 
and  
Lines 2207 and 2208: 
Amer.J.Clin.Nutr. 87, 1405-1413. 
 
ie - with or without dots in the titles of scientific journals; after the number of the respective volume - comma or :, etc. 
Unification concerns all the Section - "References". 
National Heart 
Forum 
1. Introduction The National Heart Forum (NHF) welcomes the process of developing Dietary Reference Values (DRVs) for nutrients. We 
agree that DRVs can be used for a variety of purposes including diet assessment and planning, providing reference values in 
food labelling, in establishing food based dietary guidelines (FBDG) as well as nutrient profiles. We consider EFSA‟s work of 
essential and necessary for harmonising DRVs and FBDGs as much as possible across Europe.  
 
However, the European level guidelines, while useful, should not supersede existing dietary guidelines at the country level. 
EFSA should clarify the purpose of the European DRVs in relation to national dietary guidelines.  
 
Given the importance of DRVs for a wide variety of applications, we recommend that in instances where the evidence is 
insufficient, EFSA should adopt a precautionary approach and develop the best estimates based on the available evidence. 
 
We recommend that EFSA define a clear time-period over which the DRVs will apply eg 10 years. EFSA should also set time-
scales for the evaluation of the effectiveness of the DRVs on improving the diet of the European population, after which they 
should be revised. 
National Heart 
Forum 
1. Introduction We would like to know whether EFSA has consulted bodies that have developed DRVs in European countries such as the UK 
Scientific Advisory Committee on Nutrition, and recommend that it does so in the development of the European DRVs. 
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National Heart 
Forum 
2. Categories, 
structure and 
function 
The National Heart Forum (NHF) welcomes the process of developing Dietary Reference Values (DRVs) for nutrients. We 
agree that DRVs can be used for a variety of purposes including diet assessment and planning, providing reference values in 
food labelling, in establishing food based dietary guidelines (FBDG) as well as nutrient profiles. We consider EFSA‟s work of 
essential and necessary for harmonising DRVs and FBDGs as much as possible across Europe.  
 
However, the European level guidelines, while useful, should not supersede existing dietary guidelines at the country level. 
EFSA should clarify the purpose of the European DRVs in relation to national dietary guidelines.  
 
Given the importance of DRVs for a wide variety of applications, we recommend that in instances where the evidence is 
insufficient, EFSA should adopt a precautionary approach and develop the best estimates based on the available evidence. 
 
We recommend that EFSA define a clear time-period over which the DRVs will apply eg 10 years. EFSA should also set time-
scales for the evaluation of the effectiveness of the DRVs on improving the diet of the European population, after which they 
should be revised. 
National Heart 
Forum 
4. Overview of 
dietary reference 
values and 
recommendations 
a) Lines 144-146 Trans fats: the current recommendation that TFA intakes should be „as low as possible‟ is not helpful to the 
use of DRVs for the assessment and planning of diets or the use of DRVs as basis for reference values food labeling. A target 
will be needed on which to monitor progress and achievement towards attaining the lowest possible TFA intakes in the 
European population.  
 
b) A number of existing guidelines already recommend 1%E or less eg the WHO/FAO population nutrient intake goals and the 
German, Austrian, Swiss and French recommendations (line 1036). Such a target is achievable in practice, as demonstrated by 
the low average population trans fat intakes of 0.5-0.6%E which have been achieved in countries such as Denmark, Finland, 
Norway and Sweden [Lines 682-683].  
 
c) Given the importance of DRVs for a variety of purposes, and EFSA‟s acknowledgement that trans fat intakes should be as 
low as possible, the National Heart Forum recommends that an EU population intake target of less than 1%E is set. Industry 
should use the mid-point value of 0.5%E for their GDAs. 
 
d) Lines 2041-2: “The Panel recommends that TFA intake should be as low as possible within the context of a nutritionally 
adequate diet.” We agree with this statement, but recommend that an interim target of <1%E is set for the population to 
facilitate this process. A corresponding target of 0.5%E should be set for the food industry for the purposes of GDAs, to support 
the elimination of unnecessary industrially produced TFAs from the food supply. 
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National Heart 
Forum 
4. Overview of 
dietary reference 
values and 
recommendations 
Lines 63-65 Saturated fats: the current recommendation that SFA intakes should be „as low as possible‟ is not helpful to the use 
of DRVs for the assessment and planning of diets or the use of DRVs as basis for reference values food labeling. Targets will be 
key to the monitoring and assessment of efforts to reduce SFA intakes in the European population if this is a dietary goal. As 
noted in section 4.1.2 [Lines 758-780] the majority of existing guidelines in for example, Germany, Austria, Switzerland, US, 
UK and France, set SFA population targets of max 10%E or less. This target is achievable in practice, as evidenced by low 
intake values in South European countries [line 627], and the lower range level of less than 9%E recorded in Europe [Line626].  
Given the importance of DRVs for a variety of purposes, we therefore recommend that based on the available evidence, a SFA 
target of <5%E is set for the European population. A food industry target of 5%E should be set for the purposes of GDAs for 
adults in the first instance. 
 
Lines 1989-1991: “There is no threshold of SFA intakes below which no adverse effects are observed. Thus no Upper Limit can 
be set.” We agree. However, given the huge benefits to be had from reducing SFA intakes at the individual and population 
level, EFSA should set an interim target of <5%E intake. This target will help facilitate the evaluation and assessment of action 
to reduce population intakes, and it can subsequently be revised downwards once it has been met. 
National Heart 
Forum 
4. Overview of 
dietary reference 
values and 
recommendations 
The National Heart Forum (NHF) welcomes the process of developing Dietary Reference Values (DRVs) for nutrients. We 
agree that DRVs can be used for a variety of purposes including diet assessment and planning, providing reference values in 
food labelling, in establishing food based dietary guidelines (FBDG) as well as nutrient profiles. We consider EFSA‟s work of 
essential and necessary for harmonising DRVs and FBDGs as much as possible across Europe.  
 
However, the European level guidelines, while useful, should not supersede existing dietary guidelines at the country level. 
EFSA should clarify the purpose of the European DRVs in relation to national dietary guidelines.  
 
Given the importance of DRVs for a wide variety of applications, we recommend that in instances where the evidence is 
insufficient, EFSA should adopt a precautionary approach and develop the best estimates based on the available evidence. 
 
We recommend that EFSA define a clear time-period over which the DRVs will apply eg 10 years. EFSA should also set time-
scales for the evaluation of the effectiveness of the DRVs on improving the diet of the European population, after which they 
should be revised. 
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National Heart 
Forum 
5. Criteria 
(endpoints) on 
which to base the 
dietary reference 
values 
Lines 63-65 Saturated fats: the current recommendation that SFA intakes should be „as low as possible‟ is not helpful to the use 
of DRVs for the assessment and planning of diets or the use of DRVs as basis for reference values food labeling. Targets will be 
key to the monitoring and assessment of efforts to reduce SFA intakes in the European population if this is a dietary goal. As 
noted in section 4.1.2 [Lines 758-780] the majority of existing guidelines in for example, Germany, Austria, Switzerland, US, 
UK and France, set SFA population targets of max 10%E or less. This target is achievable in practice, as evidenced by low 
intake values in South European countries [line 627], and the lower range level of less than 9%E recorded in Europe [Line626].  
Given the importance of DRVs for a variety of purposes, we therefore recommend that based on the available evidence, a SFA 
target of <5%E is set for the European population. A food industry target of 5%E should be set for the purposes of GDAs for 
adults in the first instance. 
 
Lines 1989-1991: “There is no threshold of SFA intakes below which no adverse effects are observed. Thus no Upper Limit can 
be set.” We agree. However, given the huge benefits to be had from reducing SFA intakes at the individual and population 
level, EFSA should set an interim target of <5%E intake. This target will help facilitate the evaluation and assessment of action 
to reduce population intakes, and it can subsequently be revised downwards once it has been met. 
National Heart 
Forum 
6. Data on which to 
base dietary 
reference values 
a) Lines 144-146 Trans fats: the current recommendation that TFA intakes should be „as low as possible‟ is not helpful to the 
use of DRVs for the assessment and planning of diets or the use of DRVs as basis for reference values food labeling. A target 
will be needed on which to monitor progress and achievement towards attaining the lowest possible TFA intakes in the 
European population.  
 
b) A number of existing guidelines already recommend 1%E or less eg the WHO/FAO population nutrient intake goals and the 
German, Austrian, Swiss and French recommendations (line 1036). Such a target is achievable in practice, as demonstrated by 
the low average population trans fat intakes of 0.5-0.6%E which have been achieved in countries such as Denmark, Finland, 
Norway and Sweden [Lines 682-683].  
 
c) Given the importance of DRVs for a variety of purposes, and EFSA‟s acknowledgement that trans fat intakes should be as 
low as possible, the National Heart Forum recommends that an EU population intake target of less than 1%E is set. Industry 
should use the mid-point value of 0.5%E for their GDAs. 
 
d) Lines 2041-2: “The Panel recommends that TFA intake should be as low as possible within the context of a nutritionally 
adequate diet.” We agree with this statement, but recommend that an interim target of <1%E is set for the population to 
facilitate this process. A corresponding target of 0.5%E should be set for the food industry for the purposes of GDAs, to support 
the elimination of unnecessary industrially produced TFAs from the food supply. 
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National Heart 
Forum 
6. Data on which to 
base dietary 
reference values 
Line 1992: “The panel therefore recommends that intakes should be as low as possible.” We agree but recommend an interim 
target of <5%E intake is set to facilitate this process. 
 
Targets will be key to the monitoring and assessment of efforts to reduce SFA intakes in the European population if this is a 
dietary goal. As noted in section 4.1.2 [Lines 758-780] the majority of existing guidelines in for example, Germany, Austria, 
Switzerland, US, UK and France, set SFA population targets of 10%E or less. This target is achievable in practice, as evidenced 
by low intake values in South European countries [line 627], and the lower range level of less than 9%E recorded in Europe 
[Line626].  
 
Given the importance of DRVs for a variety of purposes, we therefore recommend that based on the available evidence, a SFA 
target of <5%E is set for the European population. A food industry target of 5%E should be set for the purposes of GDAs for 
adults in the first instance. We recommend this level owing to the significant reductions in population intake levels of saturated 
fat which have been achieved in Western European countries such as the UK, following the introduction of the initial 10%E 
targets. It is now time to revise the goal downwards to further improve population health. 
National Heart 
Forum 
6. Data on which to 
base dietary 
reference values 
Lines 63-65 Saturated fats: the current recommendation that SFA intakes should be „as low as possible‟ is not helpful to the use 
of DRVs for the assessment and planning of diets or the use of DRVs as basis for reference values food labeling. Targets will be 
key to the monitoring and assessment of efforts to reduce SFA intakes in the European population if this is a dietary goal. As 
noted in section 4.1.2 [Lines 758-780] the majority of existing guidelines in for example, Germany, Austria, Switzerland, US, 
UK and France, set SFA population targets of max 10%E or less. This target is achievable in practice, as evidenced by low 
intake values in South European countries [line 627], and the lower range level of less than 9%E recorded in Europe [Line626].  
Given the importance of DRVs for a variety of purposes, we therefore recommend that based on the available evidence, a SFA 
target of <5%E is set for the European population. A food industry target of 5%E should be set for the purposes of GDAs for 
adults in the first instance. 
 
Lines 1989-1991: “There is no threshold of SFA intakes below which no adverse effects are observed. Thus no Upper Limit can 
be set.” We agree. However, given the huge benefits to be had from reducing SFA intakes at the individual and population 
level, EFSA should set an interim target of <5%E intake. This target will help facilitate the evaluation and assessment of action 
to reduce population intakes, and it can subsequently be revised downwards once it has been met. 
National Heart 
Forum 
6. Data on which to 
base dietary 
reference values 
Total fat [Lines 608 onwards]: We note the proposed recommendation of 20-35% Energy. However, we recommend that the 
range for total fat is limited to 20%-30%E for the following reasons: 
1. reduced fat diets have a significant role in the prevention of weight gain [lines 1569-72; 1581-52],  
2. prevention of weight gain is a key population goal for the European population 
3. achievement of population level fat intake levels in the range 20-30%E is achievable in practice (line 1066) 
 
In addition, we recommend that the food industry should initially use the mid-point of 25%E as the GDA for adults and this 
should be reviewed after a period of time.  
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National Heart 
Forum 
6.1. Total fat Total fat [Lines 608 onwards]: We note the proposed recommendation of 20-35% Energy. However, we recommend that the 
range for total fat is limited to 20%-30%E for the following reasons: 
1. reduced fat diets have a significant role in the prevention of weight gain [lines 1569-72; 1581-52],  
2. prevention of weight gain is a key population goal for the European population 
3. achievement of population level fat intake levels in the range 20-30%E is achievable in practice (line 1066) 
 
In addition, we recommend that the food industry should initially use the mid-point of 25%E as the GDA for adults and this 
should be reviewed after a period of time.  
National Heart 
Forum 
6.2. Saturated fatty 
acids (SAT) 
Line 1992: “The panel therefore recommends that intakes should be as low as possible.” We agree but recommend an interim 
target of <5%E intake is set to facilitate this process. 
 
Targets will be key to the monitoring and assessment of efforts to reduce SFA intakes in the European population if this is a 
dietary goal. As noted in section 4.1.2 [Lines 758-780] the majority of existing guidelines in for example, Germany, Austria, 
Switzerland, US, UK and France, set SFA population targets of 10%E or less. This target is achievable in practice, as evidenced 
by low intake values in South European countries [line 627], and the lower range level of less than 9%E recorded in Europe 
[Line626].  
 
Given the importance of DRVs for a variety of purposes, we therefore recommend that based on the available evidence, a SFA 
target of <5%E is set for the European population. A food industry target of 5%E should be set for the purposes of GDAs for 
adults in the first instance. We recommend this level owing to the significant reductions in population intake levels of saturated 
fat which have been achieved in Western European countries such as the UK, following the introduction of the initial 10%E 
targets. It is now time to revise the goal downwards to further improve population health. 
National Heart 
Forum 
6.2. Saturated fatty 
acids (SAT) 
Lines 63-65 Saturated fats: the current recommendation that SFA intakes should be „as low as possible‟ is not helpful to the use 
of DRVs for the assessment and planning of diets or the use of DRVs as basis for reference values food labeling. Targets will be 
key to the monitoring and assessment of efforts to reduce SFA intakes in the European population if this is a dietary goal. As 
noted in section 4.1.2 [Lines 758-780] the majority of existing guidelines in for example, Germany, Austria, Switzerland, US, 
UK and France, set SFA population targets of max 10%E or less. This target is achievable in practice, as evidenced by low 
intake values in South European countries [line 627], and the lower range level of less than 9%E recorded in Europe [Line626].  
Given the importance of DRVs for a variety of purposes, we therefore recommend that based on the available evidence, a SFA 
target of <5%E is set for the European population. A food industry target of 5%E should be set for the purposes of GDAs for 
adults in the first instance. 
 
Lines 1989-1991: “There is no threshold of SFA intakes below which no adverse effects are observed. Thus no Upper Limit can 
be set.” We agree. However, given the huge benefits to be had from reducing SFA intakes at the individual and population 
level, EFSA should set an interim target of <5%E intake. This target will help facilitate the evaluation and assessment of action 
to reduce population intakes, and it can subsequently be revised downwards once it has been met. 
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National Heart 
Forum 
6.5. Trans fatty 
acids (TFA) 
a) Lines 144-146 Trans fats: the current recommendation that TFA intakes should be „as low as possible‟ is not helpful to the 
use of DRVs for the assessment and planning of diets or the use of DRVs as basis for reference values food labeling. A target 
will be needed on which to monitor progress and achievement towards attaining the lowest possible TFA intakes in the 
European population.  
 
b) A number of existing guidelines already recommend 1%E or less eg the WHO/FAO population nutrient intake goals and the 
German, Austrian, Swiss and French recommendations (line 1036). Such a target is achievable in practice, as demonstrated by 
the low average population trans fat intakes of 0.5-0.6%E which have been achieved in countries such as Denmark, Finland, 
Norway and Sweden [Lines 682-683].  
 
c) Given the importance of DRVs for a variety of purposes, and EFSA‟s acknowledgement that trans fat intakes should be as 
low as possible, the National Heart Forum recommends that an EU population intake target of less than 1%E is set. Industry 
should use the mid-point value of 0.5%E for their GDAs. 
 
d) Lines 2041-2: “The Panel recommends that TFA intake should be as low as possible within the context of a nutritionally 
adequate diet.” We agree with this statement, but recommend that an interim target of <1%E is set for the population to 
facilitate this process. A corresponding target of 0.5%E should be set for the food industry for the purposes of GDAs, to support 
the elimination of unnecessary industrially produced TFAs from the food supply. 
National Heart 
Forum 
Conclusions and 
recommendations 
a) Lines 144-146 Trans fats: the current recommendation that TFA intakes should be „as low as possible‟ is not helpful to the 
use of DRVs for the assessment and planning of diets or the use of DRVs as basis for reference values food labeling. A target 
will be needed on which to monitor progress and achievement towards attaining the lowest possible TFA intakes in the 
European population.  
 
b) A number of existing guidelines already recommend 1%E or less eg the WHO/FAO population nutrient intake goals and the 
German, Austrian, Swiss and French recommendations (line 1036). Such a target is achievable in practice, as demonstrated by 
the low average population trans fat intakes of 0.5-0.6%E which have been achieved in countries such as Denmark, Finland, 
Norway and Sweden [Lines 682-683].  
 
c) Given the importance of DRVs for a variety of purposes, and EFSA‟s acknowledgement that trans fat intakes should be as 
low as possible, the National Heart Forum recommends that an EU population intake target of less than 1%E is set. Industry 
should use the mid-point value of 0.5%E for their GDAs. 
 
d) Lines 2041-2: “The Panel recommends that TFA intake should be as low as possible within the context of a nutritionally 
adequate diet.” We agree with this statement, but recommend that an interim target of <1%E is set for the population to 
facilitate this process. A corresponding target of 0.5%E should be set for the food industry for the purposes of GDAs, to support 
the elimination of unnecessary industrially produced TFAs from the food supply. 
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National Heart 
Forum 
Conclusions and 
recommendations 
Line 1992: “The panel therefore recommends that intakes should be as low as possible.” We agree but recommend an interim 
target of <5%E intake is set to facilitate this process. 
 
Targets will be key to the monitoring and assessment of efforts to reduce SFA intakes in the European population if this is a 
dietary goal. As noted in section 4.1.2 [Lines 758-780] the majority of existing guidelines in for example, Germany, Austria, 
Switzerland, US, UK and France, set SFA population targets of 10%E or less. This target is achievable in practice, as evidenced 
by low intake values in South European countries [line 627], and the lower range level of less than 9%E recorded in Europe 
[Line626].  
 
Given the importance of DRVs for a variety of purposes, we therefore recommend that based on the available evidence, a SFA 
target of <5%E is set for the European population. A food industry target of 5%E should be set for the purposes of GDAs for 
adults in the first instance. We recommend this level owing to the significant reductions in population intake levels of saturated 
fat which have been achieved in Western European countries such as the UK, following the introduction of the initial 10%E 
targets. It is now time to revise the goal downwards to further improve population health. 
National Heart 
Forum 
Conclusions and 
recommendations 
Lines 63-65 Saturated fats: the current recommendation that SFA intakes should be „as low as possible‟ is not helpful to the use 
of DRVs for the assessment and planning of diets or the use of DRVs as basis for reference values food labeling. Targets will be 
key to the monitoring and assessment of efforts to reduce SFA intakes in the European population if this is a dietary goal. As 
noted in section 4.1.2 [Lines 758-780] the majority of existing guidelines in for example, Germany, Austria, Switzerland, US, 
UK and France, set SFA population targets of max 10%E or less. This target is achievable in practice, as evidenced by low 
intake values in South European countries [line 627], and the lower range level of less than 9%E recorded in Europe [Line626].  
Given the importance of DRVs for a variety of purposes, we therefore recommend that based on the available evidence, a SFA 
target of <5%E is set for the European population. A food industry target of 5%E should be set for the purposes of GDAs for 
adults in the first instance. 
 
Lines 1989-1991: “There is no threshold of SFA intakes below which no adverse effects are observed. Thus no Upper Limit can 
be set.” We agree. However, given the huge benefits to be had from reducing SFA intakes at the individual and population 
level, EFSA should set an interim target of <5%E intake. This target will help facilitate the evaluation and assessment of action 
to reduce population intakes, and it can subsequently be revised downwards once it has been met. 
National Heart 
Forum 
Conclusions and 
recommendations 
Total fat [Lines 608 onwards]: We note the proposed recommendation of 20-35% Energy. However, we recommend that the 
range for total fat is limited to 20%-30%E for the following reasons: 
1. reduced fat diets have a significant role in the prevention of weight gain [lines 1569-72; 1581-52],  
2. prevention of weight gain is a key population goal for the European population 
3. achievement of population level fat intake levels in the range 20-30%E is achievable in practice (line 1066) 
 
In addition, we recommend that the food industry should initially use the mid-point of 25%E as the GDA for adults and this 
should be reviewed after a period of time.  
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National Nutrition 
Council 
Conclusions and 
recommendations 
We thank the panel for an enormous amount of work accomplished to the draft for dietary reference values for fat and 
carbohydrates and dietary fibre. 
 
Fats:  
 
1. We suggest the recommendation for fat intake to be 25 – 35 E%. The suggested variation for fat intake (20-35 % of energy) 
in EFSA´s opinion is quite board. In Western countries it is extremely difficult to reach a recommended proportion of fatty 
acids in the diet, i.e. enough unsaturated fatty acids, when the intake of fat is below 25 % of energy. The current selection of fat 
containing foods in the EU countries makes this practically impossible. Furthermore, there does not seem to be additional 
benefit to limit the intake of fat below 25 % of energy. These issues are acknowledged also on page 24, lines 726-729 and 737-
739. 
 
2 Since the DRVs are meant to help EU countries draw national FBDGs, we strongly suggest that there would be an upper limit 
for saturated fatty acids including also trans fatty acids, e.g. 10 % of energy. We suggest this since it is widely used and there 
does not seem to be studies opposing this limit. Our suggestion to take into account both saturated fatty acids and trans fatty 
acids is in line with the definition given in the EU regulation (1924/2006) on nutrition and health claims. 
 
3. By stating that cis-MUFA does not have a known role in preventing of promoting diet-related diseases, the EU countries are 
left with broad interpretation regarding the FBDGs. This is why some range for MUFAs should be given, either alone or 
together with PUFAs. According to Nordic nutrition recommendations, we suggest the range to be 10-15e% for cis-MUFA and 
5-10E% for PUFA, or if the range given together for MUFA+PUFA: 20-25E% including, however, no less than two thirds of 
total fat. Could for example the population ranges in the EU countries form a basis for a range for MUFAs? Furthermore, the 
statement that cis-MUFAs are not needed in the diet seems quite awkward. Regarding dietary fats the diet cannot consist only of 
PUFAs and a minor amount of SFAs.  
 
4. It is not clear how the panel ended up with AI of 0.5 E% for alpha-linolenic acid, 4 E% of linoleic acid and 250 mg for EPA 
plus DHA? Is there solid evidence for these estimates? 
 
 
Carbohydrates: 
 
1. For diabetics it may be problematic to accept short-chain oligosaccharides as dietary fibre. 
 
2. We strongly suggest to have a 10 E% limit for added sugars. This would be in line with the WHO Report (916) Diet, 
nutrition and the prevention of chronic diseases. By allowing the intake of sucrose up to 20 E% will cause problems regarding 
accomplishment of a well-balanced diet. Furthermore, we would like to point out that this statement is not in line with the draft 
for water and liquids which has a stricter opinion regarding sucrose intake. In addition, American Heart Association has stated 
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in its very recent scientific statement that attention should be paid to sugar intake, e.g. sugar sweetened beverages and 
recommends a limit for sugar to be 5 E%.  
 
Special comment: 
 
 When launching the opinion on DRVs for nutrients EFSA has stated that they are used as a basis for reference values in food 
labelling. The Panel has come to a conclusion that the available data allow the setting of DRVs for quite few fat or carbohydrate 
components or, if values are given the range is very broad. In this situation the setting of labelling reference values will be 
difficult. However, the Panel has given earlier this year a scientific opinion (EFSA Journal (2009) 1008, 1-3) on the labelling 
reference values for energy, total fat, saturated fat, carbohydrate, sugars and salt which are included in a proposal for a 
Regulation on the provision of food information to the consumer. The basis for these reference values is contradictory with the 
opinion commented above. We feel that this situation is confusing and emphasize that the opinions of the Panel concerning 
these matters should be consistent. 
National Nutrition 
Council 
References  
Lines 2486-2487 (Fats) 
Lines 1984-1985 Carbohydrates) 
 
There are new intake data from Finland: Paturi M, Tapanainen H, Reinivuo H, Pietinen P 2008.The national FINDIET 2007 
survey (replaces Männistö et al 2003). AVAILABLE ON 
http://www.ktl.fi/attachments/suomi/julkaisut/julkaisusarja_b/2008/2008b23.pdf 
none 1. Introduction To Ms Haravgi-Nina Papadoulaki 
Spokesperson for Androulla Vassiliou, Commissioner for Health, EU 
  
Dear Ms Vassiliou 
 
The European Food Safety Authority (EFSA) issued on March 13, 2009 a draft for public consultation regarding dietary 
guidelines for Europe, consisting of two parts. One deals mainly with what type of fats one should eat, the other mainly with 
carbohydrates. 
In our opinion, these documents are not based on the current scientific knowledge of the role of fats and carbohydrates in health 
and disease. Instead, they represent the view of the lobbying organization International Life Sciences Institute (ILSI), formerly 
called Nutrition Foundation (see below). 
We are in particular concerned about the authors‟ review of the literature about saturated fat. Their references are selective and 
misleading and they have missed numerous studies having shown that saturated fat is harmless and even may be beneficial to 
health.  
 
Below we present the evidence for our objections.  
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May we suggest that the present draft becomes revised by researchers independent of the food or drug industry.  
 
September 30, 2009 
Yours sincerely 
Uffe Ravnskov, MD, PhD, independent researcher 
Magle Stora Kyrkogata 9 
S 22350 Lund, Sweden 
ravnskov@tele2.se 
  
Göran Petersson, professor,  
Dept. of Chemical and Biological Engineering, Chalmers Institute, Göteborg, Sweden. 
goranp@chalmers.se  
  
Tore Schersten, MD, PhD, professor, previously Secretary of the Swedish Medical Research Council,  
Gammelvägen 3, Båstad, Sweden. 
torescher@hotmail.com  
  
Ralf Sundberg, MD, PhD,  
Slottssstaden Medical Group, Malmö, Sweden. 
ralfsundberg@telia.com  
 
none 5.8. Cardiovascular 
disease 
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 A relevant objection against such studies is that dietary information is inaccurate. A more reliable way to study previous 
intakes with disease is analyses of fat tissue, because intake of saturated fat during the last weeks or months is reflected by the 
levels of individual fatty acids in the fat tissue. The strongest associations are found between intake and concentrations of the 
short chain acids 12:0-15:0,52-56 and of the total numbers,57-60 but weakly or not at all of the longer ones, probably because a 
high intake of simple carbohydrates stimulates endogenous synthesis of the long chain saturated fatty acids.61  
 In three case-control studies of patients with myocardial infarction and healthy control individuals no difference was found as 
regards the content of the short-chain saturated fatty acids; in two studies it was even significantly lower in the patients (table 
3).62-66 These studies concerned only patients with first myocardial infarction63-66 or patients who were not on a diet,62 and a 
diet-bias is therefore unlikely. 
 
 
Authors Cases/controls 
n Content in cases compared with controls 
12:0 14:0 15:0 
Kirkeby et al.62 27/68 No difference  
Wood et al.63 28/343 No difference  
Kark et al.64 180/492 No difference  
Clifton et al.65 79/167 Less** No difference  
Pedersen et al.66 100/98 No difference Less* Less** 
Table 3. Five case-control studies of the content of short-chain saturated fatty acids in the fat tissue of patients with myocardial 
infarction and of healthy control individuals. 
 
 
In many populations a major contribution of saturated fat comes from dairy products and all authoritative guidelines 
recommend a restriction of such food. However, in a meta-analysis of ten cohort studies including more than 400,000 
individuals Elwood et al. found that compared with low-consumers the risks of myocardial infarction, ischaemic stroke and all 
cardiovascular events in high-consumers were 0.87 (0.74-1.03), 0.83 (0.77-0.90) and 0.84 (0.78-0.90) respectively.67 In a 
thorough review of the associations between dairy products and cardiovascular disease Tolstrup found no strong evidence in 
support either.68  
All of these studies have been ignored by the authors of the draft.  
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Cohort and case-control studies of saturated fat intake 
The diet of coronary patients and healthy individuals has been compared in numerous cohort and case-control studies. In a 
previous review of 28 cohorts in 21 studies patients with CHD had eaten significantly more saturated fat than the controls in 
three cohorts, but the differences were trivial, in one cohort they had eaten significantly less and in the other 24 cohorts no 
differences were seen.34 No difference was seen either in two recent, large cohort studies,39,40 or in the study referred to by 
the WHO guideline authors; in the latter the statistical significance disappeared after controlling for other dietary factors.41 
 Even more contradictory are the findings in stroke patients. In ten prospective cohort studies of healthy people the authors 
compared the intake of saturated fat in those who had stroke at follow-up with the intake of the others.42-51 With one 
exception49 all studies found that stroke patients had eaten less saturated fat than had the non-stroke individuals; in six of the 
studies the difference was statistically significant (table 2).  
 
n Ischemic haemorrhagic Total stroke 
Stemmerman et al.42 6832 none none  
Takeya et al.43 1366 
7895 inverse* 
none none 
inverse*  
McGee et al.44 7084 inverse*  
Gillmann et al.45 832 inverse*  
Ross et al.46 18244 none 
Seino et al.47 2283 inverse*  
Iso et al.48 85761 inverse*  
He et al.49 43732 none none  
Iso et al.50 4775 inverse**  
Sauvaget et al.51 3731 none  
Table 2. Association between intake of saturated fat and stroke in ten cohort studies.  
* p<0.05; ** P<0.01 
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Effect of saturated fat intake on blood cholesterol 
Their most important argument is that saturated fat raises the concentration of cholesterol in the blood. This is no proof that 
saturated fat is harmful, and it isn‟t true either. The idea was originally put forward by Ancel Keys based on a number of 
laboratory experiments on healthy people whose diet was manipulated in may ways. However, already in 1973 the idea was 
questioned by Raymond Reiser. In a thorough review of 40 of these experiments he pointed at several types of methodological 
and interpretational errors.1 Instead of natural saturated fat many authors had used vegetable oils saturated by hydrogenation. 
This process results in the production of trans fatty acids, used for many years in the industrial production of margarine. These 
fatty acids indeed raise cholesterol, and several studies have also shown that an excess of dietary trans fat is associated with an 
increased risk of coronary heart disease. Another error in these experiments was that effects on blood cholesterol were attributed 
to saturated fat when it could be due to polyunsaturated fat as well.  
In spite of these flaws several authors maintain that saturated fat raises cholesterol, whereas monounsaturated and in particular 
polyunsaturated fat lower it, and some saturated fatty acids my be neutral.2-6 These conclusions have been based mainly on 
mathematical formulas using data from a large number of trials. But as almost all trial directors have made similar errors as 
those reviewed by Keys by changing the intake of several fats at the same time without controlling for intake of trans fat it is 
obviously difficult to rule out the effect of each type of fat.  
Even if saturated fat is hypercholesterolaemic the effect must be small. In a review of eight trials where the intake was reduced 
by 30-40 % the net reduction of cholesterol was only 0-4 %,7 and other studies have shown no effect at all. In experiments for 
instance, where carbohydrates were substituted with saturated fat, not even intakes between 20 % and 50 % of calories 
influenced total or LDL- cholesterol (table 1).8-17 These results are thus directly contrary to the draft statement that “there is a 
positive, dose-dependent relationship between the intake of a mixture of SFA and serum LDL cholesterol concentrations, when 
compared to carbohydrates.” 
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Length of trial SFA;  
cal% Change of 
t-C Change of 
LDL-C Change of HDL-C 
Noakes et al8 12 w 18 None None None 
Meckling et al.9 10 w 20 None None Up 
Sondike et al.10 12 w 22 None None None 
Sharman et al.11 6 w 25 None None None 
Hays et al.12 52 w 50 None None None 
Westman et al.13 6 m + Down Down  
Foster et al.14 12 m + None None Up 
Yancy et al.15 24 w + Down None Up 
Seshadri et al.16 6 m + None None None 
Brehm et al.17 4 m + None None Up 
Table 1. Changes of blood lipids after a low-carbohydrate diet rich in saturated fat in ten trials. In all trials the concentration of 
triglycerides went down significantly. 
 + means that the intake of saturated fat was unlimited. 
 
That other factors may override a possible hypercholesterolemic effect is obvious from studies of populations who live almost 
entirely on animal food, but have the lowest cholesterol ever measured in healthy people.18-20 In accordance, many cross-
sectional studies of the dietary habits within a population have found no association between cholesterol and the intake of 
saturated fat.21-26 
In the abovementioned low-carbohydrate trials (table 1) a high intake of saturated fat had no adverse effects on other lipids 
either. On the contrary HDL-cholesterol remained unchanged or went up and triglycerides went down significantly (table 1),8-
17 whereas a reduction of the intake had the opposite effects.27-29  
We are also surprised that Bresson et al have ignored one of the most interesting observations in this area. We refer to Ronald 
Krauss´ group and the fact that cardiovascular disease is stronger associated with small-size LDL than with other lipid fractions. 
Their crucial observation was that a high intake of saturated fat is followed by an increase of LDL size,27,30,31 thus the 
opposite of what should have been expected.  
Effects of saturated fat on the blood lipids is surrogate outcome, however. The crucial question is whether a high intake of 
saturated fat is deleterious to health and whether a reduction of the intake is beneficial. 
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Saturated fat intake and atherosclerosis 
If high intakes of saturated fat should lead to atherosclerosis, people with high intakes should be more atherosclerotic than 
people with low intakes. No such association has been found in any study. In the International Atherosclerosis Project, fifteen 
populations were ranked by raised atherosclerosis and by selected diet components. Degree of atherosclerosis was associated 
with the total fat intake, but not with the intake of saturated fat.69 In three cohort studies of healthy individuals followed for 
several years, post-mortems of those who had died at follow-up found no association either between intake of saturated fat and 
degree of atherosclerosis-70-72 
 Angiographic follow-up studies have given disparate results. In a trial including 50 men with CHD, where a low-fat diet was 
compared with usual care, progress of the angiographic changes over 39 months was associated with intakes of palmitic and 
stearic acids.73 However, the group that ate the low-fat diet was also instructed to increase their intake of fish, fruit and 
vegetables, and intake of such food have been found inversely associated with the risk of CHD in almost all studies.  
In the MARGARIN study 81 hypercholesterolaemic individuals were followed for two years after having received dietary 
advice.74At follow-up associations between the changes of intima-media thickness of the coronary and femoral arteries, 
measured by ultrasound, and intake of saturated fat were not significant in multivariate regression analyses. When the patients 
were grouped into quintiles of change of saturated fat intake, a weak association was seen with the changes of the femoral, but 
not with the changes of the coronary arteries. However, a similar bias was introduced in that study also, because vascular 
changes were inversely associated with intake of fruit. As the effect of a reduced intake of saturated fat is said to be due to a 
lowering of LDL cholesterol it is also contradictory that LDL cholesterol was lowest in those whose intake of saturated fat had 
increased during the study period. 
In contrast, a highly significant inverse association was found between intake of saturated fat and progress of angiographic 
lesions in a 3-year follow-up study of 235 postmenopausal women with CHD.75 
In the draft nothing is mentioned about these studies. 
 
The dietary trials 
The most important argument for causality is improvement or disappearance of the disease after decrease or discontinuation of 
the exposure to the suspected causal factor. To-day relevant data have been published from nine randomised, controlled trials 
where the only intervention was a change of dietary fat. Two meta-analyses of these trials found no significant effect, neither on 
cardiovascular or total mortality,34,76,77 and as mentioned above, most trials comparing high-carbohydrate-low-saturated fat 
diets with low-carbohydrate-high-saturated fat have found a better outcome as regards body weight an metabolic control in the 
latter ones. 
Most of these trials have been ignored by the draft authors. Instead they claim support from a review by Sacks and Katan78 of 
four allegedly successful dietary trials.79-82 None of them lowered mortality significantly; one of them, the Finnish Mental 
Hospital Trial79 was neither controlled or randomized; and in the and in the Dayton trial82 those who had lowered their intake 
of saturated fat were more atherosclerotic than the others. Besides, they had ignored four trials where the number of 
cardiovascular event had increased in the diet group.83-86 
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The influence of the food industry 
In 1941 the world of business intersected with the world of science through the Nutrition Foundation (NF) in the United States, 
a research body funded by the food industry. In the following years, sister foundations to NF, with names such as the British 
Nutrition Foundation, Swedish Nutrition Foundation, Nutrition Foundation of Italy, New Zealand Nutrition foundation etc. was 
started in most western countries . All these organizations promote industry interests and their goal is to increase the profit of 
the sponsoring industries. 
In most countries, the greater part of research on nutrition is financed by food industries, either directly or by proxies such as 
ILSI or the national Nutrition Foundation of that country. The problem with that is that most research on nutrition on health 
issues is performed in order to prove a health claim of a particular product from a sponsoring part. 
Recent research has shown that such sponsoring of research in the area of nutrition, increases the likelihood of being in favor of 
the product in question by a factor of ten. As a comparison, similar sponsoring of pharmaceutical products only doubles that 
kind of bias. 
As a result of this, what is regarded as science by the academic institutions in nutrition year by year, decade after decade, has 
diverged from medical science. Dietary advice from these institutions can no longer by regarded as health-promoting, rather the 
opposite. 
The expert group of EFSA, as well as national experts groups or that of WHO, share the same views of nutrition. These happen 
to be identical to the views of the food industry, which sponsored the research careers of these experts.  
In Sweden, there has been a debate on food and diet advice given by such expert groups. In this debate, qualified scientists have 
scrutinized the scientific basis of such advice in the Nordic Nutrition Recommendations, the advice on trans fats by the EFSA 
and the British SACN, the dietary advice for diabetics by the EASD, and claims by the Swedish Food authority on saturated 
fats. All were found to be utterly misleading because of selective citations (omitting relevant science), false citations (quoting 
studies that showed results opposite to the authors claims) and even referring to studies about different subjects. They illustrate 
that  
To mention an example, EFSA and SACN did not in their analyses of the risks of industrial trans fats mention the existence of a 
relevant study showing that consumption of margarine, rich in trans fats greatly increases the risk of heart disease. They could 
hardly have missed it, since a couple of years earlier this study was quoted by the Danish Ernaeringsrådet in their 
recommendation to ban industrial trans fats. The reports form EFSA and SACN were lame, and in the interest of ILSI, which 
works against a ban of such fats. 
As a matter of fact, a great number of the members of the EFSA expert panel work on behalf of ILSI, whereas the report to the 
SACN was prepared by a group from the University of Reading , whose research budget was sponsored by a manufacturer of 
industrial trans fats. 
The above illustrates that EFSA does not primarily serve its intended purpose of maintaining and protecting the health of 
European citizens, but rather the interests of the food industries behind ILSI, such as Coca-Cola, Unilever, McDonalds, 
Südzucker, Ajinomoto (producer of artificial sweeteners) to mention a few.  
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NVB (Association 
of the Dutch 
Bakery Industry) 
4. Overview of 
dietary reference 
values and 
recommendations 
Comment on table 5, line 1035-1039 and other lines about the Dietary reference values of the Netherlands.  
 
On page 93 (line 2915) the dietary reference value in the Netherlands is mentioned. However, these are the values from 2001, 
whereas the Dutch Health Council updated its advice in 2006. Therefore we recommend using the most recent dietary 
guidelines. 
  
NVB (Association 
of the Dutch 
Bakery Industry) 
Conclusions and 
recommendations 
Comment about line 56-67 in the Summary and line 1986-1993 in the Conclusions and recommendations.  
 
We would also like to react on the Summary, but because this isn''t possible we react on the Conclusions and recommendations. 
Please use this comment also for the Summary.  
 
We support the opinion of the Dutch Product Boards: Why are all the saturated fats treated as one group in the summary? The 
unsaturated fats are split up in separate groups, but the saturated fats are treated as one group. As stated in chapter 5.2.2 several 
saturated fats have different effects on cholesterol metabolism. 
NVB (Association 
of the Dutch 
Bakery Industry) 
Conclusions and 
recommendations 
Comment on line 129-146 in the Summary and line 2036-2042 in the Conclusions and recommendations. 
 
We would also like to react on the Summary, but because this isn''t possible we react on the Conclusions and recommendations. 
Please use this comment also for the Summary.  
 
We support the opinion of the Dutch Product Boards: 
We suggest adding to the statement of The Panel in the summary the following: 
The intake of TFA is close to the recommendation levels in most European countries, and are therefore not a public health issue 
anymore. The intake of total TFA is low because of the efforts made by the food industry in reducing the amount of industrial 
TFA in their products (and these efforts are ongoing). The level of ruminant TFA in meat (products) and dairy products is 
already naturally low. 
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NVB (Association 
of the Dutch 
Bakery Industry) 
Conclusions and 
recommendations 
Comment on line 66, 67 in the Summary and line 1992, 1993 in the Conclusions and recommendations. 
 
We would also like to react on the Summary, but because this isn''t possible we react on the Conclusions and recommendations. 
Please use this comment also for the Summary.  
 
We support the opinion of the Dutch Product Boards: 
In the Summary in line 66,67 the following is written: „The Panel recommends that SFA intake should be as low as possible 
within the context of a nutritionally adequate diet‟.  
In the discussed scientific research in chapter 5 this recommendation is not supported. Furthermore, according to Table 5 (page 
32), most Countries and also the WHO/FAO set the maximum SFA at 10 E%. In infants average intakes of SFA where between 
11-13 E%. In adults, average SFA intakes vary between 9 to 17 E% and nearly 30% of the reported average intakes were 15 E% 
or higher (line 620-629).  
In addition: in several economically developed countries where the SFA is close to 10%, the capacity to decrease SFA much 
further is limited to major changes in dietary patterns, and is only likely to result in modest reductions in TC and LDL-C 
We therefore believe it is appropriate to set the recommendation for SFA at 10 E%.  
NVB (Association 
of the Dutch 
Bakery Industry) 
Conclusions and 
recommendations 
We support the opinion of the Dutch Product Boards: 
In conclusion, we would like to point out the following. Consumers do not eat saturated fats or unsaturated fats as such. They 
eat these nutrients in a matrix (food stuffs), as part of a balanced diet. In practice, the matrix influences the effects of the fatty 
acids, meaning that negative effects may not occur, or may be less pronounced, due to the presence of other nutrients in the 
food. 
NVB (Association 
of the Dutch 
Bakery Industry) 
Conclusions and 
recommendations 
We would also like to react on the Summary, but because this isn''t possible we react on the Conclusions and recommendations. 
Please use this comment also for the Summary.  
 
NVB is supporting the opinion of the Dutch Product Boards that the conclusions in the summary do not reflect accurately the 
content of the report. More precise, the nuance in the report is lacking in the summary. Therefore, it is not immediately obvious 
on what basis the conclusions are drawn. Since the summary is generally the only part that policy makers read, it is important 
that the summary reflects the scientific state of the art, including the recent developments and nuances. 
NVB (Association 
of the Dutch 
Bakery Industry) 
References Recently, two WHO scientific updates were published in the European Journal of Clinical Nutrition (vol. 63, supplement 2s, pp 
S1-S75) and Annals of Nutrition and Metabolism (vol.55, no. 1-3: pp 5-300). It seems logical to take these two updates into 
account in the document.  
Ocean Nutrition 
Canada 
Conclusions and 
recommendations 
We applaud the Panel‟s proposal to establish a DRV of 250mg for EPA + DHA. This will help to broaden recognition of the 
value EPA+DHA with consumers across Europe. 
 
However, while an intake of 250mg/day provides measurable benefits, we believe this level doesn‟t deliver optimal benefits for 
the general population. Consideration of a higher level is warranted. 250mg/day EPA+DHA should be considered a minimal 
intake, rather than a target intake. We encourage the Panel to establish a higher target intake level based upon available 
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The Panel‟s opinion on intake levels for EPA+DHA included the work of Mozaffarian and Rimm (JAMA 296:1885-1896, 
2006) who concluded that the risk of CHD death was not further attenuated above an intake of 250mg/day n-3 LCPUFAs. 
Given the multitude of assumptions on which the authors dose-response assessment was based, we don‟t believe that 
250mg/day is a level above which there are no additional benefits. For example; 
1. Of the 20 studies included in the dose-response assessment, 6 studies included insufficient data to derive a robust estimation 
of n-3 LCPUFA intake. Therefore the estimated intakes may be associated with considerable error. 
2. Protective effects of n-3 LCPUFAs against CHD death are not seen in studies with the lowest intake/reference group already 
consuming a high amount of n-3 LCPUFAs. These studies probably lack sensitivity and are misleading. It appears from the 
dose-response figure in Mozaffarian and Rimm (2006) that the plateau effect is being caused by 4 data points representing 
intakes in excess of 2,000 mg/day. Had the studies in which the reference intake group was consuming in excess of 250mg/d of 
the n-3 LCPUFAs been excluded, an inverse and linear dose-response relationship between n-3 LCPUFA intake and risk of 
CHD death may have been evident up to intakes of approximately 1,000mg/day. 
3. An assumption inherent in the combining of data from subjects with and without a history of CHD is that the dose required 
for reducing risk of CHD death is the same. This may or may not be true. The most relevant studies are those in subjects free of 
CHD upon entry (Harris et al. Curr Atheroscler Rep 10:503-509, 2008). 
 
We believe the Panel‟s conclusion that intakes in excess of 250mg/day offer no additional protection against CHD death is 
challenged by the following: 
1. A significant inverse trend was noted between n-3 LCPUFA intake and risk of fatal CHD above an intake of 250 mg/d of 
EPA+DHA (Dolecek et al. World Rev Nutr Diet 66:205-216, 1991; Yuan et al. Am J Epidemiol 154:809-816, 2001; 
Mozaffarian et al. Circulation 107:1372-1377, 2003). 
2. A recent meta-analysis of 6 US epidemiologic studies (Harris et al. Curr Atheroscler Rep 10:503-509, 2008) noted a 
significant inverse dose-response between intake of the n-3 LCPUFAs beyond 250mg/d and risk of CHD death in subjects 
previously free of CHD. 
3. In 3 meta-analyses, incremental decreases in risk of CHD death have been reported with fish intakes greater than 1-170-gram 
portion per week (an amount cited by Mozaffarian and Rimm (2006) to be approximately equivalent to an intake of 250 mg/day 
of the n-3 LCPUFAs) (He et al. Circulation 109:2705-2711, 2004; Whelton et al. Am J Cardiol 93:1119-1123, 2004; König et 
al. Am J Prev Med 29:335-346, 2005).  
Taking into account these observations as well as emerging data that risk of non-fatal myocardial infarction may be reduced 
with n-3 LCPUFA intakes in excess of 250-500mg/d (He et al. Circulation 109:2705-2711, 2004; Iso et al. Circulation 113:195-
202, 2006), the Panel‟s conclusion can be modified. We recommend that the consumption of 250 mg/day of EPA+DHA should 
be considered a minimum recommended intake. 
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PIE - Platform for 
Ingredients in 
Europe 
2. Categories, 
structure and 
function 
2.1.3.1. n-6 polyunsaturated fatty acids (n-6 PUFA) 
We agree with the statement that only linoleic acid (LA) is essential, but that arachidonic acid (ARA) as such is not necessary in 
the diet is questionable. In fact the metabolism of LA into ARA, as well as into gamma linoleic acid (GLA) is shown to 
decrease with age, which also influences the metabolism of omega-3 fatty acids into eicosapentaenoic acid (EPA). 
 
References:  
- Angela Liou, Y., Innis, S. M., 2009. Dietary linoleic acid has no effect on arachidonic acid, but increases n-6 eicosadienoic 
acid, and lowers dihomo-gamma-linolenic and eicosapentaenoic acid in plasma of adult men. Prostaglandins Leukot Essent 
Fatty Acids. 80, 201-6. 
- Choi, Y. S., et al., 1988. Age-related changes in lipid metabolism in rats: the consequence of moderate food restriction. 
Biochim Biophys Acta. 963, 237-42. 
- Choi, Y. S., Sugano, M., 1988. Effects of dietary alpha- and gamma-linolenic acid on lipid metabolism in young and adult 
rats. Ann Nutr Metab. 32, 169-76. 
- Hrelia, S., et al., 1990. Delta-6-desaturation of linoleic and alpha-linolenic acids in aged rats: a kinetic analysis. Biochem Int. 
22, 659-67. 
 
 
2.1.3.1. n-6 polyunsaturated fatty acids (n-6 PUFA) 
We agree with the statement that only linoleic acid (LA) and alfa-linoleic acid (ALA) are essential. But it is also important to 
acknowledge that the „conversion‟ from ALA into EPA and DHA is clearly limited in humans; i.e. intake of LA, and ALA 
could not be sufficient to eliminate the need for intake of DHA, and EPA via the diet.  
 
Then based on the essence of ALA as such an advised intake (AI) for ALA of 0.5 E%/day may need more consideration. ALA 
is considered to be implicated in the reduction of cardiovascular disease (CVD) risk, and this fact did lead to the WHO/FAO to 
advise an intake of 1.0 E%/day. We would recommend EFSA not to divert from that. 
 
 
2.1.4. Trans fatty acids (TFA) 
It is stated that Trans fatty acids (TFA) are not synthesized by the human body. The human body produces rumenic acid (i.e. 
Conjugated Linoleic Acid (cis-9, trans-12)), which can be found in breast milk. Although it may be a product of the conversion 
of vaccenic acid (trans-9 octadecenoic acid) from (dairy) food, the statement denying human production of TFA can be 
controversial. 
 
It is unclear whether the intake of TFA includes or excludes the level of rumenic acid and vaccenic acid; e.g. if it refers to 
chemically defined TFA or to TFA as defined by the Codex alimentarius, which excludes bovine TFA (merely rumenic acid, 
and vaccenic acid). Whilst the level of vaccenic acid can be substantial, a clear definition of TFA should be included. 
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PIE - Platform for 
Ingredients in 
Europe 
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
6.4. cis-polyunsaturated fatty acids (cis- PUFA) 
There is a need to keep a balance in the metabolism of omega-3 and omega-6. Indeed it is also well known that an unbalance 
between omega-6/omega-3 can determine skin reactions (e.g. eczema) and lung problems in babies. 
Thus we suggest EFSA to provide some recommendations based on the best scientific data available. 
 
References: 
- Alm, B., et al., 2009. Early introduction of fish decreases the risk of eczema in infants. Arch Dis Child. 94, 11-5. 
- Koch, C., et al., 2008. Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, 
controlled trial. Br J Dermatol. 158, 786-92. 
- Miyake, Y., et al., 2008. Relationship between dietary fat and fish intake and the prevalence of atopic eczema in pregnant 
Japanese females: baseline data from the Osaka Maternal and Child Health Study. Asia Pac J Clin Nutr. 17, 612-9. 
- Oddy, W. H., et al., 2006. Atopy, eczema and breast milk fatty acids in a high-risk cohort of children followed from birth to 5 
yr. Pediatr Allergy Immunol. 17, 4-10. 
 
 
6.4.1. n-6 polyunsaturated fatty acids (n-6 PUFA) 
We believe that an advised intake (AI) for LA of 4 E% may need more consideration. LA is considered to imply a reduction of 
CVD risk. As such the WHO/FAO advice is an intake of 5-8 E%/day. We would recommend EFSA not to divert from that. 
PIE - Platform for 
Ingredients in 
Europe 
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
6.4.2. n-3 polyunsaturated fatty acids (n-3 PUFA) 
This EFSA Opinion makes clear that currently available evidence indicates that consumption of preformed EPA+DHA 
substantially decreases the risk of mortality from coronary heart disease and sudden cardiac death. 
 
PIE welcomes the recognition of the role these nutrients can play in addressing the nutritional aspects associated with 
cardiovascular diseases, the leading cause of mortality within Europe(1).  
 
The EFSA opinion identifies that the consumption of EPA+DHA required gaining these beneficial effects, lies in the range 250 
mg – 500 mg daily, and proposes to set an Adequate Intake (AI) at 250 mg for adults.  
 
There is a large amount of data from both observational and intervention studies on the link between EPA+DHA consumption 
and reduced risk of cardiovascular diseases, and it is for this reason that meta-analyses are required to evaluate the totality of 
evidence.  
Despite the uncertainties and variabilities within the meta-analyses, the data clearly show a dramatic reduction in risk as intake 
increases from 0 towards 250 mg/day.  
 
However, the overall analysis of data and conclusions from several studies, suggest that the maximum benefit is reached 
between 250 mg/g and 500 mg/d. It is for this reason that a review in 2008 by ILSI North America supported a DRI for 
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EPA+DHA between 250 and 500 mg/d, and agreed with international recommendations that have been set around 500 mg/d for 
the reduction in risk of coronary heart disease(2).  
 
Although PIE welcomes the proposed AI, it is our belief that setting the level at the lowest end of the range within which 
greatest benefit lies, will result in a reduction in benefit for the overall population, or lack of significant benefit for specific 
groups.  
 
There is strong evidence that shows benefit at 500 mg/d regarding reduced risk of cardiovascular diseases. For example, the 
meta-analysis of Harris et al.(3) ,discussed in the EFSA opinion, examined six epidemiological studies and illustrated a 
beneficial trend up to 500 mg/d of EPA+DHA. Moreover, in a recently published and comprehensive review of evidence, it was 
concluded that the daily target intake of EPA+DHA should be at least 500 mg/day for healthy individuals, and 800 to 1000 
mg/day for individuals with pre-existing cardiovascular disease(4).  
 
Although an intake of 250 mg/d provides a substantial benefit for primary prevention, it may not confer optimal health. It is on 
this basis that PIE hopes the opinion is only an interim value and that in the near future, a further assessment of new evidence 
will be made, such that a dietary reference value of 500 mg that might provide for optimal health of the EU population can be 
established. 
 
References: 
(1) Health Statistics, Key data on health 2002. European Communities 2002. ISBN 92-894-3730-8. 
(2) Harris WS, Mozaffarian D,Lefevre M, Toner CD, Colombo J, Cunnane JC, Holden JM, Klurfeld DM, Morris MC, Whelan 
J, 2009 Towards Establishing Dietary Reference Intakes for Eicosapentaenoic and Docosahexaenoic Acids. J. Nutr. 139: 804S–
819S. 
(3) Harris WS, Kris-Etherton PM, Harris KA, 2008. Intakes of long-chain omega-3 fatty acid associated with reduced risk for 
death from coronary heart disease in healthy adults. Curr Atheroscler Rep. 10(6), 503-9  
(4) Lavie CJ, Milani RV, Mehra MR, Ventura HO, 2009. Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases J 
Am Coll Cardiol ;54:585–94. 
PIE - Platform for 
Ingredients in 
Europe 
6.5. Trans fatty 
acids (TFA) 
Natural levels of TFA can be substantial. Considering e.g. levels of natural TFA in breast milk, levels of 6% of the total fat may 
occur (Precht and Molkentin, 1999). In that sense clarity concerning TFA, and the advised limits needs refining. 
 
References: 
- Precht, D., Molkentin, J., 1999. C18:1, C18:2 and C18:3 trans and cis fatty acid isomers including conjugated cis delta 9, trans 
delta 11 linoleic acid (CLA) as well as total fat composition of German human milk lipids. Nahrung. 43, 233-44. 
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Product Board for 
Margarine, Fats 
and Oils 
2. Categories, 
structure and 
function 
The text in line 454 is confusing: The sentence (454) „Strictly speaking, only linoleic acid is essential, as the body can 
synthesize arachidonic acid from linoleic acid.‟ is (partly) inconsistent with the sentence in line 461 „The conversion of linoleic 
acid is very limited.‟. We suggest to change line 454 in: „Although linoleic acid is essential, the synthesis of AA from linoleic 
acid is very limited, making an additional intake of ARA, or GLA appropriate.‟ 
Furthermore, the text in line 463 states that delta-5 desaturase activity is decreased in elderly women. In addition to that, there is 
evidence that (mainly) delta-6 desaturase activity decreases with age (Angela Liou and Innis, 2009; Choi and Sugano, 1988; 
Hrelia et al., 1990). 
Product Board for 
Margarine, Fats 
and Oils 
4. Overview of 
dietary reference 
values and 
recommendations 
Saturated fat:  
In the Summary in line 66,67 the following is written: „The Panel recommends that SFA intake should be as low as possible 
within the context of a nutritionally adequate diet‟.  
In the discussed scientific research in chapter 5 this recommendation is not supported. Furthermore, according to Table 5 (page 
32), most countries and also the WHO/FAO do set maximum of SFA at 10 E%. In adults, average SFA intakes vary between 
less than 9 to nearly 17 E% and nearly 30% of the reported average intakes were 15 E% or higher (line 620-629).  
In addition, in several economically developed countries where the SAFA has fallen close to 10%, the capacity to decrease SFA 
much further is limited without major changes in dietary patterns, and is only likely to result in modest reductions in cholesterol 
levels. We therefore believe it is appropriate to set a goal for SFA at 10 E%.  
 
In line 776 and in table 6 (line 2915) the dietary reference value in the Netherlands is mentioned. However, these are the values 
from 2001, whereas the Dutch Health Council updated its advice in 2006. Therefore we recommend to use the most recent 
dietary guidelines. 
Product Board for 
Margarine, Fats 
and Oils 
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
n-3 PUFA 
Why has the Panel set the AI for a-linolenic acid on 0.5 E%, whereas again a higher intake is connected with the prevention of 
CVD. Cardiovascular Disease (CVD) is indisputably a major public health issue in Europe as it is the leading cause of 
mortality: 4.3 million deaths per year that make up 48% of all deaths in Europe (CVD statistics 2008). The WHO has set in her 
recent scientific update the AI of 0.5 E% of a-linolenic acid to prevent deficiency and between 0,5-2 E% (n-3 fatty acids 
including 0,1-0,9 E% n-3 LC PUFA) as part of a healthy heart diet probably preventing chronic diseases. A DRV for ALA of 1 
E% would also be in line with the 2 g/day as ALA that EFSA recently recommended to the Commission as labelling reference 
intake values (Question No EFSA-Q-2009-00548, adopted on 30 June 2009). Two g ALA per day in a 2000 kcal/d diet 
corresponds to ~0.9E%. The Dutch Health Council have set the AI for a-linolenic acid on 1 E%. We suggest to set the AI for a-
linoleic acid on at least 1 E% for preventing cardiovascular diseases. 
 
n-6 PUFA 
Why has The Panel set the AI for linoleic acid on 4 E%, whereas recent scientific evidence suggests an even higher intake based 
on protective effects of linoleic acid on CHD as is reviewed by Harris et al. and published this year in Circulation (vol 119. no. 
6, pp 902-907)? We propose to take this review also into account in the document. The reduction in cardiovascular risk by 
replacement of SAFA by n-6 PUFA (lines 1891-1894) is also supported by a recent pooled analysis of cohort studies (Jakobsen 
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et al, Am J Clin Nutr 2009;89:1425-32). In the recent scientific update of the WHO, the WHO recommends an intake of PUFA 
acid between 6-11 E% as part of a healthy heart diet to prevent chronic diseases. Under the condition that our suggestion‟s AI 
for a-linolenic acid on 1 E% and The Panel‟s AI for long chain n-3 fatty acids on 0,1 E% is taken into consideration, it can be 
derived that the recommendation level for n-6 PUFA should be at least 4,9 E%. We suggest to set the AI for n-6 PUFA on at 
least 6 E% for preventing cardiovascular diseases. 
Product Board for 
Margarine, Fats 
and Oils 
Conclusions and 
recommendations 
General remarks 
- The Product Board for Margarine, Fats and Oils is of the opinion that the conclusions in the summary do not in all cases 
accurately reflect the content of the report. More precise, the nuance in the report is lacking in the summary. Therefore, it is not 
immediately obvious on what basis the conclusions are drawn. Since the summary is generally the part that policy makers will 
read, it is important that the summary reflects the scientific state of the art, including the recent developments and nuances. 
 
- Recently, two WHO scientific updates have been published in the European Journal of Clinical Nutrition (vol. 63, supplement 
2s, pp S1-S75) and Annals of Nutrition and Metabolism (vol.55, no. 1-3: pp 5-300). It seems logical to take these two updates 
into account in the document.  
 
Total fat 
What is the lower bound of the recommendation intake range of fat for children between 4-18 years? In line 50-55 no specific 
recommendation level is mentioned for children older than 4 years. In addition, in line 54 The Panel states that fat intakes below 
25E% have been associated with low vitamin levels in some young children. Why then come to a lower bound of 20E% as 
stated in the table on line 2055 for children >4 years? It appears more prudent to recommend a total fat intake of at least 25E%. 
 
Transfats 
We would emphasize that The Panel states in the summary that the intake of TFA is close to the recommendation levels in most 
European countries TFA are not a public health issue anymore. The intake of total TFA is low because of the efforts made by 
the food industry in reducing the amount of industrial TFA in their products (and are still doing so).  
We welcome and agree with the conclusion of the EFSA that there is insufficient evidence to establish whether there is a 
difference between ruminant and industrial TFA consumed in equal amounts on the risk of Cardiovascular Disease (CVD). 
However, 
 
Additionally, The Panel states that TFA are not synthesized by the body (line 130, 1937, 2037), but this is not correct. CLA and 
vaccenic acid can be produced in small amounts in our body. We suggest to delete this sentence.  
Safefood 4. Overview of 
dietary reference 
values and 
recommendations 
Safefood is a North-South Body promoting food safety and healthy eating on the island of Ireland. Our remit is for both 
research (inc surveillance) and communication. From both a monitoring and communications point of view Safefood has a 
general concern around the lack of specific DRVs for saturated fat, monounsaturated fats, polyunsaturated fats (PUFA), N-6 
PUFAs and trans fats. The lack of clear targets for these nutrients could make communications to consumers on these issues 
more challenging. It may also mean that development of indicators, against which to measure improved population dietary 
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intakes, are more difficult to identify.  
Scientific & 
Regulatory Affairs / 
Danone Research 
1. Introduction Line 128 
n-6:n-3 fatty acid ratio: 
Some dietary recommendations include guidelines for the n-6:n-3 ratio in the diet, as this may contribute to maintaining 
cardiovascular health. 
Recent recommendations suggest lowering the ratio preferably by a combination of an n-3 increase and an n-6 decrease. Indeed, 
in the studies by Sanders and Griffin (Griffin et al., 2006; Sanders et al., 2006), it appeared that in the context of a total PUFA 
intake equivalent to 6% of energy, decreasing the ratio by increasing the intake of very long chain n-3 fatty acids to 
approximately 1-1,5g/d resulted in potentially beneficial effects with regard to cardiovascular risk. In contrast, Stanley et al, 
2007 concluded in their review that the n-6:n-3 fatty acid ratio is not a useful concept and that it draws attention away from 
increasing absolute intakes of long chain n-3 fatty acids which have been shown to have beneficial effects on cardiovascular 
health. 
Independently of the debate on the ratio, we would at least suggest an overall recommendation to increase absolute intake of n-3 
and reasonably limit that of n-6. 
Scientific & 
Regulatory Affairs / 
Danone Research 
1. Introduction LINE 146 
If the limited data suggest that the effects of ruminant and industrial TFA on blood lipid profiles are similar when consumed in 
similar quantities, it is important to mention that very few people consume the high levels of ruminant TFA used in these 
studies and that observational studies do not support adverse CHD effects of ruminant TFA in amounts actually consumed 
(Mozaffarian et al., 2009). This is reinforced by the recent WHO scientific update on TFA (Uauy et al., 2009).  
This is also the conclusion of AFSSA (French food safety agency) in its 2009 report: TFA from natural origin do not present a 
risk in terms of cardiovascular disease as they are consumed at very low level (0,5 to 0,9% of the total energy intake).  
The EFSA recommendation concerning the dietary reference value for TFAs should then deal only with industrially derived 
TFA. Trans fat from natural origin should not be included. 
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Scientific & 
Regulatory Affairs / 
Danone Research 
1. Introduction LINE 67 (Part 2 of comment) 
More generally, it should be noted that : 
- the evidence of the role of SFA in Coronary Heart Disease is not conclusive (Mente et al., 2009); Indeed, some studies show 
that in some cases a greater saturated fat intake is associated with less progression of coronary atherosclerosis, whereas 
carbohydrate intake is associated with a greater progression (Mozaffarian et al., 2004; Griel et al., 2006). In addition the WHI 
study (Howard et al, 2006) indicates that a decrease of fat intake (leading to an intake of 9,5% SFA) does not significantly 
reduce the risk of stroke, coronary heart disease, or cerebrovascular disease in postmenopausal women.  
 
- SFA have different physiological functions depending on their chain length, justifying the previous conclusion that SFA 
should not be evaluated as one single group. (Sengupta 2006, Hashim, 1960, Tsuji, 2001, Yu et al, 1995, Kelly, 2001, Temme et 
al, 1997, Salter et al, 1998, Billet MA 2000, Casey, 1995, Rioux, 2002, Peitzsch, 1993, Borgese, 1996. Dabadie, 2005). 
 
Moreover, recommending SFA intake to be “as low as possible” could result in overly strict guidelines as this would likely be 
understood to mean “zero”. A low intake of SFA would result in an excessive consumption of MUFA and PUFA, unbalancing 
the diet, thereby doing more harm than good.  
 
In conclusion, the scientific data shows that certain types of saturated fat do not have negative but positive effects. As such, 
considering SFAs as a single group does not seem justified and doing so could actually have a negative impact on health. We 
would suggest taking into account the different physiological functions of SFA in order to evaluate the DRV. 
Scientific & 
Regulatory Affairs / 
Danone Research 
1. Introduction Line 67 
In our view, this recommendation does not reflect the recent scientific evidence on saturated fatty acids.  
Very recently (Sept 2009), during the International Conference on Saturated Fat in Copenhagen, organized by the European 
Dairy Association (EDA) in collaboration with the Danish Dairy Board, several international experts agreed that there is no 
conclusive evidence with regards to negative health effects of saturated fatty acids from milk fat. The scientists stated that there 
is no reason for considering saturated fatty acids as a single group anymore, and that more research is needed in order to make 
well-founded policy recommendations with regard to the intake of saturated fatty acids: 
 
- Prof. Bruce German (University of California) told the attendants that evidence from the past five years has changed the view 
and understanding of the effects of fat on cholesterol metabolism. For instance, dietary cholesterol does not affect blood 
cholesterol. Scientific evidence does not support the assumption that saturated fat intake should be as low as possible as this is 
often understood to mean “zero”. Moreover, Prof. German suggested that, in personalized diets, appropriate doses of saturated 
fats are likely to have a beneficial impact. 
 
- French Professor Philippe Legrand (University of Rennes) indicated that based on the latest science there is no reason to 
consider saturated fatty acids as a single group anymore in terms of structure, metabolism, functions and deleterious effects. 
Only three of the many different saturated fatty acids found in milk fat should now be considered as atherogenic. Some 
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saturated fatty acids in milk fat might even have beneficial effects on the cholesterol metabolism. For him, the saturated fatty 
acids in dairy products have an interesting composition. He pleaded for more precise studies to investigate further on a possible 
dose-effect and to put the different saturated fatty acids into perspective. 
 
- Prof Werner Buck, EDA President: „Saturated fatty acids should be considered individually and not as a whole group due to 
their different physiological effects. We are glad that recent scientific findings support our belief by clearly indicating that 
specific actions of some saturated fatty acids are even beneficial for human health.‟ 
Scientific & 
Regulatory Affairs / 
Danone Research 
1. Introduction Line 86  
However nutritional recommendation should not stress a n-6 PUFA over consumption, and promote instead a good balance 
between n-3 PUFA and n-6 PUFA. The relative intake of n-6 to n-3 PUFA is indeed clearly emerging as a new factor in the 
development of adipose tissue (Ailhaud et al., 2008).  
Line 97 
There has been evidence on negative effects on health of excessive intakes of n-6 PUFA and lipid peroxidation (Elmadfa and 
Kornsteiner, 2009). It could also contribute to excessive adipose tissue development (Ailhaud, 2006; Lecerf, 2009). Therefore, 
an upper limit should be considered in order to protect consumer health 
Scientific & 
Regulatory Affairs / 
Danone Research 
2. Categories, 
structure and 
function 
¿ Line 414 to 424 
As for PUFA, additional information about structure and functions of SFA should be added. SFA are components of reserve 
triglycerides, glycerophospholipids and sphingolipids (membrane structure, myeline…). SFA cannot be considered as a whole, 
in terms of structure, metabolism and cellular functions. They have to be classified regarding their chain length: 
 
Structure and function of short and medium chain fatty acids 
Short and medium chain SFA have a specific metabolism. As reported by Bach and Babayan (1982), triglycerides made of 
C6:0, C8:0, C10:0 and C12:0 (MCTs) have unique physical, chemical, and structural characteristics and their modifications 
(structured lipids) make special lipids tools for solving certain medical problems. They are indeed hydrolyzed both faster and 
more completely than long chain triglycerides (LCTs). The products of this hydrolysis are absorbed as fast as glucose. MCTs 
are oxidized rapidly in the organism and they have a very low tendency to deposit as body fat.  
As reported by Sengupta et al. (2006), short chain butyric acid is likely to have a protective function against colon cancer 
(inhibition of tumor proliferation, apoptosis induction). Short and medium chain SFA have an hypocholesterolemic effect at 
physiological dose. This effect of diets high in C8:0 and C10:0 was shown in humans by Hashim (1960). Medium chain SFA 
have also a beneficial role in adiposis. The human study of Tsuji et al. (2001) suggests weight loss with a diet high in medium 
chain fatty acids. C6:0, C8:0 and C10:0 have a role in weight reduction, reduced fat deposition, decrease of VLDL production, 
hypocholesterolemic effect and antiviral role (Rioux et al., 2007; Legrand, 2008). 
 
Structure and function of long chain fatty acids 
Long chain SFA are converted, in part, by ¿9-desaturation in monounsaturated fatty acids, but with significantly different 
effectiveness, increasing with the length of the chain. Stearic acid is the best substrate of ¿9-desaturase; and its conversion to 
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oleic acid is important (Legrand, 2002; Legrand, 2008). The long chain stearic acid has no negative effects on cholesterol level 
(Yu et al.; 1995) and, as presented by Kelly (2001), it has a beneficial effect on thrombogenic and atherogenic risk factors in 
males.  
Myristic acid has a positive action through an increase of HDL-cholesterol when consume at usual level (Temme et al., 1997; 
Salter et al., 1998; Billet MA, 2000). Some SFA regulate specifically the activity of proteins by acylation (myristoylation, 
palmitoylation). Some studies show that, for example, myristic acid plays a key role through its ability to acylate proteins, a 
reaction which is called N-terminal myristoylation. Various examples of important cellular regulations where the intervention of 
myristic acid is proven have been described (Casey, 1995; Rioux, 2002; Peitzsch, 1993; Borgese, 1996). Myristic acid also has 
a function in the biosynthesis of EPA and DHA (Dabadie et al., 2005; Rioux et al., 2005) and of sphyngolipids. 
 
Trans fatty acids 
¿ Line 572 
Partially hydrogenated vegetable oils can contain_1–65% of TFAs, of which isomers of elaidic acid (trans-9 and trans-10 18:1) 
are the 2 most common isomers.  
On the other hand, dairy products contain smaller amounts of TFAs (1–8% of total fatty acids in milk fat), and the main isomer 
is vaccenic acid (trans-11 18:1). Humans can utilize vaccenic acid, in the endogenous synthesis of rumenic acid (cis-9, trans-11 
18:2), a fatty acid that may not have a negative effect on biomarkers of CVD risk (17–19). These 2 sources of TFAs differ in 
their TFA isomer distribution and contribution to dietary intake, and, as a consequence, they also may have different biological 
effects (Chardigny et al., 2008) 
Scientific & 
Regulatory Affairs / 
Danone Research 
Conclusions and 
recommendations 
2055 SUMMARY OF DRVS FOR FATS (Table) 
Adults  
SFA Not in excess of 10-12% within the context of a nutritionally adequate diet. 
TFA from industrial origin As low as possible  
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Conclusions and 
recommendations 
Lines 1986 
The conclusion and recommendation on SFA should better reflect the content of Section 6.2, specifically lines 1862 to 1868 and 
also take into account the following: 
SFAs have different physiological functions depending on their chain length. (Sengupta 2006, Hashim, 1960, Tsuji, 2001, Yu et 
al, 1995, Kelly, 2001, Temme et al, 1997, Salter et al, 1998, Billet MA 2000, Casey, 1995, Rioux, 2002, Peitzsch, 1993, 
Borgese, 1996. Dabadie, 2005). Recent results show that certain types of SFA have positive effects on health, especially 
cardiovascular health (individual statements by B. German, P. Legrand and W. Buck; International Conference on Saturated 
Fat. Copenhagen. 2009). As such they should not be evaluated as one single group. 
Recommending an SFA intake „as low as possible‟ may result in an excessive consumption of MUFA and PUFA (especially for 
n-6 fatty acids (Lecerf, 2008; Ailhaud, 2006), unbalancing the diet, thereby doing more harm than good. 
We suggest to set a threshold in line with guidelines from European countries, the USA and the WHO corresponding to a 
maximum level of 10-12% of the total daily energy intake 
 
Line 2002 : n-6:n-3 fatty acid ratio 
Independently of the debate on the ratio, we would at least suggest an overall recommendation to increase absolute intake of n-3 
and reasonably limit that of n-6.  
 
Line 2042 
Evidence from studies distinguishing the ruminant and industrial origin of TFAs generally do not support an adverse effect of 
ruminant TFA (in contrast to industrial TFA) on the risk of CHD (Mozaffarian et al., 2009; Uauy et al., 2009; AFSSA - French 
food safety agency).  
Ruminant TFAs cannot be removed entirely from the diet, as they are naturally present. On the other hand the presence in food 
of TFAs resulting from the partial hydrogenation of oils can be controlled: indeed the use of industrial TFA containing foods 
should be avoided by restaurants and food manufacturers and their consumption avoided by consumers. 
 
We would therefore agree with the EFSA recommendation of a DRV for trans fatty acids to be as low as possible if limited to 
those of industrial origin. 
Scientific & 
Regulatory Affairs / 
Danone Research 
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Scientific Advisory 
Committee on 
Nutrition 
1. Introduction Summary- n-6 PUFA 
 
Line 78; include „it‟ in the sentence  
 
Summary- TFA 
Line 137; comma should be full stop 
 
Summary-CLA 
 
Line 148; there is more data on CLA and oxidative damage than is covered here. It may be worth looking again at the evidence 
in relation to safety and upper limits. 
 
Introduction 
 
The opinion lacks information on the methodology employed to identify the relevant evidence. It is recommended that this 
should be included together with assessments of quality and any data analysis used to inform the DRVs for fat.  
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Scientific Advisory 
Committee on 
Nutrition 
2. Categories, 
structure and 
function 
Section 2.1.3.1- n-6 polyunsaturated fatty acids (n-6 PUFA) 
 
There is no clear indication in this section that DHA is much more difficult to synthesise than AA which requires peroxisome 
transport etc. There is good evidence to support differential AA/DHA synthesis in humans. This has important implications for 
any dietary recommendation and should be made explicit. 
Scientific Advisory 
Committee on 
Nutrition 
3. Dietary sources 
and intake data 
Section 3.2 Intake data 
 
It is important to acknowledge the deficiencies in the intake data where it is used to make recommendations: 
 
• Supplement use is not taken into account. Supplement use may make an important contribution to total intake of important 
PUFA/LCPUFA (e.g. marine oil supplement use in member states with low intakes of fish). This is not considered in the report.  
 
• There is a rapidly increasing trend toward manipulation and modification of the nutrient composition of foods with many 
novel foods having the potential to have a large impact on the overall intake of highly bioactive nutrients. This complexity may 
not be captured by the intake data used in this analysis.  
 
• The methods used to assess dietary intake are known to result in a significant underestimate of intake (e.g. as verified by 
doubly labelled water); underestimates of 25% are not unusual. This should be acknowledged in the report. Also, what would be 
the implications of such underestimation for this report?  
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Scientific Advisory 
Committee on 
Nutrition 
4. Overview of 
dietary reference 
values and 
recommendations 
The logic of using absolute amounts for EPA/DHA DRVs and % of energy for everything else is not well explained. It is also 
worth noting that if fats are expressed as a % of energy then the distribution is not normal because the energy requirement is 
skewed. What effect would this have on the recommendations? 
 
There is no mention in the report of positional isomers of fatty acids within triacylgrycerol; the same overall intake of fatty 
acids could have different health consequences depending on the position on the triacylglycerol moiety. 
 
Lines 479-482 state that “The developing brain accumulates large amounts of DHA both pre- and postnatally”, see also line 
1199. The figure used for accumulation of DHA in the brain is incorrect. Also, the story is more complicated than as presented 
(see for example European Journal of Clinical Nutrition. 2004 Dec;58(12):1559-70.). 
 
Line 704; „unbeneficial‟ should be „ detrimental‟ 
 
Line 1035; this summary table is very useful. Given the importance of pregnancy and lactation in relation to fats, it would be 
useful to summarise the pregnancy/lactation recommendations, already in raw form in the appendices, in the same way. 
 
Section 4.1.4.1 PUFAs (n-6 PUFAs) 
 
Line 854; should define „triene/tertaene‟ 
 
Section 4.1.4.2 PUFAs (n-3 PUFAs) 
 
The Scientific Advisory Committee on Nutrition (SACN) recommended intake of EPA and DHA is 450mg/day which is the 
equivalent of two portions of fish per week, one of which should be oily. This based on the evaluation of evidence, in terms of 
cardiovascular disease risk, as detailed in the SACN report “Advice on fish consumption: benefits & risks”. We note that 
EFSA‟s DRV‟s for n-3 PUFA‟s are set lower than this, making it possible for white fish to be considered “oily”. Therefore, we 
urge EFSA revisit the evidence it has based its recommendations on. 
 
http://www.sacn.gov.uk/reports_position_statements/reports/advice_on_fish_consumption_benefits__risks.html 
 
Line 866; It is not clear what is meant here. The logic of retroconversion of DHA to EPA should also be made explicit. 
 
4.2- children 
Line 943 „children‟ should be „children and infants‟ 
Scientific Advisory 
Committee on 
5.8. Cardiovascular 
disease 
Lines 1629-1630; „decreasing intakes … at the expense of‟? 
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Nutrition 
Scientific Advisory 
Committee on 
Nutrition 
6.1. Total fat Line 1830; „in itself‟ should be „in themselves‟ 
Scientific Advisory 
Committee on 
Nutrition 
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
6.4.2 n-3 PUFA 
 
It is considered that EFSA‟s DRV for n-3 PUFA‟s of 250mg/day does not reflect the evidence available relating to 
cardiovascular disease. A level closer to the SACN recommendation of 450mg/day would be more appropriate. This is based on 
the balance of the scientific evidence from RCTs and observational studies and on two portions of fish, one oily (one portion is 
2.8g DHA/EPA/week) and one white (one portion average 0.4g/DHA/EPA week). This is a weekly total of 3.2g/week which 
equates to 450mg/day.  
Scientific Advisory 
Committee on 
Nutrition 
Conclusions and 
recommendations 
Conclusions and recommendations- saturated fats 
 
The lack of definite information about saturated fat levels is a major concern given the national guidelines presently existing 
throughout Europe (e.g. UK Committee on Medical Aspects of Food Policy, COMA, DH 1994) and its impact on public health. 
 
Trans Fats 
 
EFSA have not set a DRV for trans fats, however it would be useful to have a figure to inform health policy. 
 
In light of the health sensitivities around trans fats SACN assessed the previous recommendations set by COMA in 1994 and 
upheld the COMA recommendation that the average trans fatty acid intake should not exceed 2% food energy, as there is 
currently no firm scientific basis for revision. The review was published in 2007 and can be found at: 
 
http://www.sacn.gov.uk/reports_position_statements/position_statements/update_on_trans_fatty_acids_and_health_-
_december_2007.html) 
 
The review included a re-estimation of trans fats intake for adults aged 19-64 years using consumption data from the UK 
National Diet and Nutrition Survey for adults in 2000/01 and the new trans fat values provided by industry. A new value for 
mean trans fat intake for all adults aged 19-64 years was estimated at 1.0% of food energy. This is lower than the original 
NDNS estimate of mean trans fat intake in this age group - 1.2% food energy. It was not possible to take account of all the 
reductions in trans fat levels so this figure is an overestimate of actual intake. 
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The Omega-3 
Centre 
1. Introduction  
1. Shorter chain omega-3s versus long chain omega-3s 
 
The DRVs for omega-3s must discriminate between the physiologically active long chain omega-3s (EPA, DHA) and the 
shorter chain omega-3s (alpha-linolenic acid (ALA)). Whilst ALA is an essential fatty acid, it is poorly converted into DHA 
(around 1% in infants and considerably lower in adults). In a recent review on ALA and conversion to omega-3 long chain 
polyunsaturated fatty acids in humans, the authors concluded “present evidence indicates that n-3 LCPUFA status can be 
improved by increasing their intake or by decreasing LA intake, and a combination of the two is likely to be most effective”.  
Based on this evidence, it is unclear why the EFSA Draft scientific opinion, Line 107 states without qualification, “The human 
body can synthesize EPA and DHA from alpha-linolenic acid”.  
The Omega-3 Centre recommends that the EFSA develop DRVs for omega-3s that distinguish between the shorter chain 
omega-3 ( ALA ) needs, and long chain omega-3s (DHA, EPA and DPA) needs.  
This is important to ensure consumers are not misled or confused about how to meet their omega-3 needs – they need both 
shorter chain and long-chain omega-3s (LC O3s) for cardiovascular health. In most western countries, it is the long-chain 
omega-3s that are consumed inadequately: 
• Australia - population intakes in 1995 (the most recent national nutrition survey) were significantly lower that the NHMRC 
Suggested Dietary Targets for adult women and men (430mg/day and 610mg/day respectively) and there was a great difference 
between the mean and median intakes which is likely to reflect a low consumption of fish by the majority. In children, the 
majority are below the Suggested Dietary Targets (around 87-90% of children do not meet the SDTs for their age group)  
• USA – average intake of EPA and DHA is between 100 and 200mg/day requiring a four-fold increase in fish/seafood 
consumption to meet recommendations for intake  
• United Kingdom – average intake has been estimated to be 120mg for men based on The Dietary and Nutritional Survey of 
British Adults in 1990.  
The O3C recommends labelling information on food and beverage products that assists consumers in increasing their daily long 
chain omega-3 (LC O3s) recommendations for heart health.  
The Omega-3 
Centre 
1. Introduction Executive Summary and recommendations 
 
The Omega-3 Centre endorses the requirement for Population Reference Intakes for fatty acids for the European population, 
including long chain polyunsaturated fatty acids.  
 
The various health benefits of consuming long chain omega-3s are well-documented and indicate their importance in 
cardiovascular health. 
  
It is essential that the dietary reference values for long chain omega-3s: 
• Distinguish between the shorter chain omega-3 (ALA) and long chain omega-3s to achieve optimal health benefits from 
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increased intakes of long chain omega-3s 
• Are consistent with current recommendations for long chain omega-3s and cardiovascular health of 500mg/day DHA & EPA 
• Provide scientifically validated reference values for the development of content claims to increase consumer understanding of 
useful sources of long-chain omega 3s and thereby lead to health benefits from increased intakes of these beneficial fatty acids 
in the European diet.  
 
Key Recommendations 
 
The Omega-3 Centre recommends that the EFSA develop DRVs for omega-3s that distinguish between the shorter chain 
omega-3 ( ALA ) needs and the long chain omega-3s (DHA, EPA and DPA). 
 
The Omega-3 Centre recommends labelling information on food and beverage products that assists consumers in increasing 
their daily long chain omega-3 recommendations for heart health.  
 
The Omega-3 Centre endorses the proposed EFSA Recommended Intakes of an additional 100-200mg DHA per day for 
pregnancy and lactation. 
 
The Omega-3 Centre endorses the “dietary advice for children of 1-2 fatty fish meals/week or at-least 250mg EPA & DHA per 
day”. 
 
The Omega-3 Centre recommends DRVs are set for long chain omega-3s at a level that will lead to a public health benefit by 
encouraging adequate levels of enrichment of foods/beverages to increase the population‟s long chain omega-3 intake.  
 
The Omega-3 Centre recommends an increase of the proposed AI to 500mg in order to be compatible with the recent evidence 
based recommendations for long chain omega-3s and cardiovascular health 
 
The O3C recommends that EFSA undertake dietary modelling based on current dietary patterns to establish minimum content 
levels for long chain omega-3s that would lead to beneficial intake levels. 
 
The O3C recommends assessment of the impact on industry stakeholders in development of content criteria claims 
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The Omega-3 
Centre 
4. Overview of 
dietary reference 
values and 
recommendations 
3. Long chain omega-3s, RIs in pregnancy and lactation and recommendations for children 
 
The Omega-3 Centre endorses the proposed EFSA Recommended Intakes of an additional 100-200mg DHA per day for 
pregnancy and lactation as this is consistent with European consensus evidence-based guidelines that pregnant women should 
aim to achieve a dietary intake of LC-03s that supplies a DHA intake of at least 200mg/day (Koletzko, B et al The roles of long-
chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus 
recommendations J.Perinat.Med.36(2008) 5-14).  
 
In addition, The Omega-3 Centre endorses the “dietary advice for children of 1-2 fatty fish meals/week or at-least 250mg EPA 
& DHA per day”.  
The Omega-3 
Centre 
5. Criteria 
(endpoints) on 
which to base the 
dietary reference 
values 
2. Long chain omega-3s and cardiovascular health 
 
The various health benefits of consuming the long chain omega-3s (LC O3s), particularly EPA and DHA have been well-
documented in the adult population for cardiovascular health. Specifically, EPA and DHA can reduce the risk of arrhythmias, 
decrease triglyceride levels, slow the growth rate of atherosclerotic plaques, and reduce blood pressure slightly (Brownawell 
AM, Harris WS, Hibbeln JR et al. Nutrition Reviews 67(7):391-397). 
 
In the revision of nutrient reference values in Australia and New Zealand as endorsed by the NHMRC (2006), the essential roles 
of DHA and EPA were recognised and included: 
• DHA‟s important role as a structural membrane lipid, particularly in nerve tissue and the retina 
• Cardiovascular benefits of long chain omega-3s 
• Anti-inflammatory benefits of long chain omega-3s.  
 
The Adequate Intakes (AIs) were based on the median intakes assessed in the National Nutrition Survey of Australia in 1995 
and reflect low intakes within the Australian population and are not considered helpful in determining optimal intakes for 
health.  
 
The Suggested Dietary Targets (SDTs) were a new concept (in 2006) for Australian and New Zealand nutrient reference values. 
The SDTs were based on the 90th percentile of intake as this provided potential benefit whilst being a safe level: NHMRC 
Nutrient Reference Values (2006) recommend Suggested Dietary Targets (SDTs) of 430mg/day and 610mg/day of EPA, DPA 
and DHA for females and males over the age of 14 years, respectively for cardiovascular health (NHMRC. Nutrient Reference 
Values for Australia and New Zealand. Canberra. Commonwealth of Australia 2006). 
 
These levels are consistent with the National Heart Foundation of Australia (NHFA) Position Statement, Fish, fish oils and 
omega-3 polyunsaturated fatty acids (2008) - which recommends 500mg daily of DHA and EPA to lower risk of cardiovascular 
disease through a combination of the following: 
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• Two or three serves (150g serve) of oily fish per week 
• Fish oil capsules or liquid 
• Food and drinks enriched with marine omega-3s  
 
These Australian guidelines (NHMRC SDTs and NHFA) are consistent with the American Heart Association (AHA) guidelines 
that state: “Evidence from prospective secondary prevention studies suggests that EPA+DHA supplementation ranging from 0.5 
to 1.8 g/d (either as fatty fish or supplements) significantly reduces subsequent cardiac and all-cause mortality. For linolenic 
acid, total intakes of 1.5 to 3 g/d seem to be beneficial”. Based on the evidence the AHA Dietary Guidelines recommend 
including at least two servings of fish per week (particularly fatty fish). In addition, the data support inclusion of vegetable oils 
(eg, soybean, canola, walnut, flaxseed) and food sources (eg, walnuts, flaxseeds) high in linolenic acid in a healthy diet for the 
general population (American Heart Association 2008).  
 
A more recent review (2009) of long chain omega-3s and cardiovascular protection, in the American College of Cardiology 
journal concludes “based on considerable evidence, the target EPA + DHA consumption should be at least 500 mg/day for 
individuals without overt CV diseases, and at least 800-1000 mg/day for individuals with known CHD and HF” (Lavie CJ, 
Milani RV, Mehra MR, Ventura HO. J Am Coll Cardiol 2009 Aug 11; 54(7):585-94).  
 
In summary, there is increasing evidence to recommend a Suggested Dietary Target of 500mg/day for long chain omega-3s 
(EPA + DHA) for cardiovascular benefit. This recommended level is not consistent with the EFSA‟s proposed AI of 250mg/day 
for EPA & DHA for cardiovascular benefits (Lines 116-118).  
 
The Omega-3 Centre recommends an increase of the proposed AI to 500mg in order to be compatible with the recent evidence 
based recommendations for long chain omega-3s and cardiovascular health 
The Omega-3 
Centre 
5. Criteria 
(endpoints) on 
which to base the 
dietary reference 
values 
4. Content Claims 
 
Content claims on food labels such as “source of omega-3s”, “good source of omega-3s” are a simple and effective means of 
communicating the nutritional benefits of a food or beverage at point-of-sale. It is important therefore that the DRVs are set at 
adequate levels to ensure omega-3 content claims are validated scientifically and will have the desired public health benefit – 
increased long chain omega-3 intake (DHA, EPA) with attendant cardiovascular health benefits.  
 
In Australia, Food Standards Australia New Zealand (FSANZ) has recommended the inclusion of a General Level Health 
Claim: “EPA and DHA contributes to heart health” in their most recent consultation paper (P293, Nutrition, Health & Related 
Claims Consultation Paper for First Review 20 March 2009). FSANZ proposed a minimum content of 50mg DHA and EPA per 
serving of food which the O3C supports as this reflects 10% of the 500mg daily intake target recommended by the National 
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Heart Foundation of Australia for achieving a heart health benefit. 
 
The O3C recommends DRVs are set for long chain omega-3s at a level that will lead to a public health benefit by encouraging 
adequate levels of enrichment of foods/beverages to increase the population‟s long chain omega-3 intake.  
 
Setting the level too low will mean many food products and beverages can claim to be sources of long chain omega-3 when 
their contribution to total intake would be negligible. Given the low mean and even lower median population intake of long 
chain omega-3s, it would seem prudent to have content claim criteria set at levels that will make a difference to intake levels 
and thereby improve public health outcomes.  
 
The O3C recommends that EFSA undertake dietary modelling based on current dietary patterns to establish minimum content 
levels for long chain omega-3s that would lead to beneficial intake levels.  
 
The O3C recommends assessment of the impact on industry stakeholders in development of content criteria claims in terms of 
product development and innovation. For example, what levels of long chain omega-3 enrichment are feasible in specific 
products from both a sensory and cost-effective perspective?  
Unilever Conclusions and 
recommendations 
Lines 2010-2012 and 2021-2023. 
-> Unilever reacts on the proposed DRVs for linoleic acid (LA) and alpha-linolenic acid (ALA). The EFSA panel recommends, 
based on the „minimal level to prevent deficiency symptoms‟, AI levels of 4 E% for LA and 0.5 E% for ALA. LA and ALA 
deficiencies are virtually non-existent in the general population, whereas Cardiovascular Disease (CVD) is indisputably a major 
public health issue in Europe as it is the leading cause of mortality: 4.3 million deaths per year that make up 48% of all deaths 
in Europe (CVD statistics 2008). 
-> Unilever believes that the panel should use its own „criterion of adequacy‟: „disease risk reduction in relation to the nutrient 
intake pattern‟, in line with current insights that dietary recommendations should also take prevention of morbidity and 
premature mortality via optimal nutrition into account. In fact, several other authoritative bodies do so: The US Institute of 
Medicine set Acceptable Macronutrient Distribution Ranges of 5-10 E% for LA and 0.6-1.2 E% for ALA (Dietary Reference 
Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Institute of Medicine (IoM) 
2002). The WHO judged the evidence that LA and ALA decrease the risk of CVD as „convincing‟ and recommended 5-8 E% 
for n-6 fatty acids and 1-2 E% for n-3 fatty acids (Joint WHO/FAO expert consultation. Diet, Nutrition, and the prevention of 
chronic diseases. WHO Technical report series 916. Geneva 2003). The EC-sponsored Eurodiet report (2001) recommends 
intakes of 4-8 E% for LA and of 2 g for ALA, which is about 0.8 E% . 
- >This EFSA draft scientific opinion states (lines 1891–1894) that “There is [also] evidence from dietary intervention studies 
that decreasing the intakes of products rich in SFA by a replacement of products rich in n-6 PUFA (without changing total fat 
intake) reduced the number of cardiovascular events.” This is strongly supported by a recent pooled analysis of cohort studies, 
which confirms a significant inverse relation between „increased PUFA at the expense of SFA‟ and coronary heart disease risk 
throughout the normal population range of intake (Jakobsen et al, Am J Clin Nutr 2009;89:1425-32). The median total PUFA 
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intake in the 11 populations included in this analysis varied between 2.3 E% and 9.0 E%, with most populations having an 
intake of around 5-6 E%. The highest (90th percentile) PUFA intake levels ranged from 3.7 E% to 10.4 E%, and were between 
7 E% and 9 E% for most populations. Because LA makes up approximately 80 to 90% of total dietary PUFA, it can be derived 
that in these general populations, intakes of at least 6 E% for LA and of at least 1.0 E% are associated with the lowest risk of 
CHD. 
-> A DRV for ALA of 1 E% would also be in line with the 2 g/day as ALA that EFSA recently recommended to the 
Commission as labelling reference intake values (Question No EFSA-Q-2009-00548, adopted on 30 June 2009). Two g ALA 
per day in a 2000 kcal/d diet corresponds to ~0.9E%. 
-> CONCLUSION: The proposed AI levels of 4E% for LA and 0.5 E% for ALA, are based on prevention of deficiency 
symptoms. This is in contrast with other international dietary recommendations that, taking prevention of CHD into account, 
advice substantially higher intake levels of LA and ALA for optimal health. From the available evidence, it can be derived that 
AI levels for preventing cardiovascular diseases should be at least 6 E% for LA and 1 E% for ALA. Unilever believes that with 
the currently proposed AI levels, EFSA does not seize the opportunity to help the European population achieving intakes of LA 
and ALA that have been shown to reduce the risk of CHD. If the EU implements these recommendations of the EFSA panel, 
evidence-based claims and other communications aimed at motivating consumers to increase intakes of LA and ALA will be 
extremely difficult to make. 
University of 
Aberdeen 
1. Introduction These comments cover the multiple sections. Web site did not seem to respond to individual submissions. 
 
Dietary reference values for fat 
It is important to acknowledge the deficiencies in the intake data where it is used to make recommendations: 
• Supplement use is not taken into account. Supplement use may make an important contribution to total intake of important 
PUFA/LCPUFA (e.g. marine oil supplement use in member states with low intakes of fish). This is not considered in the report. 
• There is a rapidly increasing trend toward manipulation and modification of the nutrient composition of foods with many 
novel foods having the potential to have a large impact on the overall intake of highly bioactive nutrients. This complexity may 
not be captured by the intake data used in this analysis. 
• The methods used to assess dietary intake are known to result in a significant underestimate of intake (e.g. as verified by 
doubly labelled water); underestimates of 25% are not unusual. This should be acknowledged in the report. Also, what would be 
the implications of such underestimation for this report? 
 
Section 2.1.3.1: No clear indication here that DHA is much more difficult to synthesise than AA – requiring peroxisome 
transport etc. There is good evidence to support differential AA/DHA synthesis in humans. This has important implications for 
any dietary recommendation and should be made explicit. 
 
Section 4: The logic of using absolute amounts for EPA/DHA DRVs and % of energy for everything else is not well explained. 
It is also worth noting that if fats are expressed as a % of energy then the distribution is not normal as the energy requirement is 
skewed. What effect would this have on the recommendations? 
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There is no mention in the report of positional isomers of fatty acids within triacylgrycerol; the same overall intake of fatty 
acids could have different health consequences depending on the position on the triacylglycerol moiety. 
 
Lines 479-482 state that “The developing brain accumulates large amounts of DHA both pre- and postnatally”, see also line 
1199. The figure used for accumulation of DHA in the brain is incorrect. Also, the story is more complicated than as presented 
(see for example European Journal of Clinical Nutrition. 2004 Dec;58(12):1559-70.). 
line 78; „it‟ missing 
Line 137; coma should be full stop 
Line 704; „unbeneficial‟ should be „ detrimental‟ 
Line 854; should define „triene/tertaene‟ 
Line 943 „children‟ should be „children and infants‟ 
Lines 1629-1630; „decreasing intakes … at the expense of‟? 
Line 1830; „in itself‟ should be „in themselves‟ 
Line 866; Not clear what is meant here. Should also be explicit about the logic of retroconversion of DHA to EPA. 
Line 148; There is more data on CLA and oxidative damage than is covered here. It may be worth looking again at the evidence 
in relation to safety/upper limit. 
Line 1035; this summary table is very useful. Given the importance of pregnancy and lactation in relation to fats it would be 
useful to summarise the pregnancy/lactation recommendations, already in raw form in the appendices, in the same way. 
University of 
Aberdeen 
3. Dietary sources 
and intake data 
Dietary reference values for fat 
It is important to acknowledge the deficiencies in the intake data where it is used to make recommendations: 
• Supplement use is not taken into account. Supplement use may make an important contribution to total intake of important 
PUFA/LCPUFA (e.g. marine oil supplement use in member states with low intakes of fish). This is not considered in the report. 
• There is a rapidly increasing trend toward manipulation and modification of the nutrient composition of foods with many 
novel foods having the potential to have a large impact on the overall intake of highly bioactive nutrients. This complexity may 
not be captured by the intake data used in this analysis. 
• The methods used to assess dietary intake are known to result in a significant underestimate of intake (e.g. as verified by 
doubly labelled water); underestimates of 25% are not unusual. This should be acknowledged in the report. Also, what would be 
the implications of such underestimation for this report? 
University Pablo 
Olavide 
5.2. Serum lipids 
and lipoproteins 
- 5.2.3. Page 38, lines 1253-1257. There exist several studies showing a clear effect of Cis-MUFA on serum lipid and 
lipoprotein profile. For example: 
 
• Pérez- Jiménez F., López-Miranda J, Mata P. Protective effect of dietary monounsaturated fat on arteriosclerosis: beyond 
cholesterol. Atherosclerosis 2002, 163: 385-398. 
• Mensink FH, Katan MB. Effect of a diet enriched with monounsaturated or polyunsaturated fatty acids on levels of low 
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density and high density lipoprotein cholesterol in healthy women and men. New Engl J Med 1989, 321: 436-41.  
• Mata P, Alvarez-Sala L, Rubio MJ, Nuño J, De Oya M. Effects of long term monounsaturated - vs polyunsaturated-enriched 
diets on lipoproteins in healthy men and women. Am J Clin Nutr 1992, 55: 846-50.  
• Gardner CD, Kraemer HC. Monounsaturated versus polyunsaturated dietary fat and serum lipid. Arterioscler Throm Vasc Biol 
1995, 15: 1917-27.  
• López S, Bermúdez B, Pacheco YM, López-Lluch G, Moreda W, Villar J, Abia R, Muriana FJ. Dietary oleic and palmitic 
acids modulate the ratio of triacylglycerols to cholesterol in postprandial triacylglycerol-rich lipoproteins in men and cell 
viability and cycling in human monocytes. J Nutr. 2007 Sep;137(9):1999-2005. 
• Sánchez-Muniz FJ, Bastida S, Gutiérrez-García O, Carbajal A.Olive oil-diet improves the simvastatin effects with respect to 
sunflower oil-diet in men with increased cardiovascular risk: a preliminary study. Nutr Hosp. 2009 May-Jun;24(3):333-9. 
• Moreno JA, Pérez-Jiménez F, Moreno-Luna R, Pérez-Martínez P, Fuentes-Jiménez F, Marín C, Portugal H, Lairon D, López-
Miranda J. The effect of apoE genotype and sex on ApoE plasma concentration is determined by dietary fat in healthy subjects. 
Br J Nutr. 2009 Jun;101(12):1745-52. 
University Pablo 
Olavide 
5.4. Inflammation 
and immne 
function 
5.4.1. Page 42, line 1410 and 5.4.4. Page 42, lines 1435-1436. The studies published by Fuentes F et al. (Fuentes F, López-
Miranda J, Pérez-Martínez P, Jiménez Y, Marín C, Gómez P, Fernández JM, Caballero J, Delgado-Lista J, Pérez-Jiménez F. 
Chronic effects of a high-fat diet enriched with virgin olive oil and a low-fat diet enriched with alpha-linolenic acid on 
postprandial endothelial function in healthy men. Br J Nutr. 2008 Jul;100(1):159-65.), Pacheco YM et al (A meal rich in oleic 
acid beneficially modulates postprandial sICAM-1 and sVCAM-1 in normotensive and hypertensive hypertriglyceridemic 
subjects. Pacheco YM, López S, Bermúdez B, Abia R, Villar J, Muriana FJ. J Nutr Biochem. 2008 Mar;19(3):200-5) and 
Jiménez-Gomez Y et al (Jiménez-Gómez Y, López-Miranda J, Blanco-Colio LM, Marín C, Pérez-Martínez P, Ruano J, 
Paniagua JA, Rodríguez F, Egido J, Pérez-Jiménez F. Olive oil and walnut breakfasts reduce the postprandial inflammatory 
response in mononuclear cells compared with a butter breakfast in healthy men. Atherosclerosis. 2009, 204: 70-6) show that a 
Mediterranean diet rich in MUFA plays a key role in postpandrial endothelial function and inflammatory biomarkers.  
University Pablo 
Olavide 
5.4. Inflammation 
and immne 
function 
5.4.1. Page 42, line 1410 and 5.4.4. Page 42, lines 1435-1436. The studies published by Fuentes F et al. (Fuentes F, López-
Miranda J, Pérez-Martínez P, Jiménez Y, Marín C, Gómez P, Fernández JM, Caballero J, Delgado-Lista J, Pérez-Jiménez F. 
Chronic effects of a high-fat diet enriched with virgin olive oil and a low-fat diet enriched with alpha-linolenic acid on 
postprandial endothelial function in healthy men. Br J Nutr. 2008 Jul;100(1):159-65.), Pacheco YM et al (A meal rich in oleic 
acid beneficially modulates postprandial sICAM-1 and sVCAM-1 in normotensive and hypertensive hypertriglyceridemic 
subjects. Pacheco YM, López S, Bermúdez B, Abia R, Villar J, Muriana FJ. J Nutr Biochem. 2008 Mar;19(3):200-5) and 
Jiménez-Gomez Y et al (Jiménez-Gómez Y, López-Miranda J, Blanco-Colio LM, Marín C, Pérez-Martínez P, Ruano J, 
Paniagua JA, Rodríguez F, Egido J, Pérez-Jiménez F. Olive oil and walnut breakfasts reduce the postprandial inflammatory 
response in mononuclear cells compared with a butter breakfast in healthy men. Atherosclerosis. 2009, 204: 70-6) show that a 
Mediterranean diet rich in MUFA plays a key role in postpandrial endothelial function and inflammatory biomarkers.  
University Pablo 
Olavide 
5.6. Glucose 
tolerance and 
insulin sensitivity 
- 5.6.2. Page 44, lines 1499-1507, 5.6.5 Page 45, lines 1551-1552, 5.9.1. Page 50, lines 1724-1733 and 5.9.4. Page 50, lines 
1753-1755. There exist several studies showing that Cis-MUFA improves insulin resistance and glucose homeostasis: 
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• Bos MB, de Vries JH, Feskens EJ, van Dijk SJ, Hoelen DW, Siebelink E, Heijligenberg R, de Groot LC. Effect of a high 
monounsaturated fatty acids diet and a Mediterranean diet on serum lipids and insulin sensitivity in adults with mild abdominal 
obesity. Nutr Metab Cardiovasc Dis. 2009 Aug 17. 
• Paniagua JA, de la Sacristana AG, Sánchez E, Romero I, Vidal-Puig A, Berral FJ, Escribano A, Moyano MJ, Peréz-Martinez 
P, López-Miranda J, Pérez-Jiménez F. A MUFA-rich diet improves posprandial glucose, lipid and GLP-1 responses in insulin-
resistant subjects. J Am Coll Nutr. 2007 Oct;26(5):434-44.  
• Paniagua JA, Gallego de la Sacristana A, Romero I, Vidal-Puig A, Latre JM, Sanchez E, Perez-Martinez P, Lopez-Miranda J, 
Perez-Jimenez F. Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin 
expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care. 2007 Jul; 30(7):1717-23.  
• Low CC, Grossman EB, Gumbiner B. Potentiation of effects of weight loss by monounsaturated fatty acids in obese NIDDM 
patients. Diabetes. 1996 May; 45(5):569-75. 
• Berglund L, Lefevre M, Ginsberg HN, Kris-Etherton PM, Elmer PJ, Stewart PW, Ershow A, Pearson TA, Dennis BH, Roheim 
PS, Ramakrishnan R, Reed R, Stewart K, Phillips KM; DELTA Investigators. Comparison of monounsaturated fat with 
carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and 
postprandial states. Am J Clin Nutr. 2007 Dec; 86(6):1611-20. 
• Julios U. Fat modification in the diabetes diet. Exp Clin Endocrinol Diabetes. 2003 Apr; 111(2):60-5.  
• Ros E. Dietary cis-monounsaturated fatty acids and metabolic control in type 2 diabetes. Am J Clin Nutr. 2003 Sep; 78(3 
Suppl):617S-625S. 
• Salas J, López Miranda J, Jansen S, Zambrana JL, Castro P, Paniagua JA, Blanco A, López Segura F, Jiménez Perepérez JA, 
Pérez Jiménez F. The diet rich in monounsaturated fat modifies in a beneficial way carbohydrate metabolism and arterial 
pressure. Med Clin (Barc). 1999 Dec 11;113(20):765-9  
University Pablo 
Olavide 
5.7. Body weight 
control and energy 
balance 
- 5.7.2. Page 46, lines 1585-1593. The writing of the statement is confusing and difficult to understand. Thus, it should be 
clarified. 
University Pablo 
Olavide 
6.3. Cis-
monounsaturated 
fatty acids (Cis-
MUFA) 
We consider that the following statement “Cis-MUFA are synthesised by the body, have no known role in preventing or 
promoting diet-related diseases, and therefore not required in the diet” written in lines 69-70, 1876-1877 and 1995-1996, should 
be eliminated or modified. The reason is that the mentioned statement is completely different of a previous EFSA opinion from 
July 2005 (Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission 
related to nutrition claims concerning omega-3 fatty acids, monounsaturated fat, polyunsaturated fat and unsaturated fat; 
Request Nº EFSA-Q-2004-107). In this request it is textually written “Substitution of saturated fatty acids (SFA) in the diet by 
an equal amount of MUFA reduces low density lipoprotein (LDL) cholesterol; elevated plasma LDL-cholesterol has been 
causally linked to coronary heart disease. Because SFA intakes of many EU populations exceed levels (about 10% energy) 
widely recommended for maintenance of lower levels of plasma LDL-cholesterol, MUFA consumption plays an important 
nutritional role in limiting SFA intake”. 
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VBZ (Association of 
the Dutch Bakery 
and Confectionary 
Industry) 
4. Overview of 
dietary reference 
values and 
recommendations 
Comment on table 5, line 1035-1039 and other lines about the Dietary reference values of the Netherlands.  
 
On page 93 (line 2915) the dietary reference value in the Netherlands is mentioned. However, these are the values from 2001, 
whereas the Dutch Health Council updated its advice in 2006. Therefore we recommend using the most recent dietary 
guidelines. 
VBZ (Association of 
the Dutch Bakery 
and Confectionary 
Industry) 
Conclusions and 
recommendations 
Comment about line 56-67 in the Summary and line 1986-1993 in the Conclusions and recommendations.  
 
We would also like to react on the summary, but because this isn''t possible we react on the conclusions and recommendations. 
Please use this comment also for the summary.  
 
We support the opinion of the Dutch Product Boards: Why are all the saturated fats treated as one group in the summary? The 
unsaturated fats are split up in separate groups, but the saturated fats are treated as one group. As stated in chapter 5.2.2 several 
saturated fats have different effects on cholesterol metabolism.  
 
VBZ (Association of 
the Dutch Bakery 
and Confectionary 
Industry) 
Conclusions and 
recommendations 
Comment about line 66,67 in the Summary and line 1992-1993 in the Conclusions and recommendations.  
 
We would also like to react on the Summary, but because this isn''t possible we react on the Conclusions and recommendations. 
Please use this comment also for the Summary.  
 
We support the opinion of the Dutch Product Boards:  
In the Summary in line 66,67 the following is written: „The Panel recommends that SFA intake should be as low as possible 
within the context of a nutritionally adequate diet‟.  
In the discussed scientific research in chapter 5 this recommendation is not supported. Furthermore, according to Table 5 (page 
32), most Countries and also the WHO/FAO set the maximum SFA at 10 E%. In infants average intakes of SFA where between 
11-13 E%. In adults, average SFA intakes vary between 9 to 17 E% and nearly 30% of the reported average intakes were 15 E% 
or higher (line 620-629).  
In addition: in several economically developed countries where the SFA is close to 10%, the capacity to decrease SFA much 
further is limited to major changes in dietary patterns, and is only likely to result in modest reductions in TC and LDL-C 
We therefore believe it is appropriate to set the recommendation for SFA at 10 E%.  
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VBZ (Association of 
the Dutch Bakery 
and Confectionary 
Industry) 
Conclusions and 
recommendations 
Comment on line 129-146 in the Summary and line 2036-2042 in the Conclusions and recommendations. 
 
We would also like to react on the Summary, but because this isn''t possible we react on the Conclusions and recommendations. 
Please use this comment also for the Summary.  
 
We support the opinion of the Dutch Product Boards: 
We suggest adding to the statement of The Panel in the summary the following: 
The intake of TFA is close to the recommendation levels in most European countries, and are therefore not a public health issue 
anymore. The intake of total TFA is low because of the efforts made by the food industry in reducing the amount of industrial 
TFA in their products (and these efforts are ongoing). The level of ruminant TFA in meat (products) and dairy products is 
already naturally low. 
VBZ (Association of 
the Dutch Bakery 
and Confectionary 
Industry) 
Conclusions and 
recommendations 
We support the opinion of the Dutch Product Boards: 
In conclusion, we would like to point out the following. Consumers do not eat saturated fats or unsaturated fats as such. They 
eat these nutrients in a matrix (food stuffs), as part of a balanced diet. In practice, the matrix influences the effects of the fatty 
acids, meaning that negative effects may not occur, or may be less pronounced, due to the presence of other nutrients in the 
food.  
VBZ (Association of 
the Dutch Bakery 
and Confectionary 
Industry) 
Conclusions and 
recommendations 
We would also like to react on the summary, but because this isn''t possible we react on the conclusions and recommendations. 
Please use this comment also for the summary.  
 
VBZ is supporting the opinion of the Dutch Product Boards that the conclusions in the summary do not reflect accurately the 
content of the report. More precise, the nuance in the report is lacking in the summary. Therefore, it is not immediately obvious 
on what basis the conclusions are drawn. Since the summary is generally the only part that policy makers read, it is important 
that the summary reflects the scientific state of the art, including the recent developments and nuances. 
VBZ (Association of 
the Dutch Bakery 
and Confectionary 
Industry) 
References Recently, two WHO scientific updates were published in the European Journal of Clinical Nutrition (vol. 63, supplement 2s, pp 
S1-S75) and Annals of Nutrition and Metabolism (vol.55, no. 1-3: pp 5-300). It seems logical to take these two updates into 
account in the document.  
VU University 
Amsterdam 
5.2. Serum lipids 
and lipoproteins 
Lines 1337-1338: 
The numbers have been interchanged. 0.036 should be 0.061 and 0.061 should be 0.036  
VU University 
Amsterdam 
6.4. Cis-
polyunsaturated 
fatty acids (Cis-
PUFA) 
This is a valuable overview of the literature. However, the recommendation for linoleic acid is puzzling and will not help to 
promote the health of Europeans.  
Line 1897 states: 
"The Panel proposes to set an AI for linoleic acid of 4 E%, based on the lowest estimated mean intakes of the various 
population groups from a number of European countries, where overt linoleic deficiency symptoms are not present." 
This comparison of population groups is not useful for deriving the Adequate Intake for the prevention of linoleic acid 
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deficiency. For such prevention, 1 E% is already sufficient, as shown in the studies cited in the report. However, it seems more 
prudent to base the AI on the prevention of coronary heart disease. The clinical trials which showed that dietary linoleic acid 
prevents coronary heart disease employed intakes in the range of 9 to 21 E%, with a mean of 14 E%. This would therefore be 
the most rational AI value. As 14 E% is impractably high EFSA would be justified to set the recommendation somewhat lower, 
e.g. at 8-10 E%. But setting the AI at 4 E% will send a signal that this is a healthy intake, while in fact the country with this 
intake – Finland – historically has a high rate of coronary heart disease. The low intake of linoleic acid and high intake of 
saturated fat in Finland is a major cause of this [Pietinen P et al. Changes in diet in Finland from 1972 to 1992: impact on 
coronary heart disease risk. Prev Med. 1996 ;25(3):243-50] . The present EFSA AI may increase instead of decrease coronary 
heart disease in the EU.  
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